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Résumé 
L’asthme est l’une des maladies chroniques les plus fréquentes durant la grossesse, 
affectant environ 4% à 12% des femmes enceintes et ayant une prévalence qui a augmenté 
au cours des dernières décennies. Plusieurs études ont identifié l'asthme comme un facteur 
de risque pour plusieurs enjeux de santé défavorables chez le fœtus et la mère. Les lignes 
directrices de traitement recommandent l’utilisation de médicaments antiasthmatiques 
pendant la grossesse afin de contrôler l’asthme et d’éviter les problèmes de santé maternels 
et fœtaux. L’évaluation de la littérature sur l'utilisation maternelle de médicaments 
antiasthmatiques et le risque de malformations congénitales majeures a relevé plusieurs 
études sur l’innocuité des bêta2-agonistes inhalés à courte durée d’action (BACA) et des 
corticostéroïdes inhalés (CSI) pendant la grossesse, mais peu de données sur les bêta2-
agonistes à longue durée d’action (BALA) ainsi que sur les thérapies combinées (BALA-
CSI). Un programme de recherche en trois volets a été développé pour combler ces lacunes. 
Dans le premier volet, nous avons entrepris une revue systématique de la littérature sur 
l'impact de l'utilisation de BACA et de BALA pendant la grossesse sur le risque de 
différents problèmes périnataux. Vingt et une études originales ont été identifiées. Quatre 
études ont rapporté une augmentation significative du risque de malformations congénitales 
avec BACA, une étude a rapporté une augmentation significative du risque de 
malformations congénitales avec BALA et quatre études ont rapporté un risque significatif 
accru de malformations congénitales avec bêta2-agonistes (BACA et/ou BALA). Toutefois, 
aucun risque majeur n’a été trouvé pour les autres complications périnatales. Fait important, 
la plupart des études récupérées ont subi plusieurs limitations méthodologiques, y compris 
l'utilisation des femmes non-asthmatiques comme groupe de référence et la faible puissance 
statistique. De plus, les résultats qui en découlent doivent être interprétés avec prudence. 
Dans le deuxième volet, nous avons utilisé la base de données Québec Asthma and 
Pregnancy Database qui comprend toutes les grossesses de femmes asthmatiques et un 
échantillon aléatoire de femmes non-asthmatiques ayant accouchées entre 1990 et 2010 
pour effectuer deux études. La première était une étude comparant la prévalence des 
malformations congénitales majeures entre les femmes enceintes asthmatiques traitées avec 
une combinaison de BALA-CSI et celles traitées avec une dose plus élevée de CSI en 
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monothérapie. Dans une sous-cohorte, il y’avait 643 femmes qui utilisaient un BALA plus 
CSI à dose faible et 305 qui ont utilisé une dose moyenne de CSI ; l'autre sous-cohorte 
comprenait 198 utilisatrices de BALA plus CSI à dose moyenne et 156 utilisatrices de CSI 
à dose élevée. La prévalence de malformations majeures a été 6,9% et 7,2%, 
respectivement. Le risque de malformations congénitales majeures était similaire entre ces 
deux groupes de femmes avec un odds ratio ajusté (OR) de 1,1 (IC 95%: 0,6-1,9) pour les 
femmes souffrant d’asthme modéré et un OR ajusté de 1,2 (IC 95%: 0,5-2,7) pour les 
femmes souffrant d’asthme sévère. La seconde était une étude méthodologique visant à 
étudier l’impact de six différentes définitions opérationnelles de malformations 
congénitales qui varient selon la source des données  et la méthode de classification sur 
l’estimation de la prévalence des malformations et de l'association entre l'asthme maternel 
et les malformations majeures. Sur 467,946 grossesses, 12,3% étaient de femmes enceintes 
souffrant d’asthme actif. Nous avons démontré que la source des données et la méthode de 
classification ont eu un impact considérable sur la prévalence des malformations 
congénitales majeures (augmentation entre 10,0% et 50,4%), alors qu’elles ont eu peu 
d’influence sur l’association entre l’asthme maternel et les malformations congénitales. 
Dans le troisième volet du programme de recherche, nous avons développé une procédure 
systématique pour la classification des médicaments utilisés au cours du premier trimestre 
de grossesse en agents tératogènes et potentiellement tératogènes dans un contexte de 
recherche. Nous avons développé une procédure systématique qui s’actualise facilement, 
avec des composantes objectives dans la plupart de ses processus. Nous avons établi une 
liste comprenant 91 médicaments tératogènes, et une autre liste comprenant 81 
médicaments potentiellement tératogènes. Les résultats présentés dans cette thèse ont fourni 
des données importantes sur l’innocuité des traitements de l'asthme pendant la grossesse, 
aidant les cliniciens et les femmes enceintes à choisir un traitement pharmacologique 
sécuritaire pour maintenir l’asthme sous contrôle. De plus, les données présentées dans 
cette thèse sur la minimisation du biais d'indication, les définitions opérationnelles de 
malformations congénitales et l’identification des médicaments tératogènes pourront 
aisément être utilisées par les chercheurs en pharmacoépidémiologie, en tératologie et en 
épidémiologie périnatale.  
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congénitales, tératogènes. 
 
Abstract 
Asthma is one of the most prevalent chronic diseases during pregnancy, affecting 
about 4% to 12% of pregnant women and shows an increasing prevalence over time. In the 
past decades, several studies have identified asthma as a risk factor for several poor fetal 
and maternal outcomes. A consensus exists on favoring the use of asthma medications 
during pregnancy to maintain asthma under control to prevent adverse maternal and fetal 
outcomes. An assessment of the published literature on maternal asthma medications and 
the risk of major congenital malformations revealed more data on the safety of short-acting 
beta2-agonists (SABA) and inhaled corticosteroids (ICS) during pregnancy compared to 
long-acting beta2-agonists (LABA), as well as a paucity of data on the fetal safety of 
combination therapies (e.g. LABA-ICS). A three-part research program was developed to 
fill this knowledge gap and answer other intriguing questions we faced, adding necessary 
evidence in this field. In the first part, we summarized the published evidence on the impact 
of maternal use of SABA and LABA during pregnancy and different perinatal outcomes in 
a comprehensive systematic review. Twenty-one original studies were identified. Four 
studies reported a significant increased risk of congenital malformations with SABA, one 
study reported a significant increased risk of congenital malformations with LABA and 
four studies reported a significant increased risk of congenital malformations with beta2-
agonists (SABA and/or LABA). However, no major increased risk was found for the other 
perinatal outcomes. Importantly, most of the retrieved studies suffered several 
methodologic limitations, including using non-asthmatic women as the reference group and 
low statistical power. Moreover, the non-significant results reported should be interpreted 
with caution. In the second part, we used the Quebec Asthma and Pregnancy Database – 
which includes all pregnancies in asthmatic women and a random sample in nonasthmatic 
women between 1990 and 2010 – to conduct two studies. The first was a comparative 
safety study examining the prevalence of major congenital malformations in pregnant 
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asthmatic women treated with a combination of LABA-ICS compared to those treated with 
a higher dose of ICS monotherapy. In one subcohort there were 643 women who used a 
LABA plus low-dose ICS and 305 women who used a medium-dose ICS; the other 
subcohort included 198 users of a LABA plus a medium dose ICS and 156 users of a high-
dose ICS. The prevalence of major malformations was 6.9% and 7.2%, respectively. The 
risk of major malformations did not differ when a combination therapy was used among 
both moderate and severe asthmatic women (aOR: 1.1; 95% CI: 0.6–1.9 and aOR: 1.2; 95% 
CI: 0.5–2.7 respectively). The second was a methodological study aiming to compare the 
prevalence of major malformations using six different case ascertainment definitions that 
vary by the source of data and the classification method, as well as to evaluate the impact of 
these definitions on the association between maternal asthma and major malformations. 
From the 467,946 pregnancies, 12.3% were with active asthma. We demonstrated that the 
source of data and the classification method had a considerable impact on the prevalence of 
major malformations (increases between 10.0% and 50.4%), but only a small influence on 
the measure of association. In the third part of the research program, we aimed at 
constructing a systematic procedure for the classification of proven and potential 
teratogenic medications during the first trimester of pregnancy to be used for research. We 
structured a procedure that is both systematic and updatable, with objective components in 
most of its processes. We identified a substantial list of teratogenic medications, including 
91 medications, and an extensive list of potentially teratogenic medications, including 81 
medications. The results presented in the current thesis provided essential evidence on the 
safety of asthma treatments during pregnancy, helping clinicians and mothers to choose the 
optimal therapeutic regimen to keep asthma under control. The added knowledge on 
indication bias minimization, congenital malformations ascertainment and teratogenic 
medications are directly transferable to researchers in pharmacoepidemiology, teratology 
and other related research fields. 
Keywords: asthma, pregnancy, beta2-agonists, corticosteroids, congenital malformations, 
teratogens. 
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Introduction 
Asthma is one of the most prevalent chronic diseases during pregnancy.
1
 The 
disease affects about 4% to 12% of pregnant women and shows an increasing prevalence 
over time.
2-6
 In the past decades, several studies have identified asthma as a risk factor for 
several poor fetal and maternal outcomes. Numerous studies have shown associations 
between suboptimal control of asthma and more severe asthma during pregnancy and 
increased maternal and fetal risks.
2,5,7-9
 In contrast, better-controlled asthma and mild-to-
moderate actively managed asthma are associated with decreased risks.
10,11
 A consensus 
has been formed through the years on favoring the use of asthma medications during 
pregnancy to maintain asthma under control to prevent adverse maternal and fetal 
outcomes.
5,12
  
The ultimate goal of asthma therapy in pregnancy is maintaining adequate 
oxygenation for the fetus and preventing maternal hypoxic episodes.
13
 Asthma medications 
are categorized into two classes; 1) quick relief medications (e.g. short-acting beta2-
agonists [SABA]), and 2) long-term controller medications (e.g. inhaled corticosteroids 
[ICS] and long-acting beta2-agonists [LABA]). SABA have been widely used for years for 
the quick relief of asthma symptoms during pregnancy, while ICS are considered the 
mainstay of controller therapy during pregnancy.
5,14
 More data on the safety of SABA and 
ICS during pregnancy are available in the literature compared to LABA due to their 
precedence in the markets.
15
 LABA are used for patients with moderate and severe 
persistent asthma not fully controlled with inhaled corticosteroids alone.
15
 
According to recent reports from the Public Health Agency of Canada, major 
congenital malformations are present in approximately 3%–5% of newborns and 8%–10% 
of stillbirths in Canada.
16
 Major congenital malformations are considered among the 
leading causes of infant, fetal, and post neonatal mortality in North America and Europe.
16-
20
 Ten studies investigated the risk of congenital malformations associated with the use of 
SABA and LABA separately. 
21-30
 Among these studies,  five used a control group of 
asthmatic women  
23,24,27,30,31
 with two reporting a significant increased risk of congenital 
malformations, 
23,30
  the first with Fenoterol use (SABA) 
23
 and the second with LABA 
use.
30
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The association between maternal ICS use and the risk of congenital malformations 
was examined in twenty-three studies.
21,22,28,29,32-50
 ICS users were compared with women 
with asthma who did not use any ICS during pregnancy in six studies 
39,41,43,44,49,51
. 
Moreover, one study examined fluticasone against other ICS 
33
 and one study examined 
high ICS dose compared to lower ICS dose.
34
 A significant increased risk of all 
malformations was found in one study when high daily doses of ICS (>1000 mg/d 
equivalent beclomethasone dipropionate) were compared to lower daily doses of ICS (> 0-
1000 mg/d) (adjusted odds ratio [OR], 1.66; 95%CI 1.02, 2.68).
34
 
Current recommendations for the addition of LABA to ICS - for persistent 
asthmatic pregnant women - are based on the established evidence of better asthma control 
with a combination therapy compared to ICS monotherapy outside of pregnancy.
14,52
 
However, the evidence on the fetal safety of the combination therapy is scarce. Women 
with persistent asthma are encouraged to continue taking their asthma medications if 
pregnancy occurs and should be managed optimally with the right treatment regimen that 
reduces the adverse asthma symptoms and exacerbations. One of the important clinical 
decisions that the physician has to make is to whether prescribe LABA in addition to the 
current dose of ICS or increase the ICS dose, if asthma cannot be controlled with low dose 
ICS.  
Combination treatment regimens (LABA plus ICS) were examined in three recent 
studies 
28,33,35
, two of which used asthmatics and non-asthmatics as a reference group.
28,35
. 
The third study examined fluticasone and salmeterol combination users against other ICS 
monotherapy users and did not find a significant difference.
33
 However, some 
methodologic limitations were present. To the best of our knowledge, we found no study 
that compared the risk of congenital malformations between women exposed to 
combination therapy (LABA plus ICS) and women exposed to ICS monotherapy at higher 
doses during pregnancy. 
Since administrative health data are collected for administrative and payment 
purposes, researchers planning on using these databases should identify the possible threats 
to their studies validity and apply strategies to tackle these limitations. The use of accurate 
and valid operational definitions for the outcomes of interest is essential. Regarding 
4 
 
congenital malformations research, discrepancies in the estimated prevalence of major 
malformations can be easily located in prior reports that used computerized administrative 
databases, which can be attributed to several factors including the source of data, the 
diagnostic codes validity, the classification method, and the period of assessment.
53-55
 All 
these factors should be considered in specifying and developing the case ascertainment 
definitions in pharmacoepidemiologic studies. 
Quebec’s Medical Claims database - Régie de l’Assurance-Maladie du Québec 
(RAMQ) -  and the hospitalisations records - Maintenance et Exploitation des Données 
pour l’Étude de la Clientèle Hospitalière (MED-ECHO) - have been used previously for 
congenital malformations research.
56-59
 The accuracy of congenital malformations 
diagnoses recorded in RAMQ and MED-ECHO databases was reported in two studies.
60,61
 
However, no study has investigated the prevalence of congenital malformations diagnoses 
reported in each database separately. Beside the variation in the prevalence estimates, the 
case ascertainment definitions might also influence the estimates of the associations 
between maternal exposures and congenital malformations. 
In observational studies of congenital malformations, it is essential to control for the 
maternal exposure to proven and potential teratogenic medications, as failure to do so can 
affect the study validity. The increase in the body of knowledge on currently used 
medications make it difficult to identify a list of teratogenic medications that should be 
used in research. While strong evidence of teratogenicity exists for some medications (e.g. 
thalidomide), the evidence is not conclusive for most of the currently used medications. 
Several databases and references on teratogenic risks are currently available, providing 
either complete or partial evidence for the teratogenicity of medications.
62-73
 However, 
there are substantial discrepancies between the lists of medications that should be 
considered teratogenic, and significant imprecision is added when categories are used (e.g., 
moderate- vs high-risk teratogens).
62-73
. Moreover, the current lists of teratogenic 
medications used in research are outdated and require constant review of the literature to 
incorporate the newly generated evidence and recent updates.
65
 Therefore, harnessing the 
full potential of several reliable resources is essential to the creation of a comprehensive 
overview. 
5 
 
This thesis consists of six chapters and we present it by articles; including one 
systematic review (published; 2014), one comparative safety study (published; 2015), one 
methodological study (published; 2016) and one evidence synthesis review (published; 
2016). The studies are in a journal manuscript format presented with their figures, tables 
and references in Chapter 5. The thesis contains separate chapters for the introduction, 
review of the literature, objectives, methods and discussion.  
In the first part of this thesis, we present a systematic review in which we aimed to 
summarize the existing human data on the impact of the use of inhaled SABA and LABA 
for the treatment of asthma during pregnancy on several perinatal outcomes, which are 
major and any congenital malformations, small for gestational age, birth weight, low birth 
weight, gestational age and preterm delivery.  
In the second part of this thesis, we used the Quebec Asthma and Pregnancy 
Database, which includes all pregnancies in asthmatic women and a random sample of 
pregnancies in nonasthmatic women between January 1, 1990 and March 31, 2010, to 
conduct two studies. The first was a comparative safety study examining the prevalence of 
major congenital malformations in pregnant asthmatic women treated with a combination 
of LABA and ICS compared to those treated with a higher dose of ICS monotherapy. The 
second study was a methodological study aiming to compare the prevalence of major 
malformations using different case ascertainment definitions that vary by the source of data 
and the classification method, and to evaluate the impact of these definitions on the 
association between maternal asthma and major malformations.   
Given the observational nature of the studies included in the current thesis and 
generally in the field of congenital malformations, the third part of the thesis present our 
approach to tackling the issue of the discrepancies and inconsistencies of teratogens lists 
that can be used in perinatal and reproductive research. Using reliable references and 
resources, we developed a systematic and updatable procedure for the classification of 
medications into those with sufficient human evidence of teratogenic risk and those with 
potential teratogenic risk during the first trimester of pregnancy. Finally, we will discuss in 
6 
 
chapter 6 the different strengths and limitations of our research projects and summarize 
their implications for practice and future research opportunities.  
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Review of the literature 
 
2.1 Asthma definition 
Asthma is a complex disorder characterized by variable and recurring symptoms, 
airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
74
 
Asthma hyperresponsiveness leads to recurrent episodes of wheezing, breathlessness and 
coughing. Asthma episodes – typically characterized by airflow obstruction – are often 
reversible, spontaneously or with the use of asthma treatments.
14
 The onset of asthma for 
most patients begins early in life with the pattern of disease persistence determined by 
early, recognizable risk factors including atopic disease, recurrent wheezing, and a parental 
history of asthma.
74
 For some patients, the development of chronic inflammation may be 
associated with permanent alterations in the airway structure—referred to as airway 
remodeling—that are not prevented by or fully responsive to currently available 
treatments.
75
 Therefore, the paradigm of asthma has been expanded over the last 10 years 
from bronchospasm and airway inflammation to include airway remodeling in some 
patients.
74,76
 
 
2.2 Asthma prevalence 
Asthma is considered one of the most common chronic diseases, affecting as many 
as 300 million people worldwide.
14,74
 Moreover, higher estimates were observed with less 
conservative criteria for the diagnosis of clinical asthma.
74
 The prevalence of asthma have 
markedly increased over the last 60 years, especially in western countries, where it 
represents now a considerable burden on the individuals and the healthcare systems.
14,77
 
The prevalence of asthma in Canada and the United States is among the highest in the 
world, reaching over 13% for children and about 8% to 12% for adults.
78-81
  
 
2.3 Asthma severity and control 
9 
 
While being complementary notions in the management of asthma, asthma severity 
and control may overlap in their ways of assessment but each has its distinguished clinical 
importance.
14,74
 The severity of asthma could influence the control over time. Canadian 
experts have recommended that the dose of inhaled corticosteroids necessary to obtain good 
control of asthma should be included when evaluating asthma severity level.
52,82
 
 
2.3.1 Asthma severity 
Asthma severity is defined as the intrinsic intensity of the disease process.
74
 
According to GINA 2015, asthma severity is assessed retrospectively from the level of 
treatment required to control symptoms and exacerbations.
14
 It is not a static feature and 
may change over months or years.
14
 Severity is most easily and directly measured in a 
patient who is not receiving long-term control therapy.
80
 Severity can also be measured, 
once asthma control is achieved, by the step of care required to maintain control.
74
 
According to United States (US) National Asthma Education and Prevention Program 
(NAEPP) guidelines for the diagnosis and management of asthma, asthma severity is 
measured taking into account the level of asthma symptoms, night-time symptoms, use of 
SABA, pulmonary function and airway limitation, rate of exacerbations, and limitations to 
normal activities.
74
 Using these factors, asthma severity level can be classified into four 
categories; intermittent, mild persistent, moderate persistent, and severe persistent (see 
Table 2.3.1 and Table 2.3.2).
74
 The stepwise approach for managing asthma is then used to 
manage asthma in each patient according to his/her severity level (see Figure 2.3.1 and 
Table 2.3.2).  
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Table 2.3.1 Classification of asthma severity measured before treatment is started 
according to US National Asthma Education and Prevention Program guidelines 
 Clinical features before treatment
#
 
 Symptoms
¶
 
Night-time 
symptoms 
Lung function 
Severe 
persistent 
Continual symptoms 
Limited physical activity 
Frequent exacerbations 
Frequent 
FEV1 or PEF ≤60% 
pred 
PEF variability 
>30% 
 Moderate 
persistent 
Daily symptoms 
Daily use of inhaled SABA 
Exacerbations affect activity 
Exacerbations more than twice per week; 
may last days 
More than once per 
week 
FEV1 or PEF >60 
and ≤80% pred 
PEF variability 
>30% 
Mild persistent 
Symptoms more than twice per week but 
no more than once per day 
Exacerbations may affect activity 
More than twice 
per month 
FEV1 or PEF ≥80% 
pred 
PEF variability 20–
30% 
Intermittent 
Symptoms no more than twice per week 
Asymptomatic and normal PEF between 
exacerbations 
Exacerbations are brief (from a few hours 
to a few days); intensity may vary 
No more than twice 
per month 
FEV1 or PEF ≥80% 
pred 
PEF variability 
<20% 
Asthma severity was classified by clinical characteristics before treatment. FEV1: forced expiratory volume in 
one second; PEF: peak expiratory flow; % pred: % predicted; SABA: short-acting β2-agonist. 
#
: the presence of 
one of the features of severity is enough to place the patient in that category. An individual should be assigned 
to the most severe grade in which any feature occurs. An individual’s classification may change over time. ¶: 
Patients at any level can have mild, moderate or severe exacerbations. Some patients with intermittent asthma 
experience severe and life-threatening exacerbations separated by long periods of normal lung function and no 
symptoms. 
 
From US National Asthma Education and Prevention Program guidelines for the diagnosis 
and management of asthma, Expert Panel Report 3, 2007 
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Table 2.3.2 Classifying severity in patients after asthma becomes well controlled, by 
lowest level of treatment required to maintain control. 
Classification of Asthma Severity 
Intermittent Persistent 
Step 1 
Mild Moderate Severe 
Step 2 Step 3 or 4 Step 5 or 6 
From US National Asthma Education and Prevention Program guidelines for the diagnosis 
and management of asthma, Expert Panel Report 3, 2007 
 
Figure 2.3.1 Stepwise approach for managing asthma in adults according to the US 
National Asthma Education and Prevention Program guidelines
 
Source: US National Asthma Education and Prevention Program guidelines for the diagnosis and 
management of asthma, Expert Panel Report 3, 2007 
12 
 
 
2.3.2 Asthma control 
According to the US NAEPP guidelines, asthma control is defined as the degree to 
which the manifestations of asthma are minimized by therapeutic intervention and the goals 
of therapy are met.
74
 Asthma control is assessed through measuring the components of 
control, including the level of asthma symptoms, night-time awakenings, interference with 
normal activities, SABA use for quick relief, pulmonary function (FEV1 or peak flow), 
exacerbations, the progressive loss of lung function, and the treatment related side-effects.
74
 
The NAEPP guidelines classifies asthma control into three classes; well controlled, not well 
controlled and very poorly controlled (see Table 2.3.3).
74
  
 
 
Table 2.3.3 Classification of asthma control in adults according to US National 
Asthma Education and Prevention Program guidelines 
COMPONENTS OF 
CONTROL 
CLASSIFICATION OF ASTHMA CONTROL 
 
 WELL CONTROLLED 
NOT WELL 
CONTROLLED 
VERY POORLY 
CONTROLLED 
Impairment 
Symptoms ≤ 2 days/week > 2 days/week Throughout the day 
Night-time 
awakenings 
≤ 2 times/month 1–3 times/week ≥ 4 times/week 
Interference with 
normal activity 
None Some limitation Extremely limited 
Short-acting beta-2- 
agonist 
use for symptom 
control 
(not prevention of 
exercise- 
induced 
bronchospasm) 
≤ 2 days/week > 2 days/week Several times/day 
FEV1 or peak flow  
> 80% predicted or 
personal best 
60%–80% predicted or 
personal best 
< 60% predicted or 
personal best 
Validated questionnaires 
 ATAQ 0 1–2 3–4 
 ACQ ≤ 0.75 ≥ 1.5 NA 
 ACT ≥ 20 16–19 ≤ 15 
13 
 
Risk 
Exacerbations 
requiring oral systemic 
corticosteroids 
0–1/year 2–3/year  > 3/year 
 Consider severity and interval since last exacerbation. 
Progressive loss of 
lung function 
Evaluation requires long-term follow-up care. 
Treatment-related 
adverse effects 
Medication side effects can vary in intensity from none to very troublesome and 
worrisome. The level of intensity does not correlate to specific levels of control but 
should be considered in the overall assessment of risk.  
ATAQ = Asthma Therapy Assessment Questionnaire, ACQ = Asthma Control Questionnaire, ACT = Asthma 
Control Test, FEV1 = forced expiratory volume in 1 second. 
From the US National Asthma Education and Prevention Program guidelines for the 
diagnosis and management of asthma, Expert Panel Report 3, 2007 
 
The GINA guidelines uses similar aspects for measuring asthma control, and 
classifies it into controlled, partly controlled, and uncontrolled.
14
 In control-based asthma 
management, pharmacological and non-pharmacological treatment is adjusted in a 
continuous cycle that involves assessment, treatment and review as presented in Fig 2.3.2.
14
 
Asthma outcomes have been shown to improve after the introduction of practical tools for 
implementation of control-based management strategies.
14
  
Figure 2.3.2 The control-based asthma management cycle (GINA 2015) 
 
14 
 
 
 
Source: The Global Strategy for Asthma Management and Prevention, Global Initiative for 
Asthma (GINA) 2015. Available from: http://www.ginasthma.org/. 
 
2.4 Asthma management and treatment 
Asthma treatment goal is to prevent and control asthma symptoms, reduce the 
frequency and severity of asthma exacerbations, and reverse airflow obstruction.
14,74,82
 
Recommendations in the treatment choices reflect the scientific fact that asthma is a 
chronic disorder with episodes of airflow limitation, cough, and mucus production.
80
 
Asthma medications are categorized into two classes: quick-relief medications which are 
taken as needed to achieve prompt reversal of acute pulmonary obstruction and relief of the 
accompanying bronchoconstriction (these medications are also known as acute rescue or 
reliever medications) and long-term controller medications which are taken daily on a long-
term basis to achieve and maintain control of persistent asthma (these medications are also 
known as long-term preventive, maintenance, or controller medications). Patients with 
persistent asthma are in need of both classes of medication.
14,74
  
An asthma attack or exacerbation could occur due to several triggers.
14
 The typical 
symptoms of an exacerbation include dyspnea, wheezing, cough, and chest tightness.
14,74
 
The onset may be sudden, with a feeling of constriction in the chest and breathing 
difficulties.
14,74
 Due to its potential risks, exacerbations should be managed as soon as their 
signs and symptoms are recognized.
14,74
  
 
2.4.1 Relievers  
These are quick-relief medications which are used as needed to treat acute asthma 
symptoms and exacerbations.
14,74
 
 Short-acting beta2-agonists (SABA): examples include salbutamol, 
terbutaline, fenoterol, levalbuterol, metaproterenol, and pirbuterol. SABA are 
15 
 
considered the first line therapy for the relief of acute asthma symptoms, acute 
exacerbations and as pre-treatment for exercise-induced bronchoconstriction 
(see Figure 2.3.1).
14,74
 
 Short-acting anticholinergics: the most frequently used is ipratropium 
bromide, which provides additive benefit to SABA in moderate and severe 
exacerbations.
14
 It can also be considered as alternative bronchodilator for 
patients intolerant to inhaled beta2-agonists.
14,74
 
 Systemic corticosteroids: examples include prednisone, prednisolone, and 
methylprednisolone. Short courses of oral corticosteroids or parenteral 
corticosteroid solutions can be used for moderate and severe exacerbations to 
speed recovery and prevent exacerbation recurrence.
74
  
 
2.4.2 Controller medications 
Controller medications are daily-use long-term medications that help keep asthma 
symptoms under control. The most effective are those that reduce the underlying 
inflammation of asthma.
14,74
  
 
 Corticosteroids: Corticosteroids are the most potent and effective anti-
inflammatory medications currently available.
14,74,82
 The main advantage of 
inhaled corticosteroids (ICS) in asthma management is their anti-inflammatory 
activity, which reduces the bronchial hyper-reactivity. ICS have fewer side 
effects than oral or systemic corticosteroids, and are considered the cornerstone 
therapy for persistent asthma management.
14,74
 The most commonly used ICS 
are beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, 
fluticasone propionate, mometasone furoate, and triamcinolone acetonide. Due 
to their high efficacy and low systemic levels when used as prescribed, ICS 
have superiority over any other single long-term controller medication.
74
 After 
initiating the ICS therapy, the patients' symptoms improve in the first one to 
two weeks, with a maximum effect in 4 to 8 weeks.
83
 ICS use is associated 
16 
 
with a decrease in asthma symptoms, emergency visits and hospitalizations for 
asthma, frequency and severity of exacerbations, mortality due to asthma and 
an improvement in lung functions and quality of life.
14,74
 
Systemic corticosteroids are often used to achieve quick control of severe 
asthma symptoms. 
14,74,83
 Long-term oral corticosteroids therapy (tablets or 
syrup) are used only as needed in cases of uncontrolled severe persistent 
asthma (see Figure 2.3.1), and their discontinuation is recommended as soon as 
asthma control is achieved.
14,74,83
  
 Long-acting beta2-agonists (LABA): Long-acting bronchodilators (mainly 
salmeterol and formoterol) are used alongside ICS for long-term control of 
asthma symptoms. 
14,74
  LABA have bronchodilation period of at least 12 
hours after a single dose. 
14,74
  LABA should not be taken alone in asthma, as 
they do not have a chronic anti-inflammatory activity and their use as 
monotherapy showed a significant increase in asthma related deaths.
14,74
  
LABA and ICS combination is recommended for long-term control in 
moderate and severe persistent asthma (steps 3 to 6 in the stepwise approach 
for managing asthma, see Figure 2.3.1).
74
 The LABA are also currently 
available in combination with ICS in a single ready-to-use inhaler 
(fluticasone/salmeterol and budesonide/formoterol). The combination of 
LABA and ICS is one of the  preferred treatment choices when a low or 
medium dose of ICS fails to achieve the efficient control of asthma.
14
 Their use 
in combination with an ICS allows asthma control at lower ICS doses, 
improves the lung functions, decreases SABA use and reduces exacerbations. 
14,74
 
 Chromones: Mild to moderate anti-inflammatory medications (e.g. cromolyn 
sodium and nedocromil). They are recommended as an alternative, but not 
preferred, medication for patients with mild persistent asthma (see Figure 
2.3.1). They also can be used as preventive treatment prior to exercise or 
unavoidable exposure to known allergens.
74
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 Leukotriene receptor antagonists (LTRA): LTRA (e.g. zafirlukast and 
montelukast) are possible alternative therapies to low doses of ICS.
74
 They are 
less effective than ICS and may be appropriate for initial controller treatment 
for patients who are unable or unwilling to use ICS, patients who experience 
intolerable side-effects from ICS or patients with concomitant allergic 
rhinitis.
14
 
 Methylxanthines: Sustained-release theophylline is a mild-to-moderate 
bronchodilator mainly used as adjuvant to inhaled corticosteroids for 
prevention of nocturnal asthma symptoms.
74
 It only has weak efficacy in 
asthma and reported several side-effects, which may be life-threatening at 
higher doses.
14,74
 
 Biologic-based therapy (e.g. omalizumab mepolizumab, reslizumab): Given 
that a large proportion of asthma symptoms are triggered by allergic reactions, 
immunoglobulin E (IgE), the antibody intimately involved in allergic 
responses, has been one target of therapy.
84
 
85
Omalizumab is a monoclonal 
antibody directed against IgE, and acts to prevent its ability to function with 
multiple cell types.
86,87
 Omalizumab has been shown to be safe and effective 
for adults and children in the treatment of asthma.
88
 Omalizumab has been 
available to patients with asthma for more than 10 years.
87
 However, it is 
ineffective in some patients whose asthma remains uncontrolled, and these 
patients subsequently discontinue this therapy. Recently, the FDA has 
approved reslizumab, a new interleukin-5-antagonist monoclonal anti-body 
that is administered by I.V. infusion once every 4 weeks.
89,90
 
 
 
2.5 Asthma during pregnancy 
Asthma is considered one of the most frequent chronic diseases that affect pregnant 
women.
1,91
 Asthma has a prevalence of 3.7% to 12% among pregnant women.
2-6,92
 
Furthermore, asthma during pregnancy is showing an overall increasing prevalence over 
18 
 
time.
2-6
 Among the well-known asthma management guidelines that include pregnancy 
recommendations are: the GINA (2015)
14
, British Thoracic Society
93
, the NAEPP-EPR3
5
 
and the Canadian Thoracic Society guidelines (1999).
82
 The NAEPP published explicit and 
detailed guidelines for asthma management during pregnancy in 2004. The following 
sections will focus on the most updated pregnancy guidelines; the NAEPP (2004) and parts 
of GINA (2015).
5,14
 
 
2.5.1 Impact of pregnancy on asthma 
Among asthmatic pregnant women, approximately one third of the patients suffer 
from worsening of their asthma symptoms, one third experiences some improvements, and 
one third has their asthma symptoms remaining unchanged.
94-96
 In a meta-analysis of 14 
studies, the distribution of changes in asthma symptoms during pregnancy was in 
agreement with the rule of thirds, however in some studies this distribution may be still 
population-dependent.
97
 Importantly, since the course of asthma can change during 
pregnancy, pregnant women need a closer follow up and rapid therapy adjustments to 
achieve optimal control of symptoms.
7,96,98,99
  
It has been shown that more severe asthma is more likely to worsen during 
pregnancy.
4,10,100,101
 The fewest symptoms occur after 37 weeks and nearly 75% of women 
return to their pre-pregnancy status within 3 months after delivery.
102
 Moreover, the change 
in course of asthma tends to be consistent during successive pregnancies and exacerbations 
during delivery are relatively rare.
5,98,102
 Asthma is an extremely variable disease, and a 
number of physiologic changes occur during pregnancy, which could worsen or improve 
asthma.
1,5,102,103
  
During the pregnancy period, the uterus expands and causes elevation of the 
diaphragm by 4-5 centimeters, resulting in a decrease in lung functional residual capacity 
(FRC) of 10%-25%.
104
 This decrease does not usually cause significant changes in the 
forced vital capacity, peak expiratory flow rate, or forced expiratory volume in 1 second 
(FEV1).
104,105
 Minute ventilation (VE) may be elevated as much as 50% by the third 
trimester of pregnancy due to progesterone-driven increases in tidal volume and respiratory 
19 
 
rate.
104
 Concomitantly, oxygen consumption can increase up to 35%.
104,106
 Estrogen 
changes in pregnancy affect the upper respiratory tract and the airway mucosa resulting in 
mucosal edema, hypersecretion and capillary congestion.
104,105
 Differing levels of certain 
circulating hormones in an individual patient during pregnancy may account in part for why 
some patients’ asthma worsens while other patients’ asthma is improved.102,104 
A physiological suppression of the immune system occurs during pregnancy, 
primarily to protect the fetus from the mother when paternally originated antigens are 
expressed.
4
 Several cellular processes arise and both regulatory T cells (Tregs) and natural 
killer (NK) cells appear to play important roles.
4
 It has been shown that regulatory NK cells 
and Tregs inhibit fetal attack of maternal NK and T cells.
4
 A shift towards a T-helper cell 
type 2 (Th2)-predominant inflammatory occurs during pregnancy, with a simultaneous 
Tregs suppression of Th1 cell-induced fetal rejection.
107
 Asthma is also categorized as a 
Th2-predominant inflammatory state.
4
  
Both interleukin-4 (IL- 4) and interferon γ (IFN-γ) synthesizing T lymphocytes 
increase in pregnant women with uncontrolled asthma in comparison to those without 
asthma.
108
 Moreover, pregnant women with asthma had a 20-fold increase in IFN-γ-
producing T cells compared with non-pregnant patients having the same level of asthma 
severity.
102
 These results imply that cellular responses change with the variation in the 
severity and control of asthma (mainly poorly controlled asthma).
102
 They also demonstrate 
the heterogeneous response of the immune system in asthmatic women during pregnancy, 
and partially explain why asthma worsens, improves or remains unchanged during 
pregnancy.
102,105
 
 
2.5.2 Impact of asthma on pregnancy 
The critical effect of asthma during pregnancy on the fetal development is 
demonstrated through the possibility of inducing hypoxia combined with acute or 
compensated respiratory acidosis, besides an acute respiratory alkalosis that decreases the 
placental blood flow, increases systemic and pulmonary vascular resistance, and decreases 
cardiac output.
109,110
 In cases of fetal lack of oxygen, the oxygen extraction rate by fetal 
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tissues increases and could lead to long-term effects of hypoxia as intrauterine growth 
retardation, preterm birth, neonatal hypoxia or perinatal morbidity and mortality.
110-113
  
Pregnancy outcomes of asthmatic women compared to non-asthmatic women were 
examined in several studies, and results have shown increased risks in various adverse 
maternal and fetal outcomes among asthmatic mothers.
2,8-10,99
 The risk of placental and 
maternal complications in pregnancy were examined in a recent meta-analysis.
8
 The 
authors examined the association between maternal asthma and cesarean delivery, 
gestational diabetes, hemorrhage, placenta previa, placental abruption, chorioamnionitis, 
and premature rupture of membranes.
8
 Compared to non-asthmatic women, maternal 
asthma was associated with a significantly increased risk of caesarean section (RR 1.31; 
95% CI 1.22–1.39, I2 = 90.8%), gestational diabetes (RR 1.39; 95% CI 1.17–1.66, I2 = 
88.4%), haemorrhage (antepartum: RR 1.25; 95% CI 1.10–1.42, I2 = 71.3%; postpartum: 
RR 1.29; 95% CI 1.18–1.41, I2 = 39.1%), placenta praevia (RR 1.23; 95% CI 1.07–1.40, I2 
= 0.0%), placental abruption (RR 1.29, 95% CI 1.14–1.47, I2 = 44.8%) and premature 
rupture of membranes (RR 1.21, 95% CI 1.07–1.37, I2 = 74.6%).8 Furthermore, moderate-
to-severe asthma significantly increased the risk of both caesarean section (RR 1.19, 95% 
CI 1.09–1.31, I2 = 0.0%) and gestational diabetes (RR 1.19, 95% CI 1.06–1.33, I2 = 
65.5%), compared with mild asthma.
8
 The limitations of the meta-analysis include: 1) there 
were fewer studies with prospective design, 2) in many studies, asthma was defined by self-
report, 3) there was limited ability to account for the influence of some confounding factors 
such as socioeconomic status, smoking history, preexisting hypertension and BMI because 
this information was not included in most primary studies, and 4) although active 
management assessment was based on author clinical involvement, this does not equate to 
adequate control, limiting the ability to evaluate the potentially important effect of asthma 
control on the outcomes evaluated. 
Preeclampsia was examined in another meta-analysis, which showed a significant 
increased risk of preeclampsia among mothers with asthma (RR 1.54; 95% CI 1.32 - 1.81, 
I
2
 = 80.3%).
99
 Adjustment for various covariates in six studies confirmed the effect of 
asthma on pre-eclampsia, as the adjusted odds of pre-eclampsia remained significantly 
increased in women with asthma compared with women without asthma.
99
 A recently 
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published large population-based study using the Swedish Medical Birth Registry reported 
a significant increased risk of preeclampsia (aOR 1.15; 95% CI 1.06 - 1.24) and caesarean 
section (aOR 1.29; 95% CI 1.23 - 1.34) in pregnancies of asthmatic versus non-asthmatic 
women.
114
 In a recent study conducted by our research group using the Quebec health 
databases, Blais et al. found that the risk of gestational diabetes was not associated with 
asthma severity or control, through comparing severe to mild asthma and uncontrolled to 
controlled asthma. Also, the risk of pregnancy-induced hypertension was not associated 
with asthma severity, but severe asthma was associated with an increased risk of caesarean 
delivery.
115
 As being in the focus of this thesis, a summary of the evidence on maternal 
asthma and the risk of both congenital malformations and other perinatal outcomes are 
presented in the following subsections. 
 
2.5.2.1 Maternal asthma and congenital malformations 
Although it could be difficult to separate the effect of the disease – and its severity 
and control levels – from the effects of asthma medications, the whole body of evidence 
suggest that maternal asthma could significantly increase the risk of several adverse 
perinatal outcomes, including congenital malformations.  A recent systematic review and 
meta-analysis by Murphy et al. examined the risk of congenital malformations, among 
other outcomes, in pregnant women with asthma.
2
 The authors retrieved 16 publications 
and included 12 publications in their pooled meta-analysis. The authors also performed 
several sensitivity analyses separating prospective and retrospective studies and studies 
with and without active management of asthma.
2
 There were four prospective cohort 
studies (all had active asthma management) and eight retrospective cohort studies (none 
had active management). In the primary analysis, asthma was associated with a significant 
increase in the risk of any congenital malformations (RR 1.11, 95% CI 1.02–1.21).2 
Sensitivity analysis showed that the effect was only significant in the retrospective cohort 
studies (without active management, RR 1.12, 95% CI 1.03–1.22), and not in the 
prospective cohort studies (with active asthma management, RR 1.40, 95% CI 0.54–3.59).2 
The power of the prospective studies was considerably low (10% power to detect an RR of 
1.11).
2
 A separate meta-analysis on the adjusted odds ratio from four retrospective studies 
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showed significant increased odds of congenital malformations (aOR 1.18, 95% CI 1.03–
1.35).
2
 
Major malformations were also examined through pooling results from four studies, 
showing increased risk of malformations that did not reach statistical significance (RR 1.31, 
95% CI 0.57–3.02), however, there was significant heterogeneity between studies (I2 = 
70.9%, P < 0.1).
2
 The authors also retrieved results on specific congenital malformations. 
The pooled meta-analysis of two studies demonstrated a significant increased risk of cleft 
lip and/or cleft palate among infants from women with asthma compared with infants from 
women without asthma (RR 1.30, 95% CI 1.01–1.68).2 The limitations of the meta-analysis 
include: 1) there were fewer studies with prospective design, 2) asthma was defined by self-
report in many studies, 3) reporting and recall bias in some studies, 4) the presence of 
significant heterogeneity in some analyses, and 5) the very large sample sizes in some of 
the retrospective studies could have resulted in heterogeneity that is overstated compared 
with traditional meta-analyses. 
Exacerbations are potentially dangerous to the fetus as they can provoke maternal 
hypoxia combined with respiratory alkalosis, which could decrease the placental blood 
flow.
116,117
 Hypoxia could cause abnormal development of the fetus,
118
 and it has been 
found to be associated with an increased risk of cleft lip and palate in mice.
119
 
Exacerbations are common during pregnancy, reaching about 30% among pregnant women 
with severe asthma.
120
 Asthma exacerbations were associated with congenital 
malformations in several studies.
2,117,121-123
 In the meta-analysis by Murphy et al., a separate 
sensitivity analysis combining three studies on the effect of asthma exacerbations revealed 
an increased risk of congenital malformations, but did not reach statistical significance (RR 
1.18, 95% CI 0.94–1.47).2 Another sensitivity analysis on major congenital malformations 
from two studies revealed similar results (RR 1.26, 95% CI 0.95–1.67), with no significant 
heterogeneity between the studies (I
2
 = 0%, P = 0.71).
2
 However, there is a potential 
methodological and clinical heterogeneity that were not examined in the meta-analysis, 
which could have resulted from the variability in the study designs/risk of bias, and the 
variability in the patients’ severity profiles. Moreover, the pooled result was heavily 
affected by the weight of one large study versus the second small one (13117 participants 
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versus 73 participants). In a recent study using the Quebec health databases, Blais et al. 
examined asthma exacerbations in a large representative cohort of 36,587 pregnancies of 
asthmatic women (publicly insured, privately insured and on social welfare assistance) and 
the risk of any and major congenital malformations.
117
 The study showed that only severe 
maternal asthma exacerbations (i.e. requiring hospitalization) during the first trimester are 
associated with a significant increased risk of congenital malformations (aOR 1.64, 95% CI 
1.02–2.64) and a non-significant increased risk of major malformations (aOR 1.70, 95% CI 
0.95–3.02).117 
 
2.5.2.2 Maternal asthma and other perinatal outcomes 
Perinatal outcomes reported to be significantly increased among newborns of 
asthmatic women versus non-asthmatic women include SGA, LBW, preterm delivery, 
transient tachypnea of the newborn, neonatal hypoxia, and neonatal 
hyperbilirubinemia.
7,10,11,99,105
 Furthermore, severe or uncontrolled asthma was associated 
with adverse perinatal outcomes in different observational studies, including perinatal 
mortality, IUGR, preterm birth, LBW.
5,94,117,124
 On the other hand, it has been shown that 
women with well controlled asthma have little or no increased risk of adverse perinatal 
outcomes.
5,94,125,126
 It is worth mentioning that the published evidence has been somehow 
conflicting, where large database studies reporting increased risks, while no significant 
increased risks found in smaller clinical prospective cohort studies.  In general, the 
published studies varied substantially in terms of design and sample size. 
Murphy et al. published a comprehensive systematic review and meta-analysis on 
maternal asthma and the risk of perinatal outcomes.
99
 The outcomes examined included 
LBW, mean birthweight, SGA and preterm delivery.
99
 The authors reviewed the evidence 
between 1975 and 2012 and included very large sample sizes of pregnant women (over 
1,000,000 for LBW and over 250,000 for preterm delivery).
99
 
In the meta-analysis of 11 studies, maternal asthma was associated with a 
significantly increased risk of LBW (defined as a birthweight < 2500 g) compared with 
women without asthma (RR 1.46, 95% CI 1.22 – 1.75).99 In addition, the mean birthweight 
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of newborns of asthmatic mothers was 93 g lower than newborns of control mothers (95% 
CI -160 – -25 g). In a sensitivity analysis, the study design was acknowledged as a potential 
source of heterogeneity, where the prospective studies showing no effect of asthma (n = 3, 
RR 1.07, 95% CI 0.76 – 1.49), and the retrospective studies showing a significant effect (n 
= 8, RR 1.54, 95% CI 1.26 – 1.87).99 These results were further confirmed in the active 
management sensitivity analysis (active management; RR 1.55, 95% CI 0.69 – 3.46, no 
active management; RR 1.50, 95% CI 1.23 – 1.82).99 
In the same meta-analysis by Murphy et al., asthma was associated with a 
significant increased risk of SGA (11 studies: RR 1.22, 95% CI 1.14–1.31).99 In the 
sensitivity analysis by study design, results obtained from retrospective and prospective 
studies were similar, and analysis of two studies adjusting for confounding factors showed 
a similar effect size of asthma on SGA (aOR 1.21, 95% CI 1.10 – 1.34).99 Maternal asthma 
was associated as well with a significant increased risk of preterm delivery – defined as 
delivery prior to 37 weeks of gestation – (RR 1.41, 95% CI 1.23–1.62). Sensitivity analysis 
on confounding factors revealed similar results (4 studies: aOR 1.38, 95% CI 1.24 – 1.53). 
Sensitivity analysis on the presence or absence of active management revealed that a 
significant effect is present only among studies with no active management of asthma (RR 
1.50, 95% CI 1.28 – 1.75).99 Moreover, asthma was also associated with an increased risk 
of preterm labour – defined as premature uterine contractions prior to 37 weeks of gestation 
– (RR 1.71, 95% CI 1.14–2.57).99 
It is worth noting that the majority of asthmatic women included in that systematic 
review had asthma of mild severity, and consequently the effect sizes of the observed risks 
could be larger in other subgroups of asthmatic women, such as moderate and severe 
asthma, uncontrolled asthma, and asthmatic women experiencing exacerbations during 
pregnancy. In fact, several studies have reported increased perinatal risks with the increase 
in asthma severity or the decrease in asthma control.
4,117,127
 
In the recent study by Rejno et al. using the Swedish National Birth Registry, the 
authors examined the associations between maternal asthma and several birth and post-
partum outcomes, namely birth weight, gestational age, SGA, large for gestational age 
(LGA), Apgar at 5 minutes, and asphyxia/hypoxia.
114
 The authors adjusted for several 
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maternal confounding characteristics and examined the separate effects of both asthma 
severity and asthma control.
114
 The study found a significant association between asthma 
and birth weight of 2000-3499 grams (30 % increased odds) as compared to ≥3500 grams, 
and SGA (OR 1.23, 95% CI 1.13–1.33).114 Regarding asthma severity, compared to mild 
maternal asthma, moderate to severe maternal asthma was associated with an increased risk 
of SGA (OR 1.71, 95% CI 1.34–2.17) and birth weight 2000-3499 grams compared to 
≥3500 grams. Uncontrolled asthma was associated with a significant increased risk of 
giving birth in week 37–38 (OR 1.29, 95% CI 1.07–1.56) among women with moderate to 
severe asthma but not among those with mild asthma.
114
 
Several mechanisms were postulated to explain the observed increased perinatal 
risks among pregnant asthmatic women as demonstrated in different studies, including: 1) 
hypoxia and other physiologic consequences of poorly controlled asthma; 2) medications 
used for asthma treatment; and 3) other factors associated with asthma but not caused by 
the disease or the treatments (e.g. abnormal placental function).
99,102,105
 
 
2.5.2.3 Pharmacologic treatment of asthma during pregnancy 
The GINA 2015 guidelines states that: “[…] Although there is a general concern 
about any medication use in pregnancy, the advantages of actively treating asthma in 
pregnancy markedly outweigh any potential risks of usual controller and reliever 
medications”.14 Consequently, the use of asthma medications is justified even when their 
safety has not been clearly proven. The GINA guidelines propose a strategy where the 
treatments are recommended based on the lowest effective dose that provides adequate 
control of asthma symptoms.
14
 Similarly, the US NAEPP guidelines for the management of 
asthma during pregnancy (published on 2005) states that it is safer for the pregnant mothers 
to be treated with asthma medications than to have asthma symptoms or exacerbations.
5
 
According to the US NAEPP guidelines for managing asthma during pregnancy, 
asthma control is defined as minimizing asthma symptoms during the day or night, 
minimizing asthma exacerbations, achieving no limitations on daily activities, maintenance 
of normal pulmonary function, minimal use of SABA, and minimizing the medications side 
effects.
5
 Differences exist in the treatment steps between asthmatic pregnant and non-
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pregnant women, obviously for the fact that among pregnant women the treatments should 
maintain control of asthma symptoms not only for the health and quality of life of the 
patient, but also to maintain a healthy fetal growth throughout the gestation period.
5,74
 In 
the NAEPP guidelines, the stepwise approach for the pregnant women is ordered into 4 
steps, instead of 6 steps for the non-pregnant patients (see Figure 2.3.1 and Table 2.5). 
5,74
 
Other differences are: 1) the use of zileuton in steps 3 and 4 (moderate persistent asthma) 
among non-pregnant patients, 2) use of omalizumab for patients who have allergies in steps 
5 and 6 (severe persistent asthma) among non-pregnant patients, and 3) the 
recommendations for making repeated attempts to reduce systemic corticosteroid levels in 
pregnant patients suffering from severe persistent asthma (step 4) (see Figure 2.3.1 and 
Table 2.5).
5,74
   
The US NAEPP guidelines for managing asthma during pregnancy classified the 
severity of asthma into 4 categories: 1) mild intermittent, 2) mild persistent, 3) moderate 
persistent, and 4) severe persistent (similar to adult non-pregnant asthmatics, Table 2.3.1). 
5
 
With the purpose of achieving the desired control of asthma symptoms, physicians use the 
stepwise approach to manage asthma during pregnancy (see Table 2.5).
5
 For example, in 
the case of mild intermittent asthma, a SABA is used as needed to control asthma 
symptoms, which is typically sufficient for this level of severity. If the patient’s symptoms 
are relieved and pulmonary functions normalized, SABA should be continued only as 
needed for no more than twice per week.
5
 SABA are also prescribed for patients 
experiencing exercise-induced bronchospasm, shortly before exercise.
5,74
 Salbutamol (also 
referred to as albuterol) is the preferred SABA due to its safety profile. Indeed, salbutamol 
is one of the most studied asthma medications with an ample quantity of efficacy and safety 
evidence during pregnancy.
5,14
 SABA are used as well in persistent asthma as quick relief 
medications.
5
 However, the use of SABA more than 2 times per week in intermittent 
asthma is an indicator of uncontrolled asthma, which may require initiating or increasing a 
controller therapy.
5,14
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Table 2.5 Stepwise Approach for Managing Asthma during pregnancy and lactation: 
Treatment 
Classify Severity: Clinical 
Features Before Treatment or 
Adequate Control 
Medications Required to Maintain Long-Term 
Control 
Symptoms/Day 
--------------------- 
Symptoms/Night 
PEF or FEV1 
---------------- 
PEF 
Variability 
Daily Medications 
 
Step 4 Severe Persistent 
Continuous 
-------------- 
Frequent 
<60% 
------------- 
>30% 
Preferred treatment: 
- High-dose inhaled corticosteroid 
AND 
- Long-acting inhaled beta2-agonist 
AND, if needed, 
- Corticosteroid tablets or syrup long term (2 
mg/kg per day, generally not to exceed 60 mg 
per day) (Make repeat attempts to reduce 
systemic corticosteroid and maintain control 
with high-dose inhaled corticosteroid.*) 
Alternative treatment: 
- High-dose inhaled corticosteroid* 
AND 
- Sustained release theophylline to serum 
concentration of 5–12 micrograms/mL 
Step 3 Moderate Persistent 
Daily 
------------------ 
>1 night/week 
>60%-<80% 
------------ 
>30% 
Preferred treatment:  
EITHER 
- Low-dose inhaled corticosteroid* and long-
acting inhaled beta2-agonist 
OR 
- Medium-dose inhaled corticosteroid* 
If needed (particularly in patients with recurring 
severe exacerbations): 
- Medium-dose inhaled corticosteroid* and 
long-acting inhaled beta2-agonist. 
Alternative treatment:  
- Low-dose inhaled corticosteroid* and either 
theophylline or leukotriene receptor 
antagonist** 
If needed: 
- Medium-dose inhaled corticosteroid* and 
either theophylline or leukotriene receptor 
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antagonist** 
Step 2 Mild Persistent 
>2 days/week but 
<daily 
----------------- 
>2 nights/month 
>80% 
------------- 
20 to 30% 
Preferred treatment:  
- Low-dose inhaled corticosteroid* 
Alternative treatment (listed alphabetically): 
cromolyn, leukotriene receptor antagonist**  
OR sustained-release theophylline to serum 
concentration of 5–12 micrograms/mL. 
Step 1 Mild Intermittent 
<2 days/week 
----------------- 
<2 nights/month 
>80% 
----------- 
<20% 
No daily medication needed.  
Severe exacerbations may occur, separated by long 
periods of normal lung function and no 
symptoms. A course of systemic corticosteroid 
is recommended. 
Quick Relief All Patients 
Short-acting bronchodilator: 2-4 puffs short-acting inhaled beta2-agonist*** as needed 
for symptoms  
Intensity of treatment will depend on severity of exacerbation; up to 3 treatments at 20-
minute intervals or a single nebulizer treatment as needed. Course of systemic 
corticosteroid may be needed.  
Use of short-acting inhaled beta2-agonist*** >2 times a week in intermittent asthma 
(daily, or increasing use in persistent asthma) may indicate the need to initiate 
(increase) long-term-control therapy. 
 
 
Step Down  
Review treatment every 1 to 6 months; a gradual stepwise reduction in treatment may be 
possible.  
Step up  
If control is not maintained, consider step up. First, review patient medication technique, 
adherence, and environmental control.  
Goals of Therapy: Asthma Control 
Minimal or no chronic symptoms day or night  
Minimal or no exacerbations  
No limitations on activities; no school/work missed  
Maintain (near) normal pulmonary function  
Minimal use of short-acting inhaled beta2- agonist***  
Minimal or no adverse effects from medications 
* There are more data on using budesonide during pregnancy than on using other inhaled 
corticosteroids. 
** There are minimal data on using leukotriene receptor antagonists in humans during 
pregnancy, although there are reassuring animal data submitted to FDA. 
*** There are more data on using albuterol during pregnancy than on using other short-
acting inhaled beta2-agonists. 
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Source: National Asthma Education and Prevention Program. Managing asthma during 
pregnancy: recommendations for pharmacologic treatment; National Heart, Lung, and 
Blood Institute; 2005  
 
 
SABA use in the management of asthma during pregnancy is widely endorsed due 
to the known selectivity of beta2-agonists and their minimal systemic effects when 
inhaled.
5,14,24
 Besides, SABA have a crucial role in the management of acute exacerbations 
during pregnancy, both home and hospital/clinic managed.
14,74
 For the home management, 
a salbutamol inhaler is recommended and in the hospital or clinic management, salbutamol 
is usually given through a nebulizer. 
14
  
For persistent asthma management, ICS are the cornerstone therapy in the 
management of all types of persistent asthma during pregnancy. LABA are used in cases of 
moderate and severe persistent asthma (Table 2.5), in combination with low or medium 
dose inhaled corticosteroids. The choice between salmeterol and formoterol is not 
supported with sufficient data, so salmeterol is relatively preferred as it has been available 
in the markets for longer periods. 
5
  
LABA have been introduced in the 1990s as a major therapeutic development in the 
management of asthma.
128
 LABA are used for patients with moderate and severe persistent 
asthma not fully controlled with inhaled corticosteroids alone. According to the guidelines 
of asthma management during pregnancy, there is only limited observational data on the 
use of LABA during pregnancy. 
5
 However, since the publication of the NAEPP guidelines, 
there has been several new studies investigating the maternal and fetal safety of LABA 
during pregnancy, which we will discuss in thorough details in the following sections 
(subsection 2.6.1.2 and 5.1).
7,129
 Both salmeterol and formoterol are available in the 
markets in separate forms or in combinations with ICS. In animal models, both salmeterol 
and formoterol have shown fetal risks, with delayed fetal ossification and other adverse 
outcomes at high doses.
130
  
The associations between ICS maternal use and perinatal outcomes were examined 
in several studies.
2,129,131
 As being in the center of this thesis, we will present the summary 
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of the evidence on ICS and major malformations in a separate detailed subsection below. 
The other adverse perinatal outcomes associated with ICS maternal use were summarized 
in a few systematic reviews, the most comprehensive is by Breton et al..
129,131
 Breton et al. 
reviewed 14 studies examining ICS and different perinatal outcomes (the latest study was 
published in 2007 and 6 more studies were published since that date [discussed below]).
131
 
Significant associations between ICS use during pregnancy and mean birth weight were 
found in two cohort studies. 
132,133
 In a study by Murphy et al. an increased mean birth 
weight in female newborns was observed compared with the babies of asthmatic women 
who did not use ICS.
132
 Norjavaara and de Verdier reported a significant effect of ICS use 
on the mean birth weight among 1409 girls and 1559 boys compared to all girls and boys 
born in Sweden between 1995 and 1998.
133
 No studies reported significant associations 
between ICS use during pregnancy and low birth weight. Regarding preterm delivery, only 
Perlow et al. reported a significant association between the risk of preterm delivery and ICS 
use during pregnancy.
40
 Preterm delivery occurred significantly more often in women who 
used an ICS compared with women without asthma (cOR 4.0; 95% IC, 1.1–15.5).40 No 
significant increased risk of either stillbirth or perinatal mortality among pregnant women 
using ICS was observed.
131
 It is worth mentioning that this review identified only nine 
studies using a control group of women with asthma not using ICS during pregnancy 
(which could be considered the most appropriate control group). 
More recently, a cohort study by our group examined the relationship between 
asthma controllers and preterm delivery, LBW and SGA.
134
 Among the 7376 included 
pregnancies, 56.9% were exposed to ICS. Adjusted odds ratio revealed no increased risk of 
preterm delivery, LBW or SGA with ICS use at any dose (low: >0–62.5, >62.5–125, >125–
250; moderate: >250–500; and high doses: >500 mcg/day of fluticasone equivalent).134 Due 
to the presence of a trend of increased risk of some outcomes with ICS doses above 125 
mcg/day (where confounding by asthma severity could have played a role), further 
evidence is needed to explain this trend. 
134
 It is difficult to establish whether any of the 
observed adverse events in the previously mentioned studies were attributable to the 
medications or the effect of uncontrolled asthma. Among the suggested effective ways to 
tackle this type of bias is to perform a study where two medications that have similar 
indications can be examined to compare their relative safety.  
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Very few comparative studies of ICS medications during pregnancy have been 
published. Dombrowski et al. found fewer hospital admissions for the triamcinolone group 
compared to those treated with beclomethasone and a lower trend for low-birthweight 
infants.
45
 Bakhireva et al. found no significant differences in SGA or mean birth weight 
between users of beclomethasone, budesonide, or fluticasone and control groups of non-
asthmatic patients and users of SABA.
44
 Namazy et al. found no significant differences in 
the prevalence of SGA or mean birth weight between users of beclomethasone, budesonide, 
or fluticasone.
135
 Importantly, these studies had limited sample sizes. Clifton et al. reported 
a significant reduction in birth weight and length centile in users of the fluticasone-
salmeterol combination compared with budesonide but no significant difference when 
fluticasone was compared with budesonide.
136
 In a recent large cohort study published by 
our group, Cossette et al. found no statistically significant differences in the prevalence of 
LBW, preterm delivery, and SGA between women exposed to fluticasone (n=3190) and 
those exposed to budesonide (n=608) during pregnancy.
137
  This lack of difference suggests 
that upon becoming pregnant, women with well-controlled asthma before pregnancy do not 
have to consider switching to another ICS.
137
 
The maternal use of SABA and LABA and the associated risks of adverse perinatal 
outcomes were examined in several studies.
102,129,131
 In the first part of this thesis, we 
present a systematic review that summarizes the body of evidence on the impact of the use 
of inhaled SABA and LABA for the treatment of asthma during pregnancy on several 
perinatal outcomes, which are major and any congenital malformations, SGA, birth weight, 
LBW, gestational age and preterm delivery. As being part of the focus of this thesis, SABA 
and LABA use and the risk of major malformations will be elaborated in detail in the 
subsection 2.6.1. Major – and not any or all – malformations were chosen as the primary 
outcome in this thesis for two reasons: 1) major malformations are more relevant to our 
objectives – compared to minor malformations – as they represent the more severe and life-
threatening cases, and 2) the likelihood of misclassifications is greater for minor versus 
major malformations. 
Under-treatment is a major concern in the management of asthma during pregnancy. 
It is considered one of the most important causes of uncontrolled asthma during pregnancy, 
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leading to an increased risk of adverse maternal and perinatal outcomes through the 
potential increase in asthma exacerbations. 
5,14
 For the most part, under-treatment is caused 
by the non-adherence of asthmatic pregnant women to their asthma controller medications 
due to their fears of a potential harm to their fetus.
94
 In a study using maternal interviews, 
one of the important reasons for non-adherence was the concern about medication use, 
specifically corticosteroids, which surpassed the concern of the potential risk of 
uncontrolled asthma.
94
 Therefore, asthma education is a key component in the management 
asthma during pregnancy, particularly regarding the adverse effects of uncontrolled asthma 
on the newborn and other self-management strategies such as how to handle new or 
increased asthma symptoms. 
5,14
 
In an online survey among pregnant women 18 to 44 years old about asthma 
treatments, 39 % reported having discontinued or reduced it, and a third of them did so 
without their physician consultation.
138
 Another study showed that among women who 
used asthma medications prior to pregnancy, SABA claims were reduced by 52% during 
pregnancy and ICS by 36%.
139
  Corroborating these results, in a study published by our 
group using administrative health databases from Quebec, we found that nearly 50% of 
asthmatic women discontinued or reduced their use of ICS during pregnancy as compared 
to the dose taken prior to pregnancy.
101
 These behaviors put the asthmatic pregnant women 
at risk of exacerbations and inadequate control during pregnancy. 
Data from the Netherlands between 2004 and 2009 showed a significant decrease in 
the filled prescriptions for asthma during the first trimester compared to 3 months prior to 
pregnancy.
140
 In particular, prescriptions filled for long-acting bronchodilators and 
combination therapies (38.2% of pregnancies with 3 prescriptions in the year prior to 
pregnancy did not use any asthma medication during the first trimester).
140
 In another 
study, there was a prescriptions decline of 23% in ICS, 13% in SABA and 54% in oral 
corticosteroids during the first trimester.
141
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2.6 Asthma treatments and major congenital malformations 
2.6.1 Beta2-agonists and major congenital malformations 
In the first part of this thesis, we present a systematic review (full manuscript in 
chapter 5, section 5.1) in which we aimed to summarize the existing human data on the 
impact of the use of inhaled SABA and LABA for the treatment of asthma during 
pregnancy on several perinatal outcomes, including major congenital malformations. The 
latest search for publications in that systematic review was performed on January 1, 2013. 
For the current chapter of the thesis, we updated our search for additional articles published 
since that date and until April 1, 2016. In this section (2.6.1) and in Table 2.6.A below we 
present the whole body of literature with no cut-off date until April 1, 2016.  
We identified 15 studies that examined the association between the maternal 
exposure to beta2-agonists and major congenital malformations (see Table 2.6.A). 
24-
30,35,36,38,43,44,51,142,143
 Among those, eight examined beta2-agonists as a group (SABA and/or 
LABA use),
25,26,35,36,43,44,142,143
 eleven examined SABA separately,
24-30,38,51,142,143
 and eight 
examined LABA separately.
25,27-30,51,142,143
  
A major factor affecting the validity of the results in those studies is the type of the 
reference group. Using non-asthmatics as a reference group carries a potential risk to the 
study validity. As previously discussed in the sections above, asthma itself and its 
accompanying symptoms have been identified as significant risk factors for several 
perinatal outcomes, including congenital malformations. Therefore, confounding by 
indication (i.e. asthma itself) should be highlighted when interpreting the results of the 
identified studies. Therefore, better conclusions could always be withdrawn from studies 
comparing beta2-agonists users against asthmatic non-users, as this comparison could more 
easily separate the effect of the medications from the disease itself. Importantly as well is 
the bias due to confounding by severity (i.e. the severity of asthma symptoms and 
exacerbations) which should be also taken into consideration. The reason is that this bias 
could affect all types of studies, even the ones that used a comparison group of asthmatics 
non-users. 
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2.6.1.1 Short acting beta2-agonists and major congenital 
malformations 
The following section summarizes the whole body of evidence on SABA use and 
major congenital malformations, partially presented in the systematic review (in chapter 5) 
and updated here until April 1, 2016. From the eleven studies that examined SABA 
separately from LABA, six were cohort studies and five were case-control studies (Table 
2.6.A). The sample sizes varied between studies, ranging between 50 to over 35000 
exposed pregnancies. In general, the number of exposed pregnancies were larger in the 
cohort studies. Only three studies used a reference group of asthmatic non-users.
24,27,30
 
Schatz et al. examined the safety of the maternal exposure to any SABA during pregnancy 
in relation to fetal development.
24
 Major and minor congenital malformations, among other 
perinatal outcomes, were reported separately for anytime use during pregnancy and during 
the 1
st
 trimester. Adjustment for asthma severity was based on medication requirement, and 
the use of other asthma medications. The authors also adjusted for smoking as a potential 
confounder and the analyzed data were prospectively gathered. Anytime and first trimester 
use of SABA during pregnancy were associated with a cOR of 0.65 and 0.74 respectively 
(p-value > 0.05 for both). 
24
 The study suffered some limitations, specifically the small 
sample sizes (9.7% power to detect the observed cOR of 0.74 in the 1
st
 trimester) and using 
a medication requirement scale (that classify the asthma severity based only on the 
medications used and no other factors, such as asthma exacerbations) to adjust for the 
asthma severity which could be incomplete since other important factors better indicate the 
severity level, such as asthma exacerbations and hospitalizations for asthma. The authors 
concluded that SABA use is warranted but needs additional safety assessments. 
24
  
In a matched case-control study using the Health Improvement Network primary 
care database (THIN) in the United Kingdom, Tata et al. examined the risk of major 
malformations with maternal SABA use, both anytime during pregnancy and only during 
the 1
st
 trimester.
27
 The reference group was formed of pregnant asthmatic women not 
exposed to SABA. Adjusted odds ratios of 1.06 (95% IC, 0.94–1.19) with anytime during 
pregnancy and 1.01 (95% IC, 0.86–1.18) in the 1st trimester SABA use were reported. 27 
The authors adjusted for several important potential confounders, including maternal 
35 
 
smoking, body mass index, socioeconomic status, maternal age and child sex, but did not 
adjust for maternal asthma severity nor asthma control.  
The third study that used asthmatics non-users of SABA as a reference group is a 
large cohort study published earlier by our group.
30
 The study comprised data from three 
health administrative databases from Quebec and examined SABA use during the first 
trimester, both as any exposure and as dose-per-week analyses (non-use: reference 
category, > 0 to 3 doses, > 3 to 10 doses, and > 10 doses per week). 
30
 Adjustments were 
performed for socio-demographic variables, maternal and fetal conditions and markers of 
asthma severity and control. SABA use in the 1
st
 trimester was not found to be associated 
with an increased risk of major malformations (aOR 0.93; 95% CI, 0.80-1.08). Moreover, 
the analysis on SABA doses-per-week revealed no association with major and major 
system-specific malformations. 
30
 A remarkable strength in this study is its sample size, 
which included 7182 SABA users offering an 80% power to detect an aOR of 1.2. Other 
strengths include adjustment for asthma severity and control levels and avoidance of recall 
bias. The study limitations include the absence of medications dispensing data from 
hospitals, possible misclassification of SABA doses and the possibility of residual 
confounding due to incapacity to adjust for known risk factors, like maternal obesity and 
smoking. 
We identified eight studies that used a reference group of non-asthmatic pregnant 
women or a mixed population of asthmatic and non-asthmatic women. 
25,26,28,29,38,51,142,143
 
Kallen and Olausson used the Swedish Medical Birth Register in a cohort study and 
reported an increased risk of cardiovascular defects with salbutamol use (aOR=1.38, 95% 
CI=1.12-1.70), while no significant increased risk was found with terbutaline use 
(aOR=1.08, 95% CI=0.94-1.23).
51
 In a recent report using a larger sample from the same 
database, Kallen reported a significant increased risk of both major malformations (aOR 
1.10, 95% CI 1.04-1.10) and major cardiac malformations (aOR 1.17, 95% CI 1.07-1.29) 
with any SABA use in the 1
st
 trimester.
28
 However, both studies have used the general 
population as the reference group, which included non-asthmatic women. The authors as 
well did not exclude the possibility of the presence of a potential confounding by 
indication, which could explain the observed associations.
28,51
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In a series of case-control reports conducted by the National Birth Defects 
Prevention Study (NBDPS) in the US, some associations were observed between SABA 
use and major congenital malformations. 
25,142,143
  Munsie et al. reported a significant 
increased risk of separate cleft lip and cleft palate with aOR 1.79, 95% CI 1.07-2.99 and 
aOR 1.65, 95% CI 1.06-2.58, respectively.
143
 Lin et al. reported cOR of 1.62 (calculated 
using provided data in the study) for the risk of gastroschisis, a major para-umbilical 
abdominal wall defect, with salbutamol and/or pirbuterol use.
25
 Lin et al. also reported 
similar associations with major isolated selected defects in another study (see footnotes, 
Table 2.6.A).
142
 However, there are major methodologic limitations in all of the NBDPS 
studies, namely: 1) the reference group contained non-asthmatic women, 2) potential recall 
bias as the interviews were completed 6 weeks to 2 years after the delivery and mothers of 
affected children may be more likely to report their exposures than mothers of controls, 3) 
not considering the frequency of the medication use or dose, 4) the inaccurate reporting of 
exposure time during pregnancy, and 5) possibility of selection bias as the response rates 
were consistently low. Given these major limitations, it is difficult to draw conclusions 
from those results. Two more studies reported no significant increased risks of major 
malformations, but have used only non-asthmatic pregnant women as the reference group 
which represents a major methodologic limitation.
29,38
 
In summary, the evidence on maternal SABA use, and salbutamol in particular, 
have demonstrated adequate fetal safety results in several well designed cohort and case-
control studies, which warrant their safe use for the management of asthma during 
pregnancy. 
 
2.6.1.2 Long acting beta2-agonists and major congenital 
malformations 
The following section summarizes the whole body of evidence on LABA use and 
major congenital malformations, partially presented in the systematic review (in chapter 5) 
and updated here until April 1, 2016. We identified eight studies in the literature that 
examined the association between the maternal use of LABA and the risk of major 
congenital malformations (Table 2.6.A). 
25,27-30,51,142,143
  The number of exposed 
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pregnancies exceeded 100 in only three studies.
28-30
 Four were cohort studies and four were 
case-control studies (Table 2.6.A). Only two of them used a reference group of asthmatic 
pregnant women in order to separate the effect of LABA from asthma disease itself,
27,30
 
among which one has found significant increased risk of major specific malformations.
30
 
A cohort study published by our group examined all major and specific major 
malformations with LABA use during the 1
st
 trimester.
30
 An increased risk of major 
malformations was observed, though it did not reach statistical significance (aOR 1.31, 
95% CI 0.74-2.31).
30
 Moreover, Significant increased risks of major cardiac and major 
other and unspecified malformations were observed (aOR 2.38, 95% CI 1.11-5.10 and aOR 
3.97, 95% CI 1.29-12.20 respectively).
30
 However, the numbers of the exposed group and 
cases identified were small and there is a possibility of residual confounding due to the 
insufficient control for asthma severity and control levels. Also using a reference group of 
asthmatic pregnant non-users women, Tata et al. in a matched case-control study reported 
an aOR of 1.12 (95% CI 0.72-1.75) with the use of any LABA anytime during pregnancy 
and an aOR of 1.09 (95% CI 0.62-1.90) with the 1
st
 trimester use.
27
 However the study 
sample size was considerably low, preventing the inferring of solid conclusions. 
27
  
We identified six studies that examined LABA and major malformations while 
using a reference group of non-asthmatic pregnant women or a mixed population of 
asthmatic and non-asthmatic women. 
25,28,29,51,142,143
 Kallen and Olausson, using the 
Swedish Medical Birth Register, reported a nonsignificant increased risk of cardiovascular 
defects with salmeterol use (aOR=1.34, 95% CI=0.96-1.88) and formoterol use (aOR=1.07, 
95% CI=0.63-1.82).
51
 In a more recent report using the same registry, Kallen reported an 
aOR=1.08, 95% CI=0.96-1.22 for all major malformations and aOR=1.12, 95% CI=0.92-
1.36 for major cardiovascular malformations.
28
 However as mentioned earlier, both studies 
used the general population as the reference group. Vasilakis-Scaramozza et al. in a cohort 
study using the General Practice Research Database (GPRD) reported a cOR of 0.80, 95% 
CI=0.40-1.50 with any LABA use during the first trimester and using non-asthmatic 
pregnant women as a reference group.
29
 
In the series of case-control reports from the NBDPS, Lin et al reported 
nonsignificant cORs of 1.33 and 1.97 for selected major malformations and all major 
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malformations respectively in two studies.
25,142
 However, the studies suffered some major 
limitations as mentioned earlier, which included the major weakness of using non-asthmatic 
women in the reference group. 
In summary, smaller body of evidence exists on LABA use during pregnancy with 
some evidence of specific congenital malformations increased risk. However, this risk 
might be attributable to the severity of asthma. In several studies we reviewed, 
methodologic limitations were common and the negative results obtained with low 
statistical power should be interpreted with caution as not to give a false impression of 
safety. 
 
2.6.1.3 SABA & LABA and major congenital malformations 
Examining the fetal safety of SABA and LABA combined as one group (i.e. any 
beta2-agonist use) may not be as informative and conclusive as separating each class by 
itself, mainly due to the unique nature of each class and their different indications. 
However, some safety results could be obtained which we will cover in this subsection. 
We identified eight studies – two cohort and six case-control studies – that 
examined the association between the maternal use of any beta2-agonist and the risk of 
major malformations (Table 2.6.A).
25,26,35,36,43,44,142,143
 The sample sizes of the identified 
studies were modest, except for one large cohort study.
43
 Only two studies used a reference 
group of asthmatic pregnant women to separate the effect of SABA and LABA from 
asthma itself, and neither of them has found a significant association.
43,44
  Bakhireva et al. 
examined the association between the maternal use of any beta2-agonist anytime during 
pregnancy and perinatal outcomes, including major malformations in a prospective cohort 
study.
44
 Comparing beta2-agonists users against asthmatic ICS users, the authors didn’t find 
any increased risk of malformations (calculated cRR = 0.95).
44
  When compared against 
non-asthmatic pregnant women, the result was a staggering cRR = 13.0, which highlights 
the importance of using the appropriate reference group, in this case asthmatic women non 
users of ICS.
44
  The prospective design limited the possibility of selection and recall bias 
and only 5% of the participants were lost to follow-up. However, self-reporting of the 
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maternal medication use (using telephone interviews conducted at enrollment, during 
pregnancy and 4 to 6 weeks after delivery) is considered a limitation, since maternal recall 
of medications use (frequency and doses) might not be highly accurate, leading to non-
differential misclassification that underestimates the medications effect. Additionally, 
maternal exposures to SABA and LABA measured anytime during pregnancy (and not in 
the first trimester only, which is the most susceptible period for a teratogenic effect) can 
underestimate the effect of the exposure on major malformations. Schatz et al. examined 
the association between beta2-agonists use anytime during pregnancy and adverse perinatal 
outcomes including major congenital malformations.
43
 The authors reported a cRR of 1.0 
with beta2-agonists use compared to asthmatic non-users.
43
  In both studies, the exposure 
timing (entire pregnancy) and combining SABA or LABA exposure prevents drawing solid 
conclusions. 
The remaining six studies that examined the association between beta2-agonists and major 
malformations used a reference group that includes non-asthmatic women, and all have 
shown significant increased risk of major congenital malformations (Table 2.6.A). 
25,26,35,36,142,143
 As previously discussed, these results are potentially confounded by the 
effect of asthma itself and asthma severity and control levels.  
Garne et al. used the EUROmediCAT database to examine asthma medications 
effect in a case-malformed control study.
35
 The authors reviewed the previously published 
studies and gathered the major malformations “signals” (i.e. significant associations) 
reported in those studies with maternal asthma medications use. Afterward, the authors 
conducted separate analysis on each association using their own data to either confirm or 
refute it. With any beta2-agonist use (which comprised over 80% SABA users) significant 
increased risks of any major malformations, gastroschisis and cleft palate were observed 
(Table 2.6.A).
35
 The authors concluded the study with an inaccurate and worrisome 
interpretation for beta2-agonists use during pregnancy, ignoring the fact that the major 
limitation of the study is its reference group which was formed of asthmatics and non-
asthmatics non users. We have discussed the major weaknesses of this study in a 
correspondence which was published in the same issue of the journal. We have included the 
correspondence in Chapter 5: Results.  
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Briefly, disentangling the effect of the medication from the disease is a challenging 
task that has to be appropriately addressed in both the design and the analysis of the study. 
Including non-asthmatic women in the reference group could have potentially 
overestimated the effect of the asthma medications. In the study by Garne et al., 
35
 53% of 
asthmatic women treated with beta2-agonists (86% using salbutamol) had no controller 
medications and were likely having undertreated uncontrolled asthma. Uncontrolled asthma 
itself, as discussed earlier, is associated with an increased risk of congenital 
malformations.
14
 Due to this confounding by indication, an increased prevalence of 
malformations was found in the β2-agonists group – corroborating results from previous 
case-control studies using similar reference groups. 
25,26,143
 SABA (salbutamol in particular) 
have shown fetal safety in several well designed cohort and case-control studies. The 
authors did not report the maternal characteristics of the women in the study (e.g. age, 
comorbidities, asthma exacerbations), which prevented the assessment of the comparability 
of the study groups. Other limitations include the lack of adjustment for important 
confounders such as socioeconomic status and asthma exacerbations, combining SABA and 
LABA under one exposure category, and multiple comparisons. 
In a series of five case-control studies from the NBDPS, beta2-agonists use 1 month 
prior to conception and during the 1
st
 trimester was shown to be associated with significant 
increased risks of anomalous pulmonary venous return
36
, esophageal atresia
142
, cleft lip 
(without cleft palate)
143
, major cardiac malformations
26
 and gastroschisis.
25
 As discussed 
earlier, these studies suffered major limitations that could have potentially affected the 
validity of the results, which included the key weakness of using non-asthmatic women in 
the reference group. 
In summary, SABA and LABA combined as one group have shown some 
associations with major malformations, specifically in studies using non-asthmatic women 
in the reference group. The studies reviewed suffered major methodologic limitations as 
well. The results are neither informative nor conclusive as compared to separating each 
class by itself, due to the major differences in their indications for asthma management.  
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2.6.2 Inhaled corticosteroids and major congenital malformations 
We identified - through our systematic search and review of the literature – thirteen 
published studies that examined the association between the maternal use of ICS during 
pregnancy and the risk of major congenital malformations, which we summarize in Table 
2.6.B. 
21,28,29,32-35,37,38,42-44,49
 Eleven of which were cohort studies and two case-control 
studies (see Table 2.6.B). We have identified few reviews as well, but could not locate any 
meta-analysis of the published results. The systematic review and meta-analysis discussed 
earlier by Murphy et al. did not examine ICS use and major malformations, but rather 
examined any congenital malformations as an outcome.
2
 Through aggregating results from 
3 studies, any ICS use was not found to be associated with an increased risk of any 
malformations (RR 0.96; 95% CI 0.89-1.04).
2
 
Among the thirteen studies located, six studies used a reference group of asthmatic 
women, which is a major step in separating the effect of the medications from the disease 
itself. 
33,34,42-44,49
   None of the six studies reported a significant association with ICS use 
(Table 2.6.B). The sample sizes of the studies were moderate to large, ranging between 150 
and 1500 exposed pregnancies. 
Charlton et al. in a recent cohort study used the GPRD database to examine the fetal 
safety of fluticasone.
33
  Using a reference group of asthmatic pregnant women who used 
other ICS and stratifying the groups based on their asthma severity, the authors did not find 
a significant increased risk of major malformations with fluticasone use (aOR 1.10; 95% CI 
0.50-2.30 among moderate asthmatics and aOR 1.20; 95% CI 0.70-2.00 among women 
with considerable to severe asthma).
33
 The authors were able to adjust for important 
confounders, including alcohol consumption, smoking status, socioeconomic status, oral 
corticosteroid use and body mass index (BMI). A limitation in the study is that its objective 
was examining the fetal safety of fluticasone compared to other ICS, so that it became 
impossible to assess if there was a class effect for ICS. Another key weakness in the GPRD 
database is that the medication exposure data is based on the prescription issued, with no 
knowledge on either if it was dispensed or used. Additionally, a change in asthma severity 
cannot be captured in the database. Specifically, for pregnant women who had a change in 
their asthma severity and who did not see a physician to give them new prescriptions, such 
42 
 
change in asthma severity and control will not be captured in the database. There was also a 
possibility of residual confounding by asthma severity due to incomplete adjustment of 
severity levels.  
In two studies conducted by our group using Quebec health administrative 
databases, Blais et al. examined ICS use during the first trimester and the risk of major 
congenital malformations.
34,49
 The first study was a two-stage sampling study that allowed 
for the adjustment for important potential confounders collected through the mothers’ 
medical charts, which included smoking status (0, 1–20, >21 cigarettes per day), alcohol 
use, illicit drug use, intake of multivitamins, intake of folic acid and exposure to 
irradiations or x rays.
49
 Compared to a reference group of asthmatic pregnant women who 
were not exposed to ICS during the first trimester, ICS users were not found to be at a 
significant increased risk of major malformations at low and moderate doses (aOR 0.90; 
95% CI 0.64-1.24 for >500 mcg/day of beclomethasone equivalent and aOR 0.56; 95% CI 
0.22-1.43 for >500-1000 mcg/day of beclomethasone equivalent).
49
 However, with the 
higher doses of >1000 mcg/day of beclomethasone equivalent a non-significant trend was 
found (aOR 1.67; 95% CI 0.56-5.03).
49
 This result should be interpreted with caution 
however due to the small number of cases reported.  
In the second study by Blais et al., a further investigation into the safety of high 
doses of ICS was conducted.
34
 Data from 3 health databases were linked and a cohort of 
13280 pregnancies was formed. ICS doses were categorized into 0, > 0-1000 and >1000 
mcg/day of beclomethasone equivalent. Compared to pregnant asthmatic users of medium 
doses of ICS (> 0-1000 mcg/day), users of high doses of ICS (>1000 mcg/day) were found 
to be at a higher risk of major malformations which did not reach statistical significance 
(aOR 1.67; 95% CI 0.91-3.06).
34
 Of note, when the same analysis was performed with all 
malformations as the outcome of interest, the results reached statistical significance (aOR 
1.66; 95% CI 1.02-2.68).
34
 The results of both studies however should be interpreted in the 
light of the observed higher proportion of women with  markers of severe and uncontrolled 
asthma among users of high doses of ICS, which could result in residual confounding and 
overestimation of the effect of ICS on congenital malformations. 
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Bakhireva et al. examined the association between maternal use of any ICS anytime 
during pregnancy and perinatal outcomes, including major malformations in a prospective 
cohort study.
44
 Compared to non-asthmatic pregnant women, the authors found a 
significant increased risk of major malformations (cRR 13.7, P < 0.05).
44
 However, the 
association was greatly attenuated when ICS users were compared to asthmatic ICS non 
users (cRR 1.10, P > 0.05), which highlights the importance of using the appropriate 
reference group in similar studies to accurately assess the effect of the medication separated 
from the effect of asthma itself. The prospective design limited the selection and recall bias 
but self-reporting of the medication use was a major limitation, since maternal recall of 
medications use (frequency and doses) might not be highly accurate, leading to non-
differential misclassification that underestimates the medications effect. Schatz et al. in 
another study examined the association between ICS use anytime during pregnancy and 
major congenital malformations.
43
 The authors used a reference group of asthmatic non-
users and reported a non significant cRR = 1.0. However, ICS use was examined anytime 
through the entire period of pregnancy and no adjustment was performed on any potential 
confounder. 
Dombrowski et al. in a randomized controlled trial compared the efficacy of inhaled 
beclomethasone (400-500 mcg/day) to oral theophylline (400 to 800 mg/day) for the 
prevention of asthma exacerbations requiring medical intervention.
42
 Despite the 
randomization, the small sample sizes have resulted in some observable differences in the 
baseline characteristics between the groups. The study concluded that the treatment of 
moderate asthma with inhaled beclomethasone versus oral theophylline led to similar rates 
of asthma exacerbations and similar obstetric and perinatal outcomes.
42
 Six cases of major 
malformations were observed among the beclomethasone group and five cases among the 
theophylline users (cRR 1.20; 95% CI 0.40-3.80).
42
 
We identified seven studies that used a reference group of non-asthmatic pregnant 
women or a mixed population of asthmatic and non-asthmatic women. 
21,28,29,32,35,37,38
  
Kallen et al. in a case control study using the Swedish Medical Birth Register found no 
significant increased risk of major malformations with ICS use early during pregnancy 
(aOR=1.05, 95% CI=0.82-1.34).
21
 In a recent report using the same registry, Kallen 
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reported a significant increased risk of major malformations (aOR=1.08, 95% CI=1.01-
1.16) with ICS use in the first trimester, and a nonsignificant increased risk of major 
cardiac malformations (aOR=1.11, 95% CI=0.99-1.25).
28
 The general population was used 
as a reference group and there was a potential confounding by indication that could explain 
the results.  
Two large cohort studies have used the Danish National Registries to examine the 
association between ICS use and major malformations, specially orofacial clefts.
32,37
 The 
largest was a study by Hviid et al that examined ICS use and cleft palates and cleft lips over 
a 12 year period in Denmark.
37
 The authors collected data on 7421 users of ICS and 
adjusted for several important potential confounders, including level of education, 
socioeconomic status, maternal comorbidities and the maternal exposure to other 
medications. The study did not find a significant increased risk of neither cleft palate only 
(aOR=0.94, 95% CI=0.30-2.92) nor cleft lip with cleft palate (aOR=0.75, 95% CI=0.34-
1.68).
37
 The second study included 1223 users of ICS and reported unadjusted cOR=1.02, 
95% CI=0.77-1.34 for all major malformations and unadjusted cOR=0.47, 95% CI=0.07-
3.34 for oral clefts.
32
 Both studies however used non-asthmatics among their reference 
group. 
Vasilakis-Scaramozza et al. in a cohort study using the GPRD database reported a 
cOR of 1.10, 95% CI=0.90-1.40 with any ICS.
29
 The study did not adjust for any potential 
confounders and restricted the reference group to only non-asthmatic pregnant women, 
which is a major methodologic limitation. The study described earlier by Garne et al. 
investigated also the safety of ICS use during pregnancy, using the EUROmediCAT 
database in a case-malformed control study.
35
 The study did not find any significant 
increased risk of any major malformations or specific major malformations.  
We have discussed the major weaknesses of this study in a correspondence 
published in the same issue of the journal. We have included the correspondence in Chapter 
5: Results. Briefly, asthmatic women treated with beta2-agonists had no controller 
medications and were likely having uncontrolled asthma. On the other hand, the ICS group 
was likely including women who were appropriately controlled due to the beneficial effect 
of ICS. Due to this confounding by control level, an increased prevalence of malformations 
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was found in the beta2-agonists group and not found among the ICS group (even showing 
protective effects in some instances). No description on the maternal characteristics of the 
women in the study was reported (e.g. asthma exacerbations, hospitalizations for asthma 
and oral corticosteroids use), which prevented the assessment of the comparability of the 
exposure groups.  
Of note, we have located some case-control studies conducted by the NBDPS in the 
US which examined the fetal safety of ICS among other asthma treatments. 
25,26,36,142,143
 
However, ICS were combined with other anti-inflammatories (e.g. cromolyn, montelukast, 
nedocromil) in all of the located studies, which prevented a valid assessment of the separate 
effect of ICS use during pregnancy and gave rise to impractical and inadequate results that 
are difficult to interpret.  
In summary, evidence on maternal ICS use during pregnancy has demonstrated 
sufficient fetal safety results in several studies. However, evidence might be still lesser for 
high doses of ICS which have their effect possibly confounded by asthma severity and 
control levels. In general, ICS are recommended to be safe for the management of asthma 
during pregnancy. 
 
2.6.3 LABA-ICS combination and major congenital malformations 
Despite being used for many years in the treatment of asthma during pregnancy, 
LABA-ICS combination therapy is one of the least studied treatment regimens. An 
explanation for such small body of knowledge is that researchers have focused on each 
medication (i.e. LABA and ICS) separately in an effort to tease out the effect of each 
medication on congenital malformations. However, women are usually treated with more 
than one single medication, making the comparison between different treatment regimens 
more relevant to the routine clinical practice and more useful for researchers, physicians 
and patients. Moreover, comparing treatment alternatives that have similar indications is 
one of the most effective methods in reducing and minimizing confounding by indication. 
Through our literature search, we have located three studies – two cohort studies and one 
case-control study – that investigated the association between LABA-ICS combination use 
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during pregnancy and the risk of major malformations.
28,33,35
 A summary of the retrieved 
studies is presented in Table 2.6.C. One study
28
 had a large number of exposed pregnancies 
(over 8000) and the other two were of small to moderate sample sizes. Another article by 
Eltonsy et al. can be located which is part of this thesis and not included in Table 2.6.C.  
Among the three studies retrieved, only one study used the more appropriate 
reference group of asthmatic pregnant women.
33
 Charlton et al. in a cohort study used the 
GPRD database to examine the fetal safety of fluticasone-salmeterol combination.
33
 Using 
a modified  asthma severity index developed by our team
144
, the authors classified the 
asthmatic pregnancies into moderate asthma (177 combination therapy users) and 
considerable to severe asthma (1032 combination therapy users). Asthmatic users of ICS 
other than fluticasone were used as a reference group. The study did not find a significant 
increased risk of major malformations with the use of combination therapy (aOR 1.30; 95% 
CI 0.50-3.20 among moderate asthmatics and aOR 1.10; 95% CI 0.60-2.00 among women 
with considerable to severe asthma).
33
 Adjustment for important confounders was 
performed, including alcohol consumption, smoking status, socioeconomic status, and 
BMI. Importantly however, the multivariate models used in the statistical analysis of the 
results above did not account for the presence of repeated measures (i.e. when 1 woman 
contribute more than 1 pregnancy into the cohort). The authors performed a sensitivity 
analysis restricted to the first pregnancy from each woman and the results changed 
drastically, especially among moderate asthmatics where the previously observed 
association was inversed (aOR 0.70; 95% CI 0.20-2.90 among moderate asthmatics and 
aOR 1.20; 95% CI 0.60-2.30 among women with considerable to severe asthma).
33
 
Moreover, since the objective of the study was to investigate the fetal safety of fluticasone 
(and its combination with salmeterol), it became difficult to generalize the results to other 
LABA-ICS combinations (e.g. budesonide-formoterol). Also, a key weakness in the GPRD 
is that the medication exposure data is based on the prescription issued, with no knowledge 
on either if it was dispensed or used. Data on the change in severity that were not 
accompanied by an issued prescription will not be captured. Finally, there was also a 
possibility of residual confounding by asthma severity due to incomplete adjustment of 
severity levels. 
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The other two studies that examined LABA-ICS combination therapy used a 
reference group that includes non-asthmatic women. The recent study by Kallen using the 
Swedish Birth Registry examined LABA-ICS combination therapy and found no 
statistically significant association between their maternal use during the first trimester and 
major malformations (aOR 1.07; 95% CI 0.95-1.21) or major cardiac malformations (aOR 
1.01; 95% CI 0.81-1.25).
28
 The second study by Garne et al. used the EUROmediCAT 
database to examine the maternal exposure to any LABA-ICS combination during the first 
trimester and major malformations.
35
 No significant association was found between LABA-
ICS and any major malformations, but a more than three folds significant increased risk of 
esophageal atresia was observed (aOR 3.63; 95% CI 1.26-10.42).
35
 This increase could be 
due to the asthma and its severity, especially that the combination therapy is usually 
indicated in cases of moderate to severe persistent asthma, or it could be due to chance 
alone. The weaknesses of the study were discussed in a correspondence included in this 
thesis in Chapter 5: Results. 
In summary, very small body of evidence exists on the fetal safety of the 
combination of LABA-ICS as a treatment regimen, despite their wide use among asthmatic 
women and the fact that LABA should be prescribed only in combination with ICS. The 
three studies retrieved suffered from methodologic limitations that prevent an accurate 
assessment of the associated risks. Given these facts, more evidence on the fetal safety of 
LABA-ICS and similar treatment regimens is clearly necessary.   
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Table 2.6.A. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Major Congenital Malformations 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists 
 
Non-users of ß2-agonists 
 
Effect 
Type of ß2-
agonists 
n* 
Major congenital 
malformation (%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
SABA and/or LABA use: cohort studies 
Bakhireva et 
al. (2005) 
Cohort 
Tel. interviews & 
medical charts 
Entire 
pregnancy 
Any 103 3.9  Non asthmatics 303 0.3  cRR 13.0 NA 
Any 103 3.9 
 Asthmatics ICS 
users a 
438 4.1 
 
cRR 0.95 NA 
Schatz et al. 
(2004) 
Cohort + 
RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Any 1,828 2.0  
 
Asthmatics non 
users bcd 
295 2.0  
 
cRR 1.0 (P >0.05)  
SABA and/or LABA use: case-control studies  
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-
agonists 
 Effect 
Users of ß2-
agonists 
Non-users of ß2-
agonists 
 
Users of ß2-
agonists 
Non-users 
of ß2-
agonists  
 
OR or RR 
95% CI or (p-
value) 
Garne et al. 
(2015) 
Case-
Malformed 
Control 
EUROmediCAT 
database (Birth registry, 
medical records & self 
reports) 
1st trimester 
 
Any  264 16539 
 
592t 43232 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.23 1.05, 1.46 
Any  264 16539 
 
97u 9481 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.46 1.10, 1.93 
Any  28 1364 
 
592t 43232 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.63
r
 1.05, 2.52 
Any  28 1364 
 
97u 9481 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.97
r
 1.19, 3.25 
Any  19 596 
 
592t 43232 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.89
z
 1.12, 3.20 
Any  19 596 
 
97u 9481 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 3.04
z
 1.53, 6.06 
Van Zutphen 
et al. (2015) 
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Any 8 206 
 
194 7912 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 2.3
v
 1.10, 4.80 
Lin et al. 
(2012) 
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Any f 10 168 
 
NA NA 
Asthmatics and 
non asthmatics 
non users  
 
aOR = 2.39
o 1.23, 4.66 
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Munsie et al. 
(2011) 
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Any f 20 570 
 
114 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.77
q
 1.08, 2.88 
1 month prior 
conception + 
1st trimester 
Any f 26 887 
 
114 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.53r 0.99, 2.37 
1 month prior 
conception + 
1st trimester 
Any f 17 1114 
 
114 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.78s 0.46, 1.31 
2nd & 3rd 
trimesters 
Any f 7 570 
 
58 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.26q 0.57, 2.80 
2nd & 3rd 
trimesters 
Any f 4 887 
 
58 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.49r 0.18, 1.36 
2nd & 3rd 
trimesters 
Any f 6 1114 
 
58 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.59s 0.25, 1.38 
Lin et al. 
(2009) 
Matched 
Case Control 
1:2 
Registry, medical 
records & tel. 
interviews  
1 month prior 
conception + 
1st trimester 
Any f 22 443  
 
22 965 
Asthmatics and 
non asthmatics 
with no Rx 
 
aOR = 2.20
w
 1.05,4.61 
Lin et al. 
(2008) 
Case Control 
1:11 
Tel. interviews& Rx 
DB 
1 month prior 
conception + 
1st trimester 
Any g 17 358 
 
96 3,932 
Asthmatics and 
non-asthmatics 
non users g  
 
 
aOR = 2.06
z
 
 
1.19,3.59   
SABA only: cohort studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists 
 
Non-users of ß2-agonists 
 
Effect 
Type of ß2-
agonists 
n* 
Major congenital 
malformation (%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
Kallen 
(2014) 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge) 
1st trimester 
(early 
pregnancy, 
usually 10-12 
weeks) 
Any 35453 3.41 
 
General 
population 
NA NA 
 
aOR = 1.10 1.04,1.10 
Any 35453 1.22 
 
General 
population 
NA NA 
 
aOR = 1.17
w
 1.07,1.29 
Vasilakis-
Scaramozza 
et al (2013) 
Cohort 
General Practice 
Research Database 
(GPRD) 
180-335 days 
before LB, 
70- 225 SB 
Any 7061 3.10 
 
Non asthmatics 
non users  
15840 2.78 
 
cOR = 1.10 0.90,1.30 
50 
 
Eltonsy et al. 
(2011) 
Cohort 
Quebec administrative 
DB  
1st trimester 
Any 7,182 5.7  
Asthmatics non 
usersg 
5,935 5.9 
 aOR = 0.93  0.80,1.08 
Any (>0–3 
doses/week) 
3,420 6.1 
  
aOR = 1.00  0.83, 1.20 
Any (>3–10 
doses/week) 
2,102 5.5 
  
aOR = 0.84  0.67, 1.06 
Any (>10 
doses/week) 
1,660 5.2 
  
aOR = 0.68 0.48, 0.95 
Kallen et al. 
(2007) 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge)  
1st trimester 
Salbut NA NA 
 
General 
population  
NA NA 
 
aOR  = 1.38h 1.12,1.70 
Terbut NA NA 
 
NA NA 
 
aOR  = 1.08i 0.94,1.23 
Schatz et al. 
(1997) 
Cohort 
Daily diary cards for 
medications completed 
by patients, tel. 
interviews & medical 
charts 
Entire 
pregnancy 
Any e 667 3.7 
 
Non asthmatics  823 6.2 
 
cRR  0.60 (P >0.05)  
1st trimester Any e 488 4.3 
 
Non asthmatics  1,000 5.6 
 
cRR 0.77 (P >0.05)  
Schatz et al. 
(1988) 
Cohort 
Questionnaire for 
patients identification, 
confirmed clinically + 
Self-Diary to report use 
of SABA  & medical 
records (for perinatal 
outcomes)  
Entire 
pregnancy 
Any bfj 259 3.9 
 
Non asthmatics 295 6.4 
 
cOR = 0.61 (P >0.05)  
1st trimester Any bfj 180 3.9 
 
Non asthmatics 295 6.4 
 
cOR = 0.61 (P >0.05)  
Entire 
pregnancy 
Any bfj 259 3.9 
 Asthmatics non 
usersg 
101 6.0 
 
cOR = 0.65 (P >0.05)  
1st trimester Any bfj 180 3.9 
 Asthmatics non 
usersg 
172 5.3 
 
cOR = 0.74 (P >0.05)  
Entire 
pregnancy 
Any bfj 259 3.5 
 General 
population 
1,999,254 3.0 
 
cOR  = 1.17 NA 
SABA only: case-control studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-
agonists 
 Effect 
Users of ß2-
agonists 
Non-users of ß2-
agonists 
 
Users of ß2-
agonists 
Non-users 
of ß2-
agonists 
 
OR or RR 
95% CI or (p-
value) 
Lin et al. 
(2012)  
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salbut 77 2776 
 
139 6587 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 1.31P NA 
Pirbuterol 3 2850 
 
3 6723 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 2.36 P NA 
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Munsie et al. 
(2011) 
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salbut 18 570 
 
101 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.79
q
 1.07, 2.99 
1 month prior 
conception + 
1st trimester 
Salbut 25 887 
 
101 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.65
r
 1.06, 2.58 
1 month prior 
conception + 
1st trimester 
Salbut 15 1114 
 
101 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.76s 0.44, 1.33 
2nd & 3rd 
trimesters 
Salbut 7 570 
 
55 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.34q 0.60, 2.98 
2nd & 3rd 
trimesters 
Salbut 4 887 
 
55 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.52r 0.19, 1.44 
2nd & 3rd 
trimesters 
Salbut 6 1114 
 
55 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.64s 0.27, 1.49 
1 month prior 
conception + 
1st trimester 
Pirbuterol/ 
Metaprot/ 
Epineph 
4 85 
 
5 153 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 1.44 NA 
Lin et al. 
(2009) 
Matched 
Case Control 
1:2 
Registry, medical 
records & tel. 
interviews  
1 month prior 
conception + 
1st trimester 
Salbutg 15 443 
 
14 965 
Asthmatics and 
non asthmatics 
with no Rx 
 
aOR = 2.37w 0.90,6.23 
Metaprotg 1 31 
 
1 42 
Asthmatics and 
non asthmatics 
with no Rx 
 
cRR = 1.35w NA 
Terbut g 1 31 
 
0 43 
Asthmatics and 
non asthmatics 
with no Rx 
 
__ NA 
Lin et al. 
(2008) 
Case Control 
1:11 
Tel. interviews & Rx 
DB 
1 month prior 
conception + 
1st trimester 
Salbut/ 
Pirbuterolg 
13 368 
 
88 4,033 
Asthmatics and 
non asthmatics 
non users g  
 
cOR = 1.62z NA 
Tata et al. 
(2008) 
Matched 
Case Control 
1:6 
THIN DB 
Entire 
pregnancy 
Any  
375 NA 
 
2085 NA 
Asthmatics non 
usersbcd 
 
aOR = 1.06 
(P = 0.336) 
0.94,1.19 
1st trimester NA NA 
 
NA NA NA 
 
aOR = 1.01 
(P = 0.941)    
0.86,1.18 
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LABA only: cohort studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists  Effect 
Type of ß2-
agonists 
n* 
Major congenital 
malformation (%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
Kallen 
(2014) 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge) 
1st trimester 
(early 
pregnancy, 
usually 10-12 
weeks) 
Any 8947 3.20 
 
General 
population 
NA NA 
 
aOR = 1.08 0.96,1.22 
Any 8947 1.14 
 General 
population 
NA NA 
 
aOR = 1.12w 0.92,1.36 
Vasilakis-
Scaramozza 
et al (2013) 
Cohort 
General Practice 
Research Database 
(GPRD) 
180-335 days 
before LB, 
70- 225 SB 
Any 424 2.59 
 
Non asthmatics 
non users  
15840 2.78 
 
cOR = 0.80 0.40,1.50 
Eltonsy et al. 
(2011) 
Cohort 
Quebec administrative 
DB  
1st trimester Any 165 
7.9  
Asthmatics non 
usersg 
12,952 
5.8  aOR = 1.31 0.74,2.31 
4.2 2.0 aOR = 2.38k 1.11,5.1 
1.8  0.5  aOR =3.97l  1.29,12.2 
Kallen et al. 
(2007) 
Cohort 
Swedish Registry 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge)  
1st trimester 
 
Salmeterol NA NA 
 
General 
population 
NA NA 
 
aOR  = 1.34m 0.96,1.88 
Formoterol NA NA 
 
NA NA 
 
aOR  = 1.07n 0.63,1.82 
LABA only: case-control studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-
agonists 
 Effect 
Users of ß2-
agonists 
Non-users of ß2-
agonists 
 
Users of ß2-
agonists 
Non-users 
of ß2-
agonists 
 
OR or RR 
(95% CI) or 
(p-value) 
Lin et al. 
(2012)  
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salmeterol 13 2840 
 
23 6703 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 1.33 P NA 
Munsie et al. 
(2011) 
Case Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salmeterol 6 83 
 
21 137 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 0.47s NA 
Lin et al. 
(2008) 
Case Control 
1:11 
Tel. interviews & Rx 
DB 
1 month prior 
conception + 
1st trimester 
Salmeterolg 2 379 
 
11 4,110 
Asthmatics and 
non asthmatics 
non users g  
 
cOR = 1.97 NA 
Tata et al. 
(2008) 
Matched 
Case Control 
1:6 
THIN DB 
Entire 
pregnancy 
Any  
25 NA 
 
131 NA 
Asthmatics non 
usersbcd 
 
aOR = 1.12 
 (P = 0.614)         
0.72,1.75 
1st trimester NA NA 
 
NA NA 
 
aOR = 1.09 
(P = 0.77)           
0.62,1.9 
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Table 2.6.B. Studies Investigating the Association between ICS Use during Pregnancy and Major Congenital Malformations 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ICS 
 
Non-users of ICS 
 
Effect 
Type of ICS n* 
Major congenital 
malformation (%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
ICS use: cohort studies 
Charlton et 
al. (2015) 
Cohort 
General Practice 
Research Database 
(GPRD) 
1st trimester 
+2 weeks 
before prior 
Fluticasone 
328 (moderate 
asthma) 
2.44 
 
Asthmatics users 
of other ICS 
2598 2.31 
 
aOR = 1.10 0.50,2.30 
Fluticasone 
1274 
(considerable to 
severe asthma) 
2.67 
 
1080 2.31 
 
aOR = 1.20 0.70,2.00 
Kallen 
(2014) 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge) 
1st trimester 
(early 
pregnancy, 
usually 10-12 
weeks) 
Any 24594 3.32 
 
General 
population 
NA NA 
 
aOR = 1.08 1.01,1.16 
Any 24594 1.14 
 
General 
population 
NA NA 
 
aOR = 1.11w 0.99,1.25 
Bjorn et al. 
(2014) 
Cohort 
Danish Medical 
Registries 
(Danish National 
Registry of Patients, 
Discharges and 
Prescriptions Database) 
1 month prior 
conception + 
1st trimester 
Any 1223 4.30 
 
Asthmatics and 
non-asthmatics 
non users 
3446 4.30 
 
cOR = 1.02 0.77,1.34 
Any 1223 0.08 
 Asthmatics and 
non-asthmatics 
non users 
3446 0.20 
 
cOR = 0.47x 0.07,3.34 
Vasilakis-
Scaramozza 
et al (2013) 
Cohort 
General Practice 
Research Database 
(GPRD) 
180-335 days 
before LB, 
70- 225 SB 
Any 4735 3.17 
 
Non asthmatics 
non users  
15840 2.78 
 
cOR = 1.10 0.90,1.40 
Hviid et al. 
(2011) 
Cohort 
Danish Medical Birth 
Registry, 
National hospital 
Discharge Register & 
Danish Prescription 
Drug Register 
1st trimester 
 
Any 7421 0.81 
 Asthmatics and 
non-asthmatics 
non users 
825215 1.05 
 
aOR = 0.75s 0.34,1.68 
Any 7421 0.40 
 Asthmatics and 
non-asthmatics 
non users 
825215 0.43 
 
aOR = 0.94r 0.30,2.92 
Blais et al. 
(2009) 
Cohort 
Quebec administrative 
DB  
1st trimester 
≥1000 mcg 
beclo 
equivalent 
154 9.7 
 Asthmatics, users 
of ≥ 0-1000 mcg 
beclo  
4392 5.7 
 
aOR = 1.67  0.91,3.06 
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Blais et al. 
(2007) 
Cohort 
Quebec administrative 
DB  
1st trimester 
> 0–500 mcg 
beclo 
equivalent 
1582 6.4 
 
Asthmatics, non 
users of ICS 
2740 6.0 
 
aOR = 0.90  0.64,1.24 
> 500-1000 
mcg beclo 
equivalent 
167 3.6 
  
aOR = 0.56 0.22, 1.43 
>1000 mcg 
beclo 
equivalent 
72 9.7 
  
aOR = 1.67 0.56, 5.03 
Bakhireva et 
al. (2005) 
Cohort 
Tel. interviews & 
medical charts 
Entire 
pregnancy 
Any 438 4.10 
 
Non asthmatics 303 0.30 
 
cRR = 13.70 (P < 0.05) 
Any 438 4.10 
 Asthmatics ICS 
non users 
103 3.90 
 
cRR = 1.10 (P > 0.05) 
Schatz et al. 
(2004) 
Cohort + 
RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Any 722 1.90 
 
Asthmatics ICS 
non users 
1401 2.00 
 
cRR = 1.00 (P > 0.05)  
Dombrowski 
et al. (2004) 
RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Beclo 193 3.10 
 
Asthmatics 
theophylline users 
189 2.60 
 
cRR = 1.20 0.40, 3.80 
Schatz et al. 
(1997) 
Cohort 
Daily diary cards for 
medications completed 
by patients, tel. 
interviews & medical 
charts 
Entire 
pregnancy 
AnyY NA 5.40 
 
Non asthmatics 
and ICS non users  
NA 4.90 
 
cRR = 1.10 (P >0.05)  
ICS use: case-control studies  
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ICS 
Cases  Controls 
Definition of non-
users of ICS 
 Effect 
Users of ICS Non-users of ICS 
 
Users of ICS 
Non-users 
of ICS 
 
OR or RR 
95% CI or (p-
value) 
Garne et al. 
(2015) 
Case-
Malformed 
Control 
EUROmediCAT 
database (Birth registry, 
medical records & self 
reports) 
1st trimester 
 
Any  133 16670 
 
349t 43475 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.85 0.68, 1.07 
Any  133 16670 
 
51u 9527 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.01 0.68, 1.49 
Kallen et al. 
(2003) 
Case control 
Swedish Medical birth 
Register & Interviews  
Early 
pregnancy 
Any 66 7404 
 
NA 577,730 
Asthmatics and 
non asthmatics 
non users 
 
aOR = 1.05 0.82, 1.34 
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Table 2.6.C. Studies Investigating the Association between LABA-ICS combination Use during Pregnancy and Major Congenital 
Malformations 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of LABA-ICS 
 
Non-users of LABA-ICS 
 
Effect 
Type of 
LABA-ICS 
n* 
Major 
congenital 
malformation 
(%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
LABA-ICS combination use: cohort studies 
Charlton et 
al. (2015) 
Cohort 
General Practice 
Research Database 
(GPRD) 
1st trimester 
+2 weeks 
before prior 
Fluticasone + 
salmeterol 
177 (moderate 
asthma) 
2.82 
 
Asthmatic users of 
ICS other than 
fluticasone 
2598 2.31 
 
aOR = 1.30 0.50,3.20 
Fluticasone + 
salmeterol 
1032 
(considerable to 
severe asthma) 
2.62 
 
1080 2.31 
 
aOR = 1.10 0.60,2.00 
Kallen 
(2014) 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge) 
1st trimester 
(early 
pregnancy, 
usually 10-12 
weeks) 
Any 8467 3.19 
 
General 
population 
NA NA 
 
aOR = 1.07 0.95,1.21 
Any 8467 1.02 
 
General 
population 
NA NA 
 
aOR = 1.01w 0.81,1.25 
LABA-ICS combination use: case-control studies  
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of 
LABA-ICS 
Cases  Controls 
Definition of non-
users of LABA-
ICS 
 Effect 
Users of LABA-
ICS 
Non-users of 
LABA-ICS 
 
Users of LABA-
ICS 
Non-users 
of LABA-
ICS 
 
OR or RR 
95% CI or (p-
value) 
Garne et al. 
(2015) 
Case-
Malformed 
Control 
EUROmediCAT 
database (Birth registry, 
medical records & self 
reports) 
1st trimester 
Any  60 16743 
 
131t 43693 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.09 0.79, 1.49 
Any  60 16670 
 
26u 9552 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.09 0.65, 1.83 
Any  3 645 
 
131t 43693 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.69o 0.52, 5.48 
Any  3 645 
 
26u 9552 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 3.63
o
 1.26, 10.42 
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Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Women may have concurrently received short-acting beta2-agonists (inhaled or systemic). 
b
 Women may have concurrently received inhaled corticosteroids. 
c
 Women may have concurrently received asthma controller medications (leukotriene modifiers). 
d
 Women may have concurrently received systemic corticosteroids (oral or intravenous). 
e
 Women may have received inhaled, oral or injectable beta2-agonists. 
f
 Women may have concurrently received asthma controller medications (theophylline or ipratropium). 
g
 Women may have concurrently received any other type of asthma medication. 
h
 The OR presented for the association between salbutamol and cardiac malformations (92 cases reported) 
i
 The OR presented for the association between terbutaline and cardiac malformations (228 cases reported) 
j
 Women may have concurrently received asthma controller medications (cromolyn). 
k
 The OR presented for the association between LABA and major cardiac malformations 
l
 The OR presented for the association between LABA and major “other and unspecified malformations” 
m
 The OR presented for the association between salmeterol and cardiac malformations (35 cases reported) 
n
 The OR presented for the association between formoterol and cardiac malformations (14 cases reported) 
o
 The OR presented for the risk of esophageal atresia 
p 
The OR presented for the association between beta2-agonists and selected defects including diaphragmatic 
hernia, esophageal atresia, small intestinal atresia, anorectal atresia, neural tube defects, omphalocele, or limb 
deficiencies with no additional major defect (isolated). 
q 
The OR presented for cleft lip only 
r
 The OR presented for cleft palate only
 
s
 The OR presented for cleft lip with cleft palate 
t
 The OR presented using a control group with non-chromosomal malformations 
u
 The OR presented using a control group with chromosomal malformations 
v
 The OR presented for the association between bronchodilators use (mainly SABA) and anomalous 
pulmonary venous return (non-significant results for the other specific heart defects examined). 
w
 The OR presented for major cardiac malformations 
x
 The OR presented for oral clefts 
y
 Women may have concurrently received intranasal corticosteroids. 
z
 The OR presented for gastroschisis 
 
DB: database; ICS: inhaled corticosteroids; Salbut: Salbutamol; Isoprot: Isoproterenol; Metaprot: 
Metaproterenol; Terbut: Terbutaline; Epineph: Epinephrine; Ephed: Ephedrine; Beclo: Beclomethasone 
dipropionate; SABA: Short acting beta2-agonists; LABA: Long acting beta2-agonists; RCT: randomized 
controlled trial; THIN: Health Improvement Network primary care database, Rx: prescription medications; 
aOR: adjusted odds ratio; cOR: crude odds ratio; cRR: crude risk ratio; cMD: crude mean difference; aMD: 
adjusted mean difference; pOR :crude prevalence odds ratio; NA: data unavailable; – : power or effect size 
impossible to calculate; NC: statistical power not calculated since results are significant. LB: live birth; SB: 
still birth.  
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2.7 Possible Teratogenic Mechanisms of Action for Beta2-agonists and 
ICS 
The biological mechanisms of teratogenicity of SABA, LABA and ICS are still 
uncertain, but several hypotheses exist. In regards to ICS, a proportion of the ICS that enter 
the systemic circulation may cross the placenta and affects the fetus, also diffusion of 
fluorinated corticosteroids (e.g. fluticasone and budesonide) is even more rapid than other 
corticosteroids.
145-147
 Since fetal endogenous levels of corticosteroids are much lower than 
maternal levels, even minimal diffusions to the fetus could have a considerable impact.
148
 
Evidence shows that corticosteroids influences maternal hypothalamic-pituitary-adrenal 
(HPA) activity, which may play a role in endocrine and metabolic alterations in the 
offspring.
149
 The early presence of the glucocorticoid receptor in the fetus implies that 
corticosteroids may affect the fetus by the glucocorticoid receptor and lead to persistent 
disorders in endocrine and metabolic control.
150
 Animal models displayed potent 
teratogenicity of corticosteroids at doses less than or similar to those used in humans, with 
cleft palate being the primary malformation induced in most species.
146,151
 Corticosteroids 
are essential for normal differentiation and growth of epithelial cells, but supraphysiologic 
doses interrupt this process.
152
  
 
Animal and human data on selective SABA (e.g. salbutamol) have shown an 
acceptable safety profile.
153
 However, non selective SABA like epinephrine can cause 
uterine vasoconstriction which could cause fetal harm.
147
 SABA has rapid onset and short 
duration of action, which probably contributes to the absence of a human teratogenic effect 
that usually requires the exposure to a potential teratogen during a critical stage of the 
embryonic development that exceed a specific dose threshold. Salbutamol produces 
bronchodilation through stimulation of beta2-adrenergic receptors in bronchial smooth 
muscle, thereby causing relaxation of bronchial muscle fibers.
154
 Although beta2-receptors 
are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors 
are the predominant receptors in the heart, there are also beta2-receptors in the human heart 
comprising 10% to 50% of the total beta-adrenergic receptors.
154
 The precise function of 
these receptors has yet to be established, raising the possibility that selective beta2-agonists 
may also have cardiac effects. After inhalation, salbutamol plasma drug levels are very 
low.
154
 However, it has been found that between 2% and 3% of salbutamol was transferred 
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from the maternal side to the fetal side of the placenta.
154
 It is currently unknown if these 
minimal diffusions to the fetus have a potential teratogenic effect. 
 
Regarding LABA, a probable teratogenic effect could arise from their potential 
effect on the corticosteroid function. Two different interactions of LABA on steroids have 
been identified, through which LABA could induce the gene transcription effect of steroids 
and subsequently their effects. First, LABA induce protein kinase A (PKA) activation 
which, in return, induces CAMP response element binding protein (CREB) binding protein 
(CBP). CBP activation is considered a rate limiting transcription factor for the steroids’ 
action.
128
 Second, LABA can directly induce ligand-independent nuclear translocation and 
activation of glucocorticoid receptors (GR) (i.e. induce migration of GR into the 
nucleus).
128,155
 The theory postulates that by inducing the steroid-induced gene 
transactivation, LABA might also enhance the steroid-induced side effects
128
 and among 
the possible side effects of oral corticosteroids maternal use is the increased risk of 
congenital malformations.
156-158
 
 
2.8 Risk Factors for Congenital Malformations 
2.8.1 Etiology of congenital malformations 
It is now believed that causes of congenital malformations could be genetic, 
environmental, or unknown, including also interactions between those factors.
159-162
 
However, the specific etiology of most human major malformations is still unknown.
160,163
 
The genetic causes represent 15 to 25%, which include chromosomal abnormalities and 
new mutations.
160,162
 Environmental causes, including maternal diseases, infectious agents, 
teratogenic drugs, alcohol, smoking and radiations, together represent about 10 to 15% of 
congenital malformations.
160,164
 Finally, about 65 to 75 % are of unknown causes, where 
multifactorial gene-environment interactions as one of its main proportions, contributing 
about 20-25%.
159-162
  In the following sub-sections and in Table 2.8 we will discuss some 
of the important risk factors for congenital malformations closely related to this thesis 
objectives. For their identification, we have reviewed the literature on asthma and asthma 
treatments during pregnancy, teratogenic medications and risks factors for major congenital 
malformations in order to determine relevant potential confounders. 
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2.8.2 Maternal characteristics, comorbidities and lifestyles 
Maternal age is one of the major factors that affect pregnancy and perinatal 
outcomes, including major congenital malformations.
165-167
 It has been shown that women 
at the extremes of the reproductive age distribution (< 18 years or > 35 years) have an 
increased risk of congenital malformations compared to mid-age women.
165,166,168
 
Chromosomal anomalies, such as Down syndrome, is more prevalent among older women, 
but the risk for non-chromosomal anomalies is still equivocal.
165-167
 
Among the environmental risk factors of congenital malformations is the area of 
residence. Urban or rural area of residence has been shown to be associated with significant 
changes in the prevalence of perinatal outcomes in several studies, including the prevalence 
of major malformations.
169-171
 The urban versus rural residence status could be a major risk 
factor for some congenital malformations, reaching more than two folds increase in the 
prevalence of certain malformations among rural residents.
169-171
   
Maternal education level and socioeconomic status were shown to be associated 
with several perinatal outcomes, including congenital malformations.
172-175
 Compared to 
better-off women, women with low socioeconomic status had a higher risk of giving birth 
to a baby with a congenital malformation.
172,173,176
 A study showed that having 10 years of 
schooling or less increases the risk of congenital malformations by almost three-folds 
compared to 4 years or more of higher education.
176
  
An estimated 4% of the environmental causes of malformations is attributed to 
maternal conditions and maternal disease states
160
, including chronic diseases like asthma, 
diabetes, chronic hypertension and epilepsy.
160,177,178
 Good metabolic control in the 
preconceptional period was shown to be associated with decreased risk of congenital 
malformations.
179
 According to several reports in the literature, pregnancies complicated by 
pre-existing maternal diabetes (both type-1 and type-2) have an approximately two to 
fourfold increased risk of major malformations.
180-182
 Chronic hypertension affects about 
3% to 5% of pregnancies, and its prevalence is increasing due to the rise in obesity and 
advanced maternal age.
65,183
 Recently, more evidence became available on the effect of 
hypertension – separate from antihypertensive medications – on the prevalence of 
malformations. A recent study of over 800,000 pregnancies found that both treated and 
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untreated maternal chronic hypertension were associated with a 20-30% increase in the risk 
of major congenital malformations. 
184
 Similar results were observed for an increased risk 
of cardiac malformations.
184
 Maternal overweight and obesity have shown associations 
with an increased prevalence of a variety of congenital malformations (e.g spina bifida, 
omphalocele and cardiac defects).
185-188
 In a large meta-analysis, maternal obesity was 
found to be associated with an increased risk of pregnancies affected by neural tube defects 
(OR 1.87; 95% CI 1.62, 2.15), spina bifida (OR 2.24; 95% CI 1.86, 2.69), cardiovascular 
anomalies (OR 1.30; 95% CI 1.12, 1.51), septal anomalies (OR 1.20; 95% CI, 1.09, 1.31), 
cleft palate (OR 1.23; 95% CI, 1.03, 1.47), cleft lip and palate (OR 1.20; 95% CI, 1.03, 
1.40), anorectal atresia (OR 1.48; 95% CI, 1.12, 1.97), hydrocephaly (OR 1.68; 95% CI, 
1.19, 2.36), and limb reduction anomalies (OR 1.34; 95% CI, 1.03, 1.73).
185
 Moreover, 
maternal obesity often leads to other morbidities (e.g. diabetes) which are themselves 
associated with increased prevalence of congenital malformations.
185-188
  
Lifestyles and maternal habits include important risk factors for congenital 
malformations.
160
 Maternal alcohol consumption can lead to a wide spectrum of birth 
defects, which range in frequency and severity from fetal alcohol-related defects to the 
distinctive fetal alcohol syndrome.
159,189,190
  Maternal alcohol intake less than once per 
week was associated with a 1.6 to 2.1 fold increased risk of NTDs, d-transposition of the 
great arteries, and multiple cleft lip with or without cleft palate and more regular alcohol 
intake increased the risks for NTDs (OR 2.1, 95% CI: 1.1, 4.0) and cleft lip with or without 
cleft palate (OR 2.6, 95% CI: 1.1, 6.1).
191
 While there is conclusive evidence that alcohol is 
teratogenic, there are no known levels of alcohol during pregnancy that is considered 
safe.
192
 Fetal alcohol syndrome comes with significant costs in health, social, educational 
and other services of the society. In 2009, the estimated annual cost of fetal alcohol 
syndrome in Canada was $6.2 billion dollars.
193
 Maternal smoking on the other side was 
examined in several studies to assess its association with congenital 
malformations.
189,190,194,195
 In a large meta-analysis including over 173,000 malformed 
babies, tobacco smoking was associated with modest significant increases in digit 
anomalies, cryptorchidism and cardiovascular and musculoskeletal system anomalies 
(aORs 1.09–1.19); and larger significant increases (aORs 1.25–1.50) in limb reduction 
defects, clubfoot, oral clefts and defects of the eyes and gastrointestinal system 
(gastroschisis and abdominal hernias).
194
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Other maternal conditions and maternal diseases were reported to have a teratogenic 
effect on the fetus. The list include: Cushings disease (increased risk of 
hyperadrenocortism), iodine deficiency (causing embryonic goiter and mental retardation), 
maternal androgen endocrinopathy (embryonic masculinization), reduced maternal folic 
acid intake (increased incidence of NTDs), maternal phenylketonuria (untreated maternal 
phenylketonuria is associated with a 6-fold-increased risk of heart defects), maternal 
starvation (increased risk of NTDs) and Zinc deficiency: (possible increased risk of 
NTDs).
147,160,163,164,196-198
 
Maternal exposure to toxins, chemicals and pollutants have been examined in 
previous reports, with several potential environmental teratogens being identified. The list 
include: carbon monoxide poisoning (CNS damage has been reported with very high 
exposures), lead (very high exposures can cause pregnancy loss and intrauterine 
teratogenesis), gasoline addiction embryopathy (increased risk of facial dysmorphology and 
mental retardation), methyl mercury (Minamata disease [cerebral palsy, microcephaly, 
mental retardation, blindness, cerebellum hypoplasia]), polychlorinated biphenyls 
(increased risk of CNS malformations, Cola-colored babies, pigmentation of gums, nails, 
teeth and groin; hypoplastic deformed nails; intrauterine growth retardation; abnormal skull 
calcification) and toluene addiction embryopathy (facial dysmorphology and mental 
retardation).
147,159,163,197-200
 
2.8.3 Fetal conditions and infections 
Embryonic and fetal infections contribute about 1% to 3% of the malformations in 
humans.
159,160
 Embryonic and fetal infections that have a proven teratogenic effect includes 
cytomegalovirus, herpes simplex virus, lymphocytic choriomeningitis virus, rubella virus, 
toxoplasmosis, syphilis, and varicella-zoster.
72,160,189
 These infections and their resulting 
syndromes are typically referred to as TORCH (Toxoplasrna gondii, Other microorganisms 
including syphilis, Rubella virus, Cytomegalovirus, and herpes viruses).
201,202
 While they 
often produce mild maternal morbidities, they cause serious fetal consequences in some 
cases, including fetal death. Common malformations attributed to TORCH infections 
include cardiac defects, occular lesions, hearing defects, central nervous system defects, 
neonatal purpuras, and hepatosplenomegaly.
201-203
 Congenital toxoplasmosis has a wide 
spectrum of clinical manifestations, with 10% of affected newborns suffering from 
systemic congenital defects.
201
 The majority of infants with congenital cytomegalovirus 
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infection have no apparent clinical manifestations, but approximately 5% to 15% of the 
children suffer major abnormalities/defects such as hearing loss, microcephaly, mental 
retardation, and motor defects.
201,203
 Maternal infection with rubella early during pregnancy 
was associated with a 70% increased risk of congenital heart lesions.
203
 
Recently, Zika virus (ZIKV) – an emerging mosquito-borne flavivirus – has 
attracted a global attention.
204
 The ZIKV infection has increased dramatically in 2015 
throughout the Americas, with Brazil being the most affected country. The preliminary 
estimates in Brazil reached 440,000 to 1.3 million cases of autochthonous ZIKV infection 
reported through December 2015.
205,206
 The report from the Ministry of Health of Brazil 
suggest that cases of microcephaly have increased by a factor of approximately 20 among 
newborns in the northeast region of the country.
207
 The World Health Organization (WHO) 
has declared the clusters of microcephaly and other neurological disorders to be a Public 
Health Emergency of International Concern.
208
 Beside microcephaly, the potential adverse 
outcomes in babies whose mothers were infected during pregnancy include also incomplete 
brain development and Guillain-Barré syndrome (GBS).
204,205,209,210
 As of September 22, 
2016, 282 travel-related cases, 2 sexually transmitted cases and 2 reports of maternal-to-
fetal transmission have been detected in Canada. To date, Public Health Canada has 
confirmed two maternal-to-fetal transmissions of Zika virus, including one with severe 
neurological congenital anomalies (http://healthycanadians.gc.ca/diseases-conditions-
maladies-affections/disease-maladie/zika-virus/surveillance-eng.php#s1).  
 
2.8.4 Pregnancy related characteristics 
Several studies have reported an increased prevalence of congenital malformations 
among multiple births compared to singletons.
211-213
. In a study including 27,727 multiple 
births and 944,967 singletons, multiple births was associated with a significant increased 
risk of major congenital malformations (OR 1.46, 95% CI: 1.42, 1.50).
212
 In two large 
studies, significant increased risks were found for several system specific categories of 
malformations including anencephalus, biliary atresia, hydrocephalus without spina bifida, 
pulmonary valve atresia and stenosis, bladder exstrophy, macrocephaly, encephalocele, 
cleft lip and palate, anomalies of the diaphragm, cardiac septal defects, atresia or stenosis 
of the large intestine or anus, tracheoesophageal fistula, malformations of the alimentary 
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tract, inguinal and umbilical hernias, and cystic kidney, with estimated odds ratios ranging 
between 1.24 and 7.44.
211,212
 
 
2.8.5 Asthma related variables 
The total body of published evidence show that maternal asthma could significantly 
increase the risk of major congenital malformations.
2,5,7-9
 Other related factors include the 
asthma severity and control levels and the asthma medications used to control its 
symptoms. Oral corticosteroids use during the first trimester was associated with an 
increased prevalence of congenital malformations in previous reports, especially orofacial 
clefts.
34,131,214
 For example, in a large study by the National Birth Defects Prevention Study 
(NBDPS) Group, maternal use of oral corticosteroids was associated with a significant 
increased risk of cleft palate (aOR 1.7, 95% CI, 1.1, 2.6).
215
 As previously discussed, 
severe and uncontrolled asthma are potential risk factors for congenital malformations and 
should be adjusted for properly.
14,43,98,216
  Numerous studies have shown associations 
between suboptimal control of asthma and more severe asthma during pregnancy and 
increased maternal and fetal risks.
2,5,7-9
 In contrast, better-controlled asthma and mild-to-
moderate actively managed asthma are associated with decreased risks.
10,11
Asthma severity 
and control can be assessed through several methods (details in Chapter 2, section 2.3). 
Among the key markers of asthma severity and control that can be used are the emergency 
department (ED) visits for asthma, hospital admissions for asthma, the use of oral 
corticosteroids and the SABA doses used per week.
121,144,217,218
 
 
2.8.6 Teratogenic medications use during pregnancy 
The term teratogen stands for an agent that can produce structural or functional 
abnormalities in an exposed embryo or fetus.
189,219
 Prescription and over the counter (OTC) 
medications are part of the environmental causes of congenital malformations, contributing 
around 1%.
159
 Congenital malformations attributed to their use certainly have a special 
importance, since they could be preventable. 
72,159,189
 Disagreements arise when trying to 
establish the specific criteria to identify and label medications as teratogens, nonetheless; 
the dose, route of exposure and gestational timing of the exposure play the major role in 
identifying any teratogen.
160,219,220
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Most women take medications at some point during pregnancy, either for the 
treatment of acute illnesses (e.g. heartburn and nausea) or for management of chronic 
diseases predating or accompanying gestation (e.g. asthma, epilepsy and depression).
221-224
 
A large proportion of maternal medication use during pregnancy involves OTC 
medications, but there is also considerable use of prescription medications – prescription 
and OTC medications use estimates ranged between 27% and 99%, based on the 
medications examined and the data sources used.
221-223
 
Evidence of proven teratogenic effect has been established for a number of currently 
available medications, acting through various mechanisms, including folate antagonism, 
vascular disruption and oxidative stress.
17
 However, the majority of medications lack 
sufficient data to appropriately evaluate their teratogenicity in humans.
222,225
 A Dutch drug 
utilization study found that 17.5% of women in the examined cohort have received one or 
more prescription drugs suspected to be associated with a teratogenic mechanism during 
the first trimester of pregnancy 
224
, and in the United States, a study showed that 23% of the 
medications most commonly used during the first trimester were included in Category X of 
the U.S. Food and Drug Administration classification  (risks involved in use of the drug 
clearly outweigh potential benefits.).
225
 
In a study published in 2011 based on expert reviews by the Teratology Information 
System (TERIS), the authors found that among 172 medications approved in the United 
States between 2000 and 2010, 97.7% had insufficient published data and 73.3% had no 
human data with which to determine their teratogenic risk in humans.
164
 Typically, when 
medications become available for longer periods of time in the markets and increasingly 
used by pregnant women, more evidence accumulate and a growing number of medications 
become eventually recognized as teratogens based on solid established human data (e.g. 
mycophenolate mofetil). Therefore, new evidence is constantly produced for currently 
marketed medications, and several information sources can be accessed for the assessment 
of their teratogenic risk. 
62,63,67,71-73,226-233
 Those information sources – usually online 
databases and reference books – on teratogenic risks provide complete or partial evidence 
for the teratogenicity of medications.
62-73,233
 However, there are substantial discrepancies 
between the lists of medications that should be considered teratogenic, and significant 
imprecision is added when categories are used (e.g., moderate- vs high-risk teratogens).
62-73
 
Moreover, currently available lists are outdated at some levels.
64,67-70
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In observational studies of congenital malformations, it is essential to control for the 
maternal exposure to proven and potential teratogenic medications, as failure to do so can 
affect the study validity. As mentioned previously, the increase in the body of knowledge 
on currently used medications make it difficult to identify a fixed list of teratogenic 
medications that should be used in research. Besides, the task becomes even more difficult 
when the potential teratogenic medications or medications with evidence of small 
teratogenic risk are being considered.
234
 For that reason, several researchers have 
developed their own teratogenic or potential teratogenic medications lists that they use in 
their own research. Such lists usually become problematic as they are inherently subjective 
in nature, especially when potential teratogens are included, and they require constant 
review of the literature to incorporate the new evidence and updates.  
To demonstrate such problematic issue, we carefully examined the studies that 
controlled for the maternal exposure to teratogenic medications presented in Table 2.8 
below.
29,30,34,49
 Two studies used a teratogens list that included only proven teratogens with 
17 medications and 7 medication classes that was published in 1998.
34,49
 One study used a 
list including only 12 medications
29
 and one study used a longer list of over 150 
medications that included both teratogenic and potential teratogenic medications.
30
 
Examining the literature in fields other than asthma during pregnancy, we often find similar 
discrepancies. A recent study on the effect of topiramate use during pregnancy on the 
prevalence of oral clefts used a list of proven and suspected teratogenic medications that 
contained 39 medications and 6 medication classes.
235
 However, the list included all statins 
but excluded other important teratogens (e.g. mycophenolate mofetil).
235
 The examples 
mentioned above highlight the importance of having an updated and thoroughly examined 
– yet objectively developed – teratogens list to be used in congenital malformations 
research.  
 
2.8.7 Potential confounders 
From the published literature on major congenital malformations risk and maternal 
asthma medications use reviewed earlier in section 2.6, we congregated the several risk 
factors considered in the studies, which we present in Table 2.8. As shown in the table, 
some risk factors are considered of major importance and were considered as potential 
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confounders in nearly all studies (e.g. maternal age), while others were rarely controlled for 
due to their questionable importance (e.g. caffeine use). Notably, the asthma related 
variables are considered some of the key potential confounders that affect the studies’ 
validity.  
Through examining the different risk factors, we identified some variables that will 
be impossible to capture through the databases used in our current research, including for 
example maternal smoking, folic acid use and BMI. However, the databases will allow us 
to adjust for important potential confounders like socioeconomic status and fetal infections. 
Typically, a risk factor has to be associated with the exposure variable in the study for it to 
be considered as a potential confounder, which is in our case the choice of the treatment 
regimen being a combination therapy or monotherapy.
236
 The potential confounders that we 
can measure in our databases and will be considered in our statistical analysis include: 
maternal age at the beginning of pregnancy, receipt of social assistance during pregnancy, 
area of residence at delivery, chronic hypertension, diabetes mellitus, exacerbation of 
asthma (defined as a filled prescription for OCS, an emergency department visit, or a 
hospitalization for asthma) three months before pregnancy, and SABA dose per week in the 
three months preceding pregnancy. 
 
 
Table 2.8 Risk factors considered as potential confounders in the literature review 
Risk factor Studies including the risk factor 
Included in the 
current studies 
Maternal characteristics, lifestyle habits and comorbidities  
Maternal age Bakhireva et al. (2005), Schatz et al. (2004), 
Garne et al. (2015), Van Zutphen et al. (2015), 
Lin et al. (2012), Munsie et al. (2011), Lin et al. 
(2009), Lin et al. (2008), Kallen (2014), 
Vasilakis-Scaramozza et al (2013), Eltonsy et al. 
(2011), Kallen et al. (2007), Schatz et al. (1997), 
Tata et al. (2008), Charlton et al. (2015), Bjorn et 
al. (2014), Hviid et al. (2011), Blais et al. (2009), 
Blais et al. (2007), Kallen et al. (2003) 
Yes 
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Socioeconomic status Bakhireva et al. (2005), Van Zutphen et al. 
(2015), Eltonsy et al. (2011), Tata et al. (2008), 
Charlton et al. (2015), Hviid et al. (2011), Blais et 
al. (2009), Blais et al. (2007) 
Yes 
Insurance status 
(public vs private) 
Schatz et al. (2004) 
No 
Area of residence Eltonsy et al. (2011), Hviid et al. (2011), Blais et 
al. (2009), Blais et al. (2007) 
Yes 
Race/ ethnicity Bakhireva et al. (2005), Schatz et al. (2004), Van 
Zutphen et al. (2015), Lin et al. (2012), Munsie et 
al. (2011), Lin et al. (2009), Lin et al. (2008), 
Schatz et al. (1997)  
No 
Education level Van Zutphen et al. (2015), Lin et al. (2012), 
Munsie et al. (2011), Lin et al. (2008), Eltonsy et 
al. (2011), Kallen et al. (2007), Hviid et al. 
(2011), Blais et al. (2009), Blais et al. (2007) 
No 
Maternal country of 
birth 
Kallen et al. (2007), Hviid et al. (2011) 
No 
Weight/ body mass 
index 
Bakhireva et al. (2005), Van Zutphen et al. 
(2015), Lin et al. (2012), Munsie et al. (2011), 
Lin et al. (2009), Kallen (2014), Vasilakis-
Scaramozza et al (2013), Kallen et al. (2007), 
Schatz et al. (1997), Tata et al. (2008), Charlton 
et al. (2015) 
No 
Smoking status Bakhireva et al. (2005), Schatz et al. (2004), Van 
Zutphen et al. (2015), Lin et al. (2012), Munsie et 
al. (2011), Lin et al. (2008), Kallen (2014), 
Vasilakis-Scaramozza et al (2013), Kallen et al. 
(2007), Schatz et al. (1997), Tata et al. (2008), 
Charlton et al. (2015), Bjorn et al. (2014), Hviid 
et al. (2011), Blais et al. (2007), Kallen et al. 
(2003) 
No 
Alcohol consumption Bakhireva et al. (2005), Van Zutphen et al. 
(2015), Lin et al. (2012), Munsie et al. (2011), 
Charlton et al. (2015), Blais et al. (2007) 
No 
Illicit drug use Lin et al. (2012), Munsie et al. (2011), Blais et al. 
(2007) 
No 
Caffeine use Lin et al. (2009)  
Hypertension Eltonsy et al. (2011), Blais et al. (2009) Yes 
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Diabetes Bakhireva et al. (2005), Lin et al. (2009), 
Vasilakis-Scaramozza et al (2013), Eltonsy et al. 
(2011), Bjorn et al. (2014), Hviid et al. (2011), 
Blais et al. (2009), Blais et al. (2007) 
Yes 
Maternal epilepsy Eltonsy et al. (2011), Hviid et al. (2011), Blais et 
al. (2009), Blais et al. (2007) 
Yes 
Thyroid disorder Blais et al. (2007) No 
Family history of 
congenital 
malformations 
Lin et al. (2009), Hviid et al. (2011), Blais et al. 
(2007) No 
History of infertility Vasilakis-Scaramozza et al (2013), Kallen et al. 
(2007), Kallen et al. (2003) 
No 
Maternal history of 
miscarriage 
Kallen et al. (2007), Blais et al. (2007) 
No 
Pregnancy related characteristics  
Year of delivery Kallen (2014), Kallen et al. (2007), Hviid et al. 
(2011), Kallen et al. (2003) 
No 
Multiple pregnancy Eltonsy et al. (2011), Blais et al. (2009), Blais et 
al. (2007)  
Yes 
Parity Bakhireva et al. (2005), Schatz et al. (2004), Lin 
et al. (2012), Munsie et al. (2011), Kallen (2014), 
Eltonsy et al. (2011), Kallen et al. (2007), Schatz 
et al. (1997), Hviid et al. (2011), Blais et al. 
(2009), Blais et al. (2007), Kallen et al. (2003) 
No 
Gravidity Bakhireva et al. (2005) No 
Preterm delivery Vasilakis-Scaramozza et al (2013), Tata et al. 
(2008) 
No 
Fetal infections Eltonsy et al. (2011), Hviid et al. (2011) No 
Teratogenic 
medication use 
Vasilakis-Scaramozza et al (2013), Eltonsy et al. 
(2011), Blais et al. (2009), Blais et al. (2007) 
Yes 
Folic acid use Van Zutphen et al. (2015), Lin et al. (2012), 
Munsie et al. (2011), Lin et al. (2008), Blais et al. 
(2007) 
No 
Vitamin use Lin et al. (2009), Blais et al. (2007) No 
Vasoactive 
medications use 
Lin et al. (2008), Lin et al. (2008) 
No 
Exposure to irradiation 
or x-rays 
Blais et al. (2007) 
No 
Infant sex Van Zutphen et al. (2015), Lin et al. (2012), 
Munsie et al. (2011), Lin et al. (2009), Tata et al. 
(2008) 
No 
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Fever during the first 
trimester 
Munsie et al. (2011), Lin et al. (2009) 
No 
Trihalomethane 
exposure 
Lin et al. (2009) 
No 
Uterine complications 
(including uterine 
defects and amniotic 
bands) 
Eltonsy et al. (2011) 
No 
Use of 
benzodiazepines, 
analgesics, beta-
blockers and oral 
contraceptives 
Hviid et al. (2011) 
No 
Asthma related variables  
ICS maternal use Garne et al. (2015), Eltonsy et al. (2011), Blais et 
al. (2007)  
Yes 
SABA use Garne et al. (2015), Blais et al. (2009), Blais et al. 
(2007) 
Yes 
LABA use Garne et al. (2015), Blais et al. (2009), Blais et al. 
(2007) 
Yes 
Other asthma 
controller medications 
use 
Eltonsy et al. (2011), Blais et al. (2009) 
Yes 
Intranasal 
corticosteroids use 
Eltonsy et al. (2011), Blais et al. (2009), Blais et 
al. (2007) 
No 
Oral corticosteroids 
use 
Eltonsy et al. (2011), Charlton et al. (2015), Blais 
et al. (2009), Blais et al. (2007) 
Yes 
Emergency department 
(ED) visit or 
hospitalization for 
asthma 
Schatz et al. (2004), Eltonsy et al. (2011), Blais et 
al. (2009), Blais et al. (2007) 
Yes 
Exacerbations/acute 
asthma attacks 
Schatz et al. (1997), Charlton et al. (2015) 
Yes 
Asthma severity level Bakhireva et al. (2005), Eltonsy et al. (2011), 
Charlton et al. (2015), Blais et al. (2009) 
No 
Asthma control Eltonsy et al. (2011), Charlton et al. (2015), Blais 
et al. (2009) 
No 
FEV1 Schatz et al. (2004), Schatz et al. (1997) No 
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2.9 Case ascertainment definitions of major congenital malformations 
Accurate identification of major congenital malformations from administrative 
databases is a key requirement for reaching valid results in studies based on cohorts 
selected from those administrative databases. Computerized health administrative databases 
have become an important source of data for congenital malformations research.  Multiple 
sources of data have been used in prior studies that assessed cases of congenital 
malformations, including hospital discharge data, vital records, specialty clinic data, and 
billing claims data.
53,237
 The recent reports from the Public Health Agency of Canada 
showed that major congenital malformations are present in approximately 3%–5% of 
newborns and 8%–10% of stillbirths in Canada.16 However, several published studies have 
demonstrated reasons which lead to discrepancies in the estimated prevalence of major 
malformations. 
53-55,237-240
 These reasons include the case ascertainment method (e.g. active 
[by trained abstractors], passive [through unverified direct reporting], or a combination of 
both), the source of data, the validity of the diagnostic codes, the classification method into 
minor or major malformations, and the period of assessment (e.g. at birth or during the 1
st
 
year of life).
53-55
 
Both the RAMQ – Quebec’s Medical Claims database – and the MED-ECHO – 
Quebec’s hospital discharge summary database – have been used for congenital 
malformations research.
56,58,59,241
 Of note, the national Canadian Congenital Anomalies 
Surveillance System (CCASS) and the Quebec’s Minister of Health and Social Services 
both rely on the MED-ECHO database for reporting the prevalence of congenital 
malformations in Quebec.
16,242
 Two recent validation studies examined the accuracy of the 
congenital malformations diagnoses recorded in MED-ECHO and RAMQ databases.
60,243
 
Using data from RAMQ, MED-ECHO and the Births and Deaths Registry, Kulaga et al. 
examined the agreement between the congenital malformations recorded in these databases 
and those in the maternal reports from a self-administered questionnaire. A proportion of 
agreement of 60% was found between the database records and the mothers’ reports, and 
among those who were concordant, the mother reported the same diagnosis as recorded in 
the databases in 90% of the cases.
60
 In a recently published validation study, Blais et al. 
examined the validity of congenital malformations diagnostic codes among asthmatics and 
non-asthmatics recorded in the RAMQ, MED-ECHO and the Births and Deaths Registry 
using the infants’ medical charts recorded by the physicians as the gold standard.243 The 
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PPV for the outcomes any congenital malformations and major congenital malformations 
were 82.2% and 78.1% respectively among asthmatic, and 79.2% and 69.0% respectively 
among non-asthmatic women.
243
 In another validation study, the validity of MED-ECHO in 
the identification of neural tube defects (NTD) was tested against hospital medical charts 
and death and stillbirth certificates.
59
 Compared to the total number of NTD in all data 
sources, MED-ECHO had a high sensitivity (92%), but its PPV for the NTD ICD-9 codes 
740.0 to 742.0 was only 56%.
59
 Similar results were reported using comparable health 
administrative databases.
244-246
 In a validation study by Devine et al using the general 
practice research database (GPRD) to identify children with neural tube defects, the overall 
reported PPV was 71% (95% CI = 63 to 78%). However, the PPV varied considerably with 
the specific NTD diagnosis.
244
 Concerns over false positive cases of NTD among live births 
in MED-ECHO files was raised, where an NTD code can be recorded for an infant with a 
suspicion of NTD, even if the diagnosis was not formally confirmed during 
hospitalization.
58
 To date, however, no study has examined the impact of the source of data 
on the estimated prevalence of congenital malformations using the MED-ECHO and/or 
RAMQ databases. 
In fact, it is currently unknown how the congenital malformation diagnoses 
recorded in the Medical Claims database (i.e. RAMQ) would affect the estimated total 
prevalence, aside from MED-ECHO estimates. Some reports using comparable 
administrative databases and surveillance systems in other Canadian provinces and the 
United States were published.
54,55,238,239,247,248
 For example, Bedard et al. used the Alberta 
Congenital Anomalies Surveillance System (ACASS), which links hospital, vital statistics, 
and medical genetic departments databases. They reported a prevalence of congenital heart 
defects of 5.59 per 1000 births, which increased to 12.42 per 1000 births when they added 
data from the outpatient pediatric cardiology clinic database and the hospital records for 
terminations of pregnancy.
55
 However, their active review of health records (involving 
manual searches for cases) and the duration of follow-up (up to 15 years after delivery) 
might have influenced the results.
55
 Metcalfe et al., who used the ACASS database as the 
gold standard, reported an accurate identification rate of 86.9% for congenital 
malformations recorded in the hospitalization database versus 51.1% in an outpatient visits 
database.
248
 The PPV decreased when several databases were used to identify congenital 
malformations, which indicates that false-positive cases were included in the results.
248
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However, the authors did not confirm the cases using medical records, and the true 
percentage of false-positive cases was unknown. In a published validation study using the 
Tennessee births and mothers linked data, the PPV of all malformations detected through 
inpatient claims compared to medical records was 69.9%, with PPV values varying 
considerably by the organ system involved (e.g. 48.9% for central nervous system, 74.5% 
for cardiac and 93.3% for orofacial malformations).
239
 The source of data used for cases 
ascertainment - being a registry, an active surveillance database, an administrative claims 
database or another type of database - has been identified as one of the potential sources of 
variability in the reported prevalence of congenital malformations.
53
 In prior reports, 5%–
20% of cases of major congenital malformations were false positives, and results vary 
according to the malformation categories and are rarely generalizable between data sources 
and classification methods.
55,238,248,249
 Beside the variation in the prevalence of congenital 
malformations among studies, the case ascertainment definitions might also influence the 
estimates for the associations between maternal exposures and congenital malformations. 
Through our literature search, we could not locate a study that examined this objective 
specifically. 
 
2.10 Knowledge gaps to be addressed 
This thesis is partitioned into 3 parts, presented by 4 articles. The first part includes 
a systematic review, the second part includes one comparative safety study and one 
methodological study, and the third part includes an evidence-synthesis study.  
As presented in the literature review above, a large body of evidence exists for 
SABA use during pregnancy, presented in several published articles.
2,26,30,102
 The case is 
different for LABA where small evidence exists and few published studies can be 
retrieved.
30,96,129
 Some systematic reviews exist on the use of asthma controller medications 
during pregnancy and maternal and fetal outcomes, however none examined SABA and 
LABA specifically. Moreover, the methodological limitations of the published studies and 
their statistical power merit a critical examination in a well-designed systematic review. In 
order to validly assess the perinatal safety profile of SABA and LABA use during 
pregnancy, a large systematic review including several important perinatal outcomes is 
needed. 
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Examining the fetal safety of asthma treatment regimens is highly important and has 
been the objective of several published articles. Yet, confounding by indication and the 
severity of asthma itself frequently obscured the results of previous studies, prohibiting 
valid inference on the fetal safety of important treatment regimens. Among the commonly 
prescribed treatment regimens used to manage asthma among pregnant women are ICS 
monotherapy and LABA-ICS combination therapies. Both treatment regimens are used 
among pregnant women with moderate to severe persistent asthma. Among the important 
decisions that physicians must make if asthma cannot be controlled with a low dose of ICS 
is whether to prescribe a LABA to supplement the current dose of ICS or to increase the 
dose of ICS. However, there has been no direct comparison of these treatment regimens to 
guide physicians on which treatment regimen is safer for the newborn. In the first article of 
the second part of this thesis, we will tackle this clinically important question by 
conducting the first comparative safety study examining the prevalence of major 
malformations of these two widely used treatment options for persistent asthma during 
pregnancy, namely LABA-ICS combination therapy versus ICS monotherapy at higher 
doses.  
The second article of the second part of this thesis will be a methodological study 
investigating the case ascertainment methods of major congenital malformations in the 
RAMQ and MED-ECHO databases. The previously published validation studies did not 
examine the difference in the prevalence of major malformations using different case 
ascertainment definitions that vary by the source of data (i.e. when the RAMQ billing 
claims are added or not to the MED-ECHO hospitalizations diagnoses). Due to the 
increasing use of both databases in perinatal epidemiology, the examination of different 
case ascertainment definitions to be used in research is warranted. Moreover, examining the 
impact of different case ascertainment definitions – that vary by the source of data and the 
classification method – on a maternal exposure-major malformations association is of high 
relevance for applicability to future research. 
The third part of this thesis will cover our approach to tackle the issue of the 
discrepancies and inconsistencies of teratogenic medications lists that can be used in 
research. Using incomplete or inaccurate lists in research represent an evident validity 
threat. The teratogens lists provided in earlier reports lack a systematic procedure for the 
classification of medications, even with the availability of relevant references and peer-
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reviewed citations. The literature lacks the presence of proven and potential teratogens lists 
to be used in research that are both systematically and subjectively developed. Despite the 
presence of several reliable resources on teratogenic risks, the currently available lists are 
outdated on several levels and there is no consensus among researchers on the preferred 
lists to use. For that reason, harnessing the full potential of several reliable resources is 
essential to the creation of a comprehensive overview. Therefore, based on the currently 
available leading teratology resources, we planned to develop a systematic and updatable 
procedure for the classification of medications into proven and potential teratogens during 
the first trimester of pregnancy for use in research. 
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CHAPTER 3: OBJECTIVES 
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Objectives of the research program presented in the thesis 
General objective of the thesis: 
We sought to examine the comparative safety of two common treatment regimens 
for maternal asthma during the first trimester of pregnancy, as well as to solve some of the 
methodologic questions that could add important knowledge in this field. 
 
The hypotheses and objectives of the four articles enclosed in the current thesis are 
listed below. 
 
3.1 Systematic review on beta2-agonists and perinatal outcomes 
We hypothesized that the maternal use of beta2-agonists during pregnancy could 
possibly be associated with an increased risk of several adverse perinatal outcomes. 
3.1.1 Primary objective 
To summarize the existing human data examining the impact of the use of inhaled 
SABA and LABA for the treatment of asthma during pregnancy on several perinatal 
outcomes, namely major and any congenital malformations, small for gestational age 
(SGA), birth weight, low birth weight (LBW), gestational age and preterm delivery. 
3.1.2 Secondary objective 
To assess the quality of each study using a validated quality assessment scale and 
perform post-hoc power calculations to evaluate the capacity of the studies in detecting 
clinically significant effects. 
 
3.2 LABA-ICS combination therapy versus ICS monotherapy and major 
congenital malformations  
We hypothesized that the risk of major congenital malformations in pregnant asthmatic 
women treated with LABA and ICS combination is higher than those treated with a higher 
dose of ICS monotherapy. 
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3.2.1 Primary objective 
To compare the prevalence of major congenital malformations in pregnant asthmatic 
women treated with a combination of LABA and ICS and those treated with a higher dose 
of ICS monotherapy. 
 
3.3 Case ascertainment definitions of major congenital malformations 
We hypothesized that using different case ascertainment definitions – that vary by 
the source of data and the classification method – will affect the observed prevalence of 
major congenital malformations and influence the association between the maternal 
exposure and major congenital malformations. 
3.3.1 Primary objective 
To compare the prevalence of major congenital malformations using different case 
ascertainment definitions that vary by the source of data and the classification method.  
3.3.2 Secondary objective 
To evaluate the impact of these case ascertainment definitions on the association 
between maternal asthma and major congenital malformations. 
 
3.4 Systematic Procedure for the Classification of Proven and Potential 
Teratogens  
We hypothesized that the currently available lists of proven and potential teratogens 
used for research are outdated, and an updatable and systematic procedure could better 
identify and classify medications into proven and potential teratogens.  
3.4.1 Primary objective 
To develop a systematic and updatable procedure for the classification of 
medications into those with sufficient evidence of teratogenic risk and those with potential 
teratogenic risk during the first trimester of pregnancy for use in research. 
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CHAPTER 4: METHODS 
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Methods 
This chapter covers the methods presented in the four manuscripts included in 
Chapter 5 more comprehensively, and includes a description of analyses that were not 
reported in the manuscripts. The first part of this chapter will cover the systematic review 
article and the details absent from its manuscript. The second part of this chapter will cover 
the sources of data used in the two manuscripts on the comparative safety of asthma 
treatment regimens and the case ascertainment definitions of congenital malformations. 
The third part will include details on the exposure assessments, outcome definitions and 
potential confounders present in those two manuscripts. The fourth part will cover some 
additional details on the teratogenic and potential teratogenic medications project.  
 
4.1 Systematic review on beta2-agonists and perinatal outcomes 
This section covers the methodologic details that were not reported in the published 
systematic review manuscript presented in Chapter 5 due to space limitations.  
4.1.1 Data sources and search strategy 
We searched six databases for original articles: PubMed, Ovid MEDLINE, 
EMBASE, Cochrane Library, Web of Science, and CINAHL. Prior to commencing the 
search, a systematic review protocol was formed, registered and published in PROSPERO, 
the International prospective register of systematic reviews; cited as PROSPERO 
2011:CRD42011001554,  (Full details presented in Appendix A, also available at:    
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001554).
250
 
Changes that occurred since the protocol publication includes the addition of the quality 
assessment of the included studies using a recognized scale. The quality assessment scale 
chosen was the Newcastle-Ottawa Scale (NOS) for the quality assessment of 
nonrandomized studies (details presented below). 
 
4.1.2 Data extraction and study selection 
We chose seven outcomes that best represent the fetal development (major and any 
malformations, SGA, mean and low birth weight) and the newborn prematurity (gestational 
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age and preterm delivery) among asthmatic women treated with SABA and LABA (full 
definitions in the manuscript). The full search strategy, including the inclusion and 
exclusion criteria, is presented in the manuscript in Chapter 5.  
 
4.1.3 Quality assessment 
The quality assessment of the included studies was performed using the Newcastle-
Ottawa Scale. A 'star system' is used in which a study is judged on three broad 
perspectives: the selection of the study groups; the comparability of the groups; and the 
ascertainment of either the exposure or outcome of interest for case-control or cohort 
studies respectively.
251
 The NOS and the manuals for both cohort and case-control studies 
are presented in Appendix B. 
 
4.1.4 Reporting methodology 
In order to ensure effective and precise reporting of the results from the conducted 
systematic review, we used a recognized reporting guidelines: the PRISMA statement.
252
 
PRISMA stands for Preferred Reporting Items for Systematic Reviews and Meta-
Analyses.
252
 It is an evidence-based minimum set of items for reporting in systematic 
reviews and meta-analyses. The aim of the PRISMA Statement is to help authors improve 
the reporting of systematic reviews and meta-analyses, through ensuring clear presentation 
of what was planned, done, and found in the systematic review and meta-analyses.
252
 The 
PRISMA statement consists of a 27-item checklist and a 4-phase flow diagram.
252
 The flow 
diagram results were included in the manuscript in Chapter 5 and the 27-item checklist is 
presented in Appendix C.  
 
4.2 Sources of data 
This subsection will cover the sources of data used in two of the four manuscripts in 
this thesis; the article on the comparative safety of asthma treatment regimens (LABA-ICS 
combination versus ICS monotherapy in higher doses) and the article on the case 
ascertainment definitions of major congenital malformations. 
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For both articles, we used the Quebec Asthma and Pregnancy Database, which 
links pregnancy data from two health administrative databases in Quebec: the Régie de 
l’assurance maladie du Québec (RAMQ) and the Maintenance et exploitation des données 
pour l’étude de la clientèle hospitalière (MED-ECHO) databases. Both databases – the 
RAMQ and MED-ECHO – have been used before by the research team of Dr. Lucie Blais 
in several studies in the field of asthma and perinatal outcomes.
30,34,121,127,253,254
 They also 
have been frequently used by several researchers in different domains, including pregnancy 
outcomes research, cardiovascular diseases, infections, among several others.
57,137,255-257
 
 
4.2.1 Régie de l’assurance maladie du Québec (RAMQ) 
The RAMQ is responsible for the health insurance coverage of 7,9 million 
individuals in Quebec, including 3,5 million covered with the RAMQ Public Drug 
Insurance Plan.
258
 Since 1997, all Quebec residents who were not covered by a private drug 
insurance plan were required to register with the RAMQ Public Drug Insurance Plan. By 
2015, among the 3,5 million covered by the RAMQ Public Drug Insurance Plan there were 
51% adherents (under 65 years of age and not covered by private insurance at their 
workplace), 35% elderly (over 65 years) and 14% recipients of social assistance.
258
 
The RAMQ database provides the information on medical services dispensed to all 
residents. The RAMQ is the Quebec claims database for medical services provided paid on 
a fee-for-service bases. The RAMQ database used to construct Quebec Asthma and 
Pregnancy Database come in multiple files that were linked together using a unique 
identifier for each individual, i.e. the health insurance number. The sociodemographic 
information on the insured individuals include sex, place of residence (3 digits’ postal 
code), date of birth and death (if deceased), among others.  Information on the admissibility 
to the Public Drug Insurance Plan include the date of the beginning and end of the 
admissibility, among others.
258
 
The medical services file contains – among others – data on each medical service 
provided, records the date the service is dispensed, where it is dispensed (clinic, emergency 
department, hospital), a diagnosis coded with ICD-9 codes, a procedure code, and the 
specialty of the treating physician. The prescription drugs file contains – among others – 
data on each prescription (including the Drug Identification Number [DIN], the dosage 
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form and the dose), the date of dispensing at the pharmacy, the duration of the treatment, 
quantity prescribed and the specialty of the prescribing physician. Importantly, the 
prescription drugs file contains data on prescriptions dispensed in community pharmacies 
only, and does not include data on medications dispensed in hospitals. 
 
4.2.2 MED-ECHO 
The MED-ECHO database is the Quebec universal hospital discharge summary 
database that is used in planning, organization and evaluation of services provided in health 
and social services sectors.
259
 The MED-ECHO database covers all residents of Quebec 
and records data on acute care hospitalizations and same-day surgeries from Quebec’s 
specialized and nonspecialized hospitals and medical centers. Unlike the RAMQ database, 
MED-ECHO database is used for planning and organization purposes and not for the 
reimbursement or payment for health professionals.
259
 The recorded data from MED-
ECHO that were contained within the Quebec Asthma and Pregnancy Database included – 
among others – are the unique patient identifier, the primary discharge, admission and up to 
15 secondary discharge diagnoses, the date of entry, the duration of hospital stay and the 
treatments received during the stay. A complete list of the recorded data in MED-ECHO is 
available at http://www.ramq.gouv.qc.ca/fr/donnees-statistiques/sur-demande/donnees-
msss/Pages/med-echo.aspx#soins. The clinical diagnoses in MED-ECHO are recorded by 
trained medical archivists using the enhanced version of the International Classification of 
Diseases (ICD) 10
th
 revision for Canada (ICD-10-CA) since 2006, and using ICD 9
th
 
revision (ICD-9) before 2006. For delivery-related hospitalizations, records were retrieved 
for the gestational age and birth weight of the baby.  
 
4.3 Pregnancies’ cohort and linked database 
For the two articles on the comparative safety of LABA-ICS combination versus 
ICS monotherapy and the case ascertainment definitions of major malformations we used 
pregnancies from the Quebec Asthma and Pregnancy Database which contains linked data 
from RAMQ and MED-ECHO. The Quebec Asthma and Pregnancy Database includes all 
pregnancies of all women in Quebec who had ≥ 1 asthma diagnosis (ICD-9: 493 or ICD-
10: J45) in the 2-year period preceding one of their deliveries and all pregnancies of a four-
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time larger random sample of other women who delivered between January 1, 1990 and 
March 31, 2010. For each pregnancy included in the cohort, babies were identified (live 
births and stillbirths) using the mother-child link of the RAMQ. The database includes 
583,071 pregnancies from all over Quebec, Canada representing about 35% of all births in 
the province during these years.
260
 
The validity of the diagnosis of asthma recorded in the RAMQ database has been 
formally validated against the patients’ medical charts as gold standard, showing a 
predictive positive value (PPV) of 75% and a predictive negative value (PNV) of 96% for 
asthma diagnosis among pulmonologists and 67% and 99% among family physicians.
261
 
The prescription data recorded in the RAMQ database has been formally evaluated and 
found to be accurate and valid (83% correct identification of the patients and drugs 
dispensed from the prescriptions).
262
 
 
4.4 Article on LABA-ICS combination versus ICS monotherapy 
4.4.1 Cohort structure and inclusion and exclusion criteria 
The flowchart representing the cohort selection is presented in the manuscript in 
Chapter 5. The cohort was selected using the following inclusion criteria: 
1. a pregnancy with a recorded singleton delivery between January 1, 1990 and 
March 31, 2009, so that at least one year of follow-up data was available for 
the newborn; 
2. at least one asthma diagnosis in the two years preceding delivery (ICD-9: 493 
or ICD-10: J45); 
3. the use of ICS in the first trimester of pregnancy (1–14 weeks); 
4. coverage with the RAMQ’s Public Drug Insurance Plan for at least three 
months before and throughout pregnancy. 
We excluded from the analysis pregnancies that met any of the following exclusion 
criteria:  
1. multiple births from a single pregnancy; 
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2. rare maternal condition affecting fetal development (rheumatic disease, 
Cushing disease, iodine deficiency, adrenal tumor, and folic acid deficiency) 
identified using ICD-9 and ICD-10 codes; 
3. teratogenic fetal infection; 
4. at least one filled prescription for a teratogenic medication in the first trimester; 
5. chronic use of an oral corticosteroid (OCS) in the first trimester (i.e.,  30 
days’ supply); 
6. at least one filled prescription for an oral beta2-agonist, leukotriene-receptor 
antagonist, theophylline, ipratropium, cromoglycate, or nedocromil in the first 
trimester; 
7. for women contributing more than one pregnancy during the study period, we 
included only the two most recent pregnancies to allow converging regression 
models. 
At the time of the conduct of this project, the work on the teratogens and potential 
teratogens lists project (included in the current thesis) was not yet concluded. Therefore, we 
used an updated list of proven teratogenic medications that we previously used for similar 
projects on congenital malformations risk.
30,216
 
Two subcohorts were established to compare the treatment regimens indicated for 
women with similar levels of asthma severity. In the first subcohort (hereafter referred to as 
the “moderate asthma subcohort”), we compared women who used LABA plus low-dose 
ICS with those who used a medium-dose ICS monotherapy. In the second subcohort 
(hereafter referred to as the “severe asthma subcohort”), we compared women who used 
LABA plus medium-dose ICS with those who used a high-dose ICS monotherapy. The 
final total cohort included 1302 pregnancies (in 1249 women), 948 pregnancies in the 
moderate asthma subcohort and 354 in the severe asthma subcohort. In this study, LABA 
plus high ICS dose users and low ICS monotherapy users were excluded. 
 
4.4.2 Exposures assessment 
For both ICS and LABA exposure assessments, we used data from the RAMQ 
database on dispensed prescriptions at community pharmacies. For the ICS exposure 
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(fluticasone, beclomethasone, triamcinolone, flunisolide, budesonide, or ciclesonide), since 
the average doses used by patients can differ from one another, we estimated the average 
daily dose taken during the first trimester, because this is considered the period of highest 
fetal risk where the majority of organs and systems develop. The estimate was made using 
an algorithm that was developed by our research team and used for previous studies.
34
 The 
algorithm is based upon the name of the medication, the equivalence between the different 
ICS products recognized by the Canadian Asthma Consensus Guidelines (in fluticasone 
equivalents), 
82
 the dose prescribed, the date and duration of the filled prescription, and the 
rate of renewal of the prescription. The daily dose of ICS was categorized as follow: low 
dose (> 0–250 g), medium dose (> 250–500 g), and high dose (> 500 g).  
LABA (salmeterol and formoterol) are not used as commonly as ICS and their 
prescribed doses do not vary as it is for ICS. Therefore, LABA use was defined as filling at 
least one prescription during the first trimester or three months before pregnancy, with the 
likelihood of its use during the first trimester based on the date and duration of the filled 
prescription, where the duration of the prescription is required to overlap with the 
beginning of the pregnancy to be considered as exposed during the first trimester. Due to 
the established safety evidence on ICS monotherapy from previous reports, compared to 
the smaller body of evidence on LABA, we chose to use ICS monotherapy in higher doses 
as the reference group. 
 
4.4.3 Outcomes definition 
The primary outcome was any major congenital malformation. Full details on the 
outcome definition is presented in the manuscript in Chapter 5. Briefly, cases of major 
congenital malformations were identified using the ICD-9/ICD-10 hospital-based 
diagnostic codes recorded in the RAMQ or MED-ECHO databases at birth or during the 
first year of life of the infant. The specific major malformation classes and their related 
diagnostic codes are presented in Table E1 in the manuscript in Chapter 5. We used the 
Two-step Congenital Malformation Classification (TCMC) method which is presented in 
full details in the article on case ascertainment definitions of major malformations (see 
below). A congenital malformation was defined as major if it was life threatening or could 
cause major cosmetic defects. When a malformation could be classified as major or minor 
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by the geneticist, we considered it as major only if there was at least one hospitalization 
with a primary diagnosis or admission diagnosis related to this malformation that was 
recorded in the MED-ECHO database during the first year of life of the newborn. 
 
4.4.4 Statistical analysis 
Using descriptive statistics, we reported and compared the characteristics of the 
pregnancies for the LABA-ICS combination group and the ICS monotherapy group within 
each subcohort. We calculated the crude prevalence of any major or a specific major 
malformation within each subcohort. The cohort of ICS users comprised 6 mutually 
exclusive groups: 1) LABA-ICS low dose, 2) LABA-ICS medium dose, 3) LABA-ICS 
high dose, 4) ICS low dose monotherapy, 5) ICS medium dose monotherapy, and 6) ICS 
high dose monotherapy. The pregnancies from ICS low dose monotherapy users and 
LABA-ICS high dose users were excluded. Using the ICS higher dose monotherapy as the 
reference group (due to the established evidence on their safety from previous reports), the 
risk of major congenital malformations was compared between the LABA-ICS 
combination therapy and ICS monotherapy separately within the two subcohorts. We used 
the pregnancy as the unit of analysis. Generalized estimating equation (GEE) models with a 
logistic link and an exchangeable correlation matrix were used to estimate the crude and 
adjusted odds ratios for major congenital malformations, while adjusting for all of the 
potential confounders (full models) listed in Table 4.6. The GEE models were used as they 
take into account the correlation between the consecutive pregnancies of individual 
women.
263
 After pre-hoc testing using the unstructured, independent and exchangeable 
correlation matrices, we chose to use the exchangeable matrix since the theoretical 
assumptions behind it are adequate for our situation, the results were similar for the three 
matrices and better stability was achieved using it (additional details on the correlation 
matrices is presented below; 4.6.2). 
In an attempt to increase the power of the analysis, compared to our primary 
stratified analysis, a sensitivity analysis combining the two subcohorts together while 
adjusting for a variable indicating from which subcohort the pregnancy came was 
performed. The indicator variable identifies if the pregnancy came from the severe asthma 
subcohort (yes) or the moderate asthma subcohort (no). The combined adjusted results 
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from this analysis represent an overall comparison of the LABA-ICS combination therapy 
and the ICS monotherapy in higher-doses. All statistical analyses were performed with the 
SAS software, version 9.3 (SAS Institute Inc., Cary, NC). 
For the power calculations, we performed post hoc power calculations to identify 
the ORs that each analysis could detect with a power of 80%. These calculations were 
based on a test for the difference between two independent proportions with a type I error 
of 0.05, the number of pregnancies exposed to each of the contrasted treatment regimens in 
the subcohorts, and the percentage of pregnancies with a congenital malformation observed 
in the reference group (higher-dose ICS monotherapy). Power calculations were performed 
using the PASS interface of the NCSS software (2007). No additional statistical analysis, 
beside the ones published in the manuscript, were performed. 
 
4.5 Article on case ascertainment definitions of major malformations 
4.5.1 Cohort structure and inclusion and exclusion criteria 
The flowchart representing the cohort selection is presented in the manuscript in 
Chapter 5. The cohort was selected using the following inclusion criteria: 
1. a pregnancy with a recorded delivery between January 1, 1990 and March 31, 
2009, so that at least one year of follow-up data was available for every 
newborn; 
2. maternal age at the beginning of pregnancy of 15–45 years; 
3. gestational duration of 20–45 weeks; 
4. fulfillment of the definitions for the presence or absence of active asthma 
during pregnancy (definitions presented below in subsection 4.5.2) 
 
We excluded from the analysis pregnancies that met any of the following exclusion 
criteria:  
1. Quadruplet births from a single pregnancy; 
2.  pregnancies missing the mother–infant link. 
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The final cohort used for the analysis included 467,946 pregnancies, 57,766 
(12.3%) were in women with active asthma and 410,180 (87.7%) were in non-asthmatic 
women. 
 
4.5.2 Exposures assessment 
The secondary objective of that study was to evaluate the impact of different case 
ascertainment definitions on the association between maternal asthma and major congenital 
malformations. Therefore, we selected an operational definition for active asthma during 
pregnancy to apply in the statistical analysis. This operational definition of asthma was 
previously validated and showed a sensitivity of 83.8% and a specificity of 76.5%.
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Asthma was defined as ≥ 1 asthma diagnosis (ICD-9 code 493, except 493.2, or ICD-10 
code J45) recorded during a hospitalization, or ≥ 2 medical claims associated with an 
asthma diagnosis within 2 consecutive years between 1988 and the delivery. Asthma was 
considered active during pregnancy if ≥ 1 medical service for asthma was recorded in the 
RAMQ or MED-ECHO databases up to 2 years before delivery. The pregnancy was 
considered as non-asthmatic (i.e. the reference group) if the woman had no diagnosis of 
asthma recorded in either database between 1988 and the delivery. The use of active 
asthma definition in this study differs from the study on LABA-ICS combination vs ICS 
monotherapy because the later study had another important inclusion criterion not 
applicable to the current study, which is ICS use in the first trimester. 
 
4.5.3 Outcomes definition 
The article investigates the impact of different case ascertainment definitions of 
major congenital malformations on the prevalence estimates observed and on maternal 
exposure-outcome association estimates (i.e. maternal asthma as exposure). The manuscript 
presented in Chapter 5 contains the full details of the different case ascertainment 
definitions that were examined. Briefly, we compared two methods for the classification of 
congenital malformations. The first, the Two-step Congenital Malformation Classification 
(TCMC) method, which was developed specifically for research and used in previous 
perinatal pharmacoepidemiologic studies.
34,216
The second method was the national 
Canadian Congenital Anomalies Surveillance System (CCASS) method. Table e1 in the 
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manuscript provides a complete description and comparison of the two classification 
methods. In the study, we aimed to compare case ascertainment definitions that differ by 
the source of data (i.e. diagnoses recorded in a hospital database [MED-ECHO] or in a 
medical billing claims database [RAMQ]) and the classification method (i.e. the TCMC or 
CCASS methods). We compared six different case ascertainment definitions (detailed in 
Table 1 in the manuscript in Chapter 5). 
 
4.5.4 Statistical analysis 
The characteristics of the pregnancies were compared between the pregnancies of 
women with active asthma and non-asthmatic women using descriptive statistics. The 
prevalence of congenital malformations was defined as follows: prevalence = number of 
pregnancies with at least one malformation among live births and stillbirths/total number of 
pregnancies with live births and stillbirths. 
Using the six different case ascertainment definitions, we calculated the prevalence 
of major malformations and system-specific categories of major malformations. Then, 
using pregnancy as the unit of analysis, we compared the prevalence of major congenital 
malformations between pregnancies of women with active asthma and non-asthmatic 
women (maternal asthma-major malformations association). We used GEE models with a 
logistic link and the exchangeable correlation matrix to estimate crude and adjusted odds 
ratios for major malformations with 95% confidence intervals. The adjusted models 
included the list of potential confounders (full models) listed in Table 4.6. 
In a sensitivity analysis not published in the article by Eltonsy et al. (published in 
MCHJ; 2016), we sought to examine the effect of the choice of the correlation matrix in the 
GEE models on the point estimates and the confidence intervals estimated. In the 
application of the GEE models, the user specifies a working correlation structure for 
describing how the responses within clusters are related to each other.
265,266
 Correlation 
structures that are commonly considered include independent, exchangeable, 
autoregressive, stationary, unstructured, and fixed. In congenital malformations research, 
independent, exchangeable, and unstructured matrices can be reasonable choices, due to the 
plausible assumptions they carry. The assumption behind the independent correlation 
structure is that responses are uncorrelated within a cluster.
265
 The assumption behind the 
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use of the exchangeable correlation structure is that any two responses within a cluster have 
the same correlation.
265
 In an unstructured correlation structure, there are less constraints on 
the correlation parameters. An unstructured correlation structure has a separate correlation 
parameter for each pair of observations within a cluster, even if the time intervals between 
the responses are the same. For a cluster that has n responses, there are n(n-1)/2 correlation 
parameters. The presence of such large number of correlation parameters to be estimated in 
the unstructured correlation structure makes it one of the most complex correlation 
structures.
265
 Although GEE models can provide relatively valid standard errors, even when 
the correlation structure is incorrectly specified, it is interesting to examine the results of 
the GEE models when using different correlation matrices that differ by complexity. In this 
sensitivity analysis, we used exchangeable, independent, and unstructured correlation 
matrices in the GEE models, and compared the results obtained using the three matrices. 
All statistical analyses were performed with SAS software, version 9.3 (SAS Institute Inc., 
Cary, NC). The results are presented in Chapter 5 results, section 5.3. 
 
4.6 Potential confounders 
4.6.1 Risk factors for major congenital malformations 
The different risk factors for congenital malformations retrieved from our literature 
review are presented in Chapter 2, section 2.7. The main reason behind excluding several 
of the risk factors in our multivariate models is the absence of these variables from the 
RAMQ and MED-ECHO databases (e.g. maternal smoking status and folic acid use). Some 
other risk factors had very low prevalence among the pregnancies included in our cohorts, 
which hindered their inclusion in our models. For example, rare maternal conditions (as 
rheumatic diseases and phenylketonuria) which had low prevalence in our cohort. The 
details of the excluded conditions are presented in section 4.3 and chapter 5. 
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4.6.2 Potential confounders included in the statistical analysis 
Table 4.6 Potential confounding variables included in the statistical analysis 
Confounding variable 
Article on 
LABA-ICS 
combination 
versus ICS 
monotherapy 
Article on 
case 
ascertainment 
definitions of 
major 
malformations 
Database used in 
identification 
Maternal sociodemographic characteristics 
Maternal age at the 
beginning of pregnancy (18–
34 and <18 or >35 years) 
X X RAMQ 
Area of residence at delivery 
(rural/urban) 
X X RAMQ 
Receipt of social assistance 
at the beginning of 
pregnancy (yes/no) 
X X RAMQ 
Maternal comorbidities and pregnancy related characteristics 
Chronic hypertension up to 1 
year before pregnancy
§
 
X X 
RAMQ and MED-
ECHO 
Diabetes mellitus up to 1 
year before pregnancy
§
 
X X 
RAMQ and MED-
ECHO 
Maternal epilepsy up to 1 
year before pregnancy
§
 
 X 
RAMQ and MED-
ECHO 
Multiple pregnancy 
 X 
RAMQ and MED-
ECHO 
Asthma related variables 
exacerbation of asthma three 
months before pregnancy 
(yes/no) * 
X  
RAMQ and MED-
ECHO 
SABA doses per week in the 
three months preceding 
pregnancy
¥
 
X  RAMQ 
§
 Identified using the ICD-9/ICD-10 diagnoses codes recorded in the MED-ECHO or 
RAMQ databases up to 1 year before pregnancy 
* Defined as a filled prescription for OCS, an emergency department visit, or a 
hospitalization for asthma 
¥ 
Classified into 0–3 or > 3 doses/week; one dose is equal to 200 g of salbutamol 
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A note on our confounders selection; we based our choices on the established 
definitions of confounding. Typically, a spurious association appears due to the sharing of 
common causes (i.e. a confounder, given that it is not in the causal pathway between the 
exposure and the outcome).
267
 In the article on the LABA-ICS combination versus ICS 
monotherapy in higher doses, several of the risk factors identified in Chapter 2, section 2.7 
do not meet these criteria. For example, while alcohol consumption is considered a strong 
risk factor for congenital malformations, there is no data suggesting that alcohol use has a 
differing prevalence between LABA-ICS combination users and ICS monotherapy users in 
high doses. 
 
In the second article on the different case ascertainment definitions of major 
malformations, the true association between asthma and major malformations is not the 
objective of the study, but rather how the estimates are affected by the differing case 
ascertainment definitions. Therefore, better statistical stability was one of our primary 
goals. 
 
 
4.7 Systematic Procedure for the Classification of Proven and Potential 
Teratogens  
This section covers the methodology details that were not reported in the 
manuscript presented in Chapter 5.  
 
4.7.1 Steps and settings 
We developed a systematic two-step procedure for teratogen identification and 
classification for research purposes. By applying the procedure, two medication lists can be 
obtained, one including “teratogenic medications” and the other including “potentially 
teratogenic medications”. Full details on the two-step procedure is presented in the 
published article in Chapter 5. 
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Briefly, Step 1 included the identification and classification of medications reported 
in the reference book Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and 
Neonatal Risk (9th ed.) by Briggs et al. 2011 (Briggs and others, 2011) into two provisional 
lists: 1) teratogenic medications, and 2) potentially teratogenic medications. Followed by a 
review by a teratology expert (B.M.) leading to either the approval of classification or 
further verification, i.e., entry on a “verification list”. Other references were searched, 
including reviews of teratogenic drugs and drug-related birth defects, textbooks of 
teratogenicity, and Briggs et al. updates (till October 2013), to identify other potential 
teratogens to be added to the verification list.  
 
In Step 2, we searched the TERIS database for the medications in the verification 
list. The details of the procedures applied in Step 2 are presented in the manuscript in 
Chapter 5. Briefly, we searched the TERIS database for each medication in the verification 
list, and if the medication was present, we classified it according to the newly developed 
“TERIS scheme” as presented in the manuscript (Chapter 5). If the medication was absent 
from the TERIS database, we classified it based on our “expert consensus”. The expert 
consensus was the opinion of two experts in teratogenicity and reproductive risk (B.M. and 
E.F.). The experts used all available published reports and resources to develop their 
ratings. For the inclusion into List 1, the experts used the criteria for proof of human 
teratogenicity proposed by Shepard and presented below in Table 4.8.
219
 The experts’ 
opinions were collected by a third author and a consensus meeting was conducted to 
resolve any conflicting decisions. 
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Table 4.7: Shepard’s amalgamation of criteria for proof of human teratogenicity (Source: 
Shepard, 1994)
219
 
(1) Proven exposure to agent at critical time(s) in prenatal development. 
(2) Consistent findings by two or more epidemiologic studies of high quality: 
(a) Control of confounding factors 
(b) Sufficient numbers 
(c) Exclusion of positive or negative bias factors 
(d) Prospective studies, if possible 
(e) Relative risk of six or more 
(3) Careful delineation of the clinical cases. A specific defect or syndrome, if present, is 
very helpful 
(4) Rare environmental exposure associated with rare defect 
(5) Teratogenicity in experimental animals 
(6) The association should make biological sense 
(7) Proof in an experimental system that the agent acts in an unaltered state Evidence of 
placental transfer 
Note: items (1), (2), and (3) or (1), (3), and (4) are essential criteria. Items (5), (6), and (7) 
are helpful but not essential. 
 
 
For a medication to be included into List 2 (potentially teratogenic medications), the 
experts used three stepwise conditions that the potential teratogen has to fully satisfy: 
1
st
 Step. The experts verified that the medication did not meet Shepard’s criteria (if 
it meets the criteria: send back to List 1, if no: proceed to Step 2). 
2
nd
 Step. The experts examined if enough evidence exists that suggest the absence 
of a teratogenic risk in humans (if yes: to not include in neither list, if no: proceed to 
Step 3).  
3
rd
 Step. The experts examined if there is 1 human study or sufficient animal data 
that shows evidence of teratogenic risk (if yes: to include the medication in List 2, if 
no: to not include in neither list).  
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4.7.2 Statistical analysis 
We tallied the number of medications included in each step with our classification 
procedure. We calculated the number and percentage of observed agreements between the 
two experts in teratogenicity. We also calculated the kappa value, with its 95% confidence 
interval (CI), and the weighted kappa for the agreement between the two experts. The 
calculation of weighted kappa assumes the categories are ordered and accounts 
for how far apart the two raters are.
268
 The following table was used to interpret the 
K value: 
Value of K Strength of agreement 
≤ 0.20 Poor 
0.21 - 0.40 Fair 
0.41 - 0.60 Moderate 
0.61 - 0.80 Good 
0.81 - 1.00 Very good 
Source: Altman DG (1999) Practical statistics for medical research. London: Chapman and 
Hall. 
Measures of agreement were calculated with GraphPad Prism 2015 (GraphPad 
Software Inc. 2015, La Jolla, CA, USA). 
 
4.8 Ethical approval 
4.8.1 Systematic review on beta2-agonists and perinatal outcomes  
Primary data was not collected. The review did not involve any human or animal 
subjects (including human material or human data). Because the study was conducted using 
online resources and research databases, no ethical committee approval was required. 
 
4.8.2 Article on LABA-ICS combination versus ICS monotherapy 
This research project was approved by the Ethics Committee of the Hôpital du 
Sacré-Cœur de Montréal. Authorization was obtained from the Commission d’Accès à 
l’Information du Québec to access and link the RAMQ and MED-ECHO databases. 
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4.8.3 Article on case ascertainment definitions of major malformations 
This research project was approved by the Ethics Committee of the Hôpital du 
Sacré-Cœur de Montréal. Authorization was obtained from the Commission d’Accès à 
l’Information du Québec to access and link the RAMQ and MED-ECHO databases. 
 
4.8.4 Systematic Procedure for the Classification of Proven and Potential 
Teratogens  
Because the study was conducted using online resources and medical references, 
and did not involve any human or animal subjects (including human material or human 
data), no institutional review board approval was required. 
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Abstract 
Background: Short and long-acting beta2-agonists (SABA and LABA) have a 
crucial role in asthma management during pregnancy, as stated in the current guidelines. 
Objective: To systematically review the evidence on beta2-agonists use during pregnancy 
and adverse perinatal outcomes. Data sources and study selection: Six databases were 
searched before January 1, 2013 for beta2-agonists use during pregnancy and congenital 
malformations, small for gestational age, mean and low birth weight, gestational age and 
preterm delivery. Original English language articles were included with no cut-off date. 
Quality assessment and post-hoc power calculations were performed. Results: Twenty-one 
original studies were identified. Four studies reported a significant increased risk of 
congenital malformations with SABA, while one study reported a significant decreased risk 
with high doses of SABA. One study reported a significant increased risk of congenital 
malformations with LABA and four studies reported a significant increased risk of 
congenital malformations with beta2-agonists (SABA and/or LABA). One study reported a 
decrease in birth weight centiles among LABA users. Limitations: All studies reporting 
significant results, except two, used non-asthmatic women as reference group, making it 
difficult to differentiate between the effect of the disease from the one of the beta2-agonists. 
Non-significant results should be interpreted with caution due to the low statistical power 
of several studies. Conclusion: Methodological limitations and lack of power of several 
studies prevent us to conclude on the perinatal safety of beta2-agonists. Until further 
evidence is available, physicians should continue prescribing them as recommended in the 
guidelines whenever needed to attain asthma control. 
 
 
Key words: Asthma, Pregnancy, Bronchodilators, Beta-2-agonists, Birth weight, 
Congenital defects, Gestational age, Preterm birth. 
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1. Introduction 
Asthma is considered to be one of the most common chronic diseases among 
pregnant women, affecting approximately 4 to 8% of the pregnancies in the United States 
and even higher among other populations.
1-3
 Pregnant women with severe or uncontrolled 
asthma are at higher risk for pregnancy complications and adverse fetal outcomes than 
women with well-controlled asthma.
2,4-8
 Due to the reported potential risk of uncontrolled 
asthma during pregnancy on the health of the mother and fetus, the National Asthma 
Education and Prevention Program (NAEPP) states that “(…) it is safer for pregnant 
women with asthma to be treated with asthma medications than it is for them to have 
asthma symptoms and exacerbations.”2 
While inhaled corticosteroids (ICS) are considered the cornerstone therapy in the 
management of persistent asthma during pregnancy,
9,10
 beta2-agonists have a crucial role in 
asthma management.
2
 During pregnancy, short-acting beta2-agonists (SABA) are used as 
reliever medications for all asthma types (mild, moderate, or severe), while long-acting 
beta2-agonists (LABA) are used in cases of moderate to severe persistent asthma, in 
combination with low or medium doses of ICS.
2,11 
It has been reported that 40 to 70% of 
asthmatic women use SABA and 8 to 13% use LABA during pregnancy.
12,13
 Despite being 
widely used during pregnancy, all of the SABA and LABA are classified as “C” under the 
US Food and Drug Administration (FDA) categorization
4
, which states that risk cannot be 
ruled out and that there is a chance of fetal harm if the drug is administered during 
pregnancy, but the potential benefits may outweigh the potential risk. Moreover, the 
Teratogen Information System (TERIS) reports that SABA and LABA have an 
“Undetermined” teratogenic risk due to the limited quality and quantity of data on the 
safety of these medications 
4
.  
Several studies examined the effect of SABA and LABA use on perinatal outcomes 
during pregnancy.
2,14-24
 Published reviews on this topic did not capture the whole evidence 
from all published studies on all clinically important perinatal outcomes. 
4,14-16,25,26
  Given 
the need to better estimate their fetal risks, we aimed to summarize the existing human data 
- from experimental trials and observational studies - examining the impact of the use of 
inhaled SABA and LABA for the treatment of asthma during pregnancy on several 
perinatal outcomes, which are major and any congenital malformations, small for 
gestational age (SGA; weight < 10
th
 percentile for the gestational age), birth weight, low 
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birth weight (LBW; weight <2500 g), gestational age and preterm delivery. We also 
assessed the quality of each study using a validated quality assessment scale and performed 
post-hoc power calculations to evaluate the capacity of the studies to detect clinically 
relevant effects.  
 
2. Methods 
2.1 Data Sources and Search Strategy 
A search strategy was formed, registered and published (PROSPERO 
2011:CRD42011001554, 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001554). 
PubMed, Ovid MEDLINE, EMBASE, Cochrane Library, Web of Science, and CINAHL 
were searched for original articles. The first search was performed using the keywords 
“asthma*” and “pregnan*”. A second search was done using the keywords “congenital”, 
“malformations”, “congenital anomalies”, “birth weight”, “low birth weight”, “small for 
gestational age”, “gestational age”, “preterm delivery”, “preterm birth”,  “embryonic 
development”, “fetal development” and “foetal development” , combined with “asthma*” 
and “pregnan*”. A third search was conducted using keywords “beta-agonist”, “short-
acting beta-agonist”, “long-acting beta-agonist” and the individual medication names 
[salbutamol, albuterol, terbutaline, metaproterenol, fenoterol, salmeterol, and formoterol], 
together with “asthma*” and “pregnan*”. Furthermore, we applied a cross-search using the 
keywords in the three searches. A Medical Subject Heading (MeSH) search was also 
conducted in MEDLINE, using the terms “asthma” and “pregnancy”. Human studies 
published in English language were only considered in our final selection and no particular 
cut-off for the date of publication was used. Only original articles were included and 
abstracts without supporting articles were excluded. No exclusion criteria were imposed on 
either the choice of the reference groups or the treatments compared to beta2-agonists. All 
types of studies (RCTs, case-control and cohort studies) were searched except case-reports, 
case-series and Prescription-Event Monitoring studies (PEM). All inhaled beta2-agonists 
were included either taken separately or in combination with ICS. The latest search was 
performed on January 1, 2013. Related articles and data cited in the reference book “Drugs 
in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk”17 were also 
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included. Bibliographies of all retained articles and reviews on the topic were searched for 
additional relevant articles. 
 
2.2 Data Extraction and Study Selection 
The search strategy, including the inclusion and exclusion criteria, is summarized in 
Figure 1. We chose seven outcomes that we believe best represent the fetal development 
(major and any malformations, SGA, mean and low birth weight) and the newborn 
prematurity (gestational age and preterm delivery) among asthmatic women treated with 
beta2-agonists. The primary search was conducted by one author (SE), while a second 
confirmatory independent search was performed by a second author (FZK). All studies 
identified in the search were independently reviewed by two co-authors and the study 
selection was made independently by two co-authors (SE and FZK). Data extraction, 
quality assessment and post-hoc power calculations were first performed by one author 
(SE). An independent data extraction and power calculation were performed by a second 
author (FZK). Discrepancies were resolved by consensus.    
Data retrieved from each study included the study reference, the design, the source 
of data, the timing of exposure, the type of beta2-agonists, the definition of the reference 
group, the sample size of the exposed and unexposed groups, the reported proportions or 
means and standard deviations for the outcomes in the exposed and unexposed groups, the 
effect size (crude or adjusted relative risk [RR], odds ratio [OR], or mean difference [MD]), 
and the p-value or 95% confidence interval (CI) associated with the effect size. In studies 
that did not report the effect size, a crude RR, OR, or MD was calculated when sufficient 
information was provided. 
 
2.3 Quality Assessment and Power Calculation 
The Newcastle-Ottawa Scale for observational studies (NOS-scale) was used for 
assessing the methodological quality of studies that passed the defined inclusion criteria.
27
 
We used the NOS-scale based on recommendations by the Cochrane Non-Randomized 
Studies Methods Working Group since all of the studies included were expected to be non-
randomized.
28
 The NOS-scale has two forms, one for cohort studies and one for case-
control studies, and studies are being judged on three domains: 1) selection of study groups 
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(score:0-4), 2) comparability of the groups (score:0-2), and 3) exposure/outcome 
ascertainment (score:0-3). An external reviewer was called for the quality assessment of the 
study published by our group 
29
 in order to avoid a conflict of interest. 
We performed a post-hoc power calculation for each study reporting non-
statistically significant results to detect a RR of 1.5, a mean difference in the birth weight of 
500 g, or a mean difference in gestational age of one week to establish a comparison 
between studies. The power calculations were based on t-tests for MD and on the test for 
the difference between two independent proportions for RR and OR. A type I error of 0.05 
was used for power calculations; all calculations were performed using PASS 2008 
interface of NCSS software.
30
 
 
3. Results  
3.1 Study Selection 
Study selection results are summarized in Figure 1. Using our selection criteria, 19 
original studies were found.
18-24,29,31-41 
After reviewing all cited references in the retrieved 
studies, we added the data from the Collaborative Perinatal Project (CPP) and the Michigan 
Medicaid study (their data were retrieved from 2 books
17,42
, see Figure 1.), having a total of 
21 studies included in our review.
17-24,29,31-42 
We did not exclude any studies even if they 
provided insufficient information for the power calculation. Thirteen were cohort studies
17-
21,23,24,29,33,34,36,39,42
, seven were case-control studies
31,32,35,37,38,40,41
, and one was a cohort 
study that contained partial data from a randomized controlled trial.
22
 Nine studies reported 
statistically significant results.
24,29,31,32,36,37,40-42 
Post-hoc power calculations were performed 
for certain outcomes in eighteen studies 
18-24,29,31-35,37-41
, while the lack of information 
prevented us from performing power calculations for certain outcomes in four 
studies.
17,19,36,42
 Results from the quality assessment of the studies using the NOS-scale are 
summarized in Table 1. 
 
3.2 Major congenital malformations 
Major congenital malformations are defined as structural and developmental 
anomalies that affect viability and/or quality of life and require intervention.
43
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Studies that investigated the association between beta2-agonists and major 
congenital malformations are presented in Table 2A: six studies examined SABA and/or 
LABA use
20,22,31,32,40,41
, nine studies examined the SABA separately
21,23,29,31,32,35,36,40,41
, and 
six studies examined LABA separately.
29,32,35,36,40,41 
 
Among the six studies that investigated SABA and/or LABA use, two studies used 
a reference group of asthmatic pregnant women unexposed to beta2-agonists during 
pregnancy; none of these two studies reported a significant increased risk of major 
malformations.
20,22
 A reference group of non-asthmatic or a combination of asthmatic and 
non-asthmatic pregnant women has been used in the other studies
20,31,32,40,41
, with four 
studies reporting a significant increased risk of major malformations.
31,32,40,41
 Indeed, Lin et 
al. in three studies reported increased risk of congenital heart defects
31
 (aOR=2.20; 95% CI: 
1.05, 4.61), gastroschisis
32
 (aOR=2.06; 95% CI: 1.19, 3.59), and other selected birth 
defects
41
 (aOR=2.39; 95% CI: 1.23, 4.66) with beta2-agonists use during the first trimester. 
In a recent case-control study by Munsie et al. an association between bronchodilator use 
(mainly SABA and LABA) and an increased risk of cleft lip only was found (aOR=1.77; 
95% CI: 1.08, 2.88).
40
 
Among the nine studies that evaluated SABA separately, three studies used 
asthmatic women unexposed to SABA during pregnancy as the reference group
23,29,35
 while 
the other six studies used non-asthmatic women or the general population as the reference 
group.
21,31,32,36,40,41
 In a study by Kallen et al. using the Swedish Medical Birth Registry, the 
authors reported an increased risk of any cardiac defect with salbutamol use in the first 
trimester (aOR=1.38; 95% CI 1.12, 1.70) when compared to the general population.
36
 In 
the study by Munsie et al., the authors found a significant increased risk of cleft lip 
(aOR=1.79; 95% CI: 1.07, 2.99) and cleft palate (aOR=1.65; 95% CI: 1.06, 2.58) with the 
maternal use of salbutamol during the periconceptional period as compared to the general 
population of asthmatics and non-asthmatics 
40
. In a recent study by our group, we reported 
a decreased risk of major malformations with the maternal use of high doses of SABA per 
week (>10 doses) as compared to no use, with an aOR of 0.68 (95% CI: 0.48, 0.95).
29
 None 
of the other five studies reported a significant association. 
Regarding the six studies that examined LABA use separately, two used a reference 
group of asthmatic women unexposed to LABA.
29,35
 In the study conducted by our research 
group, we found a significant increased risk of major cardiac (aOR=2.38; 95% CI: 1.11, 
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5.10) and major “other and unspecified malformations” (aOR=3.97; 95% CI: 1.29, 12.20) 
among LABA users compared to asthmatic non users, but the association rendered non-
significant when all major malformations were combined together.
29
 None of the other five 
studies reported a significant association between LABA use and major 
malformations.
32,35,36,40,41
  
The ten studies that reported non-significant results for major congenital 
malformations and for which we had enough information to calculate the statistical power 
had a power ranging from 6% to 100% to detect an effect size of 1.5, with only 2 studies 
having a power > 80%.
35,41
 
 
3.3 Any congenital malformations  
Congenital malformations can be defined as any structural or functional anomalies, 
including metabolic disorders.
43
 Any congenital malformations include all types of 
congenital malformations (major or minor) that could occur during fetal development.  
Studies that investigated the association between beta2-agonists use during 
pregnancy and any congenital malformations are presented in Table 2B: four studies 
examined SABA and/or LABA use
19,33,34,39
, six studies examined SABA separately
17,29,36-
38,42
, and four studies examined LABA separately.
29,36-38
 None of the four studies that 
investigated SABA and/or LABA use reported significant results; only two studies used a 
reference group of asthmatic pregnant women unexposed to beta2-agonists during 
pregnancy.
19,33
  
Among the six studies that evaluated the effect of SABA separately, two studies 
used asthmatic women unexposed to SABA during pregnancy as the reference group,
29,37
 
and a significant association was found in one study.
37 
In this matched case-control study, 
Tamasi et al. reported a significant increased risk of any malformations with maternal use 
of fenoterol during the first trimester of pregnancy (crude OR=1.6; 95% CI: 1.3, 2.0).
37
 
Reference groups formed by the general population, non-asthmatic pregnant women, or 
unspecified reference groups have been used in four studies
17,36,38,42 
and significant 
associations were reported in two of these studies.
36,42
 A significant increased risk of any 
malformations with the use of epinephrine (SABA) during the first trimester was reported 
by the CPP group (RR=1.7, P<0.05)
42
. Kallen et al. in a retrospective cohort study using 
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the Swedish Medical Birth Registry reported a slight increased risk of any malformations 
with terbutaline use in the first trimester of pregnancy (aOR=1.11; 95% CI:1.04, 1.19).
36
  
From the four studies that examined the use of LABA separately, two used a 
reference group formed of asthmatic women unexposed to LABA during pregnancy
29,37
, 
one used a reference group formed of asthmatic and non-asthmatic women
38
, and the 
reference group was the general population in one study,
36 
Only one of these studies found 
a significant result: women exposed to LABA were found to have an increased risk of 
genital malformations (aOR=6.84; 95% CI: 2.58, 18.10) and “other and unspecified 
malformations” (aOR=3.43; 95% CI: 1.39, 8.45) when compared to asthmatic women 
unexposed to LABA during pregnancy.
29 
 
The six studies that reported non-significant results for any congenital 
malformations and provided enough information to calculate the statistical power had a 
power ranging from 9% to 100% to detect an effect size of 1.5 with three studies having a 
power > 80%.
29,37,38
 
 
3.4 Small for gestational age 
Studies that investigated the association between beta2-agonists use during 
pregnancy and SGA are presented in Table 3: three studies examined SABA and/or LABA 
use
19,20,22
, three studies examined SABA separately,
18,21,23
 and two studies examined LABA 
separately.
18,24
 The three studies that examined the use of SABA and/or LABA used a 
reference group of asthmatic pregnant women unexposed to beta2-agonists during 
pregnancy 
19,20,22
, and none of these studies reported a significant increased risk of SGA 
with beta2-agonists use. Among the three studies that examined SABA separately, only one 
used a reference group formed of asthmatic women unexposed to SABA
23
; and the three 
studies reported non-significant associations between SABA exposure and SGA. Among 
the two studies that examined LABA separately, one study used a reference group formed 
of asthmatic women unexposed to LABA during pregnancy 
24
 and both studies reported 
non-significant results. 
The six studies that reported non-significant results for SGA and for which we had 
enough information to calculate the statistical power had a power ranging from 8% to 60% 
to detect an effect size of 1.5. 
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3.5 Birth weight and low birth weight 
3.5.1 Birth weight 
Studies that investigated the association between beta2-agonists and birth weight are 
presented in Table 4A: four examined SABA and/or LABA use
19,20,34,39
, one examined 
SABA separately
23
, and one examined LABA separately.
24
 Among the four studies that 
examined SABA and/or LABA use, two used a reference group formed of asthmatic 
women unexposed to beta2-agonists during pregnancy 
19,20
; none of these four studies 
reported a significant association between beta2-agonists use during pregnancy and mean 
birth weight. The only study that investigated the association between the use of SABA 
separately and birth weight did not find a significant difference in the mean birth weight 
between the compared groups.
23
 The only study that examined the association between the 
use of LABA separately and birth weight did not find a significant association with the 
mean birth weight, but found a significant decrease in the birth weight centiles among 
women exposed to salmeterol when compared to women exposed to budesonide during 
pregnancy (cMD = -39.2; P-value: 0.011).
24
  
The four studies that reported non-significant results for birth weight and for which 
we had enough information to calculate the statistical power had a power of 100% to detect 
a mean difference of 500g. 
 
3.5.2 Low birth weight 
Studies that investigated LBW are presented in Table 4B: three studies examined 
SABA and/or LABA use
22,33,34
, and two studies examined SABA separately.
21,23 
Among 
the three studies that examined SABA and/or LABA use, two of them used a reference 
group of asthmatic women unexposed to beta2-agonists
22,33
, and none of these three studies 
reported a significant association between beta2-agonists use during pregnancy and LBW. 
Among the two studies that focused on SABA, one used two references groups, one formed 
of asthmatic women unexposed to SABA and one formed of non-asthmatic women
23
, and 
the other one used a reference group formed of non-asthmatics.
21
 Both studies found no 
significant association between SABA use and LBW.  
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The four studies that reported non-significant results for LBW and for which we had 
enough information to calculate the statistical power had a power ranging from 3% to 67% 
to detect an effect size of 1.5. 
3.6 Gestational age and preterm delivery 
3.6.1 Gestational age 
Studies that investigated the impact of beta2-agonists on gestational age at birth (in 
weeks) are presented in Table 5A: three studies investigated the impact of SABA and/or 
LABA use
20,34,39
 and one study examined LABA separately.
24
Among the three studies that 
examined SABA and/or LABA use, only one used a reference group formed of asthmatic 
women (ICS users)
20
, and none of the three studies found a significant association between 
beta2-agonists and gestational age. The only study that examined LABA separately did not 
find any significant association between LABA use and gestational age.
24
 
The four studies that reported non-significant results for gestational age had a power 
to detect a mean difference of one week ranging from 90% to 100%.  
 
3.6.2 Preterm delivery 
Studies that investigated the impact of the use of beta2-agonists on preterm delivery 
(<37 weeks) are presented in Table 5B: three examined SABA and/or LABA use
22,33,34
, 
two examined SABA separately
18,23
, and one examined LABA separately.
18
 Among the 3 
studies that examined SABA and/or LABA use, 2 studies used a reference group formed of 
asthmatic women unexposed to beta2-agonists during pregnancy 
22,33
; none of these three 
studies reported a significant association between beta2-agonists and preterm delivery. One 
of the two studies that examined SABA separately used a reference group of asthmatic 
women unexposed to SABA during pregnancy
23
 and both studies reported non-significant 
associations with preterm delivery. Moreover, the study that examined LABA separately 
used a reference group of asthmatic and non-asthmatic women unexposed to LABA; and 
did not find a significant association between LABA and preterm delivery. 
The five studies that reported non-significant results for preterm delivery and for 
which we had enough information to calculate the statistical power had a power ranging 
from 12% to 76% to detect an effect size of 1.5. 
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4. Discussion 
We described 21 studies that investigated the impact of beta2-agonists use during 
pregnancy on perinatal outcomes. Eight studies reported a significant increased risk of 
congenital malformations for women exposed to SABA and/or LABA
31,32,40,41
, SABA 
separately
36,37,40,42
, or LABA separatlety
29
 during pregnancy. On the other hand, one study 
found a significant decreased risk of major malformations with high doses of SABA.
29
 
 
No 
significant associations were reported between SABA and LABA and all other perinatal 
outcomes, with the exception of one study that reported a significant decrease in birth 
weight centiles among salmeterol (LABA) users.
24
 We observed no impact of beta2-
agonists on the risk of preterm birth despite that they can inhibit uterine contractions and be 
used in IV formulation to control premature labour.
44
 This negative result might be 
explained by the fact that the drug profile of inhaled beta2-agonits shows very low 
detectable plasma levels with the administration of recommended doses, and consequently 
minor – if not negligible – tocolytic effect.45-48  
It is worth noting that six of the eight studies reporting significant increased risk of 
congenital malformations used a reference group of non-asthmatic women or a 
combination of asthmatic and non-asthmatic women, studies in which it becomes 
impossible to separate the effect of the medication from the disease. 
31, 32, 36, 40-42
 The other 
two studies used a reference group of unexposed asthmatic women during pregnancy.
 29,37 
The first reported an increased risk of any congenital malformations with fenoterol (SABA) 
during pregnancy (crude OR=1.6; 95% CI: 1.3, 2.0), but no association with other SABA. 
Self-reported questionnaires were used to classify cases (n=511) and controls (n=757) 
according to the type of medications used during pregnancy.
37
 Despite adequate statistical 
power, this study has other limitations such as non-adjustment for asthma severity and 
other confounders as well as exposure measurement during the entire pregnancy period.
37
 
This 60% increased risk is not negligible since the risk of congenital malformations in the 
general population is believed to be about 3%.
43
 The second study reported a significant 
increased risk of “major cardiac malformations” (aOR=2.38; 95% CI: 1.11, 5.1), “major 
other and unspecified malformations” (aOR=3.97; 95% CI: 1.29, 12.2) and “any genital 
malformations” (aOR=6.84; 95% CI: 2.58, 18.10) among asthmatic women exposed to 
LABA when compared to asthmatic women unexposed to LABA during the first 
trimester.
29
 Moreover, the study found that women exposed to SABA at high doses (>10 
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per week) were less likely to have a baby with a major malformation. Exposure to 
medications was measured with prescription claims collected prospectively and 
independently of the outcome, avoiding recall bias. However, prescription claims might not 
reflect exactly the actual intake of medications.
29
  
While a comparison group of asthmatic non-users of the medication under study 
seems theoretically appropriate, it should be recognized that asthmatic non-users might 
have a milder form of the disease or being under-treated, and that residual bias by 
indication might still be present. Confounding by indication can be reduced in an alternate 
way through comparing two similar therapies, i.e. two treatment regimens with the same 
indication. SABA and LABA cannot be included in a head-to-head comparison, but a 
comparison between LABA plus ICS in low or medium doses against high doses of ICS 
could be informative about the safety of LABA while minimizing confounding by 
indication, and such comparisons should be included in future studies.  
Several other methodological aspects of the studies included in the review need to 
be considered. The source of data varied from one study to the other, being through 
medical charts in some, telephone and personal interviews in others, or registry records and 
administrative databases, and different definitions were used to assess asthma according to 
the source of data used. Regarding the exposure assessment, recall bias might have affected 
case-control studies where drug data were collected retrospectively by interviews or 
questionnaires causing overestimated effects. 
31,32,37,40,41
 On the other hand, a secondary 
data source does not suffer this limitation, but could be affected by non-differential 
misclassification that underestimates the true effects.
29,33,35,36,39
 The timing of exposure 
during pregnancy could influence the results and lead to variability between studies.
49,50
 As 
for congenital malformations, the most susceptible stage for the embryonic development is 
the first trimester, where many teratogenic agents show their effect.
49,50
 On the other hand, 
the third trimester of pregnancy might be more relevant for other measures of fetal growth, 
such as mean birth weight, LBW, and SGA since the majority of the fetal growth takes 
place during this period.
14 
For congenital malformations, twelve studies examined the use 
of beta2-agonists during the first trimester
17,21,23,29,31,32,35,36,39-42
, eight during the entire 
pregnancy
19-23,34,35,37 
,one during early pregnancy
38
, and one did not specify when the 
exposure was measured.
33
 For SGA, birth weight, and LBW, nine studies examined the 
entire pregnancy
18-24,34,39
, and one had an undetermined exposure period.
33
 Regarding 
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gestational age and preterm delivery, seven examined the entire pregnancy
18,20,22-24,34,39
, and 
the timing of the exposure was not specified in one study.
33
   
The ascertainment of outcomes varied across studies. In registry and administrative 
database studies, diagnostic codes were used alone to ascertain an infant outcome.
29,33,35
 A 
potential non-differential information bias could occur if the accuracy of the information is 
not high enough, leading to effect measures closer to the null. Some studies used patients’ 
interviews or hospital medical records to minimize such bias.
20-22,31,32,36,39-41
 
Another source of bias is the non-response and non-participation rates which 
reached high levels (30% to 40%) in some studies. 
31,32,37,40,41
 We can argue that women 
exposed to beta2-agonists who choose to participate in a study were more likely to have a 
risk factor (i.e. family history of malformation) compared to non-participants. This 
conditional participation could lead to biased results that over-estimate the true effects. In 
addition, coexisting morbidity is not uncommon among pregnant asthmatic women. 
Pregnant women using anti-asthmatic medications are often using other types of 
medications and studies reporting increased risk of congenital malformations without 
adjusting for concomitant drug use or maternal co-morbidities might have overestimated 
the effects of beta2-agonists.
31,32,40,41
 Moreover, some of the studies reported only crude 
results and several of them did not adjust for the level of asthma severity and control, 
which have been shown to be associated with the outcomes under study
2,4-8
. 
Furthermore, the negative results obtained in studies with low statistical power 
should be interpreted with caution because they can give a false impression of safety. 
Among studies investigating SABA and/or LABA use, only three among the seven studies 
had a power of 80% or more to detect the specified clinically significant effect. .
20,34,39 
Moreover, only six studies out of the twelve investigating SABA separately 
23,29,35,37,38,41 
and one of the ten studies investigating LABA separately had a power of 80% or more to 
detect the specified effect size.
24
 
This review is limited by the fact that we could not pool the different study results 
into a single estimate for each outcome due to major methodological differences between 
the studies. Another limitation of this review is that it included only studies published in 
English language, and excluded studies that do not have comparison groups (i.e. case-
reports, case-series and PEM studies). 
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The strength of this review lies in the fact that we included the most relevant studies 
that provided information on the outcomes under study. In addition, we used the validated 
and recommended NOS-scale for the quality assessment of the studies. Another strength of 
this review is the post-hoc power calculation that we performed to identify studies able to 
detect clinically significant effects. Compared to previously published reviews on the effect 
of beta2-agonist use during pregnancy 
4,14-16,25,26
, the spectrum of perinatal outcomes 
investigated in the current review was larger. Previous reviews were also limited by one or 
more of the following: investigating only SABA or only LABA or combining both with 
other bronchodilators, screening fewer databases, not assessing the quality of the studies 
included, and lastly providing no data on the studies’ statistical power.4,14-16,25,26 
Beta2-agonists are key medications in the treatment of asthmatic pregnant women. 
We found a larger body of knowledge on salbutamol compared to other SABA, and that 
adds to the evidence of its safety. It is difficult to conclude on the safety of other SABA 
(i.e. fenoterol and terbutaline), so we recommend that practitioners prescribe salbutamol for 
pregnant women in concordance with the guidelines.  Regarding LABA, there is evidence 
of specific congenital malformations increased risk, but it is difficult to interpret this 
association as causal because part of this risk might be attributable to the severity of 
asthma. Until this observation is reproduced in other studies, it is difficult to make a clear 
recommendation, and the current guidelines should be followed. Future studies should be 
large enough to be able to compare equivalent treatment regimens, or to compare different 
molecules of a class in order to minimize confounding by asthma severity and to identify 
the safest treatment options. Future studies might also consider meta-analysis of drug-
specific effects from several well-conducted studies. 
5. Conclusions  
In summary, we found 21 studies that examined the effect of beta2-agonists use 
during pregnancy on congenital malformations, fetal growth, and prematurity. We found 
evidence of increased risk of congenital malformations after pregnancy exposure to 
fenoterol (SABA) in one study
37
 and LABA in another study.
29
 No increased risk was 
found for the other outcomes, except a decrease in birth weight centiles among salmeterol 
(LABA) users.
24
 However, non significant results should be interpreted with caution since a 
large percentage of the negative studies were under powered to detect clinically significant 
effects.    
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We conclude that other studies on the use of SABA and LABA during pregnancy 
are needed to obtain precise estimates of associated risks to rule on their safety profile.  
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Figure 1. Strategy for the selection of the studies.  
 
a 
Selected databases were searched for relevant articles using defined keywords. Articles 
retrieved from each database were imported into a separate EndNote library (version 
X4.0.1, Thomson Reuters). The six EndNote libraries formed from the databases were 
combined in one large EndNote library, and duplicates between databases were removed.  
 
PubMed 
3531 
articles 
MEDLINE 
2278 
articles 
Web Of 
Science 
1781 
articles 
EMBASE 
2057 
articles 
Cochrane 
Library 
91 articles 
CINAHL 
803 
articles 
7344 articles 
3197 duplicate 
articles excluded 
137 articles 
7207 irrelevant and 
duplicate articles 
excluded 
19 articles 
118 articles not 
meeting inclusion 
criteria excluded 
21 original studies 
2 books included 
aStep 1: Databases 
searched for relevant 
articles  
bStep 2: Relevant titles 
screened and further 
duplicates removed 
cStep 3: Abstracts screening 
dStep 4: Full texts obtained 
and references screened 
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b 
Titles were screened for relevance. Studies not related to the question of interest, animal 
studies, review articles, and further duplicates were excluded at this step. 
c 
Abstracts were 
examined to confirm eligibility to the final selection and full text were revised. Articles 
only providing relevant data on beta2-agonists and the pre-selected perinatal outcomes were 
included. Published abstracts without original articles were excluded. 
d 
Selected articles 
were obtained and data retrieved and processed. References were checked for additional 
articles and reviews on the topic were manually searched for further references. 
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Table 1. Assessment of Methodologic Quality of Studies According to the Newcastle-Ottawa 
Scale for Cohort and Case-control Studies  
Study ref. Country 
Newcastle-Ottawa Scale  Total Score 
(over 9 
points) 
Selection 
(max.4) 
Comparability
a
 
(max.2) 
Exposure/Outcome 
(max.3) 
Cohort Studies      
Eltonsy et al. (2011)
29
 Canada *** ** *** 8 
Clark et al. (2007)
19
 UK * * *** 4 
Kallen et al. (2007)
36
 Sweden ** * *** 6 
Clifton et al. (2006)
24
 Australia ***  ** 5 
Bakhireva et al. (2005)
20
 USA **** * *** 8 
Schatz et al. (2004)
22
 USA **** * ** 7 
Bracken et al. (2003)
18
 USA *** * ** 6 
Olesen et al. (2001)
39
 Denmark ***  ** 5 
Alexander et al. (1998)
33
 Canada ** * *** 6 
Schatz et al. (1997)
21
 USA ** * *** 6 
Michigan Medicaid 
(1993)
17
 
USA **  ** 4 
Lao et al. (1990)
34
 Hong Kong **  ** 4 
Schatz et al. (1988)
23
 USA *** * *** 7 
CPP (1977)
42
 USA **  ** 4 
Case-Control Studies      
Lin et al. (2012)
41
 USA *** * ** 6 
Munsie et al. (2011)
40
 USA *** * ** 6 
Lin et al. (2009)
31
 USA **** * *** 8 
Lin et al. (2008)
32
 USA *** * ** 6 
Tata et al. (2008)
35
 UK ** * *** 6 
Tamasi et al. (2006)
37
 Hungary ***  ** 5 
Kallen et al. (2003)
38
 Sweden *** * ** 6 
Table 2A. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Major Congenital Malformations 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists 
 
Non-users of ß2-agonists 
 
Effect 
Power 
(%) for 
RR =1.5 
Type of ß2-
agonists 
n* 
Major 
congenital 
malformation 
(%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
SABA and/or LABA use: cohort studies 
Bakhireva et 
al. (2005)20 
Cohort 
Tel. interviews & 
medical charts 
Entire 
pregnancy 
Any 103 3.9  Non asthmatics 303 0.3  cRR 13.0 NA 8 
Any 103 3.9 
 Asthmatics ICS 
users a 
438 4.1 
 
cRR 0.95 NA 17 
Schatz et al. 
(2004)22 
Cohort + 
RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Any 1,828 2.0  
 Asthmatics non 
users bcd 
295 2.0  
 
cRR 1.0 (>0.05)  12 
SABA and/or LABA use: case-control studies  
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-
agonists 
 Effect 
Power 
(%) for 
RR =1.5 
Users of ß2-
agonists 
Non-users of 
ß2-agonists 
 
Users of ß2-
agonists 
Non-users 
of ß2-
agonists  
 
OR or RR 
95% CI or (p-
value) 
Lin et al. 
(2012)41 
Case 
Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Any f 10 168 
 
NA NA 
Asthmatics and 
non asthmatics 
non users  
 
aOR = 2.39
o 1.23, 4.66 NC 
Munsie et al. 
(2011)40 
Case 
Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Any f 20 570 
 
114 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.77
q
 1.08, 2.88 NC 
1 month prior 
conception + 
1st trimester 
Any f 26 887 
 
114 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.53r 0.99, 2.37 46 
1 month prior 
conception + 
1st trimester 
Any f 17 1114 
 
114 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.78s 0.46, 1.31 52 
2nd & 3rd 
trimesters 
Any f 7 570 
 
58 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.26q 0.57, 2.80 20 
2nd & 3rd 
trimesters 
Any f 4 887 
 
58 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.49r 0.18, 1.36 24 
2nd & 3rd 
trimesters 
Any f 6 1114 
 
58 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.59s 0.25, 1.38 27 
Lin et al. 
(2009)31 
Matched 
Case 
Control 
1:2 
Registry, medical 
records & tel. 
interviews  
1 month prior 
conception + 
1st trimester 
Any f 22 443  
 
22 965 
Asthmatics and 
non asthmatics 
with no Rx 
 
aOR = 2.20 1.05,4.61 NC 
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Lin et al. 
(2008)32 
Case 
Control 
1:11 
Tel. interviews& Rx 
DB 
1 month prior 
conception + 
1st trimester 
Any g 17 358 
 
96 3,932 
Asthmatics and 
non-asthmatics 
non users g  
 
 
aOR = 2.06 
 
1.19,3.59 
 
NC 
  
SABA only: cohort studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists  Effect Power 
(%) for 
RR 
=1.5 
Type of ß2-
agonists 
n* 
Major congenital 
malformation 
(%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
Eltonsy et al. 
(2011)29 
Cohort 
Quebec 
administrative DB  
1st trimester 
Any 7,182 5.7 
 
Asthmatics non 
usersg 
5,935 5.9 
 
aOR = 0.93  0.80,1.08 100 
Any (>0–3 
doses/week) 
3,420 6.1 
  
aOR = 1.00  0.83, 1.20 99 
Any (>3–10 
doses/week) 
2,102 5.5 
  
aOR = 0.84  0.67, 1.06 98 
Any (>10 
doses/week) 
1,660 5.2 
  
aOR = 0.68 0.48, 0.95 NC 
Kallen et al. 
(2007)36 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge)  
1st trimester 
Salbut NA NA 
 
General 
population  
NA NA 
 
aOR  = 1.38h 1.12,1.70 NC 
Terbut NA NA 
 
NA NA 
 
aOR  = 1.08i 0.94,1.23 __ 
Schatz et al. 
(1997)21 
Cohort 
Daily diary cards for 
medications 
completed by 
patients. For 
outcomes, data source 
not precised 
Entire 
pregnancy 
Any e 667 3.7 
 
Non asthmatics  823 6.2 
 
cRR  0.60 (>0.05)  54 
1st trimester Any e 488 4.3 
 
Non asthmatics  1,000 5.6 
 
cRR 0.77 (>0.05)  48 
Schatz et al. 
(1988)23 
Cohort 
Questionnaire for 
patients 
identification, 
confirmed clinically 
+ 
Self-Diary to report 
use of SABA  & 
medical records (for 
perinatal outcomes)  
Entire 
pregnancy 
Any bfj 259 3.9 
 
Non asthmatics 295 6.4 
 
cOR = 0.61 (>0.05)  25 
1st trimester Any bfj 180 3.9 
 
Non asthmatics 295 6.4 
 
cOR = 0.61 (>0.05)  22 
Entire 
pregnancy 
Any bfj 259 3.9 
 Asthmatics non 
usersg 
101 6.0 
 
cOR = 0.65 (>0.05)  12 
1st trimester Any bfj 180 3.9 
 Asthmatics non 
usersg 
172 5.3 
 
cOR = 0.74 (>0.05)  15 
Entire 
pregnancy 
Any bfj 259 3.5 
 
General 
population 
1,999,254 3.0 
 
cOR  = 1.17 NA 31 
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SABA only: case-control studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-
agonists 
 Effect Power 
(%) for 
RR 
=1.5 
Users of ß2-
agonists 
Non-users of 
ß2-agonists 
 
Users of ß2-
agonists 
Non-users 
of ß2-
agonists 
 
OR or RR 
95% CI or (p-
value) 
Lin et al. 
(2012) 41 
Case 
Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salbut 77 2776 
 
139 6587 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 1.31P NA 81 
Pirbuterol 3 2850 
 
3 6723 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 2.36 P NA 8 
Munsie et al. 
(2011)40 
Case 
Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salbut 18 570 
 
101 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.79
q
 1.07, 2.99 NC 
1 month prior 
conception + 
1st trimester 
Salbut 25 887 
 
101 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.65
r
 1.06, 2.58 NC 
1 month prior 
conception + 
1st trimester 
Salbut 15 1114 
 
101 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.76s 0.44, 1.33 48 
2nd & 3rd 
trimesters 
Salbut 7 570 
 
55 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 1.34q 0.60, 2.98 22 
2nd & 3rd 
trimesters 
Salbut 4 887 
 
55 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.52r 0.19, 1.44 27 
2nd & 3rd 
trimesters 
Salbut 6 1114 
 
55 6207 
Asthmatics and 
non-asthmatics 
non users 
 
aOR = 0.64s 0.27, 1.49 31 
1 month prior 
conception + 
1st trimester 
Pirbuterol/ 
Metaprot/ 
Epineph 
4 85 
 
5 153 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 1.44 NA 9 
Lin et al. 
(2009)31 
Matched 
Case 
Control 
1:2 
Registry, medical 
records & tel. 
interviews  
1 month prior 
conception + 
1st trimester 
Salbutg 15 443 
 
14 965 
Asthmatics and 
non asthmatics 
with no Rx 
 
aOR = 2.37 0.90,6.23 14 
Metaprotg 1 31 
 
1 42 
 
cRR = 1.35 NA 6 
Terbut g 1 31 
 
0 43 
 
__ NA __ 
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Lin et al. 
(2008)32 
Case 
Control 
1:11 
Tel. interviews & Rx 
DB 
1 month prior 
conception + 
1st trimester 
Salbut/ 
Pirbuterolg 
13 368 
 
88 4,033 
Asthmatics and 
non asthmatics 
non users g  
 
cOR = 1.62 NA 26 
Tata et al. 
(2008)35 
Matched 
Case 
Control 
1:6 
THIN DB 
Entire 
pregnancy 
Any  
375 NA 
 
2085 NA 
Asthmatics non 
usersbcd 
 
aOR = 1.06 
(0.336) 
0.94,1.19 
100 
1st trimester NA NA 
 
NA NA NA 
 
aOR = 1.01 
(0.941)    
0.86,1.18 
__ 
LABA only: cohort studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists  Effect 
Power 
(%) for 
RR 
=1.5 
Type of ß2-
agonists 
n* 
Major 
congenital 
malformation 
(%) 
 
Definition n* 
Major congenital 
malformation (%) 
 
OR or RR 
95% CI or (p-
value) 
Eltonsy et al. 
(2011)29 
Cohort 
Quebec 
administrative DB  
1st trimester Any 165 
7.9  
Asthmatics non 
usersg 
12,952 
5.8  aOR = 1.31 0.74,2.31 33 
4.2 2.0 aOR = 2.38k 1.11,5.1 NC 
1.8  0.5  aOR =3.97l  1.29,12.2 NC 
Kallen et al. 
(2007)36 
Cohort 
Swedish Registry 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge)  
1st trimester 
 
Salmeterol NA NA 
 
General 
population 
NA NA 
 
aOR  = 1.34m 0.96,1.88 __ 
Formoterol NA NA 
 
NA NA 
 
aOR  = 1.07n 0.63,1.82 __ 
LABA only: case-control studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-
agonists 
 Effect 
Power 
(%) for 
RR =1.5 
Users of ß2-
agonists 
Non-users of 
ß2-agonists 
 
Users of ß2-
agonists 
Non-users 
of ß2-
agonists 
 
OR or RR 
(95% CI) or 
(p-value) 
Lin et al. 
(2012) 41 
Case 
Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salmeterol 13 2840 
 
23 6703 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 1.33 P NA 24 
Munsie et al. 
(2011)40 
Case 
Control 
Registry, medical 
records & self reports 
1 month prior 
conception + 
1st trimester 
Salmeterol 6 83 
 
21 137 
Asthmatics and 
non asthmatics 
non users  
 
cOR = 0.47s NA 23 
Lin et al. 
(2008)32 
Case 
Control 
1:11 
Tel. interviews & Rx 
DB 
1 month prior 
conception + 
1st trimester 
Salmeterolg 2 379 
 
11 4,110 
Asthmatics and 
non asthmatics 
non users g  
 
cOR = 1.97 NA 7 
Tata et al. 
(2008)35 
Matched 
Case 
Control 
1:6 
THIN DB 
Entire 
pregnancy 
Any  
25 NA 
 
131 NA 
Asthmatics non 
usersbcd 
 
aOR = 1.12 
 (0.614)         
0.72,1.75 
49 
1st trimester NA NA 
 
NA NA 
 
aOR = 1.09 
(0.77)           
0.62,1.9 
__ 
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Table 2B. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Any Congenital Malformations 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists  Effect Power 
(%) for 
RR =1.5 
Type of ß2-
agonists 
n* 
All congenital 
malformations (%) 
 
Definition n* 
All congenital 
malformations (%) 
 
OR or RR 
95% CI or 
(p-value) 
SABA and/or LABA use: cohort studies 
Clark et al. 
(2007)19 
Cohort 
Questionnaire & 
medical charts 
Entire 
pregnancy 
Any 178 2.2  Non asthmatics 717 2.2  cRR = 1.0 a NA 16 
Any 178 2.2 
 Asthmatics with no 
Rx 
370 0.8 
 
cRR = 2.75a NA 9 
  
Olesen et al. 
(2001)39 
Cohort Registry & Rx DB 
1 month prior 
until 8 weeks 
of pregnancy  
Any 272 NA  
 
Non users of any 
Rx b 
8,717 NA  
 
NA (<0.05) __ 
Alexander et 
al. (1998)33 
Cohort 
Registry (perinatal 
DB) & medical charts 
Not 
determined 
Any 303 8.5  Non asthmatics 13,709 7.7  aOR = 1.0 0.6,1.6 58 
Any 303 8.5 
 Asthmatics with no 
Rx 
375 6.9 
 
aOR = 0.9 0.6,1.4 31 
Any 303 8.5 
 Asthmatics steroid 
users c 
139 6.2 
 
aOR = 0.8 0.4,1.7 16 
Lao et al. 
(1990)34 
Cohort Hospitals DB 
Entire 
pregnancy 
Any de 54 3.8 
 
Non asthmatics 54 0.0 
 
__ NA __ 
SABA only: cohort studies 
Eltonsy et 
al. (2011)29 
Cohort 
Quebec 
administrative DB 
(medical services and 
Rx DB) 
1st trimester 
 
Any 7,182 9.6 
 
Asthmatics non 
usersc 
5,935 9.3 
 
aOR = 1.04  0.92,1.17 100 
Any (>0–3 
doses/week) 
3,420 10.0 
  
aOR = 1.08  0.94, 1.25 100 
Any (>3–10 
doses/week) 
2,102 9.9 
  
aOR = 1.07  0.90, 1.26 99 
Any (>10 
doses/week) 
1,660 8.5 
  
aOR = 0.90  0.74, 1.09 99 
Kallen et al. 
(2007)36 
Cohort 
Swedish Registers 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge)  
1st trimester 
(early 
pregnancy, 
usually 10-12 
weeks) 
Salbut NA NA 
 
General population  
NA NA 
 
aOR  = 1.09 0.97,1.75 __ 
Terbut NA NA 
 
NA NA 
 
aOR  = 1.11 1.04,1.19 NC 
Michigan 
Medicaid 
(1993)17 
Cohort Surveillance registry 1st trimester 
Isoprot 16 6.3f  NA NA NA  cRR = 1.4 NA __ 
Salbut 1,090 4.4f  NA NA NA  cRR = 1.1 NA __ 
Terbut 149 4.7f  NA NA NA  cRR = 1.2 NA __ 
Metaprot 361 4.7f  NA NA NA  cRR = 1.1 NA __ 
Isoetharine 22 0.0f  NA NA NA  __ NA __ 
Epineph 35 0.0f  NA NA NA  __ NA __ 
CPP 
(1977)42 
Cohort Surveillance registry 
Early 
pregnancy 
(1st trimester) 
Isoprot 31 NA  NA NA NA  cRR = 0.9 NA __ 
Ephed 373 NA 
 
NA NA NA 
 
cRR = 1.1 NA __ 
Epineph 189 NA 
 
NA NA NA 
 
cRR = 1.7 (<0.05)  NC 
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SABA only: case-control studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-agonists 
 Effect 
Power 
(%) for 
RR =1.5 
Users of ß2-
agonists 
Non-users of ß2-
agonists 
 
Users of ß2-
agonists 
Non-
users of 
ß2-
agonists 
 
OR or RR 
95% CI or 
(p-value) 
Tamasi et al. 
(2006)37 
Matched 
Case 
control 1:3 
Hungarian registry & 
questionnaire (self-
administered) + 
medical records 
Entire 
pregnancy 
Salbut 45 466  77 680 
Asthmatics non 
users 
 cOR = 0.9 0.6, 1.3 57 
Terbut 179 332  241 516  cOR = 1.2 0.9, 1.5 92 
Metaprot 3 508  6 751  cOR = 0.7 0.2, 3.0 10 
Fenoterol 328 183  403 354  cOR = 1.6 1.3, 2.0 NC 
Kallen et al. 
(2003)38 
Case 
control 
Swedish Medical 
birth Register & 
Interview  
Early 
pregnancy 
Salbut 29 4,986 
 
3,446 574,284 
Asthmatics and non 
asthmatics non 
users 
 cOR = 0.97                 
aOR = 0.93 
0.64, 1.36 70 
Terbut 104 4,911 
 
10,613 567,117 
 
cOR = 1.13                    
aOR = 1.14 
0.93, 1.38 98 
LABA only: cohort studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists 
 Non-users of ß2-agonists 
 Effect 
Power 
(%) for 
RR =1.5 
Type of ß2-
agonists 
n* 
All congenital 
malformations (%) 
 
Definition n* 
All congenital 
malformations (%) 
 
OR or RR 
95% CI or 
(p-value) 
Eltonsy et 
al. (2011)29 
Cohort 
Quebec 
administrative DB 
(medical services and 
Rx DB) 
1st trimester Any 165 
12.7 
 
Asthmatics non 
usersg 
12,952 
9.4 
 
aOR = 1.37  0.92,2.17 44 
3.0 0.7 aOR = 6.84g 2.58,18.10 NC 
3.0 0.9 aOR=3.43h 1.39,8.45 NC 
Kallen et al. 
(2007)36 
Cohort 
Swedish Registry 
(Medical birth, 
Congenital 
malformation and 
Hospital discharge)  
1st trimester 
(early 
pregnancy, 
usually 10-12 
weeks) 
Salmeterol NA NA  
General population 
NA NA  aOR = 1.02 0.83,1.25 __ 
Formoterol NA NA 
 
NA NA 
 
aOR = 1.06 0.80,1.40 __ 
LABA only: case-control studies 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Type of ß2-
agonists 
Cases  Controls 
Definition of non-
users of ß2-agonists 
 Effect 
Power 
(%) for 
RR =1.5 
Users of ß2-
agonists 
Non-users of ß2-
agonists 
 
Users of ß2-
agonists 
Non-
users of 
ß2-
agonists 
 
OR or RR 
95% CI or 
(p-value) 
Tamasi et al. 
(2006)37 
Matched 
case 
control  
1:3 
Hungarian registry & 
questionnaire (self-
administered) + 
medical records 
Entire 
pregnancy 
Clenbuterol 28 483 
 
56 701 
Asthmatics non 
users 
 
cOR = 0.7 0.5, 1.2 57 
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Kallen et al. 
(2003)38 
Case 
control 
Swedish Medical 
birth Registry & 
Interview 
Early 
pregnancy 
Salmeterol 15 5,000 
 
1,137 576,593 
Asthmatics and non 
asthmatics non 
users  
 
aOR = 1.50 0.90, 2.53 35 
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Table 3. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and SGA 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists  Effect Power (%) 
for RR 
=1.5 
Type of ß2-
agonists 
n* SGA (%) 
 
Definition n* SGA (%) 
 
OR or RR 
95% CI or 
(p-value) 
SABA and/or LABA use: cohort studies 
Clark et al. 
(2007)19 
Cohort 
Questionnaire & medical 
charts 
Entire 
pregnancy 
Any 
99 boys  22.2 
 
Non asthmatics 
370 boys  27.8 
 
cRR = 0.80a NA 40 
347 girls  28.8 cRR = 0.92a NA 35 
 Asthmatics with 
no Rx 
191 boys   29.3 
 
cRR = 0.76a NA 35 
79 girls  26.6 179 girls   22.9 cRR = 1.16a NA 28 
Bakhireva et 
al. (2005)20 
Cohort 
Tel.interviews & medical 
charts 
Entire 
pregnancy 
Any 103 3.9 
 
Non asthmatics 303 5.0 
 cRR = 0.78 (>0.05)  
17 
  aOR = 0.57 0.16,2.12 
Any 103 3.9 
 Asthmatics ICS 
users b 
438 6.2 
 cRR = 0.63 
0.13, 1.89 20 
aOR = 0.50 
Schatz et al. 
(2004)22 
Cohort + 
RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Any 1,828 7.1 
 Asthmatics non 
users cde 
295 7.2 
 
cRR = 0.99 (>0.05)  39 
SABA only: cohort studies 
Bracken et 
al. (2003)18 
Cohort 
Tel. interviews + medical 
charts   
Entire 
pregnancy 
Any 401 7.5 
 Asthmatics and 
non asthmatics 
non usersf 
1,800 7.7 
 cOR = 0.97g 0.65,1.47g  
60 
aOR = 1.0h 0.99,1.01h 
Schatz et al. 
(1997)21 
Cohort 
Daily diary cards for 
medications completed by 
patients. For outcomes, 
data source not precised  
Entire 
pregnancy 
Any i NA NA 
 
Non asthmatics NA NA 
 
NA (>0.05)  __ 
Schatz et al. 
(1988)23 
Cohort 
Questionnaire for patients 
identification, confirmed 
clinically + 
Self-diary to report use of 
SABA  & medical records 
(for perinatal outcomes) 
Entire 
pregnancy 
Anycjk 259 1.6 
 
Non asthmatics 295 1.0 
 
cRR = 1.6 (>0.05)  9 
 Asthmatics non 
users f 
101 3.1 
 
cRR = 0.52 (>0.05)  8 
LABA only: cohort studies 
Clifton et al. 
(2006)24 
Cohort Medical charts 
Entire 
pregnancy 
Salmeteroll 9 22.2 
 
Non asthmatics 20 10.0 
 
cRR = 2.2 (>0.05) 9 
 Asthmatics 
fluticasone users 
18 11.1 
 
cRR = 2.0 (>0.05) 8 
 Asthmatics 
budesonide users 
14 0 
 
__ NA __ 
Bracken et 
al. (2003)18 
Cohort 
Tel. interviews + medical 
charts   
Entire 
pregnancy 
Any 48 8.3 
 Asthmatics and 
non asthmatics 
non users f 
2,153 7.6 
 
cOR = 1.1g 0.39,3.11g  
18 
aOR = 1.0h 0.99,1.02h 
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Table 4A. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Birth Weight 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists  Effect 
Power (%) for  
MD = 500g Type of ß2-
agonists 
n* 
Mean birth 
weight in g 
(SD) 
 
Definition n* 
Mean birth 
weight in g 
(SD) 
 
MD in g 
95% CI or (p-
value) 
SABA and/or LABA use: cohort studies 
Clark et al. 
(2007)19 
Cohort 
Questionnaire & 
medical charts  
Entire 
pregnancy 
Any 
99 boys 3545a 
 
Non asthmatics 
370 boys 3320a  cMD = 225 b NA __ 
 347 girls 3240a  cMD = -20 b NA __ 
79 girls 3220a 
 Asthmatics with 
no Rx 
191 boys 3360a  cMD = 185 b NA __ 
 179 girls 3260a  cMD = -40 b NA __ 
Bakhireva et 
al. (2005)20 
Cohort 
Tel. interviews & 
medical charts 
Entire 
pregnancy 
Any 103 3,552 (51) 
 
Non asthmatics 303 3,540 (29) 
 
aMD = 12 (>0.05)  100 
Any 103 3,552 (51) 
 Asthmatics ICS 
users c 
438 3,524 (24) 
 
aMD = 28  (>0.05)  100 
Olesen et al. 
(2001)39 
Cohort Registry & Rx DB 
Entire 
pregnancy 
Any 272 
3,361.5 
(571.3)  
 Non users of 
any Rx d 
8717 3,414 (579)  
 
aMD = -45.8 -115.1 ,23.5 100 
Lao et al. 
(1990)34 
Cohort Hospitals DB 
Entire 
pregnancy 
Any ef 54 3,226 (453) 
 
Non asthmatics 54 3,281 (328) 
 
cMD = -55 (>0.05)  100 
  
SABA only: cohort studies 
Schatz et al. 
(1988)23 
Cohort 
Questionnaire for 
patients identification, 
confirmed clinically + 
Self-Diary to report use 
of SABA  & medical 
records (for perinatal 
outcomes) 
Entire 
pregnancy 
Any egh 259 3,416 (35)i 
 
Non asthmatics 295 3,477 (32) i 
 
cMD = -61 (>0.05)  100 
 Asthmatics non 
users g 
101 3,361 (68) i 
 
cMD = 55  (>0.05)  100 
LABA only: cohort studies 
Clifton et al. 
(2006)24 
Cohort Medical charts 
Entire 
pregnancy 
Salmeterolj 9 
3,283 
(120.3)i 
 
Non asthmatics 20 3,423.3 (122)  cMD = -140.3 (>0.05) 100 
 
Asthmatics 
fluticasone users 
18 3,441.7 (149.4) 
 
cMD = -158.7 (>0.05) 100 
 
Asthmatics 
budesonide users 
14 3,824.6 (100) 
 
cMD = -541.6 (>0.05) 100 
34.8 centile 
(9.3) 
 
Non asthmatics 20 47.7 (7.4)  cMD = -12.9 (>0.05) 75k 
 
Asthmatics 
fluticasone users 
18 53.6 (7.1) 
 
cMD = -18.8 (>0.05) 75k 
 
Asthmatics 
budesonide users 
14 74.0 (5.4) 
 
cMD = -39.2 (0.011) NC 
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Table 4B. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Low Birth Weight (< 2500 g) 
  Study 
ref. 
Design Source of data 
Exposure 
Timing 
Users of ß2-agonists  Non-users of ß2-agonists   Effect 
Power (%) 
for RR 
=1.5 
Type of 
ß2-
agonists 
n* 
Low birth 
weight 
(%) 
 
Definition n* 
Low birth 
weight 
(%) 
 
OR or RR 
95% CI or 
(p-value) 
SABA and/or LABA use: cohort studies 
Schatz et al. 
(2004)22 
Cohort 
+ RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Any 1,828 13.5 
 
Asthmatics non-
users abc 
295 15.2 
 
cRR = 0.89 (>0.05)  67 
Alexander et 
al. (1998)33 
Cohort 
Registry (perinatal DB) 
& medical charts 
Not 
determined 
Any 303 7.9  Non asthmatics 13,709 5.6  aOR = 1.4 0.8,2.2 49 
Any 303 7.9 
 Asthmatics with 
no Rx 
375 4.9 
 
aOR = 0.9 0.5,1.5 24 
Any 303 7.9 
 Asthmatic steroid 
usersd 
139 5.1 
 
aOR = 1.0 0.4,2.5 13 
Lao et al. 
(1990)34 
Cohort Hospitals DB 
Entire 
pregnancy 
Any a 54 5.6 
 
Non asthmatics 54 1.9 
 
cRR = 2.9 (>0.05)  3 
SABA only: cohort studies 
Schatz et al. 
(1997)21 
Cohort 
Daily diary cards for 
medications completed 
by patients. For 
outcomes, data source 
not precised  
Entire 
pregnancy 
Any e NA NA 
 
Non asthmatics NA NA 
 
NA (>0.05)  __ 
Schatz et al. 
(1988)23 
Cohort 
Questionnaire for 
patients identification, 
confirmed clinically + 
Self-Diary to report use 
of SABA  & medical 
records (for perinatal 
outcomes) 
Entire 
pregnancy 
Anyafg 259 4.6 
 
Non asthmatics 295 3.1 
 
cRR = 1.48 (>0.05)  15 
Asthmatics non 
usersd 
101 6.0 
 
cRR = 0.77 (>0.05)  12 
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Table 5A. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Gestational Age (weeks) 
Study 
ref. 
Design Source of data 
Exposure 
Timing 
  
Users of ß2-agonists  Non-users of ß2-agonists  Effect    
Power (%) 
for MD = 1 
week 
Type of ß2-
agonists 
n* 
Gestational 
age in weeks 
(SD) 
 
Definition n* 
Gestational 
age in weeks 
(SD) 
 
MD 
95% CI or 
(p-value) 
SABA and/or LABA use: cohort studies 
Bakhireva et 
al. (2005)20 
Cohort 
Tel. interviews & 
medical charts 
Entire 
pregnancy 
Any 103 39.4 (1.8) 
 
Non asthmatics 303 39.2 (1.5) 
 
cMD = 0.2 (>0.05)  100 
Any 103 39.4 (1.8) 
 Asthmatics ICS 
users a 
438 39.4 (1.8) 
 
cMD = 0 (>0.05)  100 
Olesen et al. 
(2001)39 
Cohort Registry & Rx DB 
Entire 
pregnancy 
Any 272 
276.2 (15 
days) 
 
Non users of any 
Rx b 
8717 
276.1 (14.5 
days) 
 
aMD = -0.2 -2.0, 1.5 100 
Lao et al. 
(1990)34 
Cohort Hospitals DB 
Entire 
pregnancy 
Any c 54 39.3 (1.7) 
 
Non asthmatics 54 39.2 (1.5) 
 
cMD = 0.1 (>0.05)  90 
LABA only: cohort studies 
Clifton et al. 
(2006)24 
Cohort Medical charts 
Entire 
pregnancy 
Salmeterold 9 39.9 (0.4)e 
 Non asthmatics 20 40.2 (0.3)e 
 
cMD = -0.3 (>0.05) 100 
 
Asthmatics 
fluticasone users 
18 39.6 (0.3)e 
 
cMD = 0.3 (>0.05) 100 
 
Asthmatics 
budesonide users 
14 39.7 (0.3)e 
 
cMD = 0.2 (>0.05) 100 
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Table 5B. Studies Investigating the Association between Beta2-agonists Use during Pregnancy and Preterm delivery (<37 weeks) 
Study 
ref. 
Design  Source of data 
Exposure 
Timing 
  
Users of ß2-agonists  Non-users of ß2-agonists  Effect Power (%) 
for RR 
=1.5 
Type of ß2-
agonists 
n* 
Preterm 
delivery (%) 
 
Definition n* 
Preterm 
delivery (%) 
 
OR or RR 
95% CI or (p-
value) 
SABA and/or LABA use: cohort studies 
Schatz et al. 
(2004)22 
Cohort + 
RCT 
Medical charts & 
interviews 
Entire 
pregnancy 
Any 1828 15.8 
 Asthmatics non 
users abc 
295 19.3 
 
cRR = 0.82 (>0.05) 76 
Alexander et 
al. (1998)33 
Cohort 
Registry (perinatal 
DB) & medical charts 
Not 
determined 
Any 303 6.0 
 
Non asthmatics 13,709 6.0 
 
aRR = 1.0 0.5,1.8 51 
Any 303 6.0 
 Asthmatics with 
no Rx 
375 5.6 
 
aRR = 1.0 (0.5,1.7) 27 
Any 303 6.0 
 Asthmatic 
steroid users d 
139 7.7 
 
aOR = 1.4 0.6, 3.0 18 
Lao et al. 
(1990)34 
Cohort Hospitals DB 
Entire 
pregnancy 
Anya 54 1.9 
 
Non asthmatics 54 0 
 
__ NA __ 
  
SABA only: cohort studies 
Bracken et al. 
(2003)18 
Cohort 
Tel. interviews & 
medical charts   
Entire 
pregnancy 
Any 529 7.6 
 Asthmatics and 
non asthmatics 
non usersd 
1,676 6.7 
 
cOR = 1.14e  0.79,1.66e  
63 
  aOR = 1.01f 1.00,1.02 f 
Schatz et al. 
(1988)23 
Cohort 
 Questionnaire for 
patients 
identification, 
confirmed clinically 
+ 
Self-Diary to report 
use of SABA  & 
medical records (for 
perinatal outcomes) 
Entire 
pregnancy 
Any agh 259 3.9 
 
Non asthmatics 295 2.7 
 
cRR = 1.44 (>0.05)  15 
 
Asthmatics non 
users d 
101 6.0 
 
cRR = 0.65 (>0.05)  12 
LABA only: cohort studies 
Bracken et al. 
(2003)18 
Cohort 
Tel. interviews & 
medical charts   
Entire 
pregnancy 
Any  64 10.9 
 Asthmatics and 
non asthmatics 
non usersd 
2,141 6.8 
 cOR = 1.69 e  0.76,3.77 e  
20 
  aOR = 0.99 f 0.97,1.02 f 
 
 
 
Footnotes 
 
Table 1 
 
a
 In rating comparability of groups, we awarded a study one star if it controlled for asthma 
severity/control, and another star if it controlled for other relevant confounders. 
 
Table 2 A 
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Women may have concurrently received short-acting beta2-agonists (inhaled or systemic). 
b
 Women may have concurrently received inhaled corticosteroids. 
c
 Women may have concurrently received asthma controller medications (leukotriene 
modifiers). 
d
 Women may have concurrently received systemic corticosteroids (oral or intravenous). 
e
 Women may have received inhaled, oral or injectable beta2-agonists. 
f
 Women may have concurrently received asthma controller medications (theophylline or 
ipratropium). 
g
 Women may have concurrently received any other type of asthma medication. 
h
 The OR presented for the association between salbutamol and cardiac malformations (92 
cases reported) 
i
 The OR presented for the association between terbutaline and cardiac malformations (228 
cases reported) 
j
 Women may have concurrently received asthma controller medications (cromolyn). 
k
 The OR presented for the association between LABA and major cardiac malformations 
l
 The OR presented for the association between LABA and major “other and unspecified 
malformations” 
m
 The OR presented for the association between salmeterol and cardiac malformations (35 
cases reported) 
n
 The OR presented for the association between formoterol and cardiac malformations (14 
cases reported) 
o
 The OR presented for the association between beta2-agonists and esophageal atresia 
p 
The OR presented for the association between beta2-agonists and selected defects 
including diaphragmatic hernia, esophageal atresia, small intestinal atresia, anorectal 
atresia, neural tube defects, omphalocele, or limb deficiencies with no additional major 
defect (isolated). 
q 
The OR presented for the association between beta2-agonists and cleft lip only 
r
 The OR presented for the association between beta2-agonists and cleft palate only
 
s
 The OR presented for the association between beta2-agonists and cleft lip with cleft palate 
 
DB: database; ICS: inhaled corticosteroids; Salbut: Salbutamol; Isoprot: Isoproterenol; 
Metaprot: Metaproterenol; Terbut: Terbutaline; Epineph: Epinephrine; Ephed: Ephedrine; 
SABA: Short acting beta2-agonists; LABA: Long acting beta2-agonists; RCT: randomized 
controlled trial; THIN: Health Improvement Network primary care database, Rx: 
prescription medications; aOR: adjusted odds ratio; cOR: crude odds ratio; cRR: crude risk 
ratio; cMD: crude mean difference; aMD: adjusted mean difference; pOR :crude 
prevalence odds ratio; NA: data unavailable; – : power or effect size impossible to 
calculate; NC: statistical power not calculated since results are significant. 
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Table 2 B  
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Matching was performed and not considered in crude calculations. 
b
 Reference group formed from women who did not purchase any prescription drugs 
during pregnancy. 
c
 Women may have concurrently received any other type of asthma medication. 
d 
Women may have concurrently received inhaled corticosteroids. 
e
 Women may have concurrently received oral asthma medication. 
f
 Expected cases of malformations were: 0.7 case with isoproterenol, 43 with salbutamol, 6 
with terbutaline, 15 with metaproterenol, 1 with isoetharine, and 1 with epinephrine. 
g
 The OR presented for the association between LABA and any genital malformations 
h
 The OR presented for the association between LABA and any “other and unspecified 
malformations” 
 
Table 3  
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Matching was performed and not considered in crude calculations. 
b
 Women may have concurrently received short-acting beta2-agonists (inhaled or 
systemic). 
c
 Women may have concurrently received inhaled corticosteroids. 
d
 Women may have concurrently received asthma controller medications (leukotriene 
modifiers). 
e
 Women may have concurrently received systemic corticosteroids (oral or intravenous). 
f
 Women may have concurrently received any other type of asthma medication. 
g
 Exposure to medication: yes/no. 
h
 Exposure to medication: average doses per month. 
i
 Women may have received inhaled, oral or injectable beta2-agonists. 
j
 Women may have concurrently received asthma controller medications (theophylline or 
ipratropium). 
k
 Women may have concurrently received asthma controller medications (cromolyn). 
l
 Salmeterol was used in combination with fluticasone propionate 
 
Table 4 A  
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Median is presented (data on means are unavailable) 
b
 Matching was performed and not considered in crude calculations. 
c
 Women may have concurrently received short-acting beta2-agonists (inhaled or systemic). 
d
 Reference group formed from women who did not purchase any prescription drugs 
during pregnancy. 
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e
 Women may have concurrently received inhaled corticosteroids. 
f
 Women may have concurrently received oral asthma medication. 
g
 Women may have concurrently received asthma controller medications (theophylline or 
ipratropium). 
h
 Women may have concurrently received asthma controller medications (cromolyn). 
i
 Standard errors of measurements (SEM) are given in parentheses  
j
 Salmeterol was used in combination with fluticasone propionate 
k
 Power calculated for a difference in the mean birth weight centile =10 
 
Table 4 B  
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Women may have concurrently received inhaled corticosteroids. 
b
 Women may have concurrently received asthma controller medications (leukotriene 
modifiers). 
c
 Women may have concurrently received systemic corticosteroids (oral or intravenous). 
d
 Women may have concurrently received any other type of asthma medication. 
e
 Women may have received inhaled, oral or injectable beta2-agonists. 
f
 Women may have concurrently received asthma controller medications (theophylline or 
ipratropium). 
g
 Women may have concurrently received asthma controller medications (cromolyn). 
 
Table 5 A 
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Women may have concurrently received short-acting beta2-agonists (inhaled or systemic). 
b
 Reference group formed from women who did not purchase any prescription drugs 
during pregnancy. 
c
 Women may have concurrently received inhaled corticosteroids. 
d
 Salmeterol was used in combination with fluticasone propionate 
e
 Standard errors of measurements (SEM) are given in parentheses  
 
Table 5 B  
 
Women participating in the different studies were asthmatic unless stated otherwise.
 
* Number of pregnancies unless stated otherwise. 
a
 Women may have concurrently received inhaled corticosteroids. 
b
 Women may have concurrently received asthma controller medications (leukotriene 
modifiers). 
c
 Women may have concurrently received systemic corticosteroids (oral or intravenous). 
d
 Women may have concurrently received any other type of asthma medication. 
e
 Exposure to medication: yes/no. 
f
 Exposure to medication: average doses per month. 
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g
 Women may have concurrently received asthma controller medications (theophylline or 
ipratropium). 
h
 Women may have concurrently received asthma controller medications (cromolyn). 
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5.2 Article on LABA-ICS combination versus ICS monotherapy in higher doses 
 
 
 
Risk of congenital malformations for asthmatic pregnant women using a long-acting 
β2-agonist and inhaled corticosteroid combination versus higher-dose inhaled 
corticosteroid monotherapy 
 
Published in The Journal of Allergy and Clinical Immunology, January 2015, Volume 
135, Issue 1, Pages 123–130.e2, http://dx.doi.org/10.1016/j.jaci.2014.07.051. 
 
 
This article is included in the current thesis by the permission of the co-authors and editors. 
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Risk of congenital malformations for asthmatic pregnant women using a long-acting 
β2-agonist and inhaled corticosteroid combination versus higher-dose inhaled 
corticosteroid monotherapy 
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Clinical implications 
Findings support the fetal safety of LABA/ICS combination in the management of 
persistent asthma during pregnancy, encouraging clinicians to prescribe either combination 
or ICS monotherapy to keep asthma under control. 
 
Capsule summary 
This comparative safety study examined the major malformations prevalence of 
two widely used treatment options for persistent asthma during pregnancy. Clinicians are 
offered new evidence on the fetal safety of LABA/ICS combination and ICS monotherapy.  
 
Keywords: Asthma, pregnancy, congenital malformations, inhaled corticosteroid, long-
acting beta2-agonist, combination therapy, high dose ICS, cohort study, comparative safety 
study, administrative health databases. 
 
Abbreviations: LABA: long-acting beta2-agonists, ICS: inhaled corticosteroids, GEE: 
generalized estimating equation , RAMQ: Régie de l’assurance-maladie du Québec, 
MED-ECHO: Maintenance et Exploitation des Données pour l’Étude de la Clientèle 
Hospitalière, PPV : predictive positive value , PNV : predictive negative value. 
 
 
 
 
 
 
141 
 
ABSTRACT 
 
Background: Current recommendations for managing persistent asthma during 
pregnancy when low-dose inhaled corticosteroids (ICSs) are insufficient include adding a 
long-acting beta2-agonist (LABA) or increasing the ICS dose. However, there are no data 
to help clinicians evaluate the safest regimen during pregnancy. Objective: We sought to 
compare the risk of major congenital malformations in asthmatic women exposed to a 
LABA plus ICS combination and those exposed to ICS monotherapy at higher doses 
during the first trimester. Methods: A cohort of asthmatic pregnant women exposed to 
ICSs during the first trimester who delivered between January 1990 and March 2009 was 
established. The primary outcome was major malformation recorded at birth or during the 
first year of life. Two subcohorts were established as follows: (1) users of a LABA plus 
low-dose ICS combination or users of a medium-dose ICS and (2) users of a LABA plus 
medium-dose ICS combination or users of a high-dose ICS. Generalized estimating 
equations were used to compare the risk of major malformations between the groups. 
Results: In one subcohort there were 643 women who used a LABA plus low-dose ICS 
and 305 who used a medium-dose ICS; the other subcohort included 198 users of a LABA 
plus medium dose ICS and 156 users of a high-dose ICS. The prevalence of major 
malformations was 6.9% and 7.2%, respectively. The adjusted odds ratio for major 
malformations was 1.1 (95% CI, 0.6-1.9) when a LABA plus low-dose ICS was used 
compared with a medium-dose ICS and 1.2 (95% CI, 0.5-2.7) when a LABA plus medium-
dose ICS was used compared with a high-dose ICS. Conclusion: The risk of major 
malformations was similar with a LABA plus ICS combination and ICS monotherapy at 
higher doses, suggesting that both therapeutic options can be considered during pregnancy 
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INTRODUCTION 
Asthma is one of the most common serious diseases among women of childbearing 
age, affecting 4%–12% of pregnant women.(1-5) Moreover, pregnant women with severe 
or uncontrolled asthma are at higher risk of pregnancy complications and adverse fetal 
outcomes than women with controlled asthma.(4, 6-8) Consequently, asthma management 
guidelines recommend the active treatment of asthma with appropriate medications during 
pregnancy to prevent asthma symptoms and exacerbation.(4, 9, 10) 
Asthma management during pregnancy is based on a stepwise approach that 
requires an initial assessment of the level of severity and subsequent evaluations of its 
control.(4, 11) When asthma cannot be controlled with a low dose of inhaled corticosteroid 
(ICS), the controller therapy options preferred by the guidelines are either the addition of a 
long-acting inhaled beta2-agonist (LABA) to low-dose ICS or increasing the dose of ICS to 
the medium-dose range. Similarly, for women with more severe asthma that is not 
controlled with a medium dose of ICS, the guidelines recommend the addition of a LABA 
to the medium-dose ICS or increasing the ICS to the high-dose range.(4, 9) 
However, there has been no direct comparison of these treatment regimens to guide 
physicians in whether it is safer to increase the dose of ICS during pregnancy or to add a 
LABA. The current literature reports increasing evidence of the safety of low-to-medium 
doses of ICS during pregnancy (compared with no use), but indicate a possible increased 
risk of congenital malformations with high doses of ICS during pregnancy. There is also 
evidence that the ICS/LABA combination is superior to an increased dose of ICS in 
nonpregnant adults.(9, 12) In contrast, only limited observational data are available on the 
safety of LABA during pregnancy,(13) and a recently published study by our group 
reported a significantly increased risk of major cardiac malformations in women exposed 
to LABA during the first trimester.(14) 
Patients’ and physicians’ perceptions of the teratogenicity of a medication could 
influence their decisions to continue or change the treatment regimen during 
pregnancy.(15-17) Among the important clinical decisions that physicians must make if 
asthma cannot be controlled with a low dose of ICS during pregnancy is whether to 
prescribe LABA to supplement the current dose of ICS or to increase the dose of ICS. 
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Evidence for the fetal safety of each treatment option is required if an informed decision is 
to be made. In this study, we compared the risk of major congenital malformations in 
pregnant asthmatic women treated with a combination of LABA and ICS and those treated 
with a higher dose of ICS monotherapy. 
 
METHODS 
Sources of the data 
The data analyzed in this study were retrieved from the Régie de l’assurance-
maladie du Québec (RAMQ) database and the Maintenance et Exploitation des Données 
pour l’Étude de la Clientèle Hospitalière (MED-ECHO) database. The RAMQ database 
contains data on the medical services provided to all residents of Quebec and data on the 
prescription medications dispensed in community pharmacies for residents covered by the 
RAMQ’s Public Drug Insurance Plan (around 42% of the residents of Quebec). The MED-
ECHO database contains data on acute-care hospitalization and covers all the residents of 
Quebec. The validity of the diagnoses of asthma and congenital malformations recorded in 
the RAMQ and MED-ECHO databases has been formally evaluated and the data were 
shown to have a predictive positive value (PPV) of 75% and a predictive negative value 
(PNV) of 96% for asthma diagnoses, and 82% and 88%, respectively, for diagnoses of 
congenital malformation.(18, 19) The prescription data recorded in the RAMQ database 
have been formally evaluated and found to be accurate and valid (83% correct 
identification of the patients and drugs dispensed from the prescriptions).(20) 
 
Study design 
To achieve our objective, a population-based retrospective cohort design was used. 
The cohort was selected from the Quebec Asthma and Pregnancy Database, which 
includes all pregnancies in asthmatic women and a random sample of pregnancies in 
nonasthmatic women between January 1, 1990 and March 31, 2010, identified from the 
hospitalization for delivery records in the MED-ECHO database. Using gestational age at 
birth and the date of birth of the newborns, we retrospectively identified the date of the 
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first day of the last menstrual period and the date of delivery for each pregnancy using a 
validated algorithm.(21) The cohort inclusion criteria were: (1) a pregnancy with a 
recorded singleton delivery between January 1, 1990 and March 31, 2009, so that at least 
one year of follow-up data was available for the newborn; (2) at least one asthma diagnosis 
in the two years preceding delivery (International Classification of Diseases [ICD] ICD-9 
code 493 [except 493.2], or ICD-10 code J45); (3) the use of ICS in the first trimester of 
pregnancy (1–14 weeks); and (4) coverage with the RAMQ’s Public Drug Insurance Plan 
for at least three months before and throughout pregnancy. The exclusion criteria were: (1) 
multiple births from a single pregnancy (2) rare maternal condition affecting fetal 
development (rheumatic disease, Cushing disease, iodine deficiency, adrenal tumor, and 
folic acid deficiency);(22) (3) fetal infection;(22) (4) at least one filled prescription for a 
teratogenic medication in the first trimester;(23, 24) (5) chronic use of an oral 
corticosteroid (OCS) in the first trimester (i.e.,  30 days’ supply); and (6) at least one 
filled prescription for an oral beta2-agonist, leukotriene-receptor antagonist, theophylline, 
ipratropium, cromoglycate, or nedocromil in the first trimester. For women contributing 
more than one pregnancy during the study period, we included only the two most recent 
pregnancies to allow converging regression models. This article reports the first results for 
congenital malformations derived from the Quebec Asthma and Pregnancy Database. 
 
Congenital malformations 
Cases of major congenital malformations were identified using the ICD-9/ICD-10 
hospital-based diagnostic codes recorded in the RAMQ or MED-ECHO databases at birth 
or during the first year of life of the infant. The codes used were specific to congenital 
malformations (ICD-9: 740–759, and ICD-10: Q00–Q99) and our list of malformations 
was compared with the list provided by the Collaborative Perinatal Group and their 
exactness and completeness verified by a geneticist from le Centre Hospitalier 
Universitaire Sainte-Justine in Montreal.(25) A congenital malformation was defined as 
major if it was life threatening or could cause major cosmetic defects. When a 
malformation could be classified as major or minor by the geneticist, we considered it as 
major only if there was at least one hospitalization with a primary diagnosis or admission 
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diagnosis related to this malformation that was recorded in the MED-ECHO database 
during the first year of life of the newborn. The specific major malformation classes and 
their related diagnostic codes are presented in Table E1. The primary outcome was any 
major congenital malformation. 
 
Subcohorts and assessment of exposure 
LABA use (salmeterol or formoterol) was defined as filling at least one prescription 
during the first trimester or three months before pregnancy, with the likelihood of its use 
during the first trimester based on the date and duration of the filled prescription (the 
algorithm used is available upon request). For ICS exposure (fluticasone, beclomethasone, 
triamcinolone, flunisolide, budesonide, or ciclesonide), we estimated the average daily 
dose taken during the first trimester. The estimate was made using an algorithm that we 
developed for previous studies, which is based upon the name of the medication, the 
equivalence between the different ICS products recognized by the Canadian Asthma 
Consensus Guidelines (in fluticasone equivalents),(26) the dose prescribed, the date and 
duration of the filled prescription, and the rate of renewal of the prescription.(27, 28) The 
daily dose of ICS was categorized as follow: low dose (> 0–250 g), medium dose (> 250–
500 g), and high dose (> 500 g). These algorithms accounted for the combination 
therapy (LABA plus ICS) being administered with a fixed-combination inhaler 
(salmeterol/fluticasone or formoterol/budesonide) or with separate inhalers. Two 
subcohorts were established to compare the treatment regimens indicated for women with 
similar levels of asthma severity. In the first subcohort (hereafter referred to as the 
“moderate asthma subcohort”), we compared women who used LABA plus low-dose ICS 
with those who used a medium-dose ICS monotherapy. In the second subcohort (hereafter 
referred to as the “severe asthma subcohort”), we compared women who used LABA plus 
medium-dose ICS with those who used a high-dose ICS monotherapy. 
 
Confounding variables 
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The following variables were identified in the literature as risk factors for 
congenital malformations and were considered potential confounders in our analysis: 
maternal age at the beginning of pregnancy (18–34 and <18 or >35 years),(29) receipt of 
social assistance during pregnancy (yes/no),(30) area of residence at delivery 
(rural/urban),(31, 32) chronic hypertension (yes/no),(33) diabetes mellitus (yes/no),(22, 33) 
exacerbation of asthma (defined as a filled prescription for OCS, an emergency department 
visit, or a hospitalization for asthma) three months before pregnancy (yes/no),(8) and 
short-acting beta2-agonists (SABA) dose per week (0–3 or > 3 doses/week; one dose is 
equal to 200 g of salbutamol) in the three months preceding pregnancy.(14) 
 
Statistical analysis 
The descriptive statistics for the characteristics of the pregnancies were calculated 
and compared between the combination therapy group and the ICS monotherapy group 
within each subcohort. We calculated the crude prevalence of any major or a specific 
major malformation within each subcohort. 
The risk of major congenital malformations was compared between the 
combination therapy and the ICS monotherapy (reference) groups separately within the 
two subcohorts. We used generalized estimating equation (GEE) models with a logistic 
link and an exchangeable correlation matrix to estimate the crude and adjusted odds ratios 
(ORs) for major congenital malformations, with adjustment for all the potential 
confounders listed above and using the pregnancy as the unit of analysis. A GEE model 
was used to take into account the correlation between the consecutive pregnancies of 
individual women.(34) Of note, the risk measured in the analysis is an actual measure of 
major malformation prevalence since the data on the aborted fetuses with malformation is 
not recorded in the databases. 
We conducted a sensitivity analysis that combined the two subcohorts together 
while adjusting for a variable indicating from which subcohort the pregnancy came. This 
sensitivity analysis was conducted to increase the power of the analysis compared with our 
primary stratified analysis. The adjusted results represent an overall comparison of the 
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combination therapy and the higher-dose ICS monotherapy. Finally, we used post hoc 
power calculations to identify the ORs that the study could detect with a power of 80%. 
These calculations were based on a test for the difference between two independent 
proportions with a type I error of 0.05, the number of pregnancies exposed to each of the 
contrasted treatment regimens in the subcohorts, and the percentage of pregnancies with a 
congenital malformation observed in the reference group (ICS monotherapy), and were 
performed with the PASS interface of the NCSS software (2007).(35) All other statistical 
analyses were performed with the SAS software, version 9.3 (SAS Institute Inc., Cary, 
NC). 
 
Ethics approval 
This research project was approved by the Ethics Committee of the Hôpital du 
Sacré-Cœur de Montréal. Authorization was obtained from the Commission d’accès à 
l’information du Québec before the information from the RAMQ and MED-ECHO 
databases was accessed and linked. 
 
RESULTS 
We first identified 6632 pregnancies (from 4619 asthmatic women) from the 
Quebec Asthma and Pregnancy Database that fulfilled our inclusion criteria, in women 
who were exposed to ICS during the first trimester (see Figure 1 for the selection process 
of the subcohorts). After applying the exclusion criteria, we retained 6355 pregnancies. 
From these, 1302 pregnancies (in 1249 women) were finally included in the two 
subcohorts (948 pregnancies in the moderate asthma subcohort and 354 in the severe 
asthma subcohort). Overall, 96 newborns (7.4%) with major malformations were detected 
during the first year of life among the 1302 pregnancies included in the two subcohorts. 
The characteristics of the pregnancies included in the moderate and severe asthma 
subcohorts are presented in Table I. In both subcohorts, most of the women were 18–34 
years of age, lived in urban areas, and did not suffer from chronic hypertension or diabetes 
mellitus. However, women in the severe asthma subcohort were more likely to have 
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suffered exacerbated asthma (p value <0.001) and to have used > 3 doses of SABA per 
week (p value <0.001) in the three months preceding the pregnancy than the women in the 
moderate asthma subcohort. In both subcohorts, the women treated with the ICS 
monotherapy were more likely to receive social assistance (p value <0.001), and to use > 3 
doses of SABA per week (p value <0.05) than those treated with the combination therapy. 
In the severe asthma subcohort, we also observed that women exposed to the high-dose 
ICS monotherapy were older than women exposed to a combination therapy (p value 
<0.05). 
In the moderate asthma subcohort, 21 cases (6.9%) of major congenital 
malformations were detected among the women treated with the combination therapy, 
whereas 46 cases (7.2%) were detected among women treated with the medium-dose ICS 
monotherapy. In the severe asthma subcohort, 14 cases (7.1%) of major congenital 
malformations were detected among women treated with the combination therapy, whereas 
15 cases (9.6%) were detected among women treated with the high-dose ICS monotherapy. 
We present the distribution of specific groups of major congenital malformations in each 
subcohort in Table E2. In both subcohorts, cardiac malformations were the most frequent 
malformations, with prevalences varying between 2.0% for women treated with LABA 
plus medium-dose ICS and 3.2% for women treated with the high-dose ICS monotherapy. 
In Table II, we present the crude and adjusted ORs for the moderate asthma 
subcohort. We observed no significant difference in the risk of major congenital 
malformations between women treated with the combination therapy and those treated 
with the medium-dose ICS monotherapy (adjusted OR: 1.1; 95% CI: 0.6–1.9). The receipt 
of social assistance during pregnancy was associated with an increased risk of major 
malformations (adjusted OR: 2.0; 95% CI: 1.2–3.5). None of the other variables included 
in the model were significantly associated with the risk of major malformations. With the 
sample size of this subcohort, we had a power of 80% to detect an OR of 1.9. 
In Table III, we present the results for the severe asthma subcohort. Women treated 
with medium-dose ICS plus LABA had a nonsignificant 20% higher risk of major 
malformations than women treated with high-dose ICS (adjusted OR: 1.2; 95% CI: 0.5–
2.7). This model also showed that women younger than 18 years or older than 34 years 
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were two times more likely to have a baby with a congenital malformation than women 
aged 18–34 years. With the sample size of this subcohort, we had a power of 80% to detect 
an OR of 2.4. 
We present the results of the sensitivity analysis, in which we combined the two 
subcohorts, in Table IV. The use of the LABA plus ICS combination therapy did not entail 
a significantly increased risk of major malformations compared with the use of a higher-
dose ICS monotherapy during the first trimester (adjusted OR: 1.0; 95% CI: 0.6–1.7). This 
model also revealed that the receipt of social assistance during pregnancy was associated 
with a significantly increased risk of major malformations (adjusted OR: 2.1; 95% CI: 1.3–
3.4). With the sample size of the combined cohort, we had a power of 80% to detect an OR 
of 1.7. 
 
DISCUSSION 
This population-based comparative safety study showed that the risk of major 
malformations did not differ when a combination therapy of LABA plus ICS or a higher 
dose of ICS monotherapy was used in the first trimester of pregnancy. This result was 
consistent in both subcohorts of moderately and severely asthmatic pregnant women. 
Moreover, both the subcohort analysis and the combined secondary analysis showed 
similar results. 
To the best of our knowledge, this study is the first to compare the risk of 
congenital malformations for different comparable treatment options for the management 
of moderate to severe asthma during pregnancy. Previous studies have compared women 
treated with LABA or ICS with either asthmatic women not exposed to the medication or 
nonasthmatic women.(13, 36) ICSs are the most frequently recommended controller 
therapy for the management of persistent asthma during pregnancy and their safety in 
terms of congenital malformations has been reported in 17 published studies.(36, 37) A 
recent meta-analysis reported no increased risk of congenital malformations with ICS 
use.(1) However, it included only three studies, “exposure” was defined as the use of an 
ICS at any dose versus no use anytime during pregnancy, and congenital malformations 
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also included minor ones. Nonetheless, in a previous study conducted by our group that 
was based on an earlier cohort (1990–2002) of asthmatic pregnant women, we found a 
63% increased risk of congenital malformations (most prominently musculoskeletal and 
cardiac malformations) in women using high doses of ICS (> 500 g/day fluticasone 
equivalents) compared with women who used low-to-moderate doses of ICS (> 0 to 500 
g/day) during the first trimester.(12) 
Of eight published studies that examined maternal LABA use and congenital 
malformations, only one reported a significant association.(13) In a database-driven study 
published by our group that was based on an earlier cohort (1990–2002) of asthmatic 
pregnant women, we found that women exposed to LABA during the first trimester were at 
greater risk of giving birth to a baby with a major cardiac or major “other and unspecified 
malformation” (adjusted OR: 2.4; 95% CI: 1.1–5.1 or adjusted OR: 4.0; 95% CI: 1.3–12.2, 
respectively).(14) That study adjusted for asthma severity/control, but we could not rule 
out the presence of residual confounding by indication. The sample size of that earlier 
cohort (1990–2002) was not sufficient to compare the LABA plus ICS combination 
therapy with the higher-dose ICS monotherapy as we did in the present study. A common 
characteristic of all studies that have examined LABA use is their small sample sizes, and 
this is probably the result of the relatively recent introduction of these drugs into the 
markets and the controversies that have surrounded them.(38, 39) Importantly, caution 
should be used in interpreting the negative results of studies with small sample sizes. 
The biological mechanisms of teratogenicity of ICS and LABA are still uncertain, 
but several hypotheses exist. A proportion of the ICS that enter the systemic circulation 
may cross the placenta and affects the fetus, also diffusion of fluorinated corticosteroids 
(e.g. fluticasone and budesonide) is even more rapid than other corticosteroids.(40-42) 
Since fetal endogenous levels of corticosteroids are much lower than maternal levels, even 
minimal diffusions to the fetus could have a considerable impact.(43) Evidence shows that 
corticosteroids influences maternal hypothalamic-pituitary-adrenal (HPA) activity, which 
may play a role in endocrine and metabolic alterations in the offspring.(44) The early 
presence of the glucocorticoid receptor in the fetus implies that corticosteroids may affect 
the fetus by the glucocorticoid receptor and lead to persistent disorders in endocrine and 
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metabolic control.(45) Animal models displayed potent teratogenicity of corticosteroids at 
doses less than or similar to those used in humans, with cleft palate being the primary 
malformation induced in most species.(42, 46) Corticosteroids are essential for normal 
differentiation and growth of epithelial cells, but supraphysiologic doses interrupt this 
process.(47). Regarding LABA, a probable teratogenic effect could arise from their 
potential effect on the corticosteroid function. It was demonstrated that LABA could 
induce the gene transcription effect of corticosteroids, which subsequently might increase 
their teratogenic effects.(48, 49) 
Our primary objective was to compare the risk of major congenital malformations 
after two currently used—and probably widely used today—treatment options for the 
management of persistent moderate-to-severe asthma during pregnancy. We minimized 
any confounding by indication by performing the primary analysis within subcohorts of 
women with similar levels of asthma severity and by adjusting for baseline severity 
markers, but because there was no randomization of the treatment, we cannot be sure that 
there was no residual confounding. Because our objective was to examine the safety of two 
similar treatment regimens, we also cannot exclude the possibility that the use of either 
high-dose ICS or LABA is associated with a higher risk of major malformations than no 
use of these medications. However, such comparisons (use versus no use) are less 
clinically relevant because not treating a woman who requires high-dose ICS or the 
addition of LABA to a lower-dose ICS to control her asthma during pregnancy is clearly 
not a treatment option. 
The present study has some important strengths. The use of two large 
administrative databases allowed us to access a large number of pregnancies in asthmatic 
women, from which we could establish our subcohorts and measure several potentially 
important confounders. Data on filled prescriptions, which were used to assess the 
women’s exposure to asthma medications during pregnancy, were prospectively collected 
independently of the outcome, avoiding any recall bias, which is common in reproductive 
research. As mentioned earlier, we minimized confounding by indication by comparing 
two treatment regimens that have similar indications. However, the results of this study 
should be interpreted with consideration of the following limitations. The use of 
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medications was measured by medication claims, which might not reflect their actual 
intake. Moreover, we considered maternal LABA exposure as dichotomous (i.e., exposed 
or not exposed during the first trimester) because in practice, the dose prescribed varies 
little between patients. This definition might have diluted the exposure because not all 
women will adhere fully (100%) to their LABA prescription and this could have 
contributed to an underestimation of the impact of the ICS/LABA combination on the risk 
of major malformations. There is also a possibility of residual confounding arising from 
unmeasured risk factors for congenital malformations, such as smoking status, maternal 
obesity, over-the-counter medications, and some other environmental teratogens.(22) 
Another source of residual confounding is the absence of information on the provider 
classification of asthma severity, since this variables is not recorded in the databases. We 
had a statistical power of 80% to detect an OR of 1.9 in the moderate asthma subcohort 
and an OR of 2.4 in the severe asthma subcohort, and associations smaller than that might 
not have been detected in our primary analysis. However, the secondary analysis, which 
combined the two subcohorts, had power of 80% to detect an OR of 1.7. Finally, the cohort 
underrepresents women of higher socioeconomic status, which may limit the 
generalizability of the study results. 
In summary, the risk of major congenital malformations was not higher among 
asthmatic pregnant women treated with a LABA plus ICS combination therapy than 
among women treated with an ICS monotherapy at a higher dose during the first trimester. 
These reassuring results are consistent with asthma management guidelines, and provide 
scientific evidence to help physicians and mothers make evidence-based treatment 
decisions during pregnancy. These results should encourage women to continue to take 
their asthma medications when required to control their asthma during pregnancy, and as 
suggested by previous research evidence, this will increase the likelihood of healthy 
pregnancies and newborns. 
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Figure 1. Cohort flow diagram and the subcohort selection process. 
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Table I. Distribution of maternal characteristics according to exposure to ICS and LABA during the 
first trimester of pregnancy in each subcohort of asthmatic women 
 Moderate asthma subcohort Severe asthma subcohort 
  LABA plus 
low-dose 
ICS 
Medium-
dose ICS 
P value 
LABA plus 
medium-
dose ICS 
High-dose 
ICS 
P value 
Total number of 
pregnancies in the 
subcohort (%) 
305 (32.2) 643 (67.8)  198 (55.9) 156 (44.1)  
  Number of pregnancies (%) 
Maternal age (years) at the 
beginning of pregnancy 
      
18–34 268 (87.9) 544 (84.6) 0.180 171 (86.4) 119 (76.3) 0.014 
< 18 or  35 37 (12.1) 99 (15.4)  27 (13.6) 37 (23.7)  
Receipt of social 
assistance during 
pregnancy 
130 (42.6) 374 (58.2) < 0.001 89 (45.0) 116 (74.4) < 0.001 
Urban area of residence at 
delivery 
243 (79.7) 497 (77.3) 0.409 152 (76.8) 125 (80.1) 0.447 
Chronic hypertension  7 (2.3) 16 (2.5) 0.857 8 (4.0) 6 (3.9) 0.926 
Diabetes mellitus 12 (3.9) 33 (5.1) 0.418 8 (4.0) 12 (7.7) 0.139 
Exacerbation of asthma 
three months before 
pregnancy 
46 (15.1) 75 (11.7) 0.141 35 (17.7) 33 (21.2) 0.410 
SABA doses/week three 
months before pregnancy 
      
0–3 144 (47.2) 249 (38.7) 0.013 59 (29.8) 21 (13.5) < 0.001 
> 3 161 (52.8) 394 (61.3) 
 139 (70.2) 135 (86.5)  
LABA: long-acting beta2-agonists, ICS: inhaled corticosteroids 
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Table II. Crude and adjusted odds ratios for major congenital malformations in the moderate 
asthma subcohort  
LABA: long-acting beta2-agonists, ICS: inhaled corticosteroids, preg: pregnancies 
 
 No. preg. 
No. cases 
(%) 
Crude OR (95% 
CI) 
Adjusted OR (95% 
CI) 
LABA plus low-dose ICS 305 21 (6.9) 0.9 (0.5–1.6) 1.1 (0.6–1.9) 
Medium-dose ICS 643 46 (7.2) Reference Reference 
Maternal age (years) at the 
beginning of pregnancy 
    
18–34 812 56 (6.9) Reference Reference 
< 18 or  35 136 11 (8.1) 1.2 (0.6–2.4) 1.1 (0.6–2.2) 
Receipt of social assistance during 
pregnancy 
 
Yes 504 46 (9.1) 2.0 (1.2–3.4) 2.0 (1.2–3.5) 
No 444 21 (4.7) Reference Reference 
Area of residence at delivery    
Urban 740 47 (6.4) Reference Reference 
Rural 208 20 (9.6) 1.5 (0.9–2.7) 1.7 (0.9–2.9) 
Chronic hypertension     
Yes 23 3 (13.0) 2.0 (0.6–7.0) 1.9 (0.6–6.1) 
No 925 64 (6.9) Reference Reference 
Diabetes mellitus     
Yes 45 5 (11.1) 1.6 (0.5–4.7) 1.4 (0.5–4.2) 
No 903 62 (6.9) Reference Reference 
Exacerbation of asthma three months 
before pregnancy 
 
 
 
 
Yes 121 9 (7.4) 1.1 (0.5–2.3) 1.0 (0.5–2.0) 
No 827 58 (7.0) Reference Reference 
SABA doses/week three months 
before pregnancy 
 
 
 
 
0–3 393 26 (6.6) Reference Reference 
> 3 555 41 (7.4) 1.1 (0.7–1.9) 1.0 (0.6–1.8) 
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Table III. Crude and adjusted odds ratios for major congenital malformations in the severe 
asthma subcohort 
LABA: long-acting beta2-agonists, ICS: inhaled corticosteroids, preg: pregnancies 
 
 
 
 No. preg. 
No. cases 
(%) 
Crude OR (95% 
CI) 
Adjusted OR 
(95% CI) 
LABA plus medium-dose ICS 198 14 (7.1) 0.7 (0.3–1.5) 1.2 (0.5–2.7) 
High-dose ICS 156 15 (9.6) Reference Reference 
Maternal age (years) at the beginning of 
pregnancy 
 
  
18–34 290 20 (6.9) Reference Reference 
< 18 or  35 64 9 (14.1) 2.2 (1.0–5.1) 2.4 (1.0–5.5) 
Receipt of social assistance during 
pregnancy 
    
Yes 205 22 (10.7) 2.4 (1.0–5.9) 2.5 (0.9–6.9) 
No 149 7 (4.7) Reference Reference 
Area of residence at delivery   
Urban 277 21 (7.6) Reference Reference 
Rural 77 8 (10.4) 1.4 (0.6–3.3) 1.6 (0.6–4.1) 
Chronic hypertension    
Yes 14 2 (14.3) 1.9 (0.4–9.1) 1.6 (0.4–7.5) 
No 340 27 (7.9) Reference Reference 
Diabetes mellitus    
Yes 20 0 (0.0) Not included Not included 
No 334 29 (8.7) Reference Reference 
Exacerbation of asthma three months 
before pregnancy 
 
  
Yes 68 5 (7.4) 0.9 (0.3–2.4) 0.8 (0.3–2.3) 
No 286 24 (8.4) Reference Reference 
SABA doses/week three months before 
pregnancy 
 
  
0–3 80 2 (2.5) Reference Reference 
> 3 274 27 (9.9) 4.3 (1.0–18.3) 3.9 (0.9–15.9) 
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Table IV. Crude and adjusted odds ratios for major congenital malformations in the 
combined cohort 
LABA: long-acting beta2-agonists, ICS: inhaled corticosteroids, preg: pregnancies 
 
 No. preg. 
No. cases 
(%) 
Crude OR (95% 
CI) 
Adjusted OR (95% 
CI) 
LABA plus ICS combination 
therapy 
503 35 (7.0) 0.9 (0.6–1.4) 1.0 (0.6–1.7) 
Higher-dose ICS monotherapy 799 61 (7.6) Reference Reference 
ICS dose group     
Moderate asthma 948 67 (7.1) Reference Reference 
Severe asthma 354 29 (8.2) 1.2 (0.8–1.9) 1.1 (0.7–1.8) 
Maternal age (years) at the beginning of pregnancy   
18–34 1102 76 (6.9) Reference Reference 
< 18 or  35 200 20 (10.0) 1.6 (0.9–2.6) 1.5 (0.9–2.5) 
  Receipt of social assistance during pregnancy   
Yes 709 68 (9.6) 2.1 (1.3–3.3) 2.1 (1.3–3.4) 
No 593 28 (4.7) Reference Reference 
Area of residence at delivery    
Urban 1017 68 (6.7) Reference Reference 
Rural 285 28 (9.8) 1.5 (0.9–2.3) 1.6 (1.0–2.5) 
Chronic hypertension     
Yes 37 5 (13.5) 2.1 (0.8–5.4) 1.8 (0.7–4.4) 
No 1265 91 (7.2) Reference Reference 
Diabetes mellitus     
Yes 65 5 (7.7) 1.0 (0.4–2.6) 0.8 (0.3–2.3) 
No 1237 91 (7.4) Reference Reference 
  Exacerbation of asthma three months before pregnancy   
Yes 189 14 (7.4) 1.1 (0.6–2.0) 1.0 (0.5–1.8) 
No 1113 82 (7.4) Reference Reference 
  SABA doses/week three months before pregnancy   
0–3 473 28 (5.9) Reference Reference 
> 3 829 68 (8.2) 1.4 (0.9–2.2) 1.3 (0.8–2.0) 
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Table E1. Specific groups of major malformations and their related ICD-9/ICD-10 codes 
 ICD-9 code ICD-10 code 
Nervous system 740, 741, 742 
Q00, Q01, Q02, Q03, Q04, Q05, 
Q06, Q07 
Cardiac 745, 746 Q20, Q21, Q22, Q23, Q24  
Circulatory system 747 Q25, Q26, Q27, Q28 
Respiratory system 748 Q30, Q31, Q32, Q33, Q34 
Eye 743 Q10, Q11, Q12, Q13, Q14, Q15, 
Ear, face, and neck 744 Q16, Q17, Q18 
Cleft palate and cleft lip 749 Q35, Q36, Q37 
Digestive system 750, 751 
Q38, Q39, Q40, Q41, Q42, Q43, 
Q44, Q45 
Genital organs 752 
Q50, Q51, Q52, Q53, Q54, Q55, 
Q56, Q640 
Urinary system 753 Q60, Q61, Q62, Q63, Q64
b
 
Limbs 
754.4, 754.5, 754.6, 754.7, 
755 
Q658, Q659, Q66, Q682, Q683, 
Q684, Q685, Q69, Q70, Q71, 
Q72, Q73, Q74 
Musculoskeletal 754a, 756 
Q65
c
, Q66, Q67, Q68
d
, Q75, Q76, 
Q77, Q78, Q79 
Integument 757 Q80, Q81, Q82, Q83, Q84 
Chromosomal 758 
Q90, Q91, Q92, Q93, Q94, Q95, 
Q96, Q97, Q98, Q99 
Other congenital anomalies 759 Q85, Q86, Q87, Q89 
A congenital malformation was defined as major if it was life-threatening or could cause 
major cosmetic defects. When a malformation could be classified as major or minor by the 
geneticist, we considered it major only if there was at least one hospitalization with a 
primary or an admission diagnosis related to this malformation in the MED-ECHO database 
during the first year of life of the newborn. 
ICD: International Classification of Diseases. 
a
 Including all ‘754’ codes except those mentioned above for limb malformations.  
b
 Including all ‘Q64’ codes except ‘Q640’. 
c
 Including all ‘Q65’ codes except those mentioned above for limb malformations.  
d
 Including all ‘Q68’ codes except those mentioned above for limb malformations.  
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Table E2. Distribution of major congenital malformations in the moderate asthma and severe 
asthma subcohorts 
 Moderate asthma subcohort Severe asthma subcohort 
 
LABA plus 
low-dose ICS 
Medium-dose 
ICS 
LABA plus 
medium-dose 
ICS 
High-dose ICS 
 No. % No. % No. % No. % 
At least one major 
malformation
a
 21 6.9 46 7.2 14 7.1 15 9.6 
Specific major malformations         
Nervous system 4 1.3 4 0.6 2 1.0 2 1.3 
Cardiac 8 2.6 15 2.3 4 2.0 5 3.2 
Circulatory system 1 0.3 2 0.3 2 1.0 2 1.3 
Respiratory system 3 1.0 4 0.6 1 0.5 0 0.0 
Eye 0 0.0 1 0.2 0 0.0 0 0.0 
Ear, face, and neck 0 0.0 0 0.0 0 0.0 0 0.0 
Cleft palate and cleft lip 1 0.3 3 0.5 0 0.0 0 0.0 
Digestive system 0 0.0 11 1.7 1 0.5 2 1.3 
Genital organs 1 0.3 2 0.3 1 0.5 1 0.6 
Urinary system 0 0.0 3 0.5 3 1.5 6 3.9 
Limbs 0 0.0 1 0.2 0 0.0 2 1.3 
Musculoskeletal
b
 2 0.7 6 0.9 1 0.5 3 1.9 
Integument 4 1.3 2 0.3 2 1.0 2 1.3 
Chromosomal 1 0.3 3 0.5 2 1.0 1 0.6 
Other congenital anomalies 2 0.7 2 0.3 0 0.0 2 1.3 
LABA: long-acting beta2-agonists, ICS: inhaled corticosteroids 
a 
The total sum of all major specific malformations exceeded the number of cases (96 infants with 
major malformations) because an infant could have more than one malformation. 
b
 Including all musculoskeletal malformations except limb malformations. 
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5.3. Article on the case ascertainment definitions of major malformations 
 
5.3.1 Published Manuscript 
 
 
 
The Impact of Different Case Ascertainment Definitions on the Prevalence of Major 
Congenital Malformations and their Association with Asthma during Pregnancy 
 
Published in Maternal and Child Health Journal, [Epub ahead of print] 
doi:10.1007/s10995-016-2147-1. http://link.springer.com/article/10.1007/s10995-016-
2147-1 
 
 
 
This article is included in the current thesis by the permission of the co-authors and editors. 
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ABSTRACT 
 
Purpose: To compare the prevalence of major malformations using different case 
ascertainment definitions and to evaluate their impact on maternal asthma-major 
malformations association. Methods: A cohort of pregnancies with and without asthma 
between 1990 and 2010 was formed. We used two classification methods: the Two step 
Congenital Malformation Classification (TCMC) and the Canadian Congenital Anomalies 
Surveillance System (CCASS). Within each method, three case definitions were compared: 
(1) ≥1 diagnosis in the hospital database; (2) ≥1 diagnosis in the hospital database or ≥2 in 
the medical claims; and (3) ≥1 diagnosis in the hospital database or ≥1 in the medical 
claims. We calculated the prevalence of major malformations and adjusted odds ratios 
(aORs) for maternal asthma association. Results: Of 467,946 pregnancies, 12.3% were 
with active asthma. The prevalence estimates were: TCMC 5.10%–7.08% and CCASS 
7.03%–10.57%. Asthma-major malformations association was weaker with the CCASS 
(aOR 1.14–1.20) versus TCMC (aOR 1.22–1.26). Conclusions: The case ascertainment 
definitions with ≥ 1 hospitalization are likely to be the most reliable in similar 
administrative databases. The case ascertainment definition had a considerable impact on 
the prevalence of major malformations, but hardly influenced the aORs. Future studies 
should formally assess the validity of the case ascertainment definitions and allow 
generalizability to other maternal exposures. 
 
 
Keywords: Congenital malformations, case definitions, asthma, pregnancy, administrative 
databases. 
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Significance  
 
What is already known on this subject? 
Several case ascertainment definitions of major congenital malformations are 
currently being used in perinatal epidemiology, but few studies compared their impacts. 
 
What this study adds? 
In this study, six different case ascertainment definitions were compared, resulting 
in a considerable impact on prevalence estimates, but little on the measures of association. 
The prevalence estimates ranged between 5.1% and 10.6%, with medical claims playing a 
major role in the prevalence increase. The case ascertainment definitions using ≥ 1 
diagnosis of major malformation recorded in hospital databases or discharge summary 
sheets are the most recommended since they have the least chance of including 
misclassified cases yet providing adequate results. 
 
Ethical Statement 
This research project was approved by the Ethics Committee of the Hôpital du 
Sacré-Cœur de Montréal. Authorization was obtained from the Commission d’Accès à 
l’Information du Québec to access and link the RAMQ and MED-ECHO databases. 
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INTRODUCTION 
Computerized administrative databases have become an important source of data in 
perinatal epidemiology, with increasing number of studies evaluating the impact of 
pregnancy exposures on perinatal outcomes including congenital malformations.(Correa & 
Kirby, 2010) Major malformations are considered among the leading causes of infant, 
fetal, and post neonatal mortality in North America and Europe. (Khoshnood et al., 2011; 
Public Health Agency of Canada. Perinatal Health Indicators for Canada 2013: a Report 
of the Canadian Perinatal Surveillance System. Ottawa, 2013.) However, discrepancies are 
present in the estimated prevalence of major malformations in prior reports. These 
differences are attributed to several factors, including the source of data, the diagnostic 
codes validity, the classification method, and the period of assessment (e.g. at birth or 
during the 1
st
 year of life).(Bedard, Lowry, Sibbald, et al., 2012; Hobbs, Hopkins, & 
Simmons, 2001; Rasmussen & Moore, 2001) All these factors should be considered in 
specifying and developing the case ascertainment definitions in epidemiological studies. 
Typically, a case ascertainment definition for congenital malformations is pre-specified by 
the investigators and operated through applying an algorithm to the raw data in the 
databases (e.g. medical records with congenital malformations diagnoses) in order to 
capture the required cases.  
Quebec is the second largest province in Canada and several health administrative 
databases were established and increasingly being used in epidemiological research. 
Among others, the Régie de l’Assurance-Maladie du Québec (RAMQ) Medical Claims 
database records data on medical services paid on a fee-for-service basis for all residents of 
Quebec and the Maintenance et Exploitation des Données pour l’Étude de la Clientèle 
Hospitalière (MED-ECHO) database records data related to all acute care hospitalisations 
in the province. Both databases have been used previously for congenital malformations 
research.(Berard et al., 2007; De Wals, Rusen, Lee, Morin, & Niyonsenga, 2003; Eltonsy, 
Forget, Beauchesne, & Blais, 2014; Tairou, De Wals, & Bastide, 2006) The accuracy of 
congenital malformations diagnoses recorded in MED-ECHO and RAMQ databases was 
reported in two studies.(Blais, Berard, Kettani, & Forget, 2013; Kulaga & Berard, 2010) 
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Kulaga et al. reported a 60% relative agreement between MED-ECHO, RAMQ, Births and 
Deaths Registry records, and the mothers’ reports.(Kulaga & Berard, 2010) Comparing the 
malformations diagnoses recorded in the linked MED-ECHO and RAMQ databases with 
the infants’ medical charts (the gold standard), Blais et al. reported a positive predictive 
value (PPV) of 78.1% for major malformations among asthmatic women and 69.0% 
among non-asthmatic women.(Blais et al., 2013) However, the aforementioned studies did 
not investigate the accuracy of the diagnoses reported in each database separately. It is 
currently unknown whether one of these two databases has a higher accuracy of 
malformations diagnoses over the other. In Quebec, medical billing claims database is used 
mainly for billing and administrative purposes with the diagnoses information being 
recorded by physicians and not mandatory. While in the hospitalizations database, the 
diagnoses recording is mandatory and performed by trained medical archivists.  
Beside the variation in the prevalence estimates, the case ascertainment definitions might 
also influence the estimates for the associations between maternal exposures and 
congenital malformations. The two most likely common scenarios of deviations from the 
truth have different causes and effects. Incomplete and non-differential ascertainment of 
congenital malformations will hardly affect the effect estimates themselves but will affect 
the precision. On the other hand, over-ascertainment by inclusion of non-malformed 
newborns or newborns with minor malformations (i.e. false positives) could lead to 
underestimating of the true impact of the exposure and lower observed effect estimates. 
Therefore, the objective of the current study was to compare the prevalence of major 
malformations using different case ascertainment definitions that vary by the source of 
data and the classification method. We also evaluated the impact of these definitions on the 
association between maternal asthma and major malformations.  
 
METHODS 
Data sources 
We used the Quebec Asthma and Pregnancy Database, including all pregnancies in all 
women with ≥ 1 asthma diagnosis (International Classification of Diseases [ICD] 9 th 
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Revision [ICD-9] code 493 or ICD-10 code J45) in the 2-year period preceding one of their 
deliveries and all pregnancies of a 4-times-larger random sample of other women who 
delivered between January 1, 1990 and March 31, 2010 in Quebec (see Figure 1). The 
database includes 583,071 pregnancies, representing about 35% of all births in the 
province in this period of time.(Statistics Canada-Components of population growth, 
Canada, provinces and territories. 
http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=510004) External validity was not 
assessed per se, but including all pregnancies from asthmatic women and a large random 
sample from non-asthmatic women should provide high external validity. 
This database contains data extracted from the MED-ECHO and RAMQ databases. Since 
the RAMQ Medical Claims database records data on all medical visits, including diagnosis 
codes and procedures, for all residents of Quebec, we hypothesized that it contained 
valuable information on congenital malformations that could be missing from the MED-
ECHO database. The diagnoses recorded in the MED-ECHO database are routinely 
collected by trained medical archivists using the ICD-10 revised for Canada (ICD-10-CA) 
since 2006, and using the ICD-9 before 2006.The RAMQ Medical Claims database records 
diagnoses coded with ICD-9 codes. We obtained data from the RAMQ and MED-ECHO 
databases from January 1, 1988 to March 30, 2010 for the mothers, and from birth to 
March 30, 2010 for the offspring. 
 
Study cohort and asthma definition 
A cohort of pregnancies in women with active asthma and women without asthma was 
selected. Asthma was defined as ≥ 1 asthma diagnosis (ICD-9 code 493, except 493.2, or 
ICD-10 code J45) recorded during a hospitalization, or ≥ 2 medical claims associated with 
an asthma diagnosis within 2 consecutive years between 1988 and the delivery.(Gershon et 
al., 2009) This operational definition of asthma was previously validated and showed a 
sensitivity of 83.8% and a specificity of 76.5%.(Gershon et al., 2009) Asthma was 
considered to be present during pregnancy (i.e. active asthma) if there was at least one 
asthma diagnosis within 2 years before delivery.The pregnancy was considered as non-
asthmatic if the woman had no diagnosis of asthma recorded in either database between 
1988 and the delivery. The pregnancies inclusion criteria were: (1) a pregnancy with 
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delivery between January 1, 1990 and March 31, 2009 (allowing 1 year of data available 
after birth to assess congenital malformations); (2) maternal age at the beginning of 
pregnancy of 15–45 years; (3) gestational duration of 20–45 weeks; and (4) fulfillment of 
the definitions for the presence/absence of active asthma during pregnancy. Quadruplet 
births from a single pregnancy were excluded to avoid zero cells and pregnancies missing 
the mother–infant link were excluded. 
Classification of congenital malformations 
Congenital malformations were identified using the ICD-9 and ICD-10 codes for 
congenital malformations recorded in MED-ECHO and RAMQ databases at birth and 
during the 1
st
 year of life for live births (≥ 20 weeks gestation) and at birth for stillbirths. 
We compared two methods for the classification of congenital malformations. The first, 
the Two-step Congenital Malformation Classification (TCMC) method, which was 
developed specifically for research and used in previous perinatal epidemiological 
studies.(Blais, Beauchesne, Lemiere, & Elftouh, 2009; Blais, Kettani, Elftouh, & Forget, 
2010; Eltonsy et al., 2014) Briefly, to facilitate the development of a complete and 
comprehensive list of congenital malformations, a system specific malformations list was 
primarily compared with a list provided by the Collaborative Perinatal Group.(Heinonen, 
Slone, & Shapiro, 1977) The full list was then verified by a geneticist from the Centre 
Hospitalier Universitaire Sainte-Justine for exactness and completeness. , The first step 
included classifying congenital malformations as major, minor, or major/minor. A 
malformation was defined as “major” if it was life-threatening or could cause major 
cosmetic defects. As judged by the geneticist, the “major/minor” category includes 
malformations that vary in their severity, depending on the condition of each case. The 
“minor” category includes malformations not classified in the major or major/minor 
categories. In the second step, the major/minor malformations were reclassified as major if 
the malformation was associated with at least one hospitalization with a primary or an 
admission diagnosis in the MED-ECHO database in the first year of life of the baby or as 
minor if not. 
The second method was the national Canadian Congenital Anomalies Surveillance System 
(CCASS) method, which has been described in more detail in the CCASS periodic 
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reports.(Public Health Agency of Canada. Congenital Anomalies in Canada 2013 : A 
Perinatal Health Surveillance Report. Ottawa, 2013.) Briefly, the ICD-9 and ICD-10 
codes for congenital malformations were classified into 14 categories of system-specific 
malformations. Then, preselected diagnostic codes for minor malformations were excluded 
from these categories. Notably, the CCASS method is the Canadian national method of 
ascertainment which is currently used with several provincial databases. The CCASS uses 
discharge abstract data (DAD) on newborns, collected from provincial and territorial 
hospitals via the Canadian Institute for Health Information (CIHI) and Québec’s MED-
ÉCHO. The CCASS was originally developed for surveillance purposes. Online Resource 
1 provides a complete description and comparison of the two classification methods. 
Congenital malformations were categorized into 16 system-specific categories, as 
presented in Online Resource 1. As presented in Table e1, the TCMC and the CCASS 
methods perfectly agree in the classification codes for nervous system, cardiac system, 
orofacial clefts, and Down syndrome. The rest of the system-specific malformations have 
codes that vary by the classification method. 
Case ascertainment definitions of congenital malformations 
We sought to compare case ascertainment definitions that differ by the source of data (i.e. 
diagnoses recorded in a hospital database [MED-ECHO] or in a medical billing claims 
database [RAMQ]) and the classification method (i.e. the TCMC or CCASS methods). We 
developed 3 case ascertainment definitions for each classification method, and they varied 
in the inclusion criteria from the strictest (i.e. using only hospital database) to the least 
strict (i.e. using ≥ 1 diagnosis from either the medical claims database or the hospital 
database). Using this methodology, we aimed at evaluating the separate effect of changing 
the classification method and changing the source of data. 
We used six case ascertainment definitions: (1) TCMC: ≥ 1 major malformation diagnosis 
recorded in the hospital database; (2) TCMC: ≥ 2 major malformation diagnoses recorded 
in the medical claims database or ≥ 1 major malformation diagnosis recorded in the 
hospital database; (3) TCMC: ≥ 1 major malformation diagnosis recorded in the medical 
claims database or ≥ 1 major malformation diagnosis recorded in the hospital database; (4) 
CCASS: ≥ 1 major malformation diagnosis recorded in the hospital database; (5) CCASS: 
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≥ 2 major malformation diagnoses recorded in the medical claims database or ≥ 1 major 
malformation diagnosis recorded in the hospital database; and (6) CCASS: ≥ 1 major 
malformation diagnosis recorded in the medical claims database or ≥ 1 major malformation 
diagnosis recorded in the hospital database. The six case ascertainment definitions are 
summarized in Table 1. 
Statistical analysis 
The characteristics of the pregnancies were compared using descriptive statistics. We 
calculated the prevalence of major malformations using the six case ascertainment 
definitions. Next, we compared the prevalence of major malformations between 
pregnancies of women with active asthma and non-asthmatic women. We used generalized 
estimating equation (GEE) models with a logistic link and pregnancy as the unit of 
analysis to estimate crude and adjusted odds ratios (cOR, aOR) for major malformations 
with 95% confidence intervals (CI). GEE models were used to account for the correlation 
between consecutive pregnancies in individual women.(Zeger, Liang, & Albert, 1988) 
Adjusted models contained risk factors for congenital malformations, including maternal 
age at the start of pregnancy (18–34 and < 18 or > 35 years),(Gill et al., 2012) receipt of 
social assistance at the start of pregnancy (yes/no),(Yang, Carmichael, Canfield, Song, & 
Shaw, 2008) area of residence at delivery (rural/urban),(Langlois, Scheuerle, Horel, & 
Carozza, 2009; Messer et al., 2010) multiple pregnancy (yes/no), and the following 
maternal co-morbidities identified from diagnoses recorded in the MED-ECHO or RAMQ 
databases up to 1 year before pregnancy: chronic hypertension (yes/no),(Liu et al., 2013) 
diabetes mellitus (yes/no),(Brent, 2001; Liu et al., 2013) and epilepsy (yes/no).(Brent, 
2001) All statistical analyses were performed with SAS software, version 9.3 (SAS 
Institute Inc., Cary, NC). 
RESULTS 
Of 467,946 pregnancies eligible for the study, 57,766 (12.3%) were in women with active 
asthma and 410,180 (87.7%) were in non-asthmatic women. The selection process is 
summarized in Figure 1. The characteristics of the pregnancies in women with active 
asthma and non-asthmatic women are presented in Table 2. Most of the women in both 
groups were 18–34 years old and lived in urban areas. However, women with active 
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asthma were more likely to receive social assistance and to suffer from other chronic 
diseases. Table 3 shows the prevalence of major malformations according to each case 
ascertainment definition. The prevalence of major malformations ranged from 5.1% to 
7.1% using the TCMC method and from 7.0% to 10.6% using the CCASS method. The 
prevalence of major malformations increased when medical claims data were added to the 
hospitalization data. Additionally, the prevalence of major malformations was 37.8%, 
42.4%, and 49.3% higher with the CCASS method than with the TCMC classification 
method for the case ascertainment definitions ≥ 1 major malformation diagnosis recorded 
in the hospital database;  ≥ 2 major malformation diagnoses recorded in the medical claims 
database or ≥ 1 major malformation diagnosis recorded in the hospital database; and ≥ 1 
major malformation diagnosis recorded in the medical claims database or ≥ 1 major 
malformation diagnosis recorded in the hospital database, respectively. 
Table 3 also shows the prevalence of system-specific major malformations. The most 
prevalent categories were cardiac malformations, and limb and musculoskeletal 
malformations, regardless of the case ascertainment definition. Only four categories 
(neural tube defects, urinary system malformations, orofacial clefts, and Down syndrome) 
had prevalence that were relatively not affected by the different definitions. However, 
some categories were strongly affected by the data source (i.e. cardiac, central nervous 
system, eye, and other chromosomal malformations), other categories were affected by the 
classification method (i.e. limb and musculoskeletal, digestive system, integument, and 
ear, face and neck malformations), while others were affected by both (i.e. circulatory 
system, respiratory system, genital organ, and other and unspecified malformations).  
Figure 2 shows the cORs and aORs for the association between maternal asthma and major 
malformations using all six case ascertainment definitions. The number and percentage of 
cases per group are presented in Online Resource 2. Using the TCMC method, maternal 
asthma was significantly associated with an increased prevalence of major malformations 
regardless of the definitions, with aORs ranging from 1.22 to 1.26. Using the CCASS 
method, maternal asthma was also significantly associated with an increased prevalence of 
major malformations regardless of the definitions, although the aORs were smaller and 
varied more, ranging from 1.14 to 1.20. Regardless of the classification method, adding 
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medical claims data to the hospitalization data had little impact on the effect size of the 
aORs.  
 
DISCUSSION 
In the current study, we compared six different case ascertainment definitions for major 
malformations that differ by the source of data and the classification method. Adding ≥ 1 
or 2 medical claim diagnoses to hospital-based diagnoses increased the prevalence of 
major malformations by 10.0% and 38.8%, respectively, for the TCMC method and by 
13.7% and 50.4%, respectively, for the CCASS method. The classification method itself 
influenced the prevalence with increases from 37.8% to 49.3% with the CCASS as 
compared with the TCMC method. We also observed weaker estimates of the association 
with maternal asthma with the CCASS (aORs 1.14–1.20) versus the TCMC (aORs 1.22–
1.26) method, even though the prevalence was always greater with the CCASS method.  
Using hospital, vital statistics, and medical genetic departments databases, Bedard et al. 
reported congenital heart defects prevalence of 5.59 per 1000 births, that increased to 
12.42 per 1000 births when outpatient pediatric cardiology database and terminations of 
pregnancy data were added.(Bedard, Lowry, Sibbald, et al., 2012) Others have evaluated 
the accuracy of diagnoses of congenital malformations recorded in administrative 
databases.(Bedard, Lowry, & Sibbald, 2012; Cooper et al., 2008; Metcalfe, Sibbald, 
Lowry, Tough, & Bernier, 2014; Rasmussen & Moore, 2001; Salemi et al., 2011) Metcalfe 
et al., using a provincial database from Canada, reported an accurate identification rate of 
86.9% for congenital malformations in the hospitalization database versus 51.1% in 
outpatient database.(Metcalfe et al., 2014)  In other prior reports, an estimated 5%–20% of 
cases of major malformations were false positives.(Bedard, Lowry, Sibbald, et al., 2012; 
Callif-Daley, Huether, & Edmonds, 1995; Metcalfe et al., 2014; Salemi et al., 2011) Using 
linked data from Quebec, Kulaga et al. reported an agreement of 60% with maternal 
reports of major malformations.(Kulaga & Berard, 2010)  Moreover, Blais et al. compared 
linked hospital and medical claims databases with data from the infants’ medical charts, 
and reported a PPV of 78.1% for major malformations in asthmatic women and 69.0% in 
non-asthmatics.(Blais et al., 2013) Of note, the above-mentioned studies have investigated 
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the accuracy of the diagnoses per se, but did not compare the impact of different case 
ascertainment definitions on the prevalence and association estimates as in the current 
study.    
We observed an increase of 10.0%–13.7% in the prevalence of major malformations for 
the case ascertainment definition of ≥ 1 hospitalization diagnosis or ≥ 2 medical claim 
diagnoses as compared to ≥ 1 hospitalization diagnosis. Meanwhile, the least strict 
definition of ≥ 1 hospitalization diagnosis or ≥ 1 medical claim diagnosis resulted in the 
greatest increase in the prevalence (by 38.8%–50.4%). It is possible that the medical 
claims included some suspected malformations that were never confirmed. For this reason, 
we believe that the definition based on ≥ 1 hospitalization diagnosis most probably 
includes the fewest false positives.  
In terms of classification methods, the CCASS led to higher prevalence of major 
malformations than the TCMC, because some minor malformations were classified as 
major malformations. Indeed, the prevalence of some categories (e.g. limb and 
musculoskeletal, and ear, face and neck) were three times higher using the CCASS 
method. The number of misclassified cases is difficult to determine due to the lack of a 
gold standard, but we hypothesize that the specificity of the CCASS is lower than that of 
the TCMC method. This outcome misclassification increases the estimated prevalence and 
can lead to an information bias (non-differential misclassification) that would 
underestimate the impact of an exposure on the prevalence of major malformations. 
(Rothman, Greenland, & Lash, 2008) This phenomenon was indeed observed with the 
aORs being closer to the null with the CCASS than with the TCMC method. There is a 
well-documented association between asthma and major malformations, with an increased 
prevalence of about 20%–30% relative to pregnancies in non-asthmatic women.(Blais & 
Forget, 2008; Blais et al., 2010; Murphy et al., 2013) The results obtained using the TCMC 
method were more consistent with these results. For these reasons, we believe that the 
TCMC method includes the fewest false positives. 
The present study has some important strengths. It comprised one of the largest 
administrative-linked pregnancy databases including more than 500,000 pregnancies over 
20 years. The study was the first to examine the number of additional cases of major 
malformations identified in outpatient medical claims database in Quebec, and the first to 
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compare the CCASS classification method used for national surveillance to the TCMC 
method designed specifically for perinatal research. While we used Quebec databases, the 
results are generalizable and can straightforwardly reflect to different settings where 
similar health administrative databases are available.  
The current study has some limitations. The lack of a gold standard means we were unable 
to estimate the PPV or the negative predictive value for the case ascertainment definitions. 
Although the accuracy of the diagnoses is expected to be greater in a hospital database 
(because of active and prospective data entry by trained medical archivists) than in a 
medical claims database maintained mainly for billing purposes, the recording of all 
diagnoses, including suspected and confirmed cases, could lead to false-positive cases. 
However, there is no reason to believe that the recording was differential between 
asthmatic and non-asthmatic women, reducing this potential bias towards the null. Finally, 
it is unlikely that one maternal exposure (i.e. asthma) will result in the increase of all major 
malformations categories. We used all major malformations combined only as an empirical 
example that provided the largest number of cases and the capacity to compare with 
previous studies. Future research should explore the associations between maternal 
exposures and specific categories of malformations (e.g. maternal diabetes and cardiac 
defects). 
In conclusion, our study showed that the case ascertainment definitions had a considerable 
impact on the prevalence of major malformations, but a small influence on the aORs.  The 
case ascertainment definition based on ≥ 1 hospitalization diagnosis combined with the 
TCMC is the preferred method, since it has the least chance of including misclassified and 
false positive cases. These results could assist in guiding future research on congenital 
malformations and the comparative effectiveness and safety of drug therapies during 
pregnancy. Future studies are needed to formally assess the validity of the proposed case 
ascertainment definitions and to estimate their impact on other maternal exposures. 
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Figure 1. Cohort selection flow-diagram 
 
 
    
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quebec Asthma and Pregnancy Database  
583,071 pregnancies, including all pregnancies of all women with ≥ 1 asthma diagnosis in the 2-year period 
preceding one of their deliveries and all pregnancies of a four-times-larger random sample in other women 
between January 1990 and March 2010 
553,638 pregnancies 
 
553,491 pregnancies 
 
147 pregnancies excluded: 
137 because the gestational duration 
was < 20 weeks 
10 because the gestational duration 
was > 45 weeks  
 
580 pregnancies excluded: 
511 because the maternal age was 
< 15 years 
69 because the maternal age was 
> 45 years 
 
554,218 pregnancies 
13 pregnancies excluded because of 
quadruplet birth 
554,231 pregnancies 
28,840 pregnancies excluded because the 
mother–infant link missing  
 
 
85,545 pregnancies excluded because 
the criteria for active asthma or non-
asthma were not met 
57,766 (12.3%) pregnancies of 
women with active asthma 
410,180 (87.7%) pregnancies 
in non-asthmatic women 
184 
 
Table 1. Case Ascertainment Definitions for the Major Congenital Malformations Used in 
This Study 
Case ascertainment 
definition 
Data source 
Hospitalization database (MED-
ECHO) 
 Medical claims database 
(RAMQ) 
TCMC 
   
  ≥ 1 hospitalization 
≥ 1 diagnostic code of major 
malformation 
  
  ≥ 1 hospitalization or 
≥ 2 medical claims 
≥ 1 diagnostic code of major 
malformation 
or ≥ 2 diagnostic codes of major 
malformation 
  ≥ 1 hospitalization or 
≥ 1 medical claim 
≥ 1 diagnostic code of major 
malformation 
or ≥ 1 diagnostic code of major 
malformation 
CCASS 
   
  ≥ 1 hospitalization 
≥ 1 diagnostic code of major 
malformation 
  
  ≥ 1 hospitalization or 
≥ 2 medical claims 
≥ 1 diagnostic code of major 
malformation 
or ≥ 2 diagnostic codes of major 
malformation 
  ≥ 1 hospitalization or 
≥ 1 medical claim 
≥ 1 diagnostic code of major 
malformation 
or ≥ 1 diagnostic code of major 
malformation 
Abbreviations: MED-ECHO: Maintenance et Exploitation des Données pour l’Étude de la 
Clientèle Hospitalière; RAMQ: Régie de l’Assurance-Maladie du Québec; TCMC: Two step 
Congenital Malformation Classification; CCASS: Canadian Congenital Anomalies 
Surveillance System classification.  
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Table 2. Characteristics of the Pregnancies of Women With Active Asthma and Non-
asthmatic Women 
 
Pregnancies of women 
with active asthma  
(n = 57,766) 
 
Pregnancies in non-
asthmatic women  
(n = 410,180) 
 
 No. % No. % 
Maternal age at the start of pregnancy 
(years) 
 
 
 
 
  < 18 1,827 3.2 6,089 1.5 
  18–34 50,643 87.7 362,548 88.4 
  ≥ 35 5,296 9.2 41,543 10.1 
Receipt of social assistance at the start 
of pregnancy 
10,510 
18.2 
40,490 
9.9 
Urban area of residence at delivery 47,863 82.9 323,578 78.9 
Multiple pregnancy 890 
1.5 
5,152 
1.3 
Diagnoses before pregnancy     
  Chronic hypertension  4,862 8.4 20,634 5.0 
  Diabetes mellitus  5,898 10.2 31,045 7.6 
  Epilepsy 342 0.6 1,316 0.3 
 
 
 
 
Table 3. Prevalence of Major Congenital Malformations According to the Classification Method and Case Ascertainment Definition 
 TCMC classification  CCASS classification 
 
≥ 1 
hospitalization 
 
 
 
≥ 1 
hospitalization 
or ≥ 2 medical 
claims 
 
≥ 1 
hospitalization 
or ≥ 1 medical 
claim 
 
 ≥ 1 
hospitalization 
 
 
 
≥ 1 
hospitalization 
or ≥ 2 medical 
claims 
 
≥ 1 
hospitalization 
or ≥ 1 medical 
claim 
 
 No. % No. % No. %  No. % No. % No. % 
Any major malformation
 a
 23,868 5.1 26,273 5.6 33,142 7.1  32,894 7.0 37,396 8.0 49,439 10.6 
System-specific malformations              
  Neural tube defects 191 0.0 224 0.1 314 0.1  191 0.0 224 0.1 314 0.1 
  Central nervous system 
b
 1,252 0.3 1,508 0.3 2,287 0.5  1,252 0.3 1,508 0.3 2,287 0.5 
  Cardiac  4,792 1.0 5,870 1.3 8,191 1.8  4,792 1.0 5,870 1.3 8,191 1.8 
  Circulatory system 1,304 0.3 1,572 0.3 2,070 0.4  3,145 0.7 3,440 0.7 4,059 0.9 
  Respiratory system 1,206 0.3 1,224 0.3 1,330 0.3  580 0.1 723 0.2 1,205 0.3 
  Eye 603 0.1 856 0.2 2,416 0.5  304 0.1 566 0.1 2,147 0.5 
  Ear, face, and neck 124 0.0 128 0.0 146 0.0  1,684 0.4 1,769 0.4 2,163 0.5 
  Orofacial clefts 599 0.1 627 0.1 697 0.2  599 0.1 627 0.1 697 0.2 
  Digestive system 3,591 0.8 3,859 0.8 4,772 1.0  1,901 0.4 2,119 0.5 2,622 0.6 
  Genital organs 898 0.2 1,100 0.2 1,480 0.3  2,577 0.6 3,052 0.7 4,255 0.9 
187 
 
  Urinary system 3,395 0.7 3,463 0.7 3,654 0.8  3,367 0.7 3,436 0.7 3,622 0.8 
  Limb and musculoskeletal 5,002 1.1 5,279 1.1 5,889 1.3  15,143 3.2 16,980 3.6 21,317 4.6 
  Integument 3,210 0.7 3,226 0.7 3,316 0.7  1,070 0.2 1,104 0.2 1,392 0.3 
  Down syndrome 494 0.1 513 0.1 560 0.1  494 0.1 513 0.1 560 0.1 
  Other chromosomal 269 0.1 601 0.1 1,193 0.3  207 0.0 211 0.1 223 0.1 
  Other and unspecified  478 0.1 515 0.1 592 0.1  984 0.2 2,366 0.5 4,813 1.0 
Abbreviations: TCMC: Two step Congenital Malformation Classification method; CCASS: Canadian Congenital Anomalies Surveillance System 
classification method; ≥ 1 hospitalization: ≥ 1 major malformation diagnosis recorded in the hospital database; ≥ 1 hospitalization or ≥ 2 medical 
claims: ≥ 2 major malformation diagnoses recorded in the medical claims database or ≥ 1 major malformation diagnosis recorded in the hospital 
database; ≥ 1 hospitalization or ≥ 1 medical claim: ≥ 1 major malformation diagnoses recorded in the medical claims database or ≥ 1 major 
malformation diagnosis recorded in the hospital database. 
a 
The sum of all system-specific malformations in each column exceeds the total number of cases with any major malformation because some 
infants had multiple malformations.  
b
 Includes neural tube defects.
  
 
Figure 2. Crude and adjusted odds ratios for major malformations in the pregnancies of 
women with active asthma versus pregnancies in non-asthmatic women using the specified 
case ascertainment definitions 
Abbreviations: TCMC: Two step Congenital Malformation Classification method; 
CCASS: Canadian Congenital Anomalies Surveillance System classification method; ≥ 1 
hospitalization: ≥ 1 major malformation diagnosis recorded in the hospital database; ≥ 1 
hospitalization or ≥ 2 medical claims: ≥ 2 major malformation diagnoses recorded in the 
medical claims database or ≥ 1 major malformation diagnosis recorded in the hospital 
database; ≥ 1 hospitalization or ≥ 1 medical claim: ≥ 1 major malformation diagnoses 
recorded in the medical claims database or ≥ 1 major malformation diagnosis recorded in 
the hospital database; cOR: crude odds ratio; aOR: adjusted odds ratio; OR: odds ratio; CI: 
confidence interval. 
 
Table e1. Congenital Malformation Classification Systems and Related ICD-9 Codes*  
 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
Specific 
malformations 
ICD-9 codes 
Nervous system
‡
 740: Anencephalus and similar 
anomalies 
741: Spina bifida 
742: Other congenital anomalies of 
nervous system 
  740: Anencephalus and similar 
anomalies 
741: Spina bifida 
742: Other congenital anomalies of 
nervous system 
 
Eye 743.0: Anophthalmos 
743.1: Microphthalmos 
743.2: Buphthalmos 
743.3: Congenital cataract and lens 
anomalies 
743.4: Coloboma and other anomalies 
of anterior segment 
743.5: Congenital anomalies of 
posterior segment 
743.8: other specified anomalies of 
eye 
743.9: Unspecified anomaly of eye 
743.6: Congenital 
anomalies of eyelids, 
lacrimal system, and orbit 
 743.0: Anophthalmos 
743.1: Microphthalmos 
743.2: Buphthalmos 
743.3: Congenital cataract and lens 
anomalies 
743.4: Coloboma and other 
anomalies of anterior segment 
743.5: Congenital anomalies of 
posterior segment 
743.8: other specified anomalies of 
eye 
743.9: Unspecified anomaly of eye 
743.6: 
Congenital 
anomalies of 
eyelids, 
lacrimal 
system, and 
orbit 
Ear, face and neck 744.0: Anomalies of ear causing 
impairment of hearing 
744.3:Unspecified 
congenital anomaly of ear 
744.4: Branchial cleft cyst 
or fistula; preauricular sinus 
744.9: Unspecified 
congenital anomalies of 
face and neck 
744.1: Accessory 
auricle 
744.2: Other 
specified 
congenital 
anomalies of ear 
744.5: Webbing of 
neck 
744.8: Other 
744.0: Anomalies of ear causing 
impairment of hearing 
744.1: Accessory auricle 
744.2: Other specified congenital 
anomalies of ear 
744.3:Unspecified congenital 
anomaly of ear 
744.4: Branchial cleft cyst or fistula; 
preauricular sinus 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
specified 
congenital 
anomalies of face 
and neck 
744.5: Webbing of neck 
744.8: Other specified congenital 
anomalies of face and neck 
744.9: Unspecified congenital 
anomalies of face and neck 
Cardiac 745: Bulbus cordis anomalies and 
anomalies of cardiac septal closure 
746: Other congenital anomalies of 
heart 
  745: Bulbus cordis anomalies and 
anomalies of cardiac septal closure 
746: Other congenital anomalies of 
heart 
 
Circulatory 
system 
747.1: Coarctation of aorta 
747.2: Other anomalies of aorta 
747.3: Anomalies of pulmonary artery 
747.4: Anomalies of great veins 
747.6: Other anomalies Of peripheral 
vascular system 
747.8: Other specified anomalies of 
circulatory system 
747.9: Unspecified anomaly of 
circulatory system 
747.0: Patent ductus 
arteriosus 
747.5: Absence or 
hypoplasia of 
umbilical artery 
747.0: Patent ductus arteriosus 
747.1: Coarctation of aorta 
747.2: Other anomalies of aorta 
747.3: Anomalies of pulmonary 
artery 
747.4: Anomalies of great veins 
747.5: Absence or hypoplasia of 
umbilical artery 
747.6: Other anomalies Of peripheral 
vascular system 
747.8: Other specified anomalies of 
circulatory system 
747.9: Unspecified anomaly of 
circulatory system 
 
Respiratory 
system 
748.1: Other anomalies of nose 
748.2: Web of larynx 
748.3: Other anomalies of larynx, 
trachea, and bronchus 
748.4: Congenital cystic lung 
748.5: Agenesis, hypoplasia, and 
dysplasia of lung 
748.0: Choanal atresia 
748.9: Unspecified anomaly 
of respiratory system 
 
 748.0: Choanal atresia 
748.1: Other anomalies of nose 
748.2: Web of larynx 
748.4: Congenital cystic lung 
748.5: Agenesis, hypoplasia, and 
dysplasia of lung 
748.6: Other anomalies of lung 
748.3: Other 
anomalies of 
larynx, 
trachea, and 
bronchus 
191 
 
 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
748.6: Other anomalies of lung 
748.8: Other specified anomalies of 
respiratory system 
748.8: Other specified anomalies of 
respiratory system 
748.9: Unspecified anomaly of 
respiratory system 
Cleft palate and 
cleft lip 
749: Cleft palate and cleft lip   749: Cleft palate and cleft lip 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
Digestive system 750.0: Tongue tie 
750.3: Tracheoesophageal fistula, 
esophageal atresia and stenosis 
750.4: Other specified anomalies of 
esophagus 
750.5: Congenital hypertrophic 
pyloric stenosis 
750.6: Congenital hiatus hernia 
750.7: Other specified anomalies of 
stomach 
750.8: Other specified anomalies of 
upper alimentary tract 
 
751.0: Meckel's diverticulum 
751.1: Atresia and stenosis of small 
intestine 
751.2: Atresia and stenosis of large 
intestine, rectum, and anal canal 
751.3: Hirschsprung's disease and 
other congenital functional disorders 
of colon 
751.4: Anomalies of intestinal fixation 
751.5: Other anomalies of intestine 
751.6: Anomalies of gallbladder, bile 
ducts, and liver 
751.7: Anomalies of pancreas 
751.8: Other specified anomalies of 
digestive system 
750.1: Other anomalies of 
tongue 
750.2: Other specified 
congenital anomalies of 
mouth and pharynx 
750.9: Unspecified anomaly 
of upper alimentary tract 
 
751.9: Unspecified anomaly 
of digestive system 
 750.1: Other Anomalies Of Tongue  
750.2: Other specified congenital 
anomalies of mouth and pharynx 
750.3: Tracheoesophageal fistula, 
esophageal atresia and stenosis 
750.4: Other specified anomalies of 
esophagus 
750.5: Congenital hypertrophic pyloric 
stenosis 
750.6: Congenital hiatus hernia 
750.7: Other specified anomalies of 
stomach 
750.8: Other specified anomalies of 
upper alimentary tract 
750.9: Unspecified anomaly of upper 
alimentary tract 
751.0: Meckel's diverticulum 
751.1: Atresia and stenosis of small 
intestine 
751.2: Atresia and stenosis of large 
intestine, rectum, and anal canal 
751.3: Hirschsprung's disease and other 
congenital functional disorders of colon 
751.4: Anomalies of intestinal fixation 
751.6: Anomalies of gallbladder, bile 
ducts, and liver 
751.7: Anomalies of pancreas 
751.8: Other specified anomalies of 
digestive system 
751.9: Unspecified anomaly of digestive 
system 
750.0: 
Tongue tie 
 
751.5: Other 
anomalies of 
intestine 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
Genital organs 752.0: Anomalies of ovaries 
752.1: Anomalies of fallopian tubes 
and broad ligaments 
752.2: Doubling of uterus 
752.3: Other anomalies of uterus 
752.4: Anomalies of cervix, vagina, 
and external female genitalia 
752.7: Indeterminate sex and 
pseudohermaphroditism 
  
752.5:Undescended and 
retractile testicle 
752.6: Hypospadias and 
epispadias and other penile 
anomalies 
752.8: Other specified 
congenital anomalies of 
genital organs 
752.9: Unspecified anomaly 
of genital organs 
 752.0: Anomalies of ovaries 
752.1: Anomalies of fallopian tubes 
and broad ligaments 
752.2: Doubling of uterus 
752.3: Other anomalies of uterus 
752.4: Anomalies of cervix, vagina, 
and external female genitalia 
752.6: Hypospadias and epispadias 
and other penile anomalies 
752.7: Indeterminate sex and 
pseudohermaphroditism 
752.8: Other specified anomalies of 
genital organs 
752.9: Unspecified anomaly of 
genital organs  
752.5: 
Undescended 
and retractile 
testicle 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
Urinary system 753.0: Renal agenesis and dysgenesis 
753.1: Cystic kidney disease 
753.2: Obstructive defects of renal 
pelvis and ureter 
753.3: Other specified anomalies of 
kidney 
753.4: Other specified anomalies of 
ureter 
753.5: Exstrophy of urinary bladder 
753.6: Atresia and stenosis of urethra 
and bladder neck 
753.7: Anomalies of urachus 
753.8: Other specified anomalies of 
bladder and urethra 
753.9: Unspecified anomaly of urinary 
system 
  753.0: Renal agenesis and 
dysgenesis 
753.1: Cystic kidney disease 
753.2: Obstructive defects of renal 
pelvis and ureter 
753.3: Other specified anomalies of 
kidney 
753.4: Other specified anomalies of 
ureter 
753.5: Exstrophy of urinary bladder 
753.7: Anomalies of urachus 
753.8: Other specified anomalies of 
bladder and urethra 
753.9: Unspecified anomaly of 
urinary system 
753.6: Atresia 
and stenosis 
of urethra and 
bladder neck 
Limb & 
Musculoskeletal 
 
754.1: Congenital musculoskeletal 
deformities of sternocleidomastoid 
muscle 
754.2: Congenital musculoskeletal 
deformities of spine 
754.3: Congenital dislocation of hip 
754.4: Congenital genu recurvatum 
and bowing of long bones of leg 
 
755.2: Reduction deformities of upper 
limb congenital 
755.3: Congenital reduction 
deformities of lower limb 
755.4: Reduction deformities, 
754.0: Of skull, face, and 
jaw 
754.5: Varus deformities of 
feet 
754.6: Valgus deformities 
of feet 
754.7: Other deformities of 
feet 
754.8: Other specified 
nonteratogenic anomalies  
754.9: unspecified 
 
755.0: Polydactyly 
755.1: Syndactyly 
 754.1: Of sternocleidomastoid 
muscle 
754.2: Of spine 
754.3: Congenital dislocation of hip 
754.4: Congenital genu recurvatum 
and bowing of long bones of leg 
754.5: Varus deformities of feet 
754.6: Valgus deformities of feet 
754.7: Other deformities of feet 
754.8: Other specified 
nonteratogenic anomalies  
 
755.0: Polydactyly 
755.1: Syndactyly 
754.0: 
Congenital 
musculoskelet
al deformities 
of skull, face, 
and jaw 
754.9: 
unspecified 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
unspecified limb 
 
756.4: Chondrodystrophy 
756.5: Congenital osteodystrophies 
756.7: Congenital anomalies of 
abdominal wall 
756.8: Other specified congenital 
anomalies of muscle tendon fascia and 
connective tissue 
 
755.5: Other anomalies of 
upper limb, including 
shoulder girdle 
755.6: Other anomalies of 
lower limb, including pelvic 
girdle 
755.8: Other specified 
anomalies of unspecified 
limb 
755.9: Unspecified anomaly 
of unspecified limb 
 
756.0: Anomalies of skull 
and face bones 
756.1: Anomalies of spine 
756.2: Cervical rib 
756.3: Other anomalies of 
ribs and sternum 
756.6: Anomalies of 
diaphragm 
756.9: Other and 
unspecified anomalies of 
musculoskeletal system. 
755.2: Reduction deformities of 
upper limb 
755.3: Reduction deformities of 
lower limb 
755.4: Reduction deformities, 
unspecified limb 
755.5: Other anomalies of upper 
limb, including shoulder girdle 
755.6: Other anomalies of lower 
limb, including pelvic girdle 
755.8: Other specified anomalies of 
unspecified limb 
755.9: Unspecified anomaly of 
unspecified limb  
 
756.0: Anomalies of skull and face 
bones 
756.1: Anomalies of spine 
756.2: Cervical rib 
756.3: Other anomalies of ribs and 
sternum 
756.4: Chondrodystrophy 
756.5: Osteodystrophies 
756.6: Anomalies of diaphragm 
756.7: Anomalies of abdominal wall 
756.8: Other specified anomalies of 
muscle, tendon, fascia, and 
connective tissue 
756.9: Other and unspecified 
anomalies of musculoskeletal system 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
Integument 757.1: Ichthyosis congenita 
757.3: Other specified congenital 
anomalies of skin 
757.0: Hereditary edema of 
legs 
757.4: Specified anomalies 
of hair 
757.5: Specified anomalies 
of nails 
757.6: Specified anomalies 
of breast 
757.8: Other specified 
anomalies of the integument 
757.9: Unspecified anomaly 
of the integument  
757.2: 
Dermatoglyphic 
anomalies 
757.0: Hereditary edema of legs 
757.1: Ichthyosis congenita 
757.2: Dermatoglyphic anomalies 
757.4: Specified anomalies of hair 
757.5: Specified anomalies of nails 
757.6: Specified anomalies of breast 
757.8: Other specified anomalies of 
the integument 
757.9: Unspecified anomaly of the 
integument 
757.3: Other 
specified 
congenital 
anomalies of 
skin 
Chromosomal
§
 758.0: Down syndrome 
758.1: Patau's syndrome 
758.2: Edward's syndrome 
758.3: Autosomal deletion syndromes 
758.4: Balanced autosomal 
translocation in normal individual 
758.5: Other conditions due to 
autosomal anomalies 
758.6: Gonadal dysgenesis 
758.7: Klinefelter's syndrome 
758.8: Other conditions due to 
chromosome anomalies 
758.9: Conditions due to anomaly of 
unspecified chromosome 
  758.0: Down syndrome 
758.1: Patau's syndrome 
758.2: Edward's syndrome 
758.3: Autosomal deletion 
syndromes 
758.4: Balanced autosomal 
translocation in normal individual 
758.5: Other conditions due to 
autosomal anomalies 
758.6: Gonadal dysgenesis 
758.7: Klinefelter's syndrome 
758.8: Other conditions due to 
chromosome anomalies 
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 TCMC classification CCASS classification  
 Major Major/Minor
†
 Minor (Excluded) Major 
Minor 
(Excluded) 
Other congenital 
malformations 
759.1: Anomalies of adrenal gland 
759.3: Situs inversus 
759.4: Conjoined twins 
759.5: Tuberous sclerosis 
759.6: Other hamartoses, NEC 
759.7: Multiple congenital anomalies, 
so described 
759.0: Anomalies of spleen 
759.2: Anomalies of other 
endocrine glands 
759.8: Other specified 
congenital anomalies 
759.9: Congenital anomaly, 
unspecified 
 758.9: Conditions due to anomaly of 
unspecified chromosome 
759.0: Anomalies of spleen 
759.1: Anomalies of adrenal gland 
759.2: Anomalies of other endocrine 
glands 
759.3: Situs inversus 
759.4: Conjoined twins 
759.5: Tuberous sclerosis 
759.6: Other hamartoses, NEC 
759.7: Multiple congenital 
anomalies, so described 
759.8: Other specified anomalies 
759.9: Congenital anomaly, 
unspecified 
 
*For congenital malformations recorded in the Maintenance et Exploitation des Données pour l’Étude de la Clientèle Hospitalière (MED-ECHO) hospitalization 
database, comparable codes from the enhanced version of the International Classification of Diseases (ICD) 10
th
 revision for Canada (ICD-10-CA) were used 
since 2006. 
†
When a malformation was classified as major or minor by the geneticist, it was only recorded as a major malformation if it was associated with at least one 
hospitalization with a primary or an admission diagnosis related to this malformation during the infant’s 1st year of life. 
‡
 Neural tube defects were reported separately. 
§
 Down syndrome was reported separately. 
TCMC: Two step Congenital Malformation Classification method; CCASS: Canadian Congenital Anomalies Surveillance System classification method; NEC: 
not elsewhere classified.
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Table e2. Crude and Adjusted Odds Ratios for Major Malformations in the Pregnancies of Women With Active 
Asthma Versus Pregnancies in Non-asthmatic Women Using the Specified Case Ascertainment Definitions 
a
 
Case ascertainment 
definition 
Asthma No. of 
pregnancies 
No. of cases of 
major 
malformation (%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
TCMC 
     
  ≥ 1 hospitalization Yes 57,766 3,532 (6.1) 1.25 (1.20, 1.29) 1.22 (1.17, 1.27) 
No 410,180 20,336 (5.0) Reference Reference 
  ≥ 1 hospitalization or 
≥ 2 medical claims 
Yes 57,766 3,903 (6.8) 1.26 (1.21, 1.30) 1.23 (1.19, 1.27) 
No 410,180 22,370 (5.5) Reference Reference 
  ≥ 1 hospitalization or 
≥ 1 medical claim 
Yes 57,766 4,998 (8.7) 1.28 (1.24, 1.33) 1.26 (1.22, 1.30) 
No 410,180 28,144 (6.9) Reference Reference 
CCASS 
     
  ≥ 1 hospitalization Yes 57,766 4,570 (7.9) 1.16 (1.12, 1.20) 1.14 (1.10, 1.18) 
No 410,180 28,324 (6.9) Reference Reference 
  ≥ 1 hospitalization or 
≥ 2 medical claims 
Yes 57,766 5,248 (9.1) 1.17 (1.14, 1.21) 1.16 (1.12, 1.19) 
No 410,180 32,148 (7.8) Reference Reference 
  ≥ 1 hospitalization or 
≥ 1 medical claim 
Yes 57,766 7,100 (12.3) 1.22 (1.18, 1.25) 1.20 (1.17, 1.24) 
No 410,180 42,339 (10.3) Reference Reference 
a
 Generalized estimating equation models were used with exchangeable correlation matrix 
Abbreviations: TCMC: Two step Congenital Malformation Classification method; CCASS: Canadian 
Congenital Anomalies Surveillance System classification method; ≥ 1 hospitalization: ≥ 1 major 
malformation diagnosis recorded in the hospital database; ≥ 1 hospitalization or ≥ 2 medical claims: ≥ 
2 major malformation diagnoses recorded in the medical claims database or ≥ 1 major malformation 
diagnosis recorded in the hospital database; ≥ 1 hospitalization or ≥ 1 medical claim: ≥ 1 major 
malformation diagnoses recorded in the medical claims database or ≥ 1 major malformation diagnosis 
recorded in the hospital database; OR: odds ratio; CI: confidence interval. 
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5.3.2 Unpublished sensitivity analysis 
The results of the GEE models according to the correlation matrix used are 
presented in Table 5.3.2. The results obtained using the independent correlation matrix 
were consistent with those obtained with the exchangeable matrix. However, when the 
unstructured correlation matrix was used, the CCASS method yielded inconsistent and 
imprecise results, mainly due to convergence issues. These inconsistencies and 
imprecisions were not observed when we used the TCMC method. 
Table 5.3.2 Crude and Adjusted Odds Ratios for Major Malformations in the Pregnancies 
of Women with Active Asthma versus Pregnancies in Non-asthmatic Women Using the 
Specified Case Ascertainment Definitions and Correlation Matrices 
Case ascertainment 
definition 
Correlation 
matrix 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
TCMC    
  ≥ 1 hospitalization 
Unstructured 1.25 (1.20, 1.29) 1.22 (1.17, 1.27) 
Exchangeable 1.25 (1.20, 1.29) 1.22 (1.17, 1.27) 
Independent 1.25 (1.20, 1.30) 1.22 (1.17, 1.27) 
  ≥ 1 hospitalization or 
≥ 2 medical claims 
Unstructured 1.26 (1.21, 1.30) 1.23 (1.19, 1.27) 
Exchangeable 1.26 (1.21, 1.30) 1.23 (1.19, 1.27) 
Independent 1.26 (1.21, 1.30) 1.23 (1.19, 1.27) 
  ≥ 1 hospitalization or 
≥ 1 medical claim 
Unstructured 1.28 (1.24, 1.33) 1.26 (1.22, 1.30) 
Exchangeable 1.28 (1.24, 1.33) 1.26 (1.22, 1.30) 
Independent 1.29 (1.25, 1.33) 1.26 (1.22, 1.30) 
CCASS    
  ≥ 1 hospitalization 
Unstructured 1.16 (0.82, 1.64) 1.09 (0.82, 1.47) 
Exchangeable 1.16 (1.12, 1.20) 1.14 (1.10, 1.18) 
Independent 1.16 (1.12, 1.20) 1.14 (1.10, 1.18) 
  ≥ 1 hospitalization or 
≥ 2 medical claims 
Unstructured 1.22 (0.89, 1.66) 1.16 (0.90, 1.49) 
Exchangeable 1.17 (1.14, 1.21) 1.16 (1.12, 1.19) 
Independent 1.18 (1.14, 1.21) 1.16 (1.12, 1.19) 
  ≥ 1 hospitalization or 
≥ 1 medical claim 
Unstructured 1.31 (1.06, 1.61) 1.27 (1.09, 1.46) 
Exchangeable 1.22 (1.18, 1.25) 1.20 (1.17, 1.24) 
Independent 1.22 (1.18, 1.25) 1.20 (1.17, 1.24) 
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Abbreviations: TCMC: Two step Congenital Malformation Classification method; CCASS: 
Canadian Congenital Anomalies Surveillance System classification method; ≥ 1 hospitalization: ≥ 1 
major malformation diagnosis recorded in the hospital database; ≥ 1 hospitalization or ≥ 2 medical 
claims: ≥ 2 major malformation diagnoses recorded in the medical claims database or ≥ 1 major 
malformation diagnosis recorded in the hospital database; ≥ 1 hospitalization or ≥ 1 medical claim: 
≥ 1 major malformation diagnoses recorded in the medical claims database or ≥ 1 major 
malformation diagnosis recorded in the hospital database; OR: odds ratio; CI: confidence interval. 
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5.4 Article on the systematic procedure for the classification of proven and 
potential teratogens  
 
 
 
Systematic Procedure for the Classification of Proven and Potential Teratogens for 
Use in Research 
 
Published in Birth Defects Research Part A: Clinical and Molecular Teratology, 2016, 
106: 285–297, DOI: 10.1002/bdra.23491, http://dx.doi.org/10.1002/bdra.23491 
 
 
This article is included in the current thesis by the permission of the co-authors and editors. 
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ABSTRACT 
Background: Although there is strong evidence that some medications are teratogenic, the 
current lists of teratogens to be used in research are outdated. 
 
Objectives: To develop an updatable and systematic procedure to the classification of 
medications proven and potentially teratogenic in the first trimester of pregnancy, for use in 
research.  
 
Methods: We developed a two-step procedure for teratogen classification. Step 1 includes 
classifying the medications from Drugs in Pregnancy and Lactation: a Reference Guide to 
Fetal and Neonatal Risk (9th ed.) into two provisional lists: 1) teratogenic medications, and 
2) potentially teratogenic medications. We also searched other references to add other 
medications. In Step 2, the Teratology Information System (TERIS) database was searched, 
and the medication was classified as teratogenic or potentially teratogenic according to a 
newly developed scheme. Expert consensus was used if a medication was not recorded in 
TERIS.  
 
Results: 114 medications were identified in Drugs in Pregnancy and Lactation: a 
Reference Guide to Fetal and Neonatal Risk, with 57 medications in each provisional list. 
78 medications were identified in other sources. 135 medications were included in Step 2; 
the TERIS scheme classified 23 medications, and 112 medications required expert opinion. 
The two experts agreed on 78.6% of the medications (kappa = 0.63). We identified 91 
teratogenic and 81 potentially teratogenic medications.  
 
Conclusions: Using reliable references, we established a systematic procedure to the 
classification of medications with evidence of or potential teratogenic risk. These 
exhaustive lists will be useful in teratology research and related fields. 
 
 
Key words: Teratogen, medication, epidemiology, birth defects, first trimester 
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INTRODUCTION 
Pregnant women living in developed countries frequently take prescription and over-the-
counter (OTC) medications, with prevalence estimates ranging between 27% and 99%, 
depending on the medications examined and the data sources used.(Daw and others, 2012; 
Friedman, 2012; Mitchell and others, 2011) Moreover, the numbers of women taking 
medications during pregnancy is growing as maternal age increases, and with the increasing 
use of medications in developed countries.(Mazer-Amirshahi and others, 2014; Shahin and 
Einarson, 2011; Thorpe and others, 2013; Wysowski and others, 2006) Maternal exposure 
to medications during pregnancy is often unavoidable because they are used to treat chronic 
diseases or because the pregnancy was not yet recognized.(Mazer-Amirshahi and others, 
2014; Mitchell and others, 2011) A Dutch report showed that 17.5% of women took a 
suspected teratogenic medication during the first trimester of pregnancy,(van Gelder and 
others, 2014a) and in the United States, it was reported that 23% of the medications most 
commonly used during the first trimester were included in Category X (risks involved in 
use of the drug clearly outweigh potential benefits.).(Thorpe and others, 2013) 
Since the tragedy of thalidomide, the teratogenic effects of a number of medications, acting 
through various mechanisms, have been demonstrated.(Adam and others, 2011; Briggs and 
others, 2011; Buonocore and others, 2010; Ferreira and others, 2013; Friedman, 2012; 
Obican and Scialli, 2011; van Gelder and others, 2014b) However, there are scarce data on 
the majority of the medications used by pregnant women to assess their potential 
teratogenic risk in humans.(Friedman, 2012; Thorpe and others, 2013) A published report 
in 2011, based on expert reviews by the Teratology Information System (TERIS), showed 
that among 172 medications approved in the United States between 2000 and 2010, 97.7% 
had insufficient published data and 73.3% had no human data with which to determine their 
teratogenic risk in humans.(Adam and others, 2011) However, new evidence is constantly 
produced for currently marketed medications, and several information sources can be 
accessed for a better assessment of teratogenic risk.(Adam and others, 2011; Briggs and 
others, 2015; REPROTOX®; Schaefer and others, 2015; Shepard, 2010; Teratogen 
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Information System (TERIS)) Observational studies are being increasingly used in 
assessing the teratogenic risk of medications used during pregnancy. Despite their benefits, 
which include the large sample sizes and low costs, observational studies incur significant 
validity threats. When observational data are used to study a teratogenic drug effect, it is 
essential to control for important risk factors for congenital malformations and most 
importantly, maternal exposure to other potential teratogens. Several databases and 
references on teratogenic risks are currently available, providing either complete or partial 
evidence for the teratogenicity of medications.(Banhidy and others, 2005; Buonocore and 
others, 2010; Goodwin, 2010; Kalter, 2010; Koren and others, 1998; Malm and others, 
2004; Polifka and Friedman, 2002; Porter and others, 2006; Queenan and others, 2010; 
Schaefer and others, 2015; Seyberth and others, 2011; Stevenson, 2006; Webster and 
Freeman, 2003) However, there are substantial discrepancies between the lists of 
medications that should be considered teratogenic, and significant imprecision is added 
when categories are used (e.g., moderate- vs high-risk teratogens).(Banhidy and others, 
2005; Buonocore and others, 2010; Goodwin, 2010; Kalter, 2010; Koren and others, 1998; 
Malm and others, 2004; Polifka and Friedman, 2002; Porter and others, 2006; Queenan and 
others, 2010; Seyberth and others, 2011; Stevenson, 2006; Webster and Freeman, 2003) 
Therefore, harnessing the full potential of several reliable resources is essential to the 
creation of a comprehensive overview. 
No updatable systematic procedure to classify medications into proven and potential 
teratogens exists, and currently available lists are outdated on several levels.(Buonocore 
and others, 2010; Kalter, 2010; Porter and others, 2006; Queenan and others, 2010; 
Seyberth and others, 2011) Therefore, based on the whole corpus of leading teratology 
resources, we aimed to develop a systematic and updatable procedure for the classification 
of medications into those with sufficient evidence of teratogenic risk and those with 
potential teratogenic risk during the first trimester of pregnancy for use in research. The 
lists should be used only for research and not for clinical or counseling purposes. 
 
METHODS 
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Steps and settings 
We developed a systematic two-step procedure for teratogen identification and 
classification. The goal was to construct two medication lists, one including “medications 
with sufficient evidence of a teratogenic risk in the first trimester”, hereinafter referred to as 
“teratogenic medications”, and the other including “medications with a potential 
teratogenic risk in the first trimester based on human and/or animal data”, hereinafter 
referred to as “potentially teratogenic medications”. The first trimester was considered the 
period of interest in our classification to maintain the reliability and validity of the results. 
Step 1, presented in Figure 1, included the identification and classification of medications 
reported in the reference book Drugs in Pregnancy and Lactation: a Reference Guide to 
Fetal and Neonatal Risk (9th ed.) by Briggs et al. 2011 (Briggs and others, 2011) into two 
provisional lists: 1) teratogenic medications, and 2) potentially teratogenic medications. 
Briggs et al. (2011) is a well-known reference that offers a careful and exhaustive summary 
of the world literature relating to drugs administered during pregnancy and 
lactation.(Briggs and others, 2011)  
Provisional List 1 (teratogenic medications) included all the medications in Briggs et al. 
(2011) listed under the pregnancy recommendations as “contraindicated—1st trimester” 
and “contraindicated”. Provisional List 2 (potentially teratogenic medications) included all 
the medications in Briggs et al. (2011) listed under the pregnancy recommendations as 
“human data suggest risk in 1st and 3rd trimesters”, “human (and animal) data suggest 
risk”, “no (limited) human data—animal data suggest risk”, “no (limited) human data—
animal data suggest moderate risk”, and “no (limited) human data—animal data suggest 
high risk”.(Briggs and others, 2011) These provisional lists were then verified by a 
teratology expert (B.M.) for the accuracy of the classification and inclusion into teratogens 
or potential teratogens lists, leading to either the approval of classification (agreement upon 
the classification of the medications in the Final lists) or further verification, i.e., entry on a 
“verification list”. We also searched other references, including reviews of teratogenic 
drugs and drug-related birth defects, textbooks of teratogenicity, and Briggs et al. updates 
(till October 2013, the latest in our possession), to identify other potential teratogens to be 
added to the verification list.(Brent, 2004; Buonocore and others, 2010; Goodwin, 2010; 
Kalter, 2010; Koren and others, 1998; Malm and others, 2004; Polifka and Friedman, 2002; 
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Porter and others, 2006; Queenan and others, 2010; Seyberth and others, 2011; Stevenson, 
2006) The medications cited in Briggs et al. updates were considered if they met any of the 
pregnancy recommendations mentioned previously for provisional Lists 1 and 2, whereas 
all possible teratogens reported in the other references were included in the verification 
list.(Brent, 2004; Buonocore and others, 2010; Goodwin, 2010; Kalter, 2010; Koren and 
others, 1998; Malm and others, 2004; Polifka and Friedman, 2002; Porter and others, 2006; 
Queenan and others, 2010; Seyberth and others, 2011; Stevenson, 2006) 
In Step 2, we searched the TERIS database for each medication included in the verification 
list. TERIS is an online clinical teratology resource.(Adam and others, 2011) It is supported 
by an expert advisory board, which assigns a teratogenicity risk rating to each medication 
included in the TERIS database. As new evidence of the teratogenicity of a medication 
becomes available, the risk ratings are updated.(Adam and others, 2011) Each adviser on 
the board independently rates the quality and quantity of data for each medication and the 
magnitude of the teratogenic risk it carries. The quality and quantity of data are classified as 
either “none”, “very limited”, “limited”, “fair”, “good”, or “excellent”, with ratings 
intermediate between two of these in some cases (e.g., good to excellent). The magnitude of 
the teratogenic risk is described as either “none”, “unlikely”, “minimal”, “small”, 
“moderate”, “high”, or “undetermined”. The medication ratings by the advisory board are 
developed through consensus after a thorough examination of the published data available 
on the medications from several sources.(Adam and others, 2011) We searched Briggs et al. 
(2011) first and then used the TERIS database for verification and classification in Step 2–
rather than being searched for potential teratogenic medications–for two reasons. First, 
Briggs et al. is the more comprehensive reference, including a larger number of 
medications than TERIS with an online index searchable by the medications’ pregnancy 
recommendations. Second, some agents have more than one magnitude of teratogenic risk 
rating in TERIS database and it is currently not possible to do a search using the "quality & 
quantity of data" ratings, which is the first step required in the TERIS scheme developed 
for the current study (described below).  
The details of the procedures applied in Step 2 are presented in Figure 2. We searched the 
TERIS database for each medication in the verification list, and if the medication was 
present, we classified it according to the newly developed “TERIS scheme” (described 
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below). If the medication was absent from the TERIS database, we classified it based on 
our “expert consensus”. The expert consensus was the opinion of two experts in 
teratogenicity and reproductive risk (B.M. and E.F.), who independently—and blinded 
from each other’s opinions and results—classified each medication into either “to be 
included in Final List 1; teratogenic medications”, “to be included in Final List 2; 
potentially teratogenic medications”, or “to be included in neither list”. The experts used all 
available published reports and resources to develop their ratings. For the inclusion into 
List 1, the experts used the criteria for proof of human teratogenicity proposed by 
Shepard.(Shepard, 1994) For a medication to be included into List 2, the experts used three 
stepwise conditions that the potential teratogen has to fully satisfy. Firstly, the experts 
verified that the medication did not meet Shepard’s criteria (if it meets the criteria send it 
back to List 1, if no: proceed to second condition). Secondly, they examined if enough 
evidence of absence of teratogenic risk in humans already exists (if yes: to not include in 
neither list, if no: proceed to third condition). Thirdly, they examined if there is 1 human 
study or sufficient animal data that shows evidence of teratogenic risk (if yes: to include the 
medication in List 2, if no: to not include in neither list). The experts’ opinions were 
collected by a third author (S.E.) and a consensus meeting was conducted to resolve any 
conflicting decisions. 
The newly developed TERIS scheme is presented in Figure 3. In this scheme, we used the 
ratings available in the database to classify each medication in our Final lists. First, we 
looked at the quality and quantity of the data on which the risk rating was based. If it was 
“none”, “very limited”, or “limited”, the medication was classified by the experts with our 
expert consensus procedure, as described above. If the rating was “fair”, “good”, or 
“excellent”, we looked at the magnitude of the teratogenic risk. If it was “undetermined”, 
then the medication was classified by the experts with our expert consensus procedure, as 
described above. If it was “none” or “unlikely”, then it was rated as “to be included in 
neither lists”; if it was “minimal”, then it was rated as “to be included in Final List 2: 
potentially teratogenic medications”; and if it was “small”, “moderate”, or “high”, it was 
rated as “to be included in Final List 1: teratogenic medications”. Whenever there was an 
intermediate rating by TERIS (e.g., quality and quantity of the data limited to fair), we used 
the highest rating (e.g., fair) to include as many medications as possible. 
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Statistical analysis 
We tallied the number of medications included in each step with our classification 
procedure. We calculated the number and percentage of observed agreements between the 
two experts in teratogenicity. We also calculated the kappa value, with its 95% confidence 
interval (CI), and the weighted kappa for the agreement between the two experts. Measures 
of agreement were calculated with GraphPad Prism 2015 (GraphPad Software Inc. 2015, 
La Jolla, CA, USA). 
Ethical approval 
Because the study was conducted using online resources and medical references, with no 
human or animal involvement, no institutional review board approval was required. 
 
RESULTS 
In Step 1, 57 medications were included in each provisional list, so a total of 114 
medications were verified for their exactness and completeness by the teratology expert. 
After verification, the classification of 57 medications was confirmed and they were 
included in the Final lists (43 in List 1: teratogenic medications and 14 in List 2: potentially 
teratogenic medications), whereas 57 medications required further verification and were 
entered onto the verification list. Fifty-two medications were identified by consulting other 
references, (Brent, 2004; Buonocore and others, 2010; Goodwin, 2010; Kalter, 2010; Koren 
and others, 1998; Malm and others, 2004; Polifka and Friedman, 2002; Porter and others, 
2006; Queenan and others, 2010; Seyberth and others, 2011; Stevenson, 2006) together 
with 26 medications from Briggs et al. (2011) updates, so a total of 135 medications were 
entered onto the verification list, and then submitted to Step 2. 
In Step 2, the TERIS scheme classified 23 medications (14 medications onto List 1: 
teratogenic medications; two medications onto List 2: potentially teratogenic medications; 
and seven medications were included on neither list) and 112 medications required 
classification by expert consensus, either because they did not appear in the TERIS 
database or when the quality and quantity of data was limited or the magnitude of 
teratogenic risk was undetermined (see Figure.3 TERIS scheme). From those 112 
medications, 34 were classified onto List 1: teratogenic medications, 65 onto List 2: 
potentially teratogenic medications; and 13 medications were included on neither list. The 
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two experts agreed on the classification of 88 medications (78.57%) and the 24 medications 
upon which they differed were resolved by consensus (6 onto List 1: teratogenic 
medications, 13 onto List 2: potentially teratogenic medications; and five medications were 
included on neither list). To reach a consensus, evidence on each medication was reviewed 
by the experts and a third author (S.E.) in a closed meeting, and discussed until a common 
decision was reached. The strength of the agreement was considered “good”, with kappa = 
0.63 (95% CI: 0.50, 0.76) and weighted kappa = 0.65. 
At the end of the two-step classification process, we had identified 91 teratogenic 
medications (List 1), presented in Table 1, and 81 potentially teratogenic medications (List 
2), presented in Table 2. 
 
DISCUSSION 
Principal findings 
In this report, we have presented a novel stepwise procedure for the classification of proven 
and potential teratogens, to be used by researchers in the fields of teratology, perinatology, 
perinatal epidemiology, and reproductive risk. The procedure utilizes existing reliable 
resources to obtain lists of medications with sufficient evidence of a teratogenic risk in the 
first trimester (referred to as “teratogenic medications”), and medications with a potential 
teratogenic risk in the first trimester (referred to as “potentially teratogenic medications”). 
Unlike previously published reports (Brent, 2004; Buonocore and others, 2010; Goodwin, 
2010; Kalter, 2010; Koren and others, 1998; Malm and others, 2004; Polifka and Friedman, 
2002; Porter and others, 2006; Queenan and others, 2010; Seyberth and others, 2011; 
Stevenson, 2006), we identified a substantial list of teratogenic medications, including 91 
medications, and also an extensive list of potentially teratogenic medications, including 81 
medications. 
Comparison with other studies 
The teratogenic medication lists available in the literature show significant discrepancies 
and have several drawbacks.(Buonocore and others, 2010; Goodwin, 2010; Kalter, 2010; 
Koren and others, 1998; Malm and others, 2004; Polifka and Friedman, 2002; Porter and 
others, 2006; Queenan and others, 2010; Seyberth and others, 2011; Stevenson, 2006; 
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Webster and Freeman, 2003) The problems associated with drawing up lists of teratogenic 
medications have been described at length in earlier reports.(Obican and Scialli, 2011; 
Scialli, 1997) The major problems lie in the imprecision and variability of the term 
“teratogen” and the errors that can arise when lists are used in counseling and clinical 
practice, not to mention the panic and anxiety they arouse in patients.(Obican and Scialli, 
2011; Scialli, 1997) Nevertheless, such lists indeed have a significant importance in 
epidemiologic and clinical research. However, incomplete or inaccurate lists raise a major 
threat to the validity of research. The teratogen lists provided in earlier reports lack a 
systematic procedure for the classification of medications, even with the availability of 
appropriate references and peer-reviewed citations.(Andrade and others, 2006; Banhidy and 
others, 2005; Buonocore and others, 2010; Goodwin, 2010; Kalter, 2010; Malm and others, 
2004; Porter and others, 2006; Seyberth and others, 2011; Stevenson, 2006; van Gelder and 
others, 2014b) The medication lists provided in the present report, constructed with the 
systematic procedure developed here, have several key advantages: 1) they come from a 
clear and systematic procedure; 2) they are easily updatable; 3) they provide a thorough list 
of potentially teratogenic medications, which is unprecedented. 
The lists presented here are intended to be used for research. From the medications in List 1 
(i.e., teratogenic medications), some may still be indicated during pregnancy to control a 
specific maternal condition (e.g., carbamazepine is indicated for seizure control in pregnant 
epileptic women, or lithium might have to be continued, including in the first trimester, by 
women suffering bipolar disorder and at risk of decompensation). Other List 1 medications 
might be contraindicated during pregnancy, but may have different magnitudes of risk. For 
example, maternal exposure to mycophenolate or isotretinoin during the first trimester is 
associated with a high risk of congenital malformations, whereas methimazole—also 
classified in List 1 here—is associated with a smaller increase in the overall risk of 
congenital malformations. Moreover, high risk can refer to the number of the exposed 
infants that become affected or to the severity of the congenital malformation itself. Our 
lists are intended for use in research and not in clinical practice. Several sources of 
accurate, free, evidence-based clinical counseling to healthcare professionals and patients 
are available through the Teratology Information Services, prominently the MotherToBaby 
(http://mothertobaby.org/) and ENTIS (http://www.entis-org.eu/) networks. 
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TERIS experts evaluate the teratogenic potential of a given medication. Their assessment is 
based on an in-depth analysis of the relevant published peer-reviewed studies and 
references, with an emphasis on human studies.(Adam and others, 2011) Their final ratings 
are obtained by consensus, after independent opinions are collected from experts in clinical 
teratology, birth defect epidemiology, experimental teratology, and related 
disciplines.(Adam and others, 2011) We noted that many drugs carry an “undetermined” 
risk rating in the TERIS database. These TERIS ratings reflect the absence of human data 
and the fact that animal studies might poorly predict the effects in humans.(Adam and 
others, 2011) Although animal data can provide useful information, they have some 
significant limitations, and certain requirements must be met to validly extrapolate animal 
results to human pregnancies.(Mazer-Amirshahi and others, 2014) In general, it is now 
agreed that we need all the data available on a medication, regardless of the source, to make 
a complete teratogenic risk assessment.(Scialli, 1997) Yet, the quality of the data could 
make us still unable to determine if a drug has the potential to be teratogenic in humans. 
Strengths and limitations 
The procedure we developed here is a systematic and updatable one, with objective 
components in most of its processes. The primary aim of this procedure is to provide lists 
of medications that can be used in research. However, the lists provided have potential 
utility in other areas. First, the list of potentially teratogenic medications (List 2) can 
effectively guide future research into medications that require further investigation in 
animal models. Second, the lists provide an encyclopedia of medications that require high-
priority postmarketing surveillance. 
Congenital malformations can arise when maternal exposure occurs above a threshold dose 
and at a critical time for the development of a specific fetal organ or system.(Ferreira and 
others, 2013) Because the majority of organs and systems develop in the first trimester—
with the exception of the central nervous system—this is considered the period of highest 
fetal risk.(Banhidy and others, 2005) To maintain the consistency of the results, we 
considered the first trimester as the period of major interest in our classifications. Further 
research to develop lists of medications causing developmental damage in the second and 
third trimesters is warranted. 
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Antineoplastics include some of the most potent human and animal teratogens (e.g. 
methotrexate).(Cardonick and Iacobucci, 2004; Selig and others, 2012) Due to their 
targeted effects on vital cellular functions, the experts’ decisions tended to include them in 
List 1, whenever their opinion was needed for their classification. Different medications in 
the same list might have different magnitudes of teratogenic risk, ranging from low to high. 
The lack of complete evidence about all the medications on the lists precludes any 
additional valid subclassification. Therefore, future research into this topic is highly 
recommended. The objectivity of the classification may have been compromised in 
instances in which expert opinion was required. However, we minimized this by blinding 
the reports of the experts and with the consensus process. The agreement between the 
experts’ opinions in this study was good. 
Reprotox and Shepard’s Catalog of Teratogenic Agents are well-established teratogen 
information resources that we thought of including in the 2-Step 
procedure.(REPROTOX®; Shepard, 2010) However, neither Reprotox nor Shepard’s 
Catalog of Teratogenic Agents have risk ratings or classifiable index as Briggs et al. 
reference book or the TERIS database. Therefore, in order to make the search and 
classification process systematic and reproducible, we chose to use them only when the 
experts classified the medications on their own and during their consensus meeting. We 
used the pregnancy recommendations given by Briggs et al. in our procedure (Step 1), but 
some potentially unsafe medications might have been included under the pregnancy 
recommendation “compatible-maternal benefit >> embryo-fetal risk” and were 
consequently not verified by our expert. However, Step 1 also included screening other 
references, in which such medications were cited. Because the literature is rapidly 
expanding, there might still be medications that were missed or of which we were unaware 
at the time we finalized the current report. When the data preparation of this report was 
finalized, the 9
th
 edition of Briggs et al. was the latest available, and the 10
th
 edition was 
published while the report was written. However, we updated our search in Briggs et al. to 
October 2013 and our search of TERIS to October 2014, with plans for future work based 
on the new edition of Briggs et al. (2015).(Briggs and others, 2015) We may have also 
overlooked some medications marketed outside North America in this study.  
Implications for research 
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In most developed countries, over 90% of pregnant women use at least one medication—
prescription medication, over-the-counter medication, or other supplement—during their 
pregnancy.(Daw and others, 2012; Ehrenstein and others, 2010) Pregnant women rarely 
participate in randomized controlled trials and evidence arising from observational studies 
has become central to the risk assessment of medications during pregnancy. However, 
observational research is characterized by various threats to internal validity, most 
importantly bias, including confounding. Therefore, confounding by indication and other 
potential confounders such as maternal age, race, smoking, alcohol consumption, chronic 
morbidities, other medication use, and obstetric history must be taken into consideration 
when analyzing the data. 
In observational studies, the maternal exposure to potential and known teratogens is a 
constant concern for researchers. Indeed, the inability to accurately control for maternal 
teratogenic exposures can markedly threaten the validity of the study, causing a false 
association to become significant or masking a true one. The lists of medications presented 
in this report can be used in numerous ways in perinatal and reproductive epidemiologic 
research (e.g., exclusion of mothers exposed to them or by using various statistical 
adjustment techniques). 
Summary 
This report describes a systematic and updatable procedure for the classification of 
medications proven and potentially teratogenic when used during the first trimester of 
pregnancy.  This procedure has identified a large number of medications that were not 
reported in similar previous reports. These exhaustive lists of proven and potential 
teratogens will be of a substantial value in teratology research and related fields.  
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Figure 1. Flow diagram of the classification of medications with a teratogenic risk or a potential 
teratogenic risk in the first trimester: Step 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification of medications listed in Briggs et al. 
into two lists according to their pregnancy 
recommendations*: 
Provisional List 1. Medications 
with sufficient evidence of a 
teratogenic risk in the first 
trimester 
 
 Contraindicated—1st 
trimester 
 Contraindicated 
Provisional List 2.  Medications 
with a potential teratogenic 
risk in the first trimester 
 Human data suggest risk in 
1st and 3rd trimesters 
 Human (and animal) data 
suggest risk  
 No (limited) human data - 
animal data suggest 
moderate risk 
 No (limited) human data - 
animal data suggest risk 
 No (limited) human data - 
animal data suggest high 
risk 
Provisional Lists 1 and 2 are revised by an 
expert in teratogenicity and reproductive 
risk (B.M.) for exactness and completeness 
Medications that require 
further confirmation 
(“verification list”) 
Medications whose classification is 
agreed: no additional steps 
Entering Step 2 
Search for possible teratogenic 
medications in Briggs et al. updates 
(to 25th Oct. 2013) and other 
sources‡ 
(“verification list”) 
*See Appendix 1 for complete definitions of pregnancy recommendations. 
‡ 
Brent, 2004; Buonocore and others, 2010; Goodwin, 2010; Kalter, 2010; Koren and others, 1998; Malm 
and others, 2004; Polifka and Friedman, 2002; Porter and others, 2006; Queenan and others, 2010; 
Seyberth and others, 2011; Stevenson, 2006 
219 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow diagram of the classification of medications with a teratogenic risk or a potential 
teratogenic risk in the first trimester: Step 2 
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Medications identified in Step 1 that require further confirmation 
(“verification list”) 
TERIS database 
TERIS scheme applied 
Classify medication in 
List 1 or List 2‡ 
Do not include 
medication in the lists  
* See Figure 3 for details of the classification procedure of drugs based on the TERIS scheme. 
‡ List 1: Medications with sufficient evidence of a teratogenic risk in the first trimester; List 2: 
Medications with a potential teratogenic risk in the first trimester. 
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Figure 3. Classification scheme for medications through TERIS 
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‡ List 1: medications with sufficient evidence of a teratogenic risk in the first 
trimester; List 2: medications with a potential teratogenic risk in the first trimester. 
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Table 1. Medications with sufficient evidence of a teratogenic risk in the first 
trimester* 
1. acenocoumarol 
2. acitretin 
3. alitretinoin 
4. amethopterin 
5. amsacrine 
6. axitinib 
7. bishydroxycoumarin 
8. bleomycin 
9. brentuximab 
10. busulfan 
11. capecitabine 
12. carbamazepine 
13. carbimazole 
14. carboplatin 
15. carmustine 
16. chlorambucil 
17. cisplatin 
18. cladribine 
19. colchicine 
20. crizotinib 
21. cyclophosphamide 
22. cytarabine 
23. dacarbazine 
24. dactinomycin 
25. danazol 
26. daunorubicin 
27. diethylstilbestrol 
28. docetaxel 
29. doxorubicin 
30. epirubicin 
31. estramustine  
32. etoposide 
33. etretinate 
34. exemestane 
35. flucytosine 
36. fludarabine 
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37. fluorouracil 
38. fluoxymesterone 
39. formestane 
40. gemcitabine  
41. idarubicin 
42. ifosfamide 
43. imatinib 
44. iodine-125 / iodine-123 
45. iodine-131 
46. isotretinoine 
47. l-asparaginase 
48. leflunomide (animal data) 
49. lenalidomide 
50. lithium  
51. lomustine 
52. mechlorethamine  
53. medroxyprogesterone  
54. melphalan 
55. mephenytoin 
56. mephobarbital 
57. methandrostenolone 
58. methimazole 
59. methotrexate 
60. methyltestosterone 
61. misoprostol 
62. mitomycin 
63. mitoxantrone  
64. mycophenolate mofetil (MMF) 
65. nicoumalone 
66. oxaliplatin 
67. paclitaxel 
68. paramethadione 
69. pemetrexed  
70. penicillamine 
71. phenobarbital 
72. phenytoin 
73. primidone 
74. procarbazine  
75. ribavirin 
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76. tamoxifene 
77. temozolomide 
78. teniposide 
79. testosterone  
80. thalidomide 
81. thioguanine 
82. thiotepa 
83. tretinoin (systemic) 
84. trimethadione 
85. trimethoprim 
86. valproic acid/divalproex 
87. vinblastine  
88. vincristine 
89. vindesine 
90. vinorelbine  
91. warfarin 
* This list is intended to be used by researchers in the context of bias control in 
epidemiological or clinical studies. It is not meant for use in clinical settings by health-care 
providers or patients, because this classification does not take into account the clinical 
context of the exposure (route of administration, dose, time of exposure, etc.) and does not 
provide an estimate of the magnitude of the teratogenic risk during pregnancy. 
Whenever there was an intermediate rating by TERIS (e.g., quality and quantity of the data 
limited to fair), we used the highest rating (e.g., fair) to include as many medications as 
possible. 
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Table 2. Medications with a potential teratogenic risk in the first trimester* 
1. abiraterone 
2. acetylsalicylic acid  
3. ambrisentan 
4. amiodarone 
5. azathioprine 
6. benazepril  
7. busereline  
8. candesartan  
9. captopril 
10. carboprost 
11. carglumic acid 
12. cetrorelix 
13. cilazapril 
14. clobazam 
15. clomiphene 
16. clomipramine  
17. dabigatran 
18. dalfampridine 
19. degarelix  
20. denosumab 
21. dexmedetomidine 
22. DHEA (dehydroepiandrosterone)/ 
prasterone 
23. dinoprostone 
24. dronedarone 
25. eculizumab 
26. enalapril  
27. eprosartan  
28. ergotamine 
29. etomidate 
30. ezogabine 
31. fingolimod 
32. fluconazole: high dose or chronic use  
33. follitropine alpha 
34. follitropine beta 
35. fosinopril  
36. gliclazide 
37. goserelin 
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38. haloperidol  
39. hydroxyurea 
40. indomethacin 
41. iodixanol 
42. ipilimumab 
43. irbesartan 
44. lamotrigine 
45. letrozole 
46. levetiracetam 
47. lisinopril 
48. losartan  
49. loxapine  
50. lutropin alfa 
51. medroxyprogesterone 
52. megestrol  
53. miglustat 
54. nandrolone  
55. nateglinide 
56. norethandrolone 
57. olmesartan  
58. oxcarbazepine 
59. oxymetholone 
60. paroxetine  
61. perindopril  
62. phenelzine  
63. phensuximide 
64. pimozide 
65. pioglitazone 
66. quinapril  
67. quinine 
68. raloxifene 
69. ramipril 
70. repaglinide 
71. riluzole 
72. rivaroxaban 
73. rosiglitazone 
74. stanozolol 
75. telmisartan 
76. tesamorelin 
77. topiramate 
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78. ulipristal 
79. urofollitropine (FSH) 
80. valsartan  
81. vigabatrin 
* This list is intended for use by researchers in the context of bias control in 
epidemiological or clinical studies. It is not meant for use in clinical settings by health-care 
providers or patients, because this classification does not take into account the clinical 
context of the exposure (route of administration, dose, time of exposure, etc.) and does not 
provide an estimate of the magnitude of the teratogenic risk during pregnancy. 
Whenever there was an intermediate rating by TERIS (e.g., quality and quantity of the data 
limited to fair), we used the highest rating (e.g., fair) to include as many medications as 
possible. 
 
 
 
 
Appendix 1: Definitions of Pregnancy Recommendations in Briggs et al. 2011, Drugs 
in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk (9th ed.) 
 
Provisional List 1. Medications with sufficient human evidence of a teratogenic risk in the 
first trimester or antineoplastics 
 Contraindicated - 1st Trimester 
Human exposures in the 1st trimester, either to the drug itself or to drugs in the 
same class or with similar mechanisms of action, have been associated with developmental 
toxicity (growth restriction, structural anomalies, functional/behavioral deficits, or death). 
The drug should not be used in the 1st trimester. 
 Contraindicated 
Human exposures at any time in pregnancy, either to the drug itself or to drugs in 
the same class or with similar mechanisms of action, have been associated with 
developmental toxicity (growth restriction, structural anomalies, functional/behavioral 
deficits, or death). Animal reproduction data, if available, confirm the risk. The drug should 
not be used in pregnancy. 
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Provisional List 2. Medications with a potential teratogenic risk in the first trimester based 
on human and/or animal data 
 Human Data Suggest Risk in 1st and 3rd Trimesters 
Evidence (for the drug or similar drugs) suggests that there may be an embryo-fetal 
risk for developmental toxicity (growth restriction, structural anomalies, 
functional/behavioral deficits, or death) in the 1st and 3rd trimesters but not in the 2nd 
trimester. The human pregnancy data outweigh any animal reproduction data. 
 Human (and Animal) Data Suggest Risk 
The human data for the drug or drugs in the same class or with the same mechanism 
of action, and animal reproduction data if available, suggest there may be a risk for 
developmental toxicity (growth restriction, structural anomalies, functional/behavioral 
deficits, or death) throughout pregnancy. Usually, pregnancy exposure should be avoided, 
but the risk may be acceptable if the maternal condition requires the drug. 
 No (Limited) Human Data - Animal Data Suggest Moderate Risk 
Either there is no human pregnancy experience or the few pregnancy exposures 
have not been associated with developmental toxicity (growth restriction, structural 
anomalies, functional/behavioral deficits, or death). The drug causes developmental toxicity 
(at doses that did not cause maternal toxicity) in one animal species at doses ≤10 times the 
human dose based on body surface area (BSA) or AUC. 
 No (Limited) Human Data - Animal Data Suggest Risk 
Either there is no human pregnancy experience or the few pregnancy exposures 
have not been associated with developmental toxicity (growth restriction, structural 
anomalies, functional/behavioral deficits, or death). The drug causes developmental toxicity 
(at doses that did not cause maternal toxicity) in two animal species at doses ≤10 times the 
human dose based on body surface area (BSA) or AUC. 
 No (Limited) Human Data - Animal Data Suggest High Risk 
Either there is no human pregnancy experience or the few pregnancy exposures 
have not been associated with developmental toxicity (growth restriction, structural 
anomalies, functional/behavioral deficits, or death). The drug causes developmental toxicity 
(at doses that did not cause maternal toxicity) in three or more animal species at doses ≤10 
times the human dose based on body surface area (BSA) or AUC. 
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Definitions excluded from selection 
 Compatible 
The human pregnancy experience, either for the drug itself or drugs in the same class or 
with similar mechanisms of action, is adequate to demonstrate that the embryo-fetal risk is 
very low or nonexistent. Animal reproduction data are not relevant. 
 No (Limited) Human Data - Probably Compatible  
There may or may not be human pregnancy experience, but the characteristics of the drug 
suggest that it does not represent a significant risk to the embryo-fetus. For example, other 
drugs in the same class or with similar mechanisms are compatible or the drug does not 
obtain significant systemic concentrations. Any animal reproduction data are not relevant. 
 Compatible - Maternal Benefit >> Embryo-Fetal Risk  
There may or may not be human pregnancy experience, but the potential maternal benefit 
far outweighs the known or unknown embryo-fetal risk. Animal reproduction data are not 
relevant. 
 Human Data Suggest Low Risk  
There is limited human pregnancy experience, either for the drug itself or drugs in the same 
class or with similar mechanisms of action, including the 1st trimester, suggesting that the 
drug does not represent a significant risk of developmental toxicity (growth restriction, 
structural anomalies, functional/behavioral deficits, or death) at any time in pregnancy. The 
limited human pregnancy data outweighs any animal reproduction data. 
 No (Limited) Human Data - Animal Data Suggest Low Risk  
Either there is no human pregnancy experience or the few pregnancy exposures have not 
been associated with developmental toxicity (growth restriction, structural anomalies, 
functional/behavioral deficits, or death). The drug does not cause developmental toxicity (at 
doses that did not cause maternal toxicity) in all animal species studied at doses ≤10 times 
the human dose based on body surface area (BSA) or AUC. 
 Contraindicated - 2nd and 3rd Trimesters  
Human exposures in the 2nd and 3rd trimesters, either to the drug itself or to drugs in the 
same class or with similar mechanisms of action, have been associated with developmental 
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toxicity (growth restriction, structural anomalies, functional/behavior deficits, or death). 
The drug should not be used in the 2nd and 3rd trimesters. 
 No (Limited) Human Data - No Relevant Animal Data  
There is no human pregnancy data or relevant data in animals, or the human pregnancy 
experience, that may or may not include the 1st trimester, is limited. The risk in pregnancy 
cannot be assessed. 
 Human Data Suggest Risk in 2nd and 3rd Trimesters  
Evidence (for the drug or similar drugs) suggests that there may be a fetal risk for 
developmental toxicity (growth restriction, structural anomalies, functional/behavioral 
deficits, or death) in the 2nd and 3rd trimesters but not in the 1st trimester. The human 
pregnancy data outweigh any animal reproduction data. 
 Human Data Suggest Risk in 3rd Trimester  
Evidence (for the drug or similar drugs) suggests that there may be a fetal risk for 
developmental toxicity (growth restriction, structural anomalies, functional/behavioral 
deficits, or death) in the 3rd trimester, or close to delivery but not in the 1st or 2nd 
trimesters. The human pregnancy data outweigh any animal reproduction data. 
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To the Editor: We have read with interest the article by Garne et al.(1) which adds new 
information on the impact of asthma treatments during pregnancy on the prevalence of 
congenital malformations. The study concluded that the use of inhaled β2-agonists (short 
and long-acting combined) is associated with an increased risk of cleft palate and 
gastroschisis, while inhaled corticosteroids (ICS) showed no increased risk for any of the 
examined malformations.  We fear however that such statement could negatively affect the 
clinicians and mothers’ confidence in short-acting β2-agonists (SABA) – specifically 
salbutamol– which was the most frequently used β2-agonist in this study. We believe that 
methodological limitations led to the observed results and should be carefully considered. 
 
The first limitation in the study is the use of a reference group formed of asthmatic and 
non-asthmatic women. Including non-asthmatic women in the reference group could 
potentially overestimate the effect of the asthma medications. Asthma itself is associated 
with an increased risk of congenital malformations, and a recent meta-analysis reported a 
30% increased risk of cleft lip among asthmatic as compared to non-asthmatic women.(2) 
In the study by Garne et al., 53% of asthmatic women treated with β2-agonists (86% using 
salbutamol) had no controller medications and were likely having uncontrolled asthma. On 
the other hand, the ICS group is likely to include women who were appropriately controlled 
due to the beneficial effect of ICS. Due to this confounding by control level, an increased 
prevalence of malformations was found in the β2-agonists group – corroborating results 
from previous case-control studies using similar exposure groups (3-5) – and not found 
among the ICS group (even showing protective effects in some instances). Moreover, the 
authors did not report the maternal characteristics of the women in the study (e.g. age, 
comorbidities, asthma exacerbations, hospitalizations for asthma and oral corticosteroids 
use), which prevented the assessment of the comparability of the exposure groups. 
 
SABA (salbutamol in particular) have shown fetal safety in several well designed cohort 
and case-control studies. In fact, in the recent Swedish study(6) cited by the authors, the 
observed increased risk of cleft palate with bronchodilator use was the lowest for SABA 
and no increased risk of gastroschisis was observed. Disentangling the effect of the 
medication from the disease is a challenging task that has to be appropriately addressed in 
both the design and the analysis of the study. Most importantly, the use of a reference group 
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formed of women with asthma is recommended. Researchers have also proposed indirect 
ways to separate the medications’ effects, including a comparison between different drugs 
that share similar indications,(6) and such studies were recently published in the 
literature.(7, 8) 
 
Other limitations in the study include the lack of adjustment for important confounders 
such as socioeconomic status and asthma exacerbations, combining short and long acting 
β2-agonists under one exposure category, and multiple comparisons. While we 
acknowledge the use of the case-malformed control design, the rationale behind its use is 
questionable since the exposure information was recorded prospectively. The use of healthy 
controls without any apparent pathology could have been more appropriate, especially in 
confirming signals from previous studies that used non-malformed controls.  
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Discussion 
 
6.1 General discussion 
Considering the relatively high and increasing prevalence of asthma among 
pregnant women, coupled with the increasing use of different treatment regimens with 
incomplete evidence on their safety during pregnancy, we sought to examine the 
comparative safety of two of the most widely used treatment regimens for asthma during 
pregnancy.  Through our endeavor, we tackled some intriguing questions we thought could 
add important knowledge in this field. 
We first conducted a systematic review to summarize the published evidence on the 
impact of maternal use of SABA and LABA during pregnancy and different perinatal 
outcomes. We found few studies that reported significant increased risk of congenital 
malformations for women exposed to SABA and/or LABA and no increased risk was found 
for the other outcomes. Importantly, most of the retrieved studies suffered several 
methodologic limitations which we described in our systematic review. Moreover, the non-
significant results from the studies should be interpreted with caution since a large 
percentage of the negative studies were underpowered to detect clinically significant 
effects. We made several recommendations on how to tackle these limitations and the 
possible future research plans to obtain precise estimates of the associated risks to rule on 
the SABA and LABA safety profiles. 
We then compared the risk of major congenital malformations in pregnant asthmatic 
women treated with a combination of LABA-ICS and those treated with a higher dose of 
ICS monotherapy. Indeed, there has been no direct comparison of these treatment regimens 
before to guide physicians in whether it is safer for the newborn to increase the dose of ICS 
during pregnancy or to add a LABA to the current ICS dose used. Through analysing 
comparable treatment regimens and classifying the asthmatic women into two groups based 
on the asthma medications they used to control their symptoms, we were able to obtain 
relatively unbiased results while minimizing confounding by asthma severity. We found 
that the risk of major malformations did not differ when a combination therapy of LABA-
ICS or a higher dose of ICS monotherapy was used in the first trimester of pregnancy 
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among moderate to severe asthmatic pregnant women (aOR: 1.0; 95% CI: 0.6–1.7 for the 
two subcohorts combined). We concluded that the findings support the fetal safety of 
LABA-ICS combination in the management of persistent asthma during pregnancy. 
We also investigated the impact of different case ascertainment definitions for major 
congenital malformations on the estimated prevalence and the maternal asthma-major 
malformations association. We demonstrated through a series of analyses that the source of 
data and the classification method had a considerable impact on the prevalence of major 
malformations, but a small influence on the aORs. Adding ≥ 1 or 2 medical claim 
diagnoses to hospital-based diagnoses increased the prevalence of major malformations by 
10.0% and 38.8%, respectively, for the TCMC method (a method that we developed for 
congenital malformations research) and by 13.7% and 50.4%, respectively, for the CCASS 
method (the national Canadian surveillance method). In terms of classification methods, the 
CCASS led to higher prevalence of major malformations than the TCMC, mainly because 
some minor malformations were classified as major malformations. We concluded that the 
case ascertainment definition based on ≥ 1 hospitalization diagnosis combined with the 
TCMC classification method is likely to be the most reliable, since it has the least chance of 
including misclassified and false positive cases. 
Finally, we aimed at constructing a systematic procedure for the classification of 
proven and potential teratogenic medications during the first trimester of pregnancy, to be 
used for research. Given that the teratogenic medication lists available in the literature show 
significant discrepancies and have several drawbacks, the challenging task was establishing 
the procedure itself when no similar precedent approach or procedures has been published 
previously in the literature. We structured a procedure that is both systematic and 
updatable, with objective components in most of its processes. We identified a substantial 
list of teratogenic medications, including 91 medications, and an extensive list of 
potentially teratogenic medications, including 81 medications. The identified lists could 
carry a substantial value in teratology research and several other related fields. 
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6.2 Contribution of our results to the literature in the fields of maternal 
asthma, perinatal outcomes and teratogenicity 
6.2.1 Asthma treatments and perinatal outcomes 
Beta2-agonists have a crucial role in asthma management during pregnancy.
5,14,21-30
 
Recent reports suggest that 40 to 70% of asthmatic women use SABA and 8 to 13% use 
LABA during pregnancy.
12,134
 Several studies have examined the perinatal safety of SABA 
and LABA, with both negative and positive findings.
21-30
 Systematic reviews on the topic 
are essential as they summarize the available body of knowledge for better evidence-based 
decision making. Published reviews on this topic did not capture the whole evidence from 
all published studies on the different clinically important perinatal outcomes.
2,129
. In our 
systematic review, we presented a critique for the published studies, in which we elaborated 
on their strengths and weaknesses and assessed their quality using the recommended 
Newcastle-Ottawa scale. We also performed a series of post-hoc power calculations to 
identify studies able to detect clinically significant effects.  
From the publications that we have reviewed, we found evidence of increased risk 
of congenital malformations after maternal exposure to fenoterol (SABA) in one study
23
 
and LABA in another study
30
, but we could not rule out the presence of residual 
confounding by indication. No increased risk was found for the other outcomes, except a 
decrease in birth weight centiles among salmeterol (LABA) users.
136
 The largest body of 
evidence on the safe use during pregnancy was available for salbutamol (SABA). The 
different methodologic limitations prevented drawing precise conclusions on the safety 
profiles of all SABA and LABA, especially with the presence of confounding by asthma 
severity and a plentiful of underpowered negative studies. Therefore, more research is 
warranted on the use of SABA and LABA during pregnancy to rule on their safety profile.  
Women suffering from persistent asthma have to be treated with the appropriate 
medications to control their asthma symptoms including exacerbations.
5,14
 Both ICS 
monotherapy and LABA-ICS combinations are widely used during pregnancy, with an 
increasing number of users over time.
269
 The guidelines of asthma management during 
pregnancy recommends both treatment regimens and the physicians generally decide based 
on individual experiences and patients’ preferences and needs, among many other 
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factors.
14,96
 Yet, the comparative safety of those two treatment regimens are not well 
described. 
We conducted the first comparative safety study that answers the specific question 
of comparing the risk of major congenital malformations between LABA-ICS combination 
versus ICS monotherapy in higher doses among pregnant women with moderate to severe 
asthma. The study showed that the risk of major malformations did not differ when a 
combination therapy of LABA plus ICS or a higher dose of ICS monotherapy was used in 
the first trimester of pregnancy. The results were consistent in both subcohorts of 
moderately and severely asthmatic pregnant women (aOR: 1.1; 95% CI: 0.6–1.9 and aOR: 
1.2; 95% CI: 0.5–2.7 respectively). We minimized confounding by indication by 
performing the primary analysis within subcohorts of women with similar levels of asthma 
severity and by adjusting for baseline severity markers. These reassuring results provide 
scientific evidence to help physicians and mothers make evidence-based treatment 
decisions during pregnancy.  
 
6.2.2 Case ascertainment definitions of major malformations 
In this methodologic study, we aimed to compare the prevalence of major 
malformations using different case ascertainment definitions that vary by the source of data 
and the classification method. We also evaluated the impact of these definitions on the 
association between maternal asthma and major malformations. Previous reports have 
examined the validity of the congenital malformation diagnoses recorded in RAMQ and 
MED-ECHO,
60,61
 but none has examined each separately, especially the impact of using the 
medical claims diagnoses – in RAMQ database – as an additional source of data with the 
hospitalizations database. Using six different case ascertainment definitions, we showed 
that medical claims can strongly affect the prevalence of major malformations estimates, 
corroborating the results from similar studies using Canadian provincial databases. 
55,248
 We 
tested in this study the suitability of the new classification method (i.e. the TCMC method), 
developed previously by our research team, in congenital malformations research. We 
compared it to an established classification method used by the national surveillance system 
in Canada (i.e. the CCASS method). The results provided significant assurance to the 
suitability of the TCMC method, showing superiority for research purposes as compared to 
240 
 
the CCASS method which better suits the surveillance needs. The study also showed that 
the case ascertainment definitions had only a small influence on the aORs estimating the 
association between asthma and congenital malformations. The study results and our 
recommendations could assist in guiding future research on congenital malformations and 
the comparative effectiveness and safety of drug therapies during pregnancy. 
 
6.2.3 Medications with proven and potential teratogenic risk 
Pregnant women rarely participate in randomized controlled trials and evidence 
arising from observational studies has become central to the risk assessment of medications 
during pregnancy. Yet in observational studies, the maternal exposure to potential and 
known teratogens is a constant concern for researchers. Several well-known teratogen 
information databases and references are currently available, including Briggs et al. 
reference book, TERIS, Reprotox and Shepard’s Catalog of Teratogenic Agents, each 
provide either complete or partial evidence for the teratogenicity of medications.  
We searched the published literature for proven and potential teratogenic 
medications lists. We observed significant discrepancies between the lists of medications 
that should be considered teratogenic, and additional imprecisions were found when 
categories are used (e.g., moderate- vs high-risk teratogens).
62-73,233
  Some researchers 
prefer developing their own lists which they regularly update and use to conduct their 
research. The main limitation in such case is that the selection process becomes primarily 
subjective and never described in details, which prevents reproducibility and adoption by 
other researchers. We were unable to locate neither a systematic procedure nor an easy-to-
update lists of proven and potential teratogens. 
In our study, we provided lists of medications which are up-to-date, until the most 
recent evidence at the publication time, but more importantly we developed a systematic 
procedure that can be used to update the lists whenever needed. The lists presented can be 
used in numerous ways in perinatal and reproductive epidemiologic research (e.g., 
exclusion of mothers exposed to them or by using various statistical techniques). We 
recommend that other researchers adopt our lists in their future research. The lists also have 
potential value in other areas. For example, the list of potentially teratogenic medications 
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can effectively guide future research into medications that require further investigation in 
animal models, and medications that require high-priority postmarketing surveillance. 
 
6.3 Strengths, limitations and internal and external validity 
 
6.3.1 Systematic review on beta2-agonists and perinatal outcomes 
The presented systematic review has some key strengths. Prior to commencing our 
search, a systematic review protocol was formed, registered and published in PROSPERO, 
the International prospective register of systematic reviews. We searched six different 
databases for original articles, besides the reference lists from retrieved articles, which 
allowed us to include the most relevant studies that provided information on the perinatal 
outcomes we examined. We covered in this review most of the essential outcomes that best 
represent the fetal development (major and any malformations, SGA, mean and low birth 
weight) and the newborn prematurity (gestational age and preterm delivery). We used the 
validated and recommended NOS-scale for the quality assessment of the studies. We used 
well-known reporting guidelines, the PRISMA statement, to ensure effective reporting of 
our results. In addition, we performed a post-hoc power calculation for each study included 
in the systematic review to identify studies that had adequate power to detect clinically 
significant effects. The performed power calculations in our review were original and a 
first, since previous systematic reviews on beta2-agonists lacked this important component. 
Compared to previously published reviews on the effect of beta2-agonist use during 
pregnancy, the spectrum of perinatal outcomes investigated in the current review was 
larger.  
The review had some limitations. The main limitation was the fact that we could not 
pool the different study results into a single estimate for each outcome due to major 
methodological differences between the studies. Another limitation is that the review 
included only studies published in English language. Moreover, we excluded studies that 
did not have comparison groups (i.e. case-reports and case-series). However, those studies 
have several inherent limitations that could have affected the quality of the systematic 
review. 
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6.3.2 Articles on LABA-ICS combination versus ICS monotherapy 
and case ascertainment definitions of major malformations 
6.3.2.1 Databases 
Among the major strengths of the two conducted studies is the use of the Quebec 
Asthma and Pregnancy Database. This database is considered one of the largest 
administrative-linked pregnancy databases in Canada, spanning over 20 years. The database 
includes 583,071 pregnancies, representing about 35% of all births in the province in this 
period of time.
260
 A remarkable advantage in the database is that it includes all pregnancies 
from asthmatic women in Quebec over a 20 years period. Indeed, the Quebec Asthma and 
Pregnancy Database is one of the largest worldwide in terms of the number of pregnancies 
from women with asthma (i.e. 36,587 pregnancies). The database was constructed through 
the linkage of two large health administrative databases from Quebec that have their unique 
strengths in research applications. Using this prospectively gathered and interlinked 
databases to identify the exposures and outcomes provided several advantages (as 
summarized below) over other methods of data collection such as self-reported 
questionnaires or maternal interviews.
236,270
 
Different studies have shown that most patients have difficulties reporting the 
details of their medication use, for example the time, the doses, and the quantity used.
271-274
 
In the article on LABA-ICS combination versus ICS monotherapy, data on filled 
prescriptions, which were used to assess the women’s exposure to asthma medications 
during pregnancy, were prospectively collected independently of the outcome, avoiding any 
recall bias, which is common in reproductive research.
236,270
 Moreover, using the health 
administrative databases allowed us to capture the history of the medication use over long 
periods (three months before and during the pregnancy period) for a large number of 
patients. Computerized health databases also provide the chance to study a sizable number 
of patients with a reasonable budget and time-frame. 
The prescription data recorded in the RAMQ database have been formally evaluated 
and found to be accurate and valid (83% correct identification of the patients and drugs 
dispensed from the prescriptions).
262
 The validity of the diagnoses of asthma recorded in 
the RAMQ and MED-ECHO databases has been formally evaluated and the data were 
shown to have a PPV of 75% and a PNV of 96% for asthma diagnoses.
261
 In the article on 
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LABA-ICS combination versus ICS monotherapy, the use of two large administrative 
databases allowed us to access a large number of pregnancies in asthmatic women, from 
which we could establish our subcohorts and measure several potentially important 
confounders. Using a large database allowed us to perform our statistical analysis for the 
two subcohorts with reasonable statistical powers (a power of 80% to detect an OR of 1.9 
and 2.4 in the two subcohorts), and allowed to perform a sensitivity analysis – using the 
two subcohorts combined – with a higher statistical power (a power of 80% to detect an OR 
of 1.7). 
Pregnancy variables recorded in the RAMQ and MED-ECHO databases have been 
formally evaluated and found to be highly valid.
261
 From the variables that have been 
validated and were used to perform our analyses are maternal age, length of gestation, date 
of delivery, and date of last menstruation.
261
 The validity of the variables was assessed by 
calculating Pearson correlation coefficient between the values obtained from the databases 
and patents’ medical charts, and the correlations were found to be high for all variables 
ranging from 0.920 to 0.999.
261
   
In the methodologic study, we used a validated definition of asthma. This 
operational definition was developed in Ontario health databases and previously validated. 
The validation study showed a sensitivity of 83.8% and a specificity of 76.5% as compared 
to patients’ charts from primary care physicians’ practices.264 Our methodologic study is 
the first to examine the number of additional cases of major malformations identified in 
outpatient medical claims database in Quebec, and the first to compare the CCASS 
classification method used for national surveillance to the TCMC method designed 
specifically for perinatal research. In this study we tested and compared the use of several 
case ascertainment definitions, providing a recommendation on the suitability of using the 
TCMC and hospitalization diagnoses for ascertainment of major congenital malformations. 
This recommendation was followed in our article on LABA-ICS combination versus ICS 
monotherapy. The validity of the diagnoses of congenital malformations recorded in the 
RAMQ and MED-ECHO databases has been formally evaluated and the data were shown 
to have a PPV of 82% and a PNV of 88% as compared to data from the infants’ medical 
charts.
61
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6.3.2.2 Study methodology 
Our choice for the studies’ design – being retrospective cohort studies – was 
suitable for our objectives as this design is highly efficient in terms of timeframe and cost-
effectiveness. The choice of the reference group is a determining factor in the validity of 
the results obtained from observational studies. Using non-asthmatics as a reference group 
carries a potential risk to the study validity. As we previously exhibited in the literature 
review chapter, asthma itself – and asthma symptoms including exacerbations – have been 
shown to be associated with several adverse perinatal outcomes, including congenital 
malformations.
2,5,7-9
  Consequently, confounding by indication (i.e. asthma itself) should be 
considered at the design stage of the study. 
In the article on LABA-ICS combination versus ICS monotherapy, we presented the 
first study – to the best of our knowledge – that compared the risk of congenital 
malformations for different comparable treatment options for the management of moderate 
to severe asthma during pregnancy. Previous studies have compared women treated with 
LABA or ICS with either asthmatic women not exposed to the medication or nonasthmatic 
women, leading to overestimating the true effect of the treatments alone.
275
 We also 
minimized confounding by indication through performing the primary analysis within 
subcohorts of women with similar levels of asthma severity and by adjusting for baseline 
severity markers. 
 
6.3.2.3 Limitations of the studies 
Random error 
Random error (i.e. chance effect) is defined as the variability in the data and it 
represent the precision of the observed estimates.
236,276
 Random error usually diminishes as 
sample size gets larger.
236,270
 A small P-value and a narrow confidence interval are 
reassuring signs against chance effect.
270,276
 In the article on LABA-ICS combination 
versus ICS monotherapy, we had a large cohort of pregnancies allowing for relatively 
adequate statistical power. We had a statistical power of 80% to detect an OR of 1.9 in the 
moderate asthma subcohort and an OR of 2.4 in the severe asthma subcohort, and 
associations smaller than that might not have been detected in our primary analysis. 
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However, the secondary analysis, which combined the two subcohorts, had a power of 80% 
to detect an OR of 1.7. 
 
Systematic error 
Systematic error (i.e. bias) mainly influences the internal validity of the study. Bias 
refers to any systematic process in the conduct of a study that leads to deviation from the 
truth and incorrect observed estimates.
236,270
 It could result due to errors in the way the 
subjects were selected, errors in the measurement of variables, or any confounding factor 
that is not completely controlled for.
236,270
 Generally, systematic bias can be classified into 
selection bias, information bias, and confounding bias.
236,270
  
Selection bias refers to any error that arises in the process of selecting study 
subjects, and in a cohort study it is frequently related to losses to follow-up. 
236,270
 In the 
two cohort studies we conducted, we don’t believe that we faced a situation in which this 
kind of bias could have strongly affected the validity of our results. The selection process 
was the same between the groups compared, but a potential loss to follow-up could have 
occurred if a woman become uninsured by the RAMQ during her pregnancy period. The 
direction and magnitude of this bias is unknown since we do not have data on the number 
of women who were lost to follow-up nor if it was differential or not between our compared 
groups. We suggest however that this bias did not strongly affect our results since we 
expect the number women in this group to be relatively small. 
Other potential sorts of selection bias might be present. Our cohort is selected from 
a sample of pregnancies that completed 20 weeks of gestation and our assessed exposures 
(i.e. LABA and ICS use) were measured prior to the 20
th
 week of gestation. In the first 
scenario (see directed acyclic graph [DAG] in Fig. 6.3.1), a possible selection bias could 
have occurred if early termination of pregnancies (a possible cause of LABA or ICS) was 
associated with major malformations in our study (the dashed arrow(s) in Fig. 6.3.1). If this 
association is present, then a non-causal pathway could have been opened that led to biased 
results. The bias will be differential only if one treatment regimen causes more early 
termination of pregnancies than the other regimen, and the deviation from the truth will 
depend on which regimen it is. No data is available on the early terminations’ prevalence 
among LABA-ICS users versus ICS monotherapy users. 
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Fig. 6.3.1 Directed acyclic graph of a potential selection bias, first scenario 
 
In the second scenario (see DAG in Fig. 6.3.2), another type of selection bias might 
have arisen, namely index event bias or collider-stratification bias.
277,278
 In the case of the 
presence of an unmeasured variable(s) that is associated with both early termination of 
pregnancy and major malformations (e.g. maternal tobacco smoking, illicit drug use or a 
genetic factor), a potential index event bias could have occurred. In such case, a biasing 
path could have been formed leading to erroneous results (see DAG in Fig. 6.3.2). The 
direction and magnitude of the bias is difficult to anticipate since they will depend on the 
characteristics of the unmeasured variable(s) and its strength. 
 
 
 
 
 
 
 
 
Fig. 6.3.2 Directed acyclic graph of a potential selection bias, second scenario 
LABA-ICS or 
ICS high doses 
 
Early termination of 
pregnancies 
Major malformations 
S (i.e. selection) 
LABA-ICS or 
ICS high doses 
 
Early termination of 
pregnancies 
Major malformations 
U (i.e. unmeasured 
variable) 
S (i.e. selection) 
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Information bias 
Information bias occurs as a result of systematic differences in the way data on 
exposure, outcome, or potential confounders are obtained from the study groups.
236,270
 
Misclassification is one of the common forms of information bias, which can be differential 
or non-differential.
236,270,276
 In retrospective cohort studies, in which information is obtained 
from past records, differential misclassification could be present if the quality and accuracy 
of information obtained is different among exposed and non-exposed persons.
236
  
The outcome assessments (i.e. cases of major congenital malformations) were 
identified using diagnoses codes recorded in the RAMQ and MED-ECHO databases which 
were not specifically validated for this study, but validation was performed earlier in a 
separate study
61
 and the outcome assessment was made independently of the exposure 
status of the mother. A possible detection bias
236,279
 could have occurred in scenarios where 
women using asthma treatments in our study (i.e. LABA and ICS) have been systematically 
exposed to more intense follow-up during and after pregnancy, leading to higher detection 
rates of congenital malformations. This bias – if present – will most likely be non-
differential (i.e. dilutes the true effect towards the null), unless more intense follow-up is 
provided for one treatment group over the other (e.g. high doses of ICS users over LABA 
plus medium doses of ICS). No evidence exists on such differential follow-up of asthmatic 
women during/after pregnancy and future research on this question is warranted. Non-
differential misclassification generally dilutes the true effect towards the null, causing 
underestimation of the OR.
236,270,276
 Regarding the non-significant result with the severe 
asthmatic subcohort, non-differential misclassification might have also played a role to 
prevent detecting an increased risk of congenital malformations. 
Regarding the exposure assessment, the use of medications was measured using 
medication claims, which might not reflect their actual intake. Moreover, we considered 
maternal LABA exposure as dichotomous (i.e., exposed or not exposed during the first 
trimester) because in practice, the dose prescribed varies little between patients. This 
definition might have diluted the exposure because not all women will adhere fully (100%) 
to their LABA prescription and this could have contributed to an underestimation of the 
impact of the LABA-ICS combination on the risk of major malformations. Another 
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limitation concerning the use of the RAMQ database is that it doesn’t record medications 
dispensed in hospitals, which may include oral corticosteroids, and this could have 
underestimated their use during pregnancy.  
In our methodologic study, a possible detection bias could have occurred when 
women with asthma are compared to non-asthmatic women, since asthmatic women might 
more often undergo medical consulting and examination, both for themselves and their 
newborns, leading to more cases being detected among asthmatic women and biasing the 
results away from the null. Also in the methodologic study, we used a definition of asthma 
which was previously validated (see subsection 6.3.2.1). However, using a validated but not 
100% accurate operational definition for asthma (i.e. with a sensitivity of 83.8% and a 
specificity of 76.5%) could have led to the incorrect classification of some asthmatic 
women as non-asthmatic and vice versa. Generally, the non-differential misclassification of 
exposure due to imperfect sensitivity and specificity in the presence of 2 exposure 
categories lead to a bias towards the null.
236
 
In the article on the case ascertainment definitions of major malformations, the 
accuracy of the diagnoses in a hospital database is expected to be greater than in a medical 
claims database maintained mainly for billing purposes due to active and prospective data 
entry by trained medical archivists. The recording of all diagnoses in the medical claims 
database, including suspected and confirmed cases, could lead to false-positive cases. 
However, there is no reason to believe that the recording was differential between asthmatic 
and non-asthmatic women, reducing this potential bias towards the null. In this article, the 
lack of a gold standard prevented us from estimating the PPV or the NPV for the different 
case ascertainment definitions. 
 
Confounding bias 
Confounding is believed to be present when a spurious association appears due to 
the sharing of common causes.
267
 The result is an observed association different from the 
true effect. When confounding occurs, the factor could be the alternative reason behind the 
association – or part of the association – observed between the exposure and the 
outcome.
236,270,276
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In the article on LABA-ICS combination versus ICS monotherapy, we used 
multivariate regression models to adjust the ORs for several confounding variables (see 
statistical analysis section in the manuscript). However, there was also a possibility of 
residual confounding arising from unmeasured risk factors for congenital malformations, 
such as cigarette smoking, maternal obesity, over-the-counter medications, and some other 
environmental teratogens.
160
 As previously mentioned, we minimized the effect of the 
confounding by indication by performing the primary analysis within subcohorts of women 
with similar levels of asthma severity and through adjusting for baseline severity markers 
(including exacerbation of asthma and SABA doses/week three months before pregnancy). 
However, because there was no randomization of the treatment at the beginning, we cannot 
be sure that there was no residual confounding. Another possible source of residual 
confounding is the absence of information on the provider classification of asthma severity, 
since this variable is not recorded in the databases. 
 
Other limitations 
All studies using repeated statistical analysis simultaneously in one population to 
assess several drug exposures are subject to multiple comparisons problems and inference 
error, resulting in statistically significant P-values by chance alone.
236,280
 As usual in 
studies of drug safety, we used a P-value <0.05 as the level for statistical significance, even 
if several comparisons were performed. We didn’t adjust for multiple comparisons in our 
study. However, we did not report significant associations in our study, so such limitation 
(i.e. significant associations due to chance alone) is not applicable to our results. 
In the article on LABA-ICS combination versus ICS monotherapy, since our 
objective was to examine the safety of two treatment regimens with similar indications, we 
cannot exclude the possibility that the use of either high-dose ICS or LABA is 
independently associated with a higher risk of major malformations than no use of these 
medications. However, such comparisons (use versus no use) are of lesser clinical 
relevance since not treating a woman who requires high-dose ICS or the addition of LABA 
to a lower-dose ICS to control her asthma during pregnancy is clearly not a recommended 
treatment option.  
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In the methodologic study, it is unlikely that one maternal exposure (i.e. asthma) 
will result in the increase of all major malformations categories. We used all major 
malformations combined only as an empirical example that provided the largest number of 
cases and the capacity to compare with previous studies. However, using all major 
malformations – and not system-specific malformations – could have diluted the effect of 
asthma on major malformations and might have prevented us from observing greater effect 
estimates for specific malformations. 
 
6.3.2.4 External validity 
External validity refers generally to which extent a study’s findings could be applied 
to other non-study populations (i.e. generalizability).
236,270,276,281
 We used the Quebec 
Asthma and Pregnancy Database, which includes all pregnancies in all women with ≥ 1 
asthma diagnosis in the 2-year period preceding one of their deliveries and all pregnancies 
of a 4-times-larger random sample of other women who delivered between January 1, 1990 
and March 31, 2010 in Quebec. The database includes 583,071 pregnancies, representing 
about 35% of all births in the province in this period of time and providing an exceptional 
external validity.
260
 
In a recent study by our research team, the combination of maternal asthma and low 
socioeconomic status was shown to have a synergic effect on the prevalence of major 
congenital malformations.
282
 In that study, the prevalence of major congenital 
malformations was 17% higher among asthmatic women compared to non-asthmatic 
women and drug insurance status at the start of pregnancy, which is considered a surrogate 
measure of socioeconomic status
283
, modified the association between maternal asthma and 
major congenital malformations.
282
 The prevalence of major congenital malformations was 
42% higher among publicly insured asthmatic women with social welfare compared to 10% 
among publicly insured women without social welfare and 13% among privately insured 
women.
282
  
In the article on LABA-ICS combination versus ICS monotherapy, our cohort 
underrepresents women with a higher socioeconomic status. This is because the database 
included only women covered by the RAMQ public drug insurance which includes women 
receiving social assistance and middle class working women. However, this under 
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representation might limit the study generalizability only if socioeconomic status is 
believed to be an effect modifier for the association between the exposure in our study (i.e. 
the choice of LABA-ICS combination or ICS monotherapy in higher doses) and major 
congenital malformations. Unlike the association between asthma and major 
malformations, there is currently no published data that indicates that the socioeconomic 
status could modify the effect of these two comparable treatment regimens. Therefore, 
further investigation into this area is recommended. Nevertheless, it is possible that since 
LABA-ICS combination regimen is generally more costly than ICS monotherapy in higher 
doses, women with lower socioeconomic status might use it only when their asthma 
reaches exceedingly severe levels. On the other hand, high socioeconomic status women 
could have access to this costly regimen regardless of their severity asthma levels. This 
could have led to the presence of more severe asthmatic women with low socioeconomic 
status in the higher dose ICS groups and less severe asthmatic women with higher 
socioeconomic status in the LABA-ICS groups. Since more severe asthma and low 
socioeconomic status are both associated with greater risk of congenital malformations, we 
might have overestimated the risk of congenital malformations among women treated with 
higher ICS doses.  
In the methodologic study, despite the fact that we used the Quebec health 
databases, the results are mostly generalizable and can straightforwardly reflect to different 
settings where similar health administrative databases are available. However, it is 
important to point out that we did not have access to a gold standard to compare it with our 
case ascertainment definitions, in order to formally assess the external validity of the 
definitions we developed.  Also in this study, the association between asthma and major 
congenital malformations could have been affected by the socioeconomic status of the 
women in the cohort. However, the objective of the study was not to unbiasedly quantify 
this association but rather to examine the effect of the differences in the case ascertainment 
definitions of major malformations and how they impact the selected empirical example 
(i.e. maternal asthma-major malformations). In fact, the crude estimates (i.e. crude odds 
ratios) of the measured associations could suffice to reach valid conclusions.  
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6.3.3 Systematic procedure for the classification of proven and 
potential teratogens  
The procedure we developed here is a systematic and updatable one, with objective 
components in most of its processes. The primary aim of this procedure is to provide lists 
of medications that are proven and potential teratogens that can be used in research. 
However, the lists provided have potential utility in other areas. Congenital malformations 
can arise when maternal exposure occurs above a threshold dose and at a critical time for 
the development of a specific fetal organ or system.
284
 Because the majority of organs and 
systems develop in the first trimester – with the exception of the central nervous system – 
this is considered the period of highest fetal risk.
73
 To maintain the consistency of the 
results, we considered the first trimester as the period of major interest in our 
classifications. Further research to develop lists of medications causing developmental 
damage in the second and third trimesters is warranted. 
In our lists, different medications in the same list might have different magnitudes 
of teratogenic risk, ranging from low to high. The lack of complete evidence about all the 
medications on the lists precludes any additional valid subclassification. Therefore, future 
research into this topic is recommended. The objectivity of the classification may have been 
compromised in instances in which expert opinion was required. However, we minimized 
this by blinding the reports of the experts and with the consensus process. The agreement 
between the experts’ opinions in this study was good. To perform and provide accurate 
classification, the experts have used a standard and recognized criteria for proof of human 
teratogenicity, the criteria suggested by Shepard.
219
 
In our methodology, TERIS database was not searched for potential teratogens but 
rather used for verification and classification of medications in Step 2. The main reasons 
are that TERIS is searchable only by the magnitude of the teratogenic risk rating and some 
agents have more than one magnitude of teratogenic risk rating.  For example, tetracycline 
has a risk rating for dental staining and another one for malformations. Also, in the TERIS 
database, there are more than 1200 agents that have their risk rating as 
“UNDETERMINED”. Therefore, when we conducted a search using “UNDETERMINED” 
as risk rating, the search-results box showed a message stating that there are too many 
results to show (i.e. impossible search). Moreover, the TERIS scheme that we developed 
use the "quality & quantity of data" ratings first then the "magnitude of teratogenic risk" 
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rating second, in order to classify the medications, and at this time it is not possible to do a 
search using the "quality & quantity of data" ratings in TERIS database. Also, there was a 
very slight chance that a medication could be present in TERIS but not in Briggs et al. 
book.  
Reprotox and Shepard’s Catalog of Teratogenic Agents are well-established 
teratogen information resources that we thought of including in the 2-Step procedure.
197,233
 
However, neither Reprotox nor Shepard’s Catalog of Teratogenic Agents have risk ratings 
or classifiable index as Briggs et al. reference book or the TERIS database. Therefore, in 
order to make the search and classification process systematic and reproducible, we chose 
to use them only when the experts classified the medications on their own and during their 
consensus meeting. Briggs et al. book was chosen first as it provides the most exhaustive 
list of medications with classifiable index, and TERIS has ready-to-use risk ratings that we 
used to develop the TERIS scheme. Neither Reprotox nor Shepard’s Catalog of Teratogenic 
Agents have such ratings. This way, we have tried to make the procedure systematic and 
easy to reproduce by other researchers as well. We used the pregnancy recommendations 
given by Briggs et al. in our procedure (Step 1), but some potentially unsafe medications 
might have been included under the pregnancy recommendation “compatible-maternal 
benefit >> embryo-fetal risk” and were consequently not verified by our expert. However, 
Step 1 also included screening other references, in which such medications were cited. 
Because the literature is rapidly expanding, there might still be medications that were 
missed or of which we were unaware at the time we finalized the current report.  
 
6.4 Research significance and clinical implications 
Implications for practice 
Through conducting our systematic review on beta2-agonists and perinatal 
outcomes, we found a larger body of knowledge on salbutamol compared to other SABA, 
and that adds to the evidence of its safety. It is difficult to conclude on the safety of other 
SABA (i.e. fenoterol and terbutaline), so we recommend that practitioners prescribe 
salbutamol for pregnant women in concordance with the guidelines.
5,14
 Regarding LABA, 
evidence of increased risk of specific congenital malformations exists, but it is difficult to 
interpret this association as causal since part of the observed risk could be attributable to 
254 
 
the severity of asthma. Until this observation is reproduced in other large studies, it is 
difficult to make a clear recommendation, and the current guidelines should be followed.  
The non-significant results we observed in several studies should be interpreted with 
caution since the majority of the negative studies were underpowered to detect clinically 
significant effects. The outcomes of our review are easily transferrable to physicians and 
specialists for the management of asthma during pregnancy. Our results could be very 
useful in adding to the physicians’ trust in SABA as a quick relief medication and solve 
some benefit-risk questions and fears. 
Our article on LABA-ICS combination versus ICS monotherapy in higher doses has 
a significant potential impact on the clinical practice of asthma management during 
pregnancy. The goal of asthma therapy – as the guidelines recommend – is to maintain 
optimal control of asthma symptoms and prevent acute asthma exacerbations. Among the 
important clinical decisions that physicians must make if asthma cannot be controlled with 
a low dose of ICS during pregnancy is whether to prescribe LABA to supplement the 
current dose of ICS or to increase the dose of ICS. However, it is still unknown whether it 
is safer for the newborn to increase the dose of ICS during pregnancy or to add a LABA. 
Our study has focused specifically on answering that question. 
The results we presented add essential evidence-based knowledge that could 
reinforce the confidence of clinicians in prescribing LABA-ICS combination to keep the 
mothers’ asthma under control, especially with the higher risk of congenital malformations 
with high doses of ICS monotherapy observed in earlier reports.
285
 This could be part of a 
larger therapeutic strategy endorsed by health professionals and decision makers to provide 
better maternal care for asthmatic pregnant women. Such strategy would focus on keeping 
asthma under control throughout the pregnancy period and minimizing the exacerbations 
risk. The results are encouraging as well for the asthmatic women, motivating them to 
continue taking their asthma medications when required to control their asthma symptoms 
during pregnancy, increasing the likelihood of healthy pregnancies and newborns. 
 
Implications for research 
The article on LABA-ICS combination versus ICS monotherapy in higher doses 
represent a model for comparative effectiveness and safety research in the field of maternal 
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asthma treatments. Researchers can benefit from adapting our methodology – including the 
analytical methods and the subgroup analysis – to other research questions in this field. The 
major advantages are minimizing the confounding by indication and severity while 
providing results that are readily transferable to clinical practice. 
In our methodologic article, we revealed how case ascertainment definitions had a 
considerable impact on the prevalence of major malformations, but a small influence on the 
aORs. Based on our research experience using large computerized administrative health 
databases from Quebec in the field of congenital malformations, we recommended the case 
ascertainment definition with ≥ 1 hospitalization diagnosis combined with the TCMC 
classification method, since it has the least chance of including misclassified and false 
positive cases. The detailed results of our study have direct implications for researchers 
working with Canadian health databases, but the main underlying results are transferrable 
to any computerized health database on congenital malformations. For researchers in this 
field, our results are highly valuable, especially on the association between asthma (as 
empirical example) and major malformations since we couldn’t locate previous studies 
investigating the effect of several case ascertainment definitions on the measure of 
association. These results could assist in guiding future research on congenital 
malformations and the comparative effectiveness and safety of drug therapies during 
pregnancy.  
We developed a systematic and updatable procedure for the classification of 
medications proven and potentially teratogenic when used during the first trimester of 
pregnancy. The objective was to provide lists that can be used primarily for research. The 
lists and the procedure itself can be of significant value for researchers in several fields, 
including teratology, perinatology, and reproductive epidemiology. We proposed ways 
through which our lists can be effectively used (e.g., exclusion of mothers exposed to them 
or by using various statistical adjustment techniques), however their use is not limited to 
those techniques. Our procedure has identified a large number of medications that were not 
reported in similar previous reports. Importantly, we identified a broad list of potentially 
teratogenic medications, which is unprecedented. Other areas of potential utility for our 
lists include screening medications that require high-priority postmarketing surveillance, 
and guiding future research into medications that require further investigation in animal 
models. 
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6.5 Future research 
For future research on SABA and LABA and perinatal outcomes, we suggest 
updating the systematic review we published to include the most recently published studies 
(i.e. published after 1 January, 2013). We also recommend including studies that examined 
comparable treatment regimens in the systematic review, as the one we conducted and 
included in the current thesis. Future reviews might also consider performing meta-analysis 
of drug-specific effects from several well-conducted studies. In the field of maternal asthma 
treatments and congenital malformations, future studies should be large enough to be able 
to compare equivalent treatment regimens, or to compare different molecules of one class 
in order to minimize confounding by asthma severity. Additional large studies on treatment 
regimens that share similar indications should be the focus of future projects. An interesting 
question that complement our research would be: does the safety results on LABA-ICS 
combination and ICS monotherapy in higher doses hold for different system-specific 
malformations or not. This question requires a larger sample size than the one we had 
obtained and is highly justified for future research efforts. 
Further research is needed to find solutions for some additional related questions 
that are equally urgent. More comparative effectiveness research is needed to identify the 
most effective and safest treatment regimens for maternal asthma among different 
subgroups of pregnant women. There is currently no data that support one treatment 
regimen over the other among specific patients’ subgroups, including for example obese 
and overweight vs non-obese patients. Additional evidence in this area will be of high 
value. Moreover, similar knowledge is highly required for the different asthma phenotypes. 
Another area of scarce evidence in the comparative effectiveness of maternal asthma 
treatment regimens is the difference in adherence rates for patients on different comparable 
treatment regimens.  
Future research on the case ascertainment definitions of major malformations could 
explore the associations between other maternal exposures and system-specific categories 
of congenital malformations (e.g. the association between maternal diabetes and cardiac 
defects). Moreover, formal assessment of the validity of the proposed case ascertainment 
definitions is certainly needed. We acknowledged the presence of some major congenital 
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malformations that could be debated to reflect minor malformations or less serious major 
malformations. We recommend the developing of a stricter case ascertainment definition 
(as a new classification method) which can be compared and validated as well in the 
validation study in the future. 
We suggest that researchers endorse the teratogenic and potential teratogenic 
medications lists we presented for their epidemiologic research that include any first 
trimester exposure. Future work based on the new edition of Briggs et al. (2015) could be 
valuable, beside the already established method to update the medications lists. Further 
research to develop lists of medications causing developmental damage in the second and 
third trimesters is warranted. Also a comparison between the risk ratings for teratogenic 
medications in Briggs et al. book and TERIS database. A major drawback with lists is that 
there is no formal assessment of the severity or frequency of the specific malformation or 
the conditions under which the adverse effect occurred. Including this information will be 
valuable for future research. Moreover, it is highly recommended to expand the lists we 
proposed to cover data on which drugs cause teratogenicity due to their pharmacological 
mechanism of action, which ones cause teratogenicity only at high doses, and the types of 
malformations found to be associated with each teratogen. 
 
6.6 Conclusion 
The studies presented in the current thesis were conducted to achieve an ultimate 
objective, which is to examine the comparative safety of two common treatment regimens 
for maternal asthma during the first trimester of pregnancy. Our research program has 
expanded to cover other related and equally important areas.  
In the first part, the results of the systematic review on beta2-agonists and perinatal 
outcomes showed a larger body of knowledge on salbutamol compared to other SABA, an 
added proof for its safe use during pregnancy. Studies on maternal use of LABA during 
pregnancy are relatively fewer and smaller in size, warranting further research on their 
association with different perinatal outcomes. Conducting larger comparative safety studies 
and meta-analysis of several well-designed studies are two future research prospects that 
we highly praise.  
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In the second part of this thesis, we used a large linkable health administrative 
databases from Quebec to answer two different questions. The results of the first study 
showed that the risk of major malformations did not differ when a combination therapy of 
LABA plus ICS or a higher dose of ICS monotherapy was used in the first trimester of 
pregnancy. These results are encouraging for the expecting mothers and carry major 
clinical relevance for the health professionals. It will be interesting to see similar results 
replicated by other researchers in future studies, and equivalent methodology being used to 
examine other perinatal outcomes. 
The results of our third study revealed how different case ascertainment definitions 
of major malformations had a considerable impact on the prevalence of major 
malformations, but a small influence on the aORs. The study results could assist in guiding 
future research on congenital malformations and pharmacoepidemiologic studies on drug 
therapies during pregnancy. A comprehensive validation study with medical records as gold 
standard is strongly suggested for future research efforts. 
In the last part we used reliable references and resources to develop a systematic 
and updatable procedure for the classification of teratogenic and potential teratogenic 
medications. The lists we developed effectively resolve the discrepancies and 
contradictions of teratogens lists previously published in the literature. The lists are to be 
used primarily for research, with significant value for researchers in teratology, 
perinatology, and reproductive epidemiology. Regular updating for the lists to include 
newly published evidence and further expansion to include additional teratogenicity details 
is interesting to see in future work. 
In conclusion, the results presented in the current thesis have a significant added 
value to the published evidence on asthma treatments during pregnancy, helping clinicians 
and mothers to choose the optimal therapeutic regimen to keep asthma under control during 
pregnancy. The thesis’ results added also constructive knowledge that could have 
remarkable research implications. The major knowledge gaps that we addressed – on 
indication bias, congenital malformations ascertainment and teratogenic medications – 
provided valuable evidence that is directly transferable to researchers in teratology, 
pharmacoepidemiology and other related research fields. 
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Review question(s) 
To perform a review of the existing literature regarding the use of beta-2-agonists during pregnancy 
and the risk of adverse perinatal outcomes, with particular focus on study power. 
 
we aim to summarize the existing human data on the impact of these medications on major and 
all congenital malformations, SGA, birth weight, LBW, gestational age, and preterm delivery. 
 
We also aim to perform post-hoc power calculations to evaluate the capacity of each study to detect the 
associations under study. 
 
Searches 
We will search the following electronic bibliographic databases: PubMed, MEDLINE, EMBASE, 
The Cochrane Library, CINAHL, and Web of Science. No date restrictions are applied, and only 
articles in the English language will be included in the final pool of studies. Abstracts without 
supporting articles are not included. 
 
Types of study to be included 
No restrictions are applied on the study designs. 
 
Condition or domain being studied 
Asthma during pregnancy, Perinatal outcomes 
 
Participants/ population 
Inclusion: Pregnant women exposed to Beta-2-agonists during pregnancy  
 
Exclusion: Men, Non-pregnant women, and pregnant women not exposed to beta-2-agonists 
 
Intervention(s), exposure(s) 
beta-2-agonists have a crucial role in asthma management during pregnancy. Short-acting beta-2-agonists 
(SABA) are used as quick relief medications for all asthma types (mild, moderate, or severe), while long-
acting beta-2-agonists (LABA) are used in cases of moderate and severe persistent asthma, in 
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combination with low or medium doses of inhaled corticosteroids. 
 
The exposure to SABA and LABA during pregnancy is the objective of this review. 
 
Comparator(s)/ control  
Beta-2-agonists users will be compared against non-users (asthmatics), non-asthmatics, and other 
asthma medication users. 
 
Outcome(s) 
Primary outcomes 
Major and all congenital malformations, small for gestational age (SGA), birth weight, low birth 
weight (LBW),gestational age, and preterm delivery 
 
Secondary outcomes 
None 
 
Data extraction, (selection and coding) 
The primary search was conducted by one author (SE), while a second confirmatory independent search 
was performed by a second author (FZK). All studies identified in the search were independently 
reviewed by two co- authors and the study selection was made independently by two co-authors (SE and 
FZK). Data extraction and post- hoc power calculations were first performed by one author (SE). An 
independent data extraction and post-hoc power calculation were performed by a second author (FZK) 
under unmasked condition. Discrepancies were resolved by consensus 
 
Data retrieved from each study included the study reference, the design, the source of data, the timing 
of exposure, the type of beta2-agonists, the definition of the reference group, the sample size of the 
exposed and unexposed groups, the reported proportions or means and standard deviations for the 
outcomes in the exposed and unexposed groups, the effect size (crude or adjusted relative risk (RR), 
odds ratio (OR), or mean difference (MD)), and the p- value or 95% confidence interval (CI) 
associated with the effect size. In studies that did not report the effect size, a crude RR, OR, or MD 
was calculated when sufficient information was provided. 
 
We performed a post-hoc power calculation for each study reporting non-statistically significant results to 
detect a RR of 1.5, a mean difference in the birth weight of 500 g, or a mean difference in gestational age 
of one week to establish a comparison between studies. The power calculations were based on t-tests for 
MD and on the test for the difference between two independent proportions for RR and OR. A type I error 
of 0.05 was used for power calculations; all calculations were performed using PASS 2008 interface of 
NCSS software. 
 
Risk of bias (quality) assessment 
All studies included in this review to be independently reviewed by two co-authors, and data extraction 
performed by the two authors independantly. 
 
Strategy for data synthesis 
We will provide a narrative synthesis of the findings from the included studies, including the design, 
the source of data, the timing of exposure, the type of beta2-agonists, the definition of the reference 
group, the sample size of the exposed and unexposed groups, the reported proportions or means and 
standard deviations for the outcomes in the exposed and unexposed groups, the effect size (crude or 
adjusted relative risk (RR), odds ratio (OR), or mean difference (MD)), and the p-value or 95% 
confidence interval (CI) associated with the effect size.. We will provide summaries of intervention 
effects for each study, and post-hoc power calculations for each study. We anticipate that there will be 
limited scope for meta-analysis because of the range of different outcomes measured across the small 
number of existing studies. 
 
We will calculate the power of each study (excluding those reporting significant results) to detect a RR of 
1.5, a mean difference in the birth weight of 500 g, or a mean difference in gestational age of 1 week to 
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establish a comparison between studies. The power calculations are based on t-tests for MD and on the 
test for the difference between two independent proportions for RR and OR. A type I error of 0.05 will be 
used for power calculations, and all calculations will be performed using PASS 2008 interface of NCSS 
software. 
 
Analysis of subgroups or subsets 
None planned 
 
Dissemination plans 
A paper will be submitted to a leading journal in this field. 
 
Contact details for further information 
Sherif Eltonsy 
C.P. 6128, Succursale 
Centre-ville Montreal 
(Quebec) H3C 3J7 
sherif.eltonsy@umont
real.ca 
Organisational affiliation of the review 
Faculty of Pharmacy, Université 
de Montréal 
http://www.pharm.umontreal.ca/ 
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Mr Sherif Eltonsy, Faculty of Pharmacy, Université de Montréal 
Mrs Fatima-Zohra Kettani, Faculty of Pharmacy, Université 
de Montréal Professor Lucie Blais, Faculty of Pharmacy, 
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Anticipated or actual start date 
01 March 2011 
 
Anticipated completion date 
15 November 2011 
 
Funding sources/sponsors 
This review is funded through grants from the Canadian Institute of Health Research (CIHR) 
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L. Blais is the recipient of a Salary Award from the Fonds de la recherché en santé du Québec (FRSQ) 
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received research support from AstraZeneca, Amgen, and GlaxoSmithKline. S. Eltonsy has declared that 
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Language 
English 
 
Country 
Canada 
 iv 
 
 
Subject index terms status 
Subject indexing assigned by CRD 
 
Subject index terms 
Adrenergic beta-Agonists; Humans; Pregnancy; Pregnancy Complications; Pregnancy Outcome 
 
Stage of review 
Completed but not published 
 
Date of registration in PROSPERO 
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Date of publication of this revision 
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Data analysis No Yes 
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Appendix B 
 
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
 
CASE CONTROL 
STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability. 
 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation 
b) yes, eg record linkage or based on self  reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases   
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls 
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint) 
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for (Select the most important factor.)   
b) study controls for any additional factor  (This criteria could be modified to indicate 
specific control for a second important  factor.) 
 
Exposure 
1) Ascertainment of exposure 
a) secure record (eg surgical records)  
b) structured interview where blind to case/control status  
c) interview not blinded to case/control status 
d) written self report or medical record only 
e) no description 
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2) Same method of ascertainment for cases and  controls 
a) yes 
b) no 
3) Non-Response rate 
a) same rate for both groups  
b) non respondents described 
c) rate different and no designation 
 
 
COHORT STUDIES 
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Outcome categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average  (describe) in the community 
b) somewhat representative of the average  in the community 
c) selected group of users eg nurses,  volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort   
b) drawn from a different  source 
c) no description of the derivation of the non exposed  cohort 
3) Ascertainment of exposure 
a) secure record (eg surgical records)  
b) structured interview 
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of   study 
a) yes 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for  (select the most important factor)  
b) study controls for any additional factor  (This criteria could be modified to indicate 
specific control for a second important  factor.) 
Outcome 
1) Assessment of outcome 
a) independent blind assessment 
b) record linkage 
c) self report 
d) no description 
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2) Was follow-up long enough for outcomes to  occur 
a) yes (select an adequate follow up period for outcome of interest)  
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for 
b) subjects lost to follow up unlikely to introduce bias - small number lost - >  % 
(select an adequate %) follow up, or description provided of those lost)  
c) follow up rate <  % (select an adequate %) and no description of those  lost 
d) no statement 
 
 
 
 
CODING MANUAL FOR CASE-CONTROL  STUDIES 
 
SELECTION 
 
1) Is the Case Definition Adequate? 
 
a) Requires some independent validation (e.g. >1 person/record/time/process to 
extract information, or reference to primary record source such as x-rays or 
medical/hospital records) 
b) Record linkage (e.g. ICD codes in database) or self-report with no reference to 
primary record 
c) No description 
 
2) Representativeness of the Cases 
 
a) All eligible cases with outcome of interest over a defined period of time, all cases 
in a defined catchment area, all cases in a defined hospital or clinic, group of 
hospitals, health maintenance organisation, or an appropriate sample of those 
cases (e.g. random sample) 
b) Not satisfying requirements in part (a), or not stated. 
 
3) Selection of Controls 
 
This item assesses whether the control series used in the study is derived from the 
same population as the cases and essentially would have been cases had the outcome 
been present. 
a) Community controls (i.e. same community as cases and would be cases if had 
outcome) 
b) Hospital controls, within same community as cases (i.e. not another city) but 
derived from a hospitalised population 
c) No description 
 
 viii 
 
4) Definition of Controls 
 
a) If cases are first occurrence of outcome, then it must explicitly state that controls 
have no history of this outcome. If cases have new (not necessarily first) 
occurrence of outcome, then controls with previous occurrences of outcome of 
interest should not be excluded. 
b) No mention of history of outcome 
 
 
COMPARABILITY 
 
1)  Comparability of Cases and Controls on the Basis of the Design or Analysis 
 
A maximum of 2 stars can be allotted in this category 
Either cases and controls must be matched in the design and/or confounders must be 
adjusted for in the analysis. Statements of no differences between groups or that 
differences were not statistically significant are not sufficient for establishing 
comparability. Note: If the odds ratio for the exposure of interest is adjusted for the 
confounders listed, then the groups will be considered to be comparable on each 
variable used in the adjustment. 
There may be multiple ratings for this item for different categories of exposure (e.g. 
ever vs. never, current vs. previous or never) 
Age = , Other controlled factors = 
 
EXPOSURE 
 
1) Ascertainment of Exposure 
 
Allocation of stars as per rating sheet 
 
2) Non-Response Rate 
 
Allocation of stars as per rating sheet 
 
CODING MANUAL FOR COHORT  STUDIES 
 
SELECTION 
 
1) Representativeness of the Exposed Cohort 
 
Item is assessing the representativeness of exposed individuals in the community, not 
the representativeness of the sample of women from some general population. For 
example, subjects derived from groups likely to contain middle class, better educated, 
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health oriented women are likely to be representative of postmenopausal estrogen 
users while they are not representative of all women (e.g. members of a health 
maintenance organisation (HMO) will be a representative sample of estrogen users. 
While the HMO may have an under-representation of ethnic groups, the poor, and 
poorly educated, these excluded groups are not the predominant users users of 
estrogen). 
 
Allocation of stars as per rating sheet 
 
2) Selection of the Non-Exposed Cohort 
 
Allocation of stars as per rating sheet 
 
3) Ascertainment of Exposure 
 
Allocation of stars as per rating sheet 
 
4) Demonstration That Outcome of Interest Was Not Present at 
Start of Study 
 
In the case of mortality studies, outcome of interest is still the presence of a disease/ 
incident, rather than death. That is to say that a statement of no history of disease or 
incident earns a star. 
 
COMPARABILITY 
 
1)   Comparability of Cohorts on the Basis of the Design or Analysis 
 
A maximum of 2 stars can be allotted in this category 
Either exposed and non-exposed individuals must be matched in the design and/or 
confounders must be adjusted for in the analysis. Statements of no differences 
between groups or that differences were not statistically significant are not sufficient 
for establishing comparability. Note: If the relative risk for the exposure of interest is 
adjusted for the confounders listed, then the groups will be considered to be 
comparable on each variable used in the adjustment. 
There may be multiple ratings for this item for different categories of exposure (e.g. 
ever vs. never, current vs. previous or never) 
Age = , Other controlled factors =
 x 
 
OUTCOME 
 
1) Assessment of Outcome 
 
For some outcomes (e.g. fractured hip), reference to the medical record is sufficient to 
satisfy the requirement for confirmation of the fracture.  This would not be adequate 
for vertebral fracture outcomes where reference to x-rays would be required. 
a) Independent or blind assessment stated in the paper, or confirmation of the 
outcome by reference to secure records (x-rays, medical records, etc.) 
b) Record linkage (e.g. identified through ICD codes on database records) 
c) Self-report (i.e. no reference to original medical records or x-rays to confirm the 
outcome) 
d) No description. 
 
2) Was Follow-Up Long Enough for Outcomes to Occur 
 
An acceptable length of time should be decided before quality assessment begins (e.g. 
5 yrs. for exposure to breast implants) 
 
3) Adequacy of Follow Up of Cohorts 
 
This item assesses the follow-up of the exposed and non-exposed cohorts to ensure 
that losses are not related to either the exposure or the outcome. 
 
Allocation of stars as per rating sheet 
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Appendix C 
 
PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
7 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  8 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
8 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
9 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
9 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
9 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
10 
 xii 
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
10 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
10 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
10 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
11 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  NA 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
NA 
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
NA 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
11 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
11, Fig.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
35-45 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  34 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
35-45 
 xiii 
 
Synthesis of results  21 Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and 
measures of consistency 
11-18, 
35-45 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  NA 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
35-45 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
18-24 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
24 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
25 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
2 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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